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Abstract
Ovarian cancer (OC) is the most lethal form of gynaecological cancer, with high-grade
serous ovarian carcinoma (HGSOC) being the most common and the deadliest subtype.
Non-coding RNAs are a recently discovered species of RNAs that do not code for proteins,
yet play a crucial role in both normal physiology and disease. e overall goal of this thesis
was to apply the power of non-coding RNAs to OC with the following aims: (1) to identify
novel small non-coding RNAs present in serum that could separate patients with HGSOC
from healthy women as well as predict their surgical outcome, (2) to assess the role of long
non-coding RNAs (lncRNAs) in promoting cisplatin resistance in cell line models of OC,
and (3) to study the eﬀects ofmutant-p53 onmRNAs and lncRNAs using a small compound
known as APR-246 as well as investigating the drug’s mechanisms of action.
Firstly, the lethality of OC could partially be attributed to the lack of specific symptoms,
leading this disease to be termed the ‘silent killer’, as well as low incidence rate of 9.4 cases
per 100,000 individuals, both requiring a highly accurate test for population screening
that remains an ongoing challenge. Measuring the levels of small non-coding RNAs,
known as microRNAs, in serum, experiments described in this thesis aimed to identify
novel microRNAs that could separate patients with HGSOC from healthy women as well
as predict their surgical outcome, one of the most important factors influencing overall
patient survival. Because serum microRNAs can be aﬀected by pre-analytical factors such
as haemolysis, the sensitivity of four methodologies to detect low levels of haemolysis was
first determined. is work is published in Plos One. e work described in this thesis
identified a novel serummicroRNA, miR-375, that could improve the accuracy of CA-125,
a routinely used biomarker in diagnosing OC, in separating patients with HGSOC from
healthy women. Next, serum microRNA miR-34a-5p was found to predict the surgical
outcome of patients with HGSOC. In fact, miR-34a-5p was found to be superior to CA-
125 for this purpose. Although the standard therapy for treating OC consists of surgical
removal of the tumour followed by chemotherapy containing platinum/taxane agents, this
regimenmay be too aggressive for a subset of patients whomight benefit from neoadjuvant
chemotherapy, i.e. chemotherapy followed by the surgery. A pre-operative expectation of
the the surgical outcome could help surgeons decide on optimal timing for surgery. Both
miR-375 and miR-34a-5p were also unaﬀected by haemolysis.
Secondly, although OC is initially sensitive to chemotherapy, most patients develop
resistancewithin two years, resulting in recurrent disease that is diﬃcult to treat. To identify
novel lncRNAs that could promote drug resistance, expression of ninety lncRNAs was
vi
profiled in cell line models of cisplatin resistance. Five lncRNAs were found to have the
potential to promote cisplatin resistance in vitro, and lncRNAUrothelial Cancer Associated
1 (UCA1) was selected for further investigations. Despite its role in promoting cisplatin
resistance in bladder cancer, UCA1 was not found to promote cisplatin resistance in cell
line models of OC.
Lastly, the tumour suppressor TP53 plays a central role in the biology of cancer and it
is almost universally mutated in HGSOC. Recent evidence suggests that p53, the protein
encoded by TP53, can significantly influence the expression of both small and long non-
coding RNAs. Experiments described in this thesis aimed to investigate the eﬀect of
mutant-p53 on protein-coding and non-coding RNAs by using a small compound known
as APR-246 which has been reported to restore wild-type p53 activities in multiple cancers
by stabilising the structure of mutant-p53. Despite currently undergoing a phase Ib/II
clinical trial for potential treatment of recurrent HGSOC, the ability of APR-246 to restore
wild-type p53 activities in HGSOC has not been tested. A global transcriptomic analysis
conducted in this thesis discovered that p53-responsive mRNAs and lncRNAs were not
robustly induced following APR-246 treatment in two cell line models of HGSOC, but
indicated that APR-246 could function by inducing high levels of reactive oxidative species
(ROS).
Overall, data presented in this thesis demonstrated the utility of small non-coding
RNAs in identifying patients with HGSOC from healthy women as well as predicting
their surgical outcome. is thesis also implicated that lncRNAs, in general, could have
a role in promoting cisplatin resistance in OC as well as suggested that APR-246 could,
based on evidence obtained from the expression of p53-responsive mRNAs and lncRNAs,
act independently of mutant-p53. Together, this research raises novel ways for clinical
management of patients with HGSOC and addresses the challenge of drug resistance using
non-coding RNAs, as well as questions the assumed mechanisms of action of the ‘p53-
activating’ drug APR-246.
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Chapter 1
Literature Review
1.1 Ovarian cancer
1.1.1 Management of ovarian cancer
1.1.1.1 Epidemiology
Ovarian cancer (OC) is the seventh most common form of cancer and the eighth most
frequent cause of death from cancer in women worldwide, which translates to roughly
239,000 new cases worldwide and 152,000 deaths from the disease annually (Ferlay et al.
2015). e age-standardised incidence rate in developed countries has been estimated to
be 9.4 per 100,000 population (Soerjomataram et al. 2012). e life time risk of being
diagnosedwith and succumbing toOC in theUnited States is approximately 1 in 70, and 1 in
95, respectively (Clarke-Pearson 2009; Romero and Bast 2012). Similar to the US, 1 in 106
women under the age of 85 will succumb to OC in Australia (AIHW 2017). Although the
5-year survival rate for patients withOChas risen from 32% in 1982-1987 to 44.4% in 2009-
2013, it remains significantly lower than other cancers such as breast cancer (72% in 1982-
1987 to 90.2% in 2009-2013) (AIHW 2017). us, there is an urgent need to gain a deeper
understanding of the disease and translate it into the clinical management of patients.
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1.1.1.2 Risk factors
Early menarche, late menopause and nulliparity have been linked to an increased risk of
developing OC (Hamajima et al. 2012). ese factors increase the number of ovulatory
cycles, implicating the role of hormones in the pathogenesis of this disease. In support of
this so-called incessant ovulation hypothesis, factors that decrease the number of ovulatory
cycles such as multiple pregnancies and prolonged lactation have been linked to reducing
the risk of developing OC (AIHW 2017; Hunn and Rodriguez 2012). Tubal ligation,
unilateral or bilateral oophorectomy (removal of the ovary), salpingectomy (removal of the
fallopian tube) and hysterectomy (removal of the uterus) have also been found eﬀective in
reducing the risk (Bassuk andManson 2015; Moorman et al. 2013; Wentzensen et al. 2016).
Germline mutations in breast cancer type 1 susceptibility gene (BRCA1) or BRCA2 are
observed in 14.1% of OC patients and 44% of the families that have germline mutations
in BRCA1/2 did not have reported family history of breast or ovarian cancer. (Alsop et al.
2012). BRCA1/2 play a role in the DNA repair pathway by homologous recombination
(HR). Other genes encoding proteins involved in this pathway such as RAD51C, RAD51D,
BRIP1, BARD1, PALB2, CHEK2, MRE11A, RAD50 and ATM are also altered in OC
(Matulonis et al. 2016). e defectiveness inHR is currently being investigated to eﬃciently
target a subset of OC patients (subsection 1.1.1.8) (Bowtell et al. 2015; Matulonis et al.
2016; Romero and Bast 2012)). In addition, inherited disorders such as Lynch syndrome,
characterised by mutations in the DNA mismatch genesMLH1,MSH2,MSH6 and PMS2,
increase risk of developing OC as well as multiple other cancers (Crispens 2012; Engel et
al. 2012). It is becoming increasingly clear that OC is a collection of histologically and
molecularly distinct diseases, with the ovary as the primary site of anatomical location.
Evidence supporting this theory andmolecular signatures is presented in subsection 1.1.2.1.
1.1.1.3 Diagnosis
OC is termed the “silent killer” due to nonspecific symptoms. Over 90% of women di-
agnosed with OC experience symptoms such as constipation, diarrhoea, nausea, vomit-
ing, abdominal bloating or pain, which are nonspecific and can also occur as symptoms of
ageing, menopause, weight gain and other benign conditions of the gastrointestinal tract
(Bankhead et al. 2008; Goﬀ et al. 2000; Jayson et al. 2014). e disease is oen detected
when these symptoms have remained unresolved, become frequent or severe, requiring a
detailed examination. Unfortunately, OC has frequently already reached an advanced stage
(stage III or IV) upon diagnosis. Diagnostic procedures involve transvaginal ultrasonogra-
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phy andmeasurement of the serum protein Cancer Antigen 125 (CA-125) (Cannistra 2004;
Goﬀ et al. 2000; Matulonis et al. 2016).
CA-125, first characterised in 1981 (Bast Jr. et al. 1981), is the only biomarker that is
widely used for routine management of OC (Felder et al. 2014; Matulonis et al. 2016).
is membrane glycoprotein is expressed by epithelial cells of the bronchus, endometrium,
ovary and cornea (Davies et al. 2007; Hattrup and Gendler 2008; Rustin et al. 2004). Due to
its expression in multiple tissues, a rise in CA-125 levels above the “normal” level cut-oﬀ of
35 U/ml is not limited to OC but can be aﬀected by pregnancy, menstruation, infection,
uterine fibroids and other factors such as the patient’s race, previous or current history
of other cancers, whether she has had a hysterectomy, smokes regularly and consumes
caﬀeine (Medeiros et al. 2009; Pauler et al. 2001; Verheijen et al. 1999). erefore, CA-
125 itself is not adequate to diagnose OC and is used in combination with modalities such
as ultrasonography which can readily detect the presence of cysts surrounded by solid
tissue mass of the carcinoma (Felder et al. 2014; Jayson et al. 2014; Matulonis et al. 2016).
Nevertheless, CA-125 remains a robust biomarker to monitor disease recurrence (Burg,
Lammes, and Verweij 1992, 1993; Felder et al. 2014).
1.1.1.4 Screening
Based on the low prevalence of OC, epidemiologists have estimated a minimum sensitivity
of 0.75 and specificity of 0.996* of a test to be eﬀective in population-wide screening
(Clarke-Pearson 2009; Hennessy, Coleman, and Markman 2009). is is a significant
hurdle to overcome. Although the baseline levels of CA-125 are variable amongst healthy
women, they tend to remain relatively stable over time in a given woman, unless oﬀset
by conditions such as OC (Skates, Pauler, and Jacobs 2001; Skates et al. 1995). An
algorithm named Risk of Ovarian Cancer Algorithm (ROCA) based on this concept
and incorporating age-standardised risk was put forward to classify risk of having OC
into three categories: low, intermediate and high (Menon et al. 2005). Recently, a
large prospective randomised clinical trial, the UK Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS), on 202,638 post-menopausal women was conducted to test the
eﬀect of no screening, transvaginal ultrasonography and transvaginal ultrasonography +
CA-125 on the diagnosis of OC. Although both of the screening methods detected OC
at an earlier stage compared to no screening (Jacobs et al. 2016), no overall diﬀerences
in the percentage of women diagnosed with OC and mortality reduction were observed
*Values of the diagnostic statistics such as sensitivity, specificity, accuracy and area under curve (AUC)
are presented in proportions instead of percentages.
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amongst the three groups (Jacobs et al. 2016). A reduction in mortality over the long-term
(7-14 years) with ROCAwas observed, but further follow-up of these women is required to
validate this finding (Jacobs et al. 2016).
Besides CA-125, multiplemeta-analyses have found human epididymis protein 4 (HE4)
to be a superior marker compared to CA-125 in detecting OC in suspected cases, and a
combination of both biomarkers was superior to either biomarker alone (Hu et al. 2016, 21
studies, N = 4,544; Chen et al. 2016, 8 studies, N = 1,832; Ferrarow et al. 2013, 16 studies,
N = 3,858). is could be due to a lack of correlation in HE4 and CA-125 levels, suggesting
that both biomarkers work independently (Chudecka-Głaz 2015). Risk of Malignancy
Algorithm (ROMA) encompassing menopausal status and levels of HE4 and CA-125 is
approved by the Food and Drug Administration (FDA) to assess the risk of epithelial
ovarian cancer (EOC) in women with a pelvic mass (ROMA® 2011).
An FDA-approved multivariate Index Assay commercially sold as the ‘OVA1’ test
(Vermillion 2009), comprising CA-125, transthyretin (prealbumin), apolipoprotein A1,
beta 2 microglobulin, and transferrin, can also be helpful with pre-operative assessment of
OC (Rai et al. 2002; Ueland et al. 2011; Zhang et al. 2004). An improvement of theOVA1 test
called ‘Overa’ wasmade available in 2015. ROMAwas found to bemore specific thanOVA1
in identifyingmalignancy inwomenwith an adnexalmass (a lump in tissue of the adnexa of
uterus) while no statistically significant diﬀerence was observed in the sensitivities of these
tests (Grenache et al. 2015). e lower specificity of OVA1 could increase the referral to
a gynaecological oncologist for further examination (Li 2012). OVA1 was more expensive
than ROMA (~USD 600 versus ~USD 100) according data available in 2012† (Li 2012),
suggesting that ROMAcould be an economic option. Despite recent improvements, ROMA
and OVA1 lack the sensitivities and specificities to be used as a population screening test,
and they must be combined with a physical examination and imaging modalities to be
clinically useful.
1.1.1.5 Role of surgery in the management of OC patients
Surgical resection of the tumour followed by chemotherapy is the standard primary
treatment for newly diagnosed cases of OC. Systematic examination of the peritoneal
cavity upon surgery to determine the spread of the tumour, including to the omentum,
diaphragm, pelvic and para-aortic lymph nodes, as well as histology of the tumour, dictate
tumour staging and grading. Adjuvant chemotherapy consists of six cycles of agents
containing platin (cisplatin, carboplatin or oxaliplatin) and taxane (paclitaxel or docetaxel),
†It was not possible to update the quote without a physician’s referral.
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with carboplatin/paclitaxel being the most common combination (Coleman, Ramirez, and
Gershenson 2017; Matulonis et al. 2016).
e goal of cytoreductive surgery is to remove the maximum amount of tumour mass
and palliate symptoms for as long as possible (Fader and Rose 2007; Matulonis et al. 2016).
Women with OC generally undergo total abdominal hysterectomy and bilateral salpingo-
oophorectomy with omentectomy and comprehensive surgical staging. Cytoreductive
surgery can be extensive, oen requiring bowel resection, splenectomy, partial hepatic or
pancreatic resection and diaphragm stripping (Fader and Rose 2007; Martín-Cameàn et al.
2016; Romanidis et al. 2014; Zapardiel et al. 2011). e extent of resectability depends
on the health of the patient, tumour location and extent of disease, as well as expertise
of the surgeon and the medical centre (Martín-Cameàn et al. 2016). Surgery performed
by gynaecological oncologists usually have better outcomes for patients in terms of overall
survival (OS) compared to non-gynaecological oncologists (Matulonis et al. 2016).
Griﬃths 1975 first conclusively demonstrated the inverse relationship between the size
of residual disease and patient survival, which has been subsequently confirmed bymultiple
independent studies (reviewed in Fader and Rose 2007). A meta-analysis of 6,885 OC
patients compiled from 81 cohorts of advanced OC treated by debulking surgery followed
by platinum-based drugs conducted by Bristow et al. 2002 led them to postulate that the
median survival period increases by 5.5% for each 10% increase inmaximal cytoreduction‡.
Based on these studies, resecting tumours to a certain size was considered ‘optimal’.
e definition of ‘optimal’ has changed over time, ranging from <2 cm, <1 cm and ‘no
macroscopic’ residual disease (0 mm, also called R0 resection). Optimal cytoreduction is
currently defined as <1 cm of residual disease at the conclusion of the surgery (Matulonis et
al. 2016; Nick et al. 2015). However, the R0 resection oﬀers the longest OS period compared
to any residual disease. For example, a retrospective pooled analysis of 7 Gynaecologic
Oncology Group (GOG) protocols performed by Winter et al. 2008 on women with Stage
IV EOC reported the median OS of R0 resected patients to be 64 months compared to 30
months for patients with 0.1-5 cm of residual disease. A meta-analysis from 3 European
AGO-OVAR prospective random trials confirmed the benefits of R0 resection over >1 mm
residual tumour (du Bois et al. 2009; N =3,126). Consequently, an increasing number of
studies have been defining ‘optimal’ cytoreduction as R0 resection, and guidelines from
reputed sources such as the National Comprehensive Cancer Network (NCCN) encourage
‡maximal cytoreduction eﬀort was graded from 0-100%, with >2 cm residual tumour as 0% and <0.5 cm
as 100%.
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Stage IV
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Proportion of patients in the TCGA−OV dataset
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Figure 1.1: Size of the residual tumour reported in the TCGA-OV dataset
Size of the residual tumour reported in the TCGA-OV dataset (Bell et al. 2011) has been colour-coded.
‘0 mm’ refers to ‘no macroscopic’ residual tumour, equivalent to the R0 status.
surgeons to be aggressive and achieve optimal cytoreduction whenever this is feasible
(Chang et al. 2013; Horowitz et al. 2015; Jayson et al. 2014; NCCN 2017; Nick et al. 2015).
Despite the benefits, the R0 status is achieved in only 20 - 25% of the patients (Figure
1.1)(Bell et al. 2011; du Bois et al. 2009; Eisenhauer et al. 2008). Importantly, considering
the aggressiveness of the surgery and significant subsequent morbidity, the overall benefits
of the surgery in patients with >1 cm residual tumour are limited or none (Bristow
2006; Bristow et al. 2007). In fact, it may be better to avoid surgery and rely purely
on chemotherapy in cases with extensive disease (Bowtell et al. 2015). Neoadjuvant
chemotherapy (NACT), in which a patient receives 3 rounds of chemotherapy to ‘shrink’
tumours prior to the surgery followed by 3 additional cycles of adjuvant chemotherapy,
remains an option for patients with advanced OC, although the eﬃciency of this approach
remains a highly debatable topic (Kehoe et al. 2015; Trimbos et al. 2003). Two initial studies
comparing NACT with standard therapy reported lower morbidity in patients receiving
NACTwhile theOS remained unchanged (Morice et al. 2003, N=85; Schwartz et al. 1999, N
= 265). Larger randomised studies have supported this finding (Vergote et al. 2010, N= 632;
Kehoe et al. 2015, N = 552). e current NCCN guidelines recommend NACT if maximal
cytoreduction is unlikely to be achieved following pre-surgical assessment of a patient with
or without minimally invasive surgical approaches. Criticisms of NACT include increased
theoretical odds of developing drug resistance by exposing a greater number of tumour
cells to chemotherapy, lost opportunities to cytoreduce where tumours could have been
optimally cytoreduced but NACT was prescribed instead, and lack of solid long-term
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survival data compared to standard therapy (Coleman, Ramirez, and Gershenson 2017;
Coleman et al. 2013).
e decision whether to use standard therapy versus NACT has the potential to make
a significant impact on the therapeutic route for OC patients. On one hand, it remains
important to identify the patients that are likely to achieve the R0 resection because of the
benefits in OS and PFS associated with it. On the other hand, NACT may well be suitable
for a subset of patients that are unlikely to achieve the R0 resection due to age, health status
or extent of the disease, and reduce their morbidity even though no significant benefit in
terms of OS has been found to date. In fact, the ‘Ovarian Cancer Action’ meeting held in
2015 recommended the integration of tools to predict the surgical outcome as one of the
seven priorities that will improve outcomes for women with advanced OC (Bowtell et al.
2015).
1.1.1.6 Prediction of surgical outcome in women with OC
1.1.1.6.1 Computed tomography Computed Tomography (CT) is the most common
imagingmodality for pre-operative assessment of OC (Ibeanu and Bristow 2010; Nick et al.
2015). e definition of optimal cytoreduction as <1 cm of residual disease is only used
in recent studies aimed at predicting surgical outcome. By using the presence of diﬀuse
peritoneal thickening and large volumes of ascites out of a total of 17 parameters, Dowdy
et al. 2004 could predict the suboptimal cytoreduction outcome with a positive predictive
value (PPV) of 0.68 and sensitivity of 0.52. Similarly, Bristow et al. 2000 devised a predictive
model using 13 radiographic criteria and GOG performance status that could predict
suboptimal cytoreduction with an accuracy of 0.93; however, this model did not reach
the same level of accuracy in an independent study (Axtell et al. 2007). Two subsequent
multicentre studies conducted in the UK reported conflicting results. Using CT pre-
surgically, Borley et al. 2015 discovered that presence of the disease at certain sites (lung
metastasis, pleural eﬀusion, deposits on large-bowel mesentery and infrarenal para-aortic
nodes) was associated with suboptimal cytoreduction. In contrast, Mackintosh et al. 2014
concluded that CT could not reliably predict the surgical outcome in multicentre studies,
possibly due to variability in radiologists’ skills in addition to diﬀerences in institutional
policies and surgical skills.
1.1.1.6.2 CA-125 Circulatory protein CA-125 has been extensively tested for its ability
to predict surgical outcome. However, these studies have generated conflicting results
on (1) whether CA-125 is a predictive marker of surgical outcome, and (2) identifying
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a reliable cut-oﬀ value for prediction (Arits et al. 2008; Barlow et al. 2006; Gemer et al.
2005; Memarzadeh et al. 2003; Rossi et al. 2004; Vorgias et al. 2009). ese studies have
defined optimal cytoreduction as <1 cm residual disease. Because of the recent advances
and positive attitudes towards aggressive surgical procedures, optimal cytoreduction (<1
cm) was achieved in roughly 85% (24/28) of the patients with CA-125 levels exceeding 5000
U/ml, ten-times higher than the proposed cut-oﬀ of 500 U/ml (Chi et al. 2009). us, CA-
125 levels seem to reflect the disease burden and need for aggressive surgery instead of
predicting the surgical outcome (Ibeanu and Bristow 2010; Nick et al. 2015).
1.1.1.6.3 HE4 Circulatory protein HE4 used in the ROMA algorithm has been found
to be superior to CA-125 in predicting surgical outcome from the primary (Angioli et al.
2013), N = 57, Shen and Li 2016, N = 83; Yang et al. 2013, N = 260; Tang et al. 2015; N = 90)
as well as secondary surgery since the first relapse (Braicu et al. 2014, N = 73). Interestingly,
the presence of ascites (Braicu et al. 2014) or the volume of ascites (>500 ml; Angioli et
al. 2013) appears to improve the predictive power of HE4. us, HE4 has the potential
to be a useful biomarker to predict surgical outcome, and should be tested vigorously in
multicentre randomised studies.
1.1.1.6.4 Laparoscopy A series of studies conducted by Fagotti and colleagues have
reported as a viable tool to predict surgical outcome with an accuracy of 0.773 - 1 (Fagotti
et al. 2005, 2006, 2008, 2014). Laparoscopy is currently being investigated in the prospective
randomised control SCORPION trial (NCT01461850 2013).
1.1.1.6.5 The Anderson Algorithm Researchers at the MD Anderson Cancer centre have
proposed an algorithmic approach (e Anderson Algorithm) to manage patients with
advanced OC as a part of the Cancer Moon Shot Program. is prospective trial consists
of laparoscopy for pre-operative assessment of the disease, consensus guidelines on the
choice of standard therapy versus NACT, involvement of multidisciplinary surgical teams
to perform aggressive surgeries and the opinion of two surgeons, with the option of
consultation with a third surgeon if required, to increase rates of the R0 resection and
anticipated subsequent increase in progression-free survival (PFS) and OS (Nick et al.
2015). In a recent review, the author reported the rate of achieving R0 resection increased
from 20% to 84% since adoption of the algorithm (Nick et al. 2015). While promising, an
agreement on the likely surgical outcome with two to three surgeons may be diﬃcult to
achieve in smaller centres, and a dedicated publication on this approach outside of a review
paper, awaits.
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1.1.1.6.6 Gene expression of the tissues e use of gene signatures to predict surgical
outcome has been limited. Bonome et al. 2008 reported a lack of gene signatures that
could cluster high-grade OC samples according to the surgical outcome (N = 185). In
contrast, Berchuck et al. 2004 reported the classification accuracy of ~0.75 based on a 32-
gene signature, suggesting that optimally and suboptimally cytoreduced tumours could be
genetically diﬀerent. Similarly, a study validating performance of gene signatures in two
publicly available datasets estimated the accuracy of prediction to be 0.56 - 0.73 (Abdallah
et al. 2015). Finally, by analysing thee Cancer Genome Atlas (TCGA) dataset, Tucker et
al. 2014 found FABP4 andADH1B to be diﬀerentially expressed in optimally (R0 resection)
versus suboptimally (>0mm) cytoreduced samples, and a PPVof 0.86was reported by using
the 75th percentile (top 25%) in FABP4 expression as the cut-oﬀ.
1.1.1.6.7 Machine learning/artificial intelligence As a novel approach, Enshaei, Robson,
and Edmondson 2015 applied a machine learning algorithm known as artificial neural
networks to predict the surgical outcome based on clinical data including age, stage, grade,
histological type, and pre-operative CA-125 levels. e accuracy of the model was 0.77 in
this single centre study, which is comparable to the accuracy prediction of CA-125 alone.
Since the value of CA-125 in predicting surgical outcome is controversial, the significance
of this model remains unclear.
1.1.1.6.8 Lymphocyte to monocyte ratio Eo et al. 2016 reported pre-operative ratio of
lymphocyte to monocyte higher than as being 3.75 as being predictive of suboptimal
cytoreduction (N = 154). However, the area under the receiver operator characteristic
curve was found to be 0.593, which is marginally higher than the result obtained by chance,
indicating that this approach is not suitable for reliable prediction.
1.1.1.7 Recurrence
Over 80% of the patients with advanced OC (Stage III or IV) are likely to experience
disease recurrence (Herzog and Pothuri 2006). Recurrent disease is rarely cured, and the
treatment options are largely focused on palliative care and a balance of eﬃcacy versus
toxicity of additional treatments (Matulonis et al. 2016). e choice of therapy also
remains empirical aer considering factors such as complications from the primary therapy,
treatment history, observed and expected toxicity and performance status (Coleman,
Ramirez, and Gershenson 2017). Most patients will undergo chemotherapy using a variety
of agents instead of secondary surgery, which is only oﬀered in limited cases where the
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complete resection of the tumour mass is highly likely to be achieved such as the presence
of isolated tumours (Jayson et al. 2014).
Recurrence could be detected in several ways. e symptoms could resemble the initial
diagnosis or patients could experience new symptoms such as lymphoedema, shortness of
breath or bloating (Herzog and Pothuri 2006). e disease could remain asymptomatic
and be detected only by radiological or physical examinations. A rise in CA-125 levels aer
surgery, especially a doubling of the initial post-operative levels, is useful in monitoring
the disease (Diaz-Padilla et al. 2012; Pignata et al. 2011; Verheijen et al. 2012). Resuming
treatments purely based on CA-125 levels without any symptoms is not recommended.
Rustin et al. 2010 evaluated the eﬀect of resuming treatment immediately aer observing a
doubling in CA-125 levels without radiological evidence of recurrent disease versus delayed
treatment upon confirmation of recurrence. As expected, women treated purely based
on a doubling in CA-125 levels received chemotherapy roughly 5 months earlier than
the ‘delayed’ group. However, no overall improvement in survival was observed, and the
women receiving chemotherapy earlier had adverse eﬀects on the quality of life (Rustin
et al. 2010).
1.1.1.8 Drug resistance
OC is initially sensitive to chemotherapy. Approximately 70% of patients with OC will
respond to the carboplatin/paclitaxel first-line chemotherapy; however, most will develop
resistance to the therapywithin first two years of the treatment, resulting in a 5-year survival
rate of ~25% for patients with advanced OC (Agarwal and Kaye 2003; Hennessy, Coleman,
and Markman 2009; Romero and Bast 2012). Recurrent OC is classified into 3 categories:
platinum-refractory, -resistant or -sensitive, depending on the progression-free interval
since the last chemotherapy.
Progression of the disease while receiving the last cycle of chemotherapy or within 4
weeks of the last platinum dose classifies a tumour as platinum-refractory (Romero and
Bast 2012). ese tumours are diﬃcult to treat as they are already resistant to almost all
available agents. e choice of treatment depends on the womans’ wishes and comorbidity
(Coleman, Ramirez, and Gershenson 2017).
Recurrencewithin the first 6months since the last platinum therapy is termed platinum-
resistant OC. A response rate of 10-30% using multiple agents has been observed (Mould
2012; Romero and Bast 2012). Considering the response to a platinum-based agent is no
better than other agents (Coleman, Ramirez, and Gershenson 2017), current recommen-
dation for treating platinum-resistant OC is nonplatin agents, such as the anti-angiogenic
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bevacizumabwithweekly paclitaxel (Pujade-Lauraine et al. 2014), pegylated liposomal dox-
orubicin or topotecan (Poveda et al. 2015), until such a time as the disease is stable, or when
the toxicity outweighs the benefits (Coleman, Ramirez, and Gershenson 2017; Matulonis
et al. 2016).
Patients with platinum-sensitive OC, where the recurrence is observed aer 6-12
months since the last platinum treatment, are good candidates for chemotherapy containing
platinum alone or in combinations with other drugs (Matulonis et al. 2016; Mould 2012;
Romero and Bast 2012). A response rate of up to 50% is observed when treating with
the carboplatin/paclitaxel combination (Parmar et al. 2003; Pujade-Lauraine et al. 2010).
Currently, only a combination of gemcitabine and carboplatin is approved in the US for
treatment of relapsed platinum-sensitive OC (Coleman, Ramirez, and Gershenson 2017;
Pfisterer et al. 2006).
Recently, PARP inhibitors (PARPi), utilising the concept of synthetic lethality (subsec-
tion 1.1.2.2), have been found promising for the treatment of recurrent OC with defects
in the HR pathway. e PARPi Olaparib was approved by the FDA in 2014 for use in pa-
tients carryingBRCA1/2mutations who developed recurrent disease (Kroeger andDrapkin
2017). Lynparza (Olaparib) was approved on the Pharmaceutical Benefits Scheme in Aus-
tralia in February, 2017 (Sibthorpe 2017). In December 2016, a second PARPi called Ruca-
parib gained FDA approval for the treatment of tumours harbouring BRCA1/2 mutations
that have been treated with two or more chemotherapies (FDA 2016). A third PARPi called
Niraparib also gained FDA approval in March 2017 as a maintenance therapy for EOC that
has shown complete or partial response to platinum-based therapy (FDA 2017). Unlike
Olaparib and Rucaparib, mutations in BRCA1/2 genes is not a pre-requisite for Niraparib.
1.1.2 Biology of high-grade serous ovarian carcinoma
High-grade serous ovarian carcinoma (HGSOC) is the most common (~75%) and aggres-
sive form of EOC with little improvement in the survival of aﬀected women for decades
(Bell et al. 2011; Bowtell et al. 2015; Kroeger and Drapkin 2017; Vaughan et al. 2011). Ur-
gent measures are required to tackle this disease; therefore, the rest of the thesis will focus
on HGSOC.
1.1.2.1 Histological subtypes
Approximately 90% of OCwere thought to originate from the surface epithelium or surface
epithelial inclusion cysts of the ovary (Chen et al. 2003; Feeley andWells 2001; Romero and
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Figure 1.2: Ovarian cancer subtypes and their mutation spectrum
‘HR’: deficiency in homologous recombination due to aberrations in CHK2, BARD1, BRIP1, PALB2,
RAD50, RAD51C, ATM, ATR, EMSY. ‘MMR’: mismatch repair (Adapted from Banerjee and Kaye 2013).
Bast 2012); however, new evidence support the fallopian origin of EOC (discussed shortly).
EOC is classified into fourmajor subtypes— serous, endometrioid, mucinous and clear cell
— based on their similarity to the epithelium of the fallopian tube, endometrium, mucin-
secreting endocervical glands and glycogen-filled vaginal rests, respectively (Figure 1.2)
(Chen et al. 2003; Lalwani et al. 2011).
Additionally, OC can also be classified based on the degree of diﬀerentiation (tumour
grade). Type I are indolent low-grade tumours that tend to be diagnosed at early stages (I
or II). Low-grade serous, low-grade endometrioid, clear cell and mucinous carcinomas are
Type I tumours (Lalwani et al. 2011). In contrast, Type II tend to be high-grade, highly
aggressive and usually diagnosed at an advanced stage. Type II tumours include HGSOC,
high-grade endometrioid, malignant mixed mesodermal tumours and undiﬀerentiated
carcinomas (Lalwani et al. 2011). Type I tumours are already resistant to conventional
chemotheraphy whereas Type II tumours tend to respond well initially. In addition, Type
I tumours tend to have frequent mutations in BRAF, KRAS, PTEN, PI3KCA and ARID1A,
which are found to be mutated in <1% of Type II tumours (Figure 1.2) (Jones et al. 2010;
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Wiegand et al. 2010). Notably, TP53, which is almost universally mutated in HGSOC, is
rarely mutated in Type I tumours (Romero and Bast 2012). According to the ‘dualistic
model’, Type I and II tumours represent two main pathways of carcinogenesis where Type
I tumours are thought to arise from borderline tumours and in a stepwise manner while
Type II tumours develop de novo (Hennessy, Coleman, and Markman 2009; Kurman and
Shih 2011; Shih and Kurman 2004). Recent molecular and histological evidence suggest
that a subset of EOC may undergo Type I to Type II conversion upon acquiring mutations
in TP53 or PI3KCA (Wu et al. 2013a).
ere is now a substantial body of evidence supporting the idea that HGSOC, in
fact, originates from the fallopian tube secretory epithelial cells. Briefly, analyses on
women facing a genetic predisposition to OC (BRCA1/2 mutations) discovered serous
tubal intraepithelial carcinomas (STIC) in the fallopian tube that closely resemble HGSOC
present at the ovary (Piek et al. 2001, 2003). Moreover, STICs were found in the fallopian
tube in 50-60% of cases of sporadic OC, and the carcinomas were almost always detected
in the fimbria (Colgan et al. 2001; Finch et al. 2006; Kindelberger et al. 2007; Medeiros
et al. 2006). Subsequently, STICs were found to harbour identical TP53 mutations to
the concomitant HGSOC, suggesting that STICs were a precursor to HGSOC (Lee et al.
2007). Powered by the tools that genetically modify key genes only in the epithelial cells of
the fallopian tube, genetically engineered mouse models provided mechanistic evidence
supporting the pathogenesis of HGSOC: transformation of the fallopian tube epithelia,
presence of STICs and their dissemination to the ovary in 56% to 100% of the mice,
depending on the model (Perets et al. 2013; Sherman-Baust et al. 2014).
1.1.2.2 Genomic landscape of HGSOC
Studies conducted by Australian Ovarian Cancer Study Group (Tothill et al. 2008) and
TCGA (Bell et al. 2011) have been instrumental in elucidating the genomic landscape
of HGSOC. e TCGA study demonstrated four subtypes of HGSOC: immunoreactive,
diﬀerentiated, proliferative andmesenchymal (Bell et al. 2011). eTP53 genewas found to
be mutated in almost all cases. Other significantly mutated genes include BRCA1/2 (~22%
cases), CSMD3, NF1, CDK12, FAT3, GABRA6 and RB1. While HGSOC was not found
to harbour a large number of mutations, the HGSOC genome showed extensive somatic
copy number alterations, probably due to mutations in TP53 and BRCA1/2 (Bell et al.
2011). Pathway analyses identified RB1, PI3K/Ras, NOTCH,HR and FOXM1 as prominent
pathways operating in the disease.
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e HR pathway was found to be defective in ~50% of the TCGA cases (Bell et al.
2011). BRCA1/2 genes were mutated in roughly 22% (including both germline and somatic
cases), and a further 11% of the cases had inactivation in one or both genes due to DNA
hypermethylation. Besides BRCA1/2, other genes in the HR pathway such as EMSY, PTEN,
RAD51C, ATM and ATR were found to be deregulated in HGSOC. Synthetic lethality by
inhibiting poly ADP ribose polymerase (PARP), a key protein in the HR pathway, remains
an appealing strategy in cases where HR is defective (subsection 1.1.1.8) (Bell et al. 2011).
Rapid advances like these attest to the value of large-scale genomic studies in enhancing
cancer treatment.
1.1.2.3 Role of TP53 in HGSOC
TP53 is the most mutated gene in human cancers (Muller and Vousden 2013; Oren and
Rotter 2010; Strano et al. 2007b). Roughly 50% of all cancers have loss ormutations inTP53
(Muller, Vousden, and Norman 2011). In its simplest manner, p53 is activated upon a wide
range of stressors, such as DNA damage, nutrient deprivation, telomere erosion, hypoxia,
ribosomal stress and/or oncogene activation, which then executes appropriate responses
such as DNA repair, apoptosis, cell cycle arrest, cell survival, DNA repair and senescence
to resolve the assault (Bieging and Attardi 2012; Vousden and Lane 2007; Vousden and
Prives 2009). e overall action of functional p53 is preservation of integrity of the genome,
explaining its moniker as the ‘guardian of the genome’ (Lane 1992).
e majority of the TP53 mutations lie in the DNA binding domain, suggesting that
deregulation of transcriptional activities is pivotal to the function of mutant-p53 (Strano
et al. 2007a; Weisz, Oren, and Rotter 2007). e mutations in the amino acid residues that
directly contact DNA (e.g. R273 and R248) are classified as the ‘contact’ mutations whereas
those aﬀecting the protein structure (e.g. R175 and H179) are known as ‘conformational’
mutations. Several ‘hotspot’ residues R273, R248Q, R175 and G245 tend to be altered in
malignancies at a higher frequency than other amino acids (Walerych, Lisek, and Del Sal
2015).
Mutations in most tumour suppressors result in a loss of protein expression due to
creation of early nonsense mutations and/or frame-shis. Loss of wild-type (wt) tumour
suppressor functions can ultimately culminate in cancer (Bieging and Attardi 2012; Muller,
Vousden, and Norman 2011; Walerych, Lisek, and Del Sal 2015). In contrast, missense
mutations are the most common type of mutations seen in TP53, which oen result in
higher expression levels of the mutant-p53 than its wt counterpart (Oren and Rotter 2010).
p53 is a tetramer consisting of a dimer of dimers (Weinberg et al. 2004). Heterodimer of wt-
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p53/mutant-p53 was found to have impaired ability of binding to p53-response elements
onDNA, inhibiting the functions of wt-p53 due to a dominant-negative eﬀect (Goh, Coﬃll,
and Lane 2010). Mutant-p53 retains the ability to bind to the DNA, but the binding sites of
mutant-p53were found to be significantly diﬀerent than the p53-response element (ukral
et al. 1995). Furthermore, a number of conformational and contact mutant-p53 were also
shown to bind to p63 and p73, proteins that are additional members of the p53 family.
Similar to inactivation of wt-p53 by mutant-p53 by dominant-negative eﬀects, mutant-
p53 associated with p63 was found to be present at sites on DNA that are not normally
recognised by p63 (Martynova et al. 2012).
Moreover, mutant-p53was found to interact with transcription factors and proteins that
do not influence transcription directly, enhancing or preventing their activities, depending
on the mutant-p53 and interacting partners (Muller and Vousden 2013). ese pieces of
evidence led investigators to propose that eﬀects of mutations in p53 extend beyond a mere
loss of wild-type p53 activities but play an active role in promoting carcinogenesis, and some
mutations in p53 such as R273H andR175Hmay oﬀer novel properties that greatly enhance
carcinogenesis, known as the gain-of-function (GOF) hypothesis (Muller and Vousden
2013; Oren and Rotter 2010; Strano et al. 2007a). Consistent with this hypothesis, mouse
models harbouringmutant-p53were found to havemore aggressive andmetastatic tumours
than p53-wild-type or p53-null mice (Doyle et al. 2010; Lang et al. 2004; Morton et al. 2010;
Olive et al. 2004). Furthermore, patients with Li–Fraumeni syndrome harbouring germline
TP53missense mutations developed tumours 9-15 years earlier than those with mutations
that resulted in a loss of p53 expression (Bougeard et al. 2008; Zerdoumi et al. 2013).
e TP53 gene is mutated in nearly 100% of cases of HGSOC (Bell et al. 2011).
Mutations in TP53 seem to be a necessary early event in the pathogenesis of HGSOC;
however, it is not suﬃcient for development of this neoplasia (Bowtell 2010). Patients with
Li-Fraumeni syndrome harbouring germline TP53 mutations have higher frequencies of
the “p53 signature”§ in the distal fallopian tube, but they are not at an increased risk of
developing HGSOC (Xian et al. 2010). In contrast, the frequency of the p53 signature
is similar in women with or without BRCA1/2 germline mutations (Lee et al. 2007).
Furthermore, the p53 signature in patients with germline BRCA1/2 were found to have a
functional second copy of the allele, reiterating that the p53 signature alone is benign, even
§e p53 signature is a benign lesion in non-ciliated epithelium of the fallopian tube characterised by
overexpression of the nuclear immunostaining of p53, partly due to mutations, in at least 12 consecutive cells.
Despite the increased p53 staining, the cells are not highly proliferative (increased Ki67 staining in <10% of
p53+ cells; Lee et al. 2007). e p53 signature is not associated with elevated risk of developing OC (Crum
et al. 2013).
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in this high-risk population (Norquist et al. 2010). STICs from these patients, on the other
hand, not only acquired mutations in TP53 but also inactivated the second functional copy
of BRCA1/2 (Norquist et al. 2010). In short, precursor STICs developed on the mutant-p53
background only aer a complete loss of BRCA1/2 (Bowtell 2010).
1.1.2.4 Mutant-p53 as a therapeutic target
Given its central role in the biology of cancer, it is not surprising that mutant-p53 is an
appealing therapeutic target (Table 1.1). Sincemutant-p53 withmissensemutations retains
its full-length polypeptide that is highly expressed in a cell, reactivating wt-p53 activities
from mutant-p53 is an intensive area of research. e following discussion is restricted to
an agent known as APR-246/PRIMA-1MET because it is currently undergoing FDA Ib/II
trials for platinum-sensitive recurrent HGSOC with mutated p53 to test its eﬃcacy with
carboplatin (NCT02098343 2014).
A small molecule known as PRIMA-1 (p53 reactivation and induction of massive
apoptosis 1) has been found to bind to mutant-p53 and activate wt-p53 activities. Briefly,
p53-null Saos-2 cells were transfected with p53-R273H expression vector or control, and a
library of small molecules was screened to identify compounds that inhibited cell growth
(Bykov et al. 2002). Subsequently, a methylated form of the drug known as APR-246
(PRIMA-1MET) was found to be much more potent than PRIMA-1 (Bykov et al. 2005b).
APR-246 induced expression of canonical p53 target genes such as Cyclin Dependent
Kinase Inhibitor 1A (CDKN1A)/p21 (Liu et al. 2015; Zandi et al. 2011), Growth Arrest
And DNA Damage Inducible Alpha (GADD45A) (Liu et al. 2015), BCL2 Associated X
(BAX) (Bykov et al. 2005b; Izetti et al. 2014; Zandi et al. 2011), BCL2 Binding Component
3 (BBC3)/PUMA (Bykov et al. 2005b; Liu et al. 2015) and Mouse double minute 2
homologue (MDM2) (Izetti et al. 2014; Zandi et al. 2011) in a range of cancer cell lines
harbouring mutant-p53, their xenogras, and, in selected cases, patient-derived xenogras
transplanted into immunoincompetent mice.
Mechanistic insights as to why APR-246 is eﬀective in diverse cell lines harbouring a
wide range of missense mutations was provided by a seminal study by Lambert et al. 2009.
APR-246 dissolved in phosphate buﬀered saline (PBS) in vitro spontaneously gave rise to
its active agent methylene quinuclidinone (MQ); however, this process was significantly
accelerated in vivo, possibly due to reactions with other molecules carrying thiol groups.
MQwas found to be aMichael acceptor which reacts with nucleophiles such as thiol groups
of the cysteine residues. Usingmass spectrometry, up to 10MQmolecules were found to be
attached to the mutant-p53. Although it remains unclear precisely where MQ binds to the
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Mechanism References
Degradation ofmutant-p53
HDAC inhibitors SAHA and NaB Destablisation of mutant-p53 fol-
lowed by proteasome degradation
Li, Marchenko, and Moll
2011; Yan et al. 2013
Dietary glucose restriction autophagy-mediated degradation Rodriguez et al. 2012
Inhibiting interactions with other proteins/pathways
RETRA Inhibiting p73/mutant-p53 inter-
actions, liberating p73 for tumour
suppression
Kravchenko et al. 2008
Statins Inhibiting mutant-p53/cholesterol-
meadited change in tumour architec-
ture
Freed-Pastor et al. 2012;
Singh and Singh 2013
Integrin inhibitors Interfering with signalling pathways
between RTK and integrin recycling
Desgrosellier and
Cheresh 2010; Muller
and Vousden 2014
Conversion to wild-type p53
PRIMA-1/PRIMA-1MET/APR-246 Michael acceptor. Stablisation of un-
folded mutant-p53
Bykov et al. 2002, 2005b
NSC319726 Restoring wt-p53 folding from p53-
R175H by increasing bioavailability of
zinc ion required for correct folding.
Yu et al. 2012
STIMA-1 Stablisation of unfolded mutant-p53.
similar to CP-31398
Zache et al. 2008b
SCH529074 Conversion to wild-type p53 Demma et al. 2010
CP-31398 Stablisation of unfolded mutant-p53 Foster et al. 1999
MIRA-1 Conversion to wild-type p53 Bykov et al. 2005c
PK7088 Stablisation of unfolded p53-Y220C Liu et al. 2013b
PhiKan083 Stablisation of unfolded p53-Y220C Boeckler et al. 2008
Table 1.1: Strategies targeting mutant-p53 for cancer therapies
Data for this table was supplied by Muller and Vousden 2014.
mutant-p53, the p53 core domain contains 10 cysteine residues, of which Cys182, Cys229,
Cys242, and Cys277 are surface accessible and could be the primary targets. Interestingly,
MQ preferred the unfolded protein state at 37 C in p53-null H1299 cells expressing
p53-R175H compared to the correctly folded structure at 32 C, which also explained its
specificity towards mutant-p53. us, by modifying mutant-p53, APR-246 is thought to
restore the original wt-p53 structure. Since the p53 protein family also comprises p63
and p73 (Khoury and Bourdon 2010), it is theoretically possible that APR-246 also aﬀects
functions of these proteins. Unlike p53, p63 and p73 are rarely mutated in cancers (Irwin
and Kaelin 2001; Melino, De Laurenzi, and Vousden 2002). However, certain mis-sence
mutations in wt-p63 are common in the developmental syndrome ectrodactyly ectodermal
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dysplasia-cle (EEC), in which APR-246 treatment partially restored expression of p63
target genes as well as rescued keratinocyte diﬀerentiation (Shen et al. 2013).
Additionally, APR-246 is found to be synergistic with anti-cancer agents including
cisplatin (Bykov et al. 2005a; Fransson et al. 2016; Izetti et al. 2014; Liu et al. 2015;
Mohell et al. 2015), carboplatin (Fransson et al. 2016), doxorubicin (Fransson et al. 2016;
Mohell et al. 2015; Saha et al. 2013), 5-fluorouracil (Bykov et al. 2005a; Liu et al. 2015),
adriamycin (Bykov et al. 2005a), camptothecin (Bykov et al. 2005a), epirubicin (Liu et al.
2015), gemcitabine (Izetti et al. 2014; Mohell et al. 2015), erlotinib (Izetti et al. 2014) and
olaparib (Deben et al. 2016) inmultiple cancers. Many of these drugs elevate the expression
ofmutant-p53, potentiating even greaterwt-p53 activities upondual drug treatment (Bykov
et al. 2016). Furthermore, MQ could also induce oxidative stress by depleting glutathione
(GSH) and inhibiting thioredoxin reductase 1 (Bykov et al. 2016; Lambert et al. 2009).
Cisplatin, carboplatin, doxorubicin, epirubicin and 5-fluorouracil generate extremely high
levels of reactive oxidative species (ROS) (Conklin 2004a; Gorrini, Harris, and Mak 2013),
indicating that oxidative stress could be a significant factor contributing to the observed
synergy.
As mentioned above, APR-246 is currently undergoing clinical trials for treatment
for OC (NCT02098343 2014). To the knowledge of the candidate, there are only three
published studies investigating eﬀects of APR-246 in OC. e first study conducted by
Mohell et al. 2015 showed that APR-246 was synergistic with cisplatin, carboplatin and
doxorubicin, and restored sensitivities of these drugs in the resistant cell lines harbouring
mutant-p53. With the exception of OVCAR-3, cell lines used in this study (IGROV-1
and 3 cell lines derived from A2780) are not representative of OC, ranking as ‘unlikely’
HGSOC or ‘hyper-mutated’ according to an analysis by Domcke et al. 2013. Additionally,
APR-246 was found to be synergistic with cisplatin in primary OC cells derived from five
patients; however, one patient carried missense mutation Y220C, one harboured wt-p53
while the majority (3/5) had frameshi or nonsense mutations that might be expected
to result in low to absent levels of mutant p53 protein. Synergy between APR-246 and
cisplatin in the absence of missense mutations suggests additional mechanisms of action
by APR-246. e eﬀect of APR-246 was found to be at least additive with cisplatin in
mice bearing xenogras of cisplatin-resistant A2780-CP20 cells, derived from A2780 cells
by gradually increasing doses of cisplatin in vitro, carrying the TP53 mutation V172F.
Immunohistological analysis showed activation of the eﬀector caspase-3 in mice treated
with the dual drug combination, but typical wt-p53-response genes such as CDKN1A were
not examined (Mohell et al. 2015). An extension of this work on cells obtained from
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ascites of 10 platinum-resistantOCpatients, of which 8 hadHGSOC and 7 carriedmissense
mutations in p53, reported strong synergy between APR-246 and cisplatin in the patients
harbouring missense TP53mutations and at least an additive eﬀect in patients harbouring
wt-p53 or nonsensemutations (Fransson et al. 2016). An induction in wt-p53-like activities
upon APR-246 was assumed, but not tested (Fransson et al. 2016). It is important to note
that a number of authors of these two studies were employed by Aprea AB, the company
undertaking clinical trials for APR-246, including the senior author KlasG.Wimanwho is a
co-founder ofAprea. Finally, an independent study showed thatAPR-246 induces apoptosis
by accumulating ROS, irrespective of the p53 status of nine EOC cell lines (Yoshikawa et
al. 2016). e authors tested this by using the ROS scavenger N-acetyl cysteine (NAC) to
rescue cells from APR-246 treatment. Again, the typical downstream gene targets of p53
were not examined.
e exact mechanisms of how APR-246 operates in OC remain unclear despite its
eﬃcacy in restoring drug sensitivities in platinum-resistant OC cell lines and a limited
number of primary cells. In particular, it has not been convincingly shown that APR-
246 induces expression of canonical p53 genes in OC from mutant-p53, which was the
predominant rationale for its current clinical trial titled ‘p53 Suppressor Activation in
Recurrent High Grade Serous Ovarian Cancer’ (NCT02098343 2014). is thesis tests this,
and whether wt-p53 is observed in mutant-p53 cell lines upon APR-246 treatment. APR-
246 will also be used to identify the eﬀect of mutant-p53 on non-coding RNAs (subsection
1.2.3).
1.2 Non-coding RNAs— a revolution
e haploid human genome is approximately 3 billion nucleotides in length. However,
the information to code for all proteins represents merely 2% of the DNA; the rest was
previously considered as ‘junk’. Intriguingly, the number of protein coding genes do not
correlate to organismal complexity, whereas the proportion of the ‘junk’ DNA increases
with complexity, while being tissue-specific in its expression (Barry 2014; Derrien et al.
2012). One of the earliest study systematically investigating the mouse transcriptome
(the FANTOM Consortium) discovered that roughly 47% (15,815/33,409) of the cloned
‘transcriptional units’ did not code for proteins (Okazaki et al. 2002). Recently, the
ENCODE project revealed that roughly 75% of the genome was transcribed in at least one
cell type (ENCODE 2012).
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Figure 1.3: Origin of non-coding RNAs (ncRNAs) frommultiple modes of transcription
(A) Transcription in sense, anti-sense or both directions (bidirectional). (B) Diversification in tran-
scripts due to the use of alternate promoters, splicing and termination. (C) ncRNAs, such as microR-
NAs, originating from introns. (D) inter-genic regions as source of ncRNAs known as long intervening
RNAs (lincRNAs). (adapted fromMercer and Mattick 2013)
With the advent of recent technologies such as tilingmicroarrays¶ and RNA sequencing
(RNA-seq), it is clear that most of the genome is actively transcribed. As shown in Figure
1.3, transcription could occur in sense and anti-sense directions, or be bidirectional. In fact,
more than half of the human genes are transcribed in an anti-sense direction (Katayama
et al. 2005). e use of alternate promoters, splicing and termination further diversify the
transcripts. Eukaryote protein coding sequences are interrupted by non-coding regions (in-
trons) that are transcribed but excised during maturation of the mRNAs. Surprisingly, the
transcription of introns was found to be tissue-specific and responsive to physical stimuli,
and, consequently, a significant proportion of intronic non-coding RNAs (ncRNAs) may
have some function (Louro, Smirnova, and Verjovski-Almeida 2009). Roughly a quarter
of small ncRNAs known as microRNAs are found to be of intronic origin (Kim and Kim
2007; Rodriguez et al. 2004). e regions between protein-coding genes (intergenic re-
gions) are also transcribed into a plethora of ncRNAs collectively known as long interven-
¶Tiling microarray is a modification of the standard microarray platform employed for quantifying gene
expression. Instead of using the probes covering the entire genome, probes with an overlap of one nucleotide
are utilised for the entire locus of interest, exposing transcription from the locus.
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Category Symbol Functions References
3’ UTR-derived RNAs uaRNAs cis and trans regulation of
protein expression or lncR-
NAs
Mercer et al. 2011
Antisense termini associ-
ated short RNAs
aTASRs Unknown Kapranov et al. 2007,
2010
Human Y RNA hY RNA DNA replication Christov et al. 2006;
Zhang et al. 2011a
microRNAs miRNAs Post-transcriptional gene
silencing
Esteller 2011; Lin and
Gregory 2015
PIWI-interacting RNAs piRNAs Suppression of transpos-
able elements
Lin 2007; Stefani and
Slack 2008
Promoter-associated short
RNAs
PASRs Epigenetic regulation of
gene expression
Fejes-Toth et al. 2009;
Han, Kim, and Morris
2007
Ribosomal 5S and 5.8S
RNAs
rRNAs Protein synthesis Stults et al. 2008
Small interfering RNAs siRNA Post-transcriptional gene
silencing
Kawaji and
Hayashizaki 2008
Small nuclear RNAs snRNAs RNA splicing Valadkhan 2005
Small nucleolar RNAs snoRNAs Maturation of rRNA Williams and Farzaneh
2012
Termini-associated short
RNAs
TASRs Unknown Kapranov et al. 2007,
2010
Tiny transcription initia-
tion RNAs
tiRNAs Epigenetic regulation of
gene expression
Taft et al. 2009, 2010
Transcription start site an-
tisense RNAs
TSSa-RNAs Transcription initiation Seila et al. 2008
Transfer RNAs tRNAs Protein synthesis Phizicky and Hopper
2010
Table 1.2: Functions and classification of small non-coding RNAs
ing RNAs (lincRNAs), many of which bind to chromatin-modifying complexes and aﬀect
gene expression (Khalil et al. 2009; Ulitsky and Bartel 2013). Furthermore, genomic regions
such as centromeres of chromosomes, which were thought to be transcriptionally inactive
due to the presence of the silencing histonemark trimethyl-histone-3-lysine-9 (H3K9me3),
were not only found to transcribe RNAs but this transcription was found to be required for
proper chromosome formation during diﬀerentiation (Casanova et al. 2013; Probst et al.
2010). Essential gene regulatory units on DNA such as promoters and enhancers are also
found to be transcriptionally active (Mercer and Mattick 2013).
21
1.2. Non-coding RNAs — a revolution
ncRNAs are broadly grouped into two categories based on their length: small (<200
nucleotides) and long non-coding RNAs (lncRNAs) (>200 nucleotides). is classification
is largely based on the RNA purification protocols that use diﬀerent buﬀers to enrich small
or long RNAs (Mattick and Rinn 2015; Mercer, Dinger, and Mattick 2009; Spizzo et al.
2012). According to a recent genomic analysis, the human genome houses roughly 21,000
protein coding genes and 58,000 lncRNAs (Iyer et al. 2015). Although investigating the role
of lncRNAs is a vigorous area of research, functions of only a small number of lncRNAs are
currently known (see subsection 1.2.2) and, as a result, a classification scheme based on
functions of lncRNAs is currently missing (Mattick and Rinn 2015). In contrast, small
ncRNAs are marginally better understood (Table 1.2). Roles of small RNAs known as
microRNAs, PIWI-interacting RNAs (piRNAs) and small nucleolar RNAs (snoRNAs) have
been well-established in post-transcriptional gene silencing, suppression of transposable
elements andmaturation of ribosomal RNA (rRNA), respectively (Table 1.2) (Esteller 2011;
Patil, Zhou, and Rana 2014; Stefani and Slack 2008; Williams and Farzaneh 2012). A
complete discussion on the roles of each of the diﬀerent types of small RNAs is out of
the scope of this thesis. Only microRNAs and lncRNAs are discussed in detail because
experiments described in this thesis tests their utility to predict the surgical outcome of
HGSOC patients, roles in cisplatin resistance and the eﬀect of mutant-p53 on lncRNAs (see
section 1.3).
1.2.1 microRNAs
1.2.1.1 Biogenesis andmechanisms
microRNAs are a group of small ncRNA with an average length of ~22 nucleotides that
play a pivotal role in post-transcriptional gene suppression (Lin and Gregory 2015). Most
microRNAs are transcribed from RNA polymerase II (Pol II) from dedicated gene loci
whereas ~25% of microRNAs originate from introns (Kim and Kim 2007; Lee et al.
2004; Rodriguez et al. 2004). e newly transcribed RNA known as primary microRNA
(pri-miRNA) is processed by enzymes into the precursor microRNA (pre-miRNA) and,
subsequently, the mature form. Upon transcription, pri-miRNAs are capped, spliced and
polyadenylated. e secondary structure of the pri-miRNA, consisting of a hairpin stem
of 33 base pairs, a terminal loop and single-stranded regions upstream and downstream of
the hairpin, is critical for its recognition and processing by the Microprocessor complex
(Denli et al. 2004; Gregory et al. 2004; Han et al. 2004; Lee et al. 2003). e double-
stranded RNase III enzyme Drosha and its essential binding partner DiGeorge syndrome
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critical region 8 (DGCR8) are the core components of the Microprocessor complex. e
Microprocessor complex is capable of recognising the single-stranded regions of the pri-
miRNAaswell as their distance from the terminal loop. WithDGCR8 acting as a ‘molecular
ruler’, Drosha cleaves the hairpin structure ~11 nucleotides away from the single-stranded
junction, liberating the pre-miRNA of ~60-70 nucleotides (Han et al. 2004; Lee et al. 2003;
Winter et al. 2009). e pre-miRNA is exported to the cytoplasm by Exportin-5 and Ran-
GTP (Yi et al. 2003).
e exported pre-miRNA is further processed by the RNAse III enzyme Dicer, cutting
the pre-miRNA close to the terminal loop and resulting in a double-stranded RNA of
~22 nucleotides with overhangs of 2 nucleotides at each 3’ end (Lin and Gregory 2015).
Transactivation-responsive RNA-binding protein (TRBP) is associated with Dicer during
this process and bridgesDicer toArgonaute proteins (Ago1-4) to participate in the assembly
of microRNA-induced silencing complex (miRISC) (Chendrimada et al. 2005). One strand
of the duplex is retained by Ago proteins (the guide strand) while the other stand is typically
degraded (Lin and Gregory 2015). e guide strand bound to Ago protein binds to the 3’
untranslated region (UTR) of mRNAs. In a minority of cases where this pairing is 100%
complementary, the mRNA is degraded through Ago2, the only catalytically active Ago
protein in humans (Ipsaro and Joshua-Tor 2015). In other cases, nucleotides 2-7 from the
5’ end of a microRNA, known as the ‘seed sequence’, are found to be complementary to 3’
UTRofmRNAs, and the dominantmode of gene silencing is through suppression ofmRNA
translation or mRNA decay by deadenylation and decapping (Fabian and Sonenberg 2012;
Ha and Kim 2014; Jonas and Izaurralde 2015).
e human genome is estimated to encode more than 3,500 microRNAs (Londin et al.
2015), which collectively regulate more than half of all protein coding genes (Friedman
et al. 2009). us, it is not surprising that deregulation of microRNA expression is linked
to various human diseases including cancer (Hesse and Arenz 2014).
1.2.1.2 microRNAs in cancer
efirst evidence of the role of microRNAs in cancer was provided by Croce and colleagues
in 2002, who demonstrated that the miR-15/16 cluster of microRNAs were frequently
deleted or downregulated in chronic lymphocytic leukaemia (CLL) (Calin et al. 2002).
Subsequently, a ground breaking study in 2005 demonstrated that microRNA profiling
could classify human cancers (Lu et al. 2005). Later in the same year, the miR-17-92 cluster
ofmicroRNAswere found to co-operatewith c-myc in promoting humanB-cell lymphomas
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(He et al. 2005). In addition, microRNAs were found to be downregulated in cancers,
indicating their profound role in cancer biology. (Lu et al. 2005).
e mammalian genome contains two copies of Dicer (Winter et al. 2009). Loss of
Dicer is selected against in mouse cancer models and loss of heterozygosity is almost never
observed in human cancers, suggesting that Dicer works as a haploinsuﬃcient tumour
suppressor (Kumar et al. 2009). Interestingly, missense mutations in the RNase IIIB
domain of Dicer occur frequently in nonepithelial ovarian cancer (Heravi-Moussavi et al.
2012). e mutant Dicer was unable to cleave the 5’ end of pre-miRNAs, resulting in a
global loss of microRNAs produced from this end (‘5p’ microRNAs), but the maturation of
microRNAs from the 3’ end (‘3p’ microRNAs) was unaﬀected (Anglesio et al. 2013). is
bias towards the loss of ‘5p’ microRNAs could lead to reduced expression of the tumour
suppressor family of microRNAs let-7, all of which are derived from the 5’ end (Lin and
Gregory 2015). Moreover, loss of microRNAs could also be achieved by genomic deletion
or epigenetic mechanisms such as DNA methylation in promoters and loss of histone
acetylation (Lujambio and Lowe 2012). While microRNAs are generally downregulated
in cancers, oncogenic microRNAs or ‘oncomiRs’, such as miR-21, miR-155, miR-210, miR-
17-92 cluster and miR-221, are upregulated in cancer (Rupaimoole and Slack 2017).
Crucial proteins implicated in cancer biology are subjected to regulation bymicroRNAs.
For example, the tumour suppressor phosphatase and tensin homolog (PTEN) is targeted
by miR-21 (Meng et al. 2007; Zhang et al. 2012a), miR-214 (Fata et al. 2012; Penna, Orso,
and Taverna 2015), miR-17-92 cluster (Xiang and Wu 2010), miR-93 (Kawano et al. 2015)
and miR-221/222 (Zhang et al. 2011b). In primary neuroblastomas, TP53 remains wild-
type, but tends to be downregulated by miR-380-5p (Swarbrick et al. 2010). In fact, more
than 20microRNAs, includingmiR-504 (Hu et al. 2010a) andmiR-125b (Le et al. 2009), are
known to directly target p53 (Feng et al. 2011; Hermeking 2012). e oncogeneMYCN is
targeted by tumour suppressor microRNAs let-7 (Johnson et al. 2007; Sampson et al. 2007)
and miR-34a (Cole et al. 2008; Wei et al. 2008; Welch, Chen, and Stallings 2007). Finally,
miR-182 (Moskwa et al. 2011), miR-146a (Garcia et al. 2011; Shen et al. 2008), miR-15a
(Zhu et al. 2009), miR-16 (Zhu et al. 2009), miR-638 (Li et al. 2011) and miR-17 (Shen et al.
2008) negatively regulate BRCA1.
microRNAs are becoming an attractive therapeutic option because of their profound
role in cancer and their ability to influence levels of a large number of mRNAs (Friedman
et al. 2009). ere are two major types of approaches to the therapy: replenishing tumour
suppressive microRNAs, and silencing disease-associated overexpressed microRNAs or
oncomiRs (reviewed in Rupaimoole and Slack 2017). Several pre-clinical studies have
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demonstrated the eﬃcacy of restoring expression of the miR-34 family of microRNAs in
inhibiting tumour growth inmousemodels of lung (Kasinski and Slack 2012; Wiggins et al.
2010), pancreatic (Pramanik et al. 2011) and prostate cancers (Liu et al. 2011a). Currently,
the eﬀect of restoringmiR-34 expression in cancers by lipid nanoparticles is being evaluated
in a phase I clinical trial (NCT01829971). InhibitingmiR-122 by lockednucleic acids (LNA)
is also being tested in clinical trials for the potential treatment of hepatitis C viral infections
(Rupaimoole and Slack 2017).
1.2.1.3 microRNAs in OC
One of the earliest studies of EOC reported that ~15% and at least 36% of microRNAs
are downregulated by genomic deletions and epigenetic silencing, respectively (Zhang et
al. 2008). miR-15a, miR-34a and miR-34b were some of the downregulated microRNAs
in late versus early stages of EOC. In particular, the Dlk1-Gtl2 locus on chromosome 14
is commonly deleted in EOC, resulting in a loss of 8 microRNAs (miR-337, miR-376a,
miR-376b, miR-432, miR-368, miR-495, miR-377 and miR-410) (Zhang et al. 2008). A
total of 17 microRNAs were found to be diﬀerentially expressed between normal ovaries
and HGSOC samples in the TCGA-OV dataset (Miles et al. 2012). Amongst them, 8
microRNAs (miR-183-3p, miR-590-5p, miR-16, miR-15b-3p, miR-15b, miR-18a, miR-18b
and miR-96) were found to be upregulated while 9 microRNAs (miR-133a, miR-140-3p,
miR-145-3p, miR-143-5p, miR-34b-5p, miR-145, miR-139-5p, miR-34c-3p, and miR-34c-
5p) were downregulated (Miles et al. 2012). Furthermore, let-7b showed hemizygous and
homozygous deletion in 86% and 7% of the samples, respectively. In contrast, the miR-31
family of microRNAs were focally amplified (Creighton et al. 2012).
1.2.1.4 SerummicroRNAs as biomarkers
Each tissue-type has a specific pattern of microRNA expression, and microRNA profiling
can distinguish various tissue-types as well as their cancers (Lu et al. 2005). Expression
of microRNAs can separate healthy ovaries from EOC (Iorio et al. 2007) and diﬀerent
subtypes of HGSOC (Bell et al. 2011). Surprisingly, microRNAs were detected in twelve
body fluids including serum, plasma, urine, saliva and tears (Weber et al. 2010), which
was unexpected because microRNAs are short, RNA is chemically labile andmost biofluids
contain RNases. Moreover, serum microRNAs can withstand extreme conditions such as
extended storage, multiple freeze-thaw cycles, high and low pH and even boiling (Becker
and Lockwood 2013; McDonald et al. 2011). e encapsulation of microRNAs into
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vesicles (exosomes, microvesicles and high-density lipoproteins), chemical modifications
or association with protein complexes such as Ago2 are currently thought to provide
protection against potent endogenous RNases present in the blood (Arroyo et al. 2011;
Kosaka, Iguchi, and Ochiya 2010; Turchinovich et al. 2011). A combination of disease-
specific expression and extraordinary stability in serum and other fluids led circulatory
microRNAs to be described as a ‘goldmine’ of non-invasive biomarkers (Cortez et al. 2011).
Indeed, circulatory microRNAs have been able to detect colorectal (Cheng et al. 2011;
Ng et al. 2009; Yong, Law, and Wang 2013; Zanutto et al. 2014), breast (Farazi et al. 2011;
Heneghan et al. 2010; Madhavan et al. 2012; Volinia et al. 2012), prostate (Mahn et al. 2011;
Mitchell et al. 2008; Nguyen et al. 2013; Selth et al. 2013; Shen et al. 2012), lung (Aushev
et al. 2013; Hu et al. 2010b; Yu et al. 2008), gastric (Komatsu et al. 2013; Liu et al. 2011b;
Tsujiura et al. 2010), and ovarian cancers as well as predicting OS, disease progression,
stage, recurrence and distinguishing between good or bad prognosis, depending on the
cancer. e literature on utility of circulatory microRNAs in detecting OC has been
summarised in Table 3.8. Briefly, Taylor and Gercel-Taylor 2008 first demonstrated that the
microRNA profile of blood-derived exosomes was similar to their expression in OC tissue,
and circulating microRNAs could be used for detecting OC. Resnick et al. 2009 reported
upregulation of 5 (miR-21, miR-92, miR-93, miR-126 andmiR-29a) and downregulation of
three microRNAs (miR-155, miR-127 and miR-99b) in EOC compared to healthy serum.
Our laboratory has previously reported elevation of members of the miR-200 family of
microRNAs in the serum from patients of serous EOC versus healthy individuals (Kan et al.
2012).
Despite the ease of access, serum microRNAs are easily swayed by pre-analytical
variables and a careful approach is required for their accurate quantification. First, serum
microRNAs are present at extremely low levels and may require large starting material
for their quantification by real-time quantitative PCR (RT-qPCR). Unfortunately, blood
components, such as haemoglobin (Akane et al. 1994), immunoglobinG (Al-Soud, Jönsson,
and Rådström 2000) and lactoferrin (Al-Soud and Rådström 2001), also tend to be co-
purified with RNA in low levels. eir eﬀect on RT-qPCR is negligible when a small
amount of RNA is used in RT-qPCR. However, these contaminants can significantly inhibit
reverse transcriptase or Taq polymerase when an excessive amount of RNA is used, which
is oen the case for microRNAs given their low abundance (Blondal et al. 2013). Second,
McDonald et al. 2011 discovered that diﬀerences in RNA extraction protocols were the
least reproducible factor in microRNA quantification, which resulted in a high level of
intra-assay imprecision. ird, release of the microRNA content of red blood cells (RBC)
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upon haemolysis can dramatically alter the profile of disease-associated serummicroRNAs.
e extent of alteration of microRNA levels due to haemolysis in plasma is provided by
two independent studies that have reported haemolysis aﬀecting 58 - 65% of detectable
microRNAs (Kirschner et al. 2013; Pritchard et al. 2012). Finally, miR-16, oen used as a
reference microRNA for quantification of serummicroRNAs, is also aﬀected by haemolysis
(Kirschner et al. 2013).
1.2.2 Biology of lncRNAs
1.2.2.1 General features of lncRNAs
LncRNAs were found to have little protein-coding potential based on criteria such as
the presence of open reading frames (ORFs) encoding peptides of >100 amino acids in
length, evolutionary selection against the mutations that disrupt the coding sequence and
homology of the putative protein product to known protein families (Derrien et al. 2012;
Guttman andRinn 2012; Lin, Jungreis, andKellis 2011). Potential limitations of approaches
based on comparative genomics include an apparent lack of conservation in lncRNAs due
to their absence in less complex organisms or the encoded proteins representing newly
evolving proteins (Derrien et al. 2012). Intriguingly, application of a new technique known
as ribosome footprinting, which identifies RNAs bound to the ribosome, revealed that
lncRNAs were frequently associated with ribosomes (Ingolia, Lareau, and Weissman 2011;
Ruiz-Orera et al. 2014). To complicate the matter further, lncRNAs such as H19 and
TUG1￿, which have not presented any evidence of protein production in independent
studies (Brannan et al. 1990; Cai and Cullen 2007; Khalil et al. 2009; Yang et al. 2011),
were also found to be associated with the ribosomes, indicating that association with
ribosomes does not always result in protein production (Guttman and Rinn 2012; Ingolia,
Lareau, and Weissman 2011). Recently, there is some evidence emerging that lncRNAs
may code for short peptides. For example, a muscle-specific 46 amino acid transmembrane
peptide myoregulin, originating from a lncRNA, was shown to regulate muscle physiology
in mouse by regulating SERCA, a pump which transports Ca2+ from the cytoplasm to the
sarcoplasmic reticulum following muscle contraction (Anderson et al. 2015). In addition,
an 11 amino acid peptide torsal-less, translated from what was previously thought to be a
ncRNA, was found to control tissue folding in Drosophila (Galindo et al. 2007). A recent
genomic analysis suggested roughly 10% (~5,000/50,000) of lncRNAs could encode short
￿e names of the lncRNA are not italicised when referring to as the expressed RNA form, whereas they
are italicised when referring to the gene on the DNA, as in mutations in H19.
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peptides termed transcripts of unknown coding potentials (TUCPs), and some of them
could be biologically active as exemplified by myoregulin and torsal-less (Iyer et al. 2015).
GENCODE version 7 is perhaps the most comprehensive resource to elucidate general
properties of lncRNAs (Derrien et al. 2012). Like mRNAs, lncRNAs are transcribed by
Pol II, and have features such as 5’ capping and 3’ polyadenylation that are hallmarks of
Pol II-dependent transcription. In addition, a small fraction of lncRNAs could also be
transcribed by Pol III. e majority (98%) of lncRNAs are spliced, but most lncRNAs tend
to have only two exons on average (Derrien et al. 2012). LncRNAs are highly enriched in the
nucleus and are less abundant thanmRNAs. More than half (65%) ofmRNAs versus 11% of
lncRNAs were present in all 16 human tissue-types tested, suggesting that the expression of
lncRNAs is highly tissue-specific (Derrien et al. 2012). Even though most lncRNAs do not
code for proteins, their promoters are evolutionarily conserved, suggesting an evolutionary
pressure tomaintain their expression. Exons of the lncRNAs also exhibitmore conservation
compared to introns or untranscribed intergenic regions (Derrien et al. 2012; Guttman et al.
2009; Ponjavic, Ponting, and Lunter 2007).
1.2.2.2 Cancer-associated lncRNAs and their mechanisms
Enrichment of lncRNAs in the nucleus suggest their role in regulating gene expression. A
2.1 kb lncRNAHOX transcript anti-sense RNA (HOTAIR) was one of the earliest lncRNAs
that excited the field by demonstrating the potential of lncRNAs in cancer biology. HOTAIR
is expressed in posterior and distal anatomical locations, where its normal function is
to epigenetically silence a ~40 kb region spanning HOXD8–HOXD11 on chromosome 2
(Rinn et al. 2007). Overexpression of HOTAIR promotes metastasis of breast, pancreatic,
endometrial, colorectal, and other cancers (Gupta et al. 2010; He et al. 2014; Kim et al.
2012; Kogo et al. 2011; Lv et al. 2013). HOTAIR recruits two epigenetic writers to deposit
silencing marks of the ‘histone code’ on the chromatin (Figure 1.4). e 5’ end of HOTAIR
binds to and directs Enhancer of zeste homolog 2 (EZH2), a core protein of the Polycomb
repressive complex 2 (PRC2), to target loci, decorating themwithH3K27me3 for chromatin
condensation (Tsai et al. 2010). Additionally, the 3’ end of HOTAIR recruits lysine-specific
demethylase 1 (LSD1) that removes methyl groups from H3K4me2, erasing the epigenetic
marks of active transcription (Tsai et al. 2010). us, by working as a scaﬀold, HOTAIR
tethers two epigenetic modulators to the target loci. Unlike typical transcription factors,
the target sites are recognised by HOTAIR itself, not PRC2 or LSD1 (Tsai et al. 2010).
Mammalian females carry double the number of X chromosomes compared to males
(XX versus XY) in each nucleated cell; therefore, one copy of the X chromosome needs to
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Figure 1.4: Epigenetic regulation of chromatin by lncRNA HOTAIR
Note: The PRC2 complex is comprised of four core proteins: RbAp46/48, EED, SUZ12 and EZH2.
Adapted fromMarsh, Shah, and Cole 2014.
be silenced in females for dosage compensation of the genes that are on the X chromosome.
is remarkable fate is achieved by a 17 kb lncRNA X-inactive specific transcript (XIST),
which utilises PRC2 to silence one entire X chromosome. e binding of PRC2 to lncRNAs
is not restricted to HOTAIR or XIST. As mentioned previously, a subset of lncRNAs known
as long intervening RNAs (lincRNAs) could originate from inter-genic regions (Figure
1.3D). Approximately 20% of lincRNAs were found to be physically associated with the
PRC2 complex (Khalil et al. 2009). PRC2 has been referred to as ‘promiscuous’ in its ability
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to bind RNAs by Professor omas Cech who was awarded the Nobel Prize in Chemistry
in 1989 for discovering the catalytic role of RNA in splicing (Davidovich et al. 2013).
Furthermore, ~30% (74/240) of lincRNAs in embryonic stem cells were found to be bound
to at least 1 out of 12 chromatin modifying complexes such as epigenetic readers (PRC1,
Cbx1, and Cbx3), writers (Tip60/P400, PRC2, Setd8, ESET and Suv39h1), and erasers
(Jarid1b, Jarid1c, and HDAC1) (Guttman et al. 2011). LncRNA SChLAP1 overexpressed
in a subset of prostate cancers antagonises tumour-suppressive functions of the chromatin-
modifying complex SWI/SNF, resulting in metastasis and poor outcomes (Prensner et al.
2013). Taken together, this body of evidence suggests that chromatin regulation by lncRNAs
is potentially a widespread phenomena.
LncRNAs can also regulate gene expression by interacting with promoters and en-
hancers. A significant proportion of enhancers themselves are known to transcribe RNAs
termed enhancer RNAs (Mercer, Dinger, and Mattick 2009). A lncRNA transcribed from
the upstream minor promoter of the dihydrofolate reductase (DHFR) locus could form a
RNA:DNA triplex with the major promoter of the gene, suppressing its transcription by
interfering with transcription factor binding (Martianov et al. 2007). In the context of can-
cer, Paupar, a lncRNA transcribed from a locus adjacent to the transcription factor Pax6
whose expression is restricted to the central nervous system, interacts with distal promoters
to regulate the cell cycle and maintain the de-diﬀerentiated state of neuroblastoma (Vance
et al. 2014). Nuclear enriched abundant transcript 1 (NEAT1), an example of structural
RNA that is essential for the formation of paraspeckles (Clemson et al. 2009), was recently
discovered as a downstream target of the oestrogen receptor alpha (ERα) in prostate cancer
(Chakravarty et al. 2014). ERα is expressed in prostate cancer regardless of the androgen re-
ceptor status. Prostate cancers expressing high levels of NEAT1 were resistant to androgen
receptor antagonists, and NEAT1 drove oncogenic growth by associating with promoters
of genes such as PSMA and GJB1 that resulted in active transcription (Chakravarty et al.
2014). A class of steroid hormone known as glucocorticoids influence cell growth, energy
expenditure and survival (Kino et al. 2010). e lncRNA Gas5 was found to be induced in
the response to absence of nutrients or growth factors. By binding to the DNA-binding do-
main of the glucocorticoid receptor, Gas5 could prevent the receptor binding to its normal
target sites. us, Gas5 inhibited the functions of the glucocorticoid receptor by working
as a competitive inhibitor or a ‘decoy’ (Kino et al. 2010). An 8 kb lncRNA Metastasis As-
sociated Lung Adenocarcinoma Transcript 1 (Malat1) has been shown to influence RNA
metabolism, alternative splicing by recruiting serine/arginine (SR) proteins and transcrip-
tional control via binding to Polycomb proteins (Dhamija and Diederichs 2016). Expres-
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sion of Malat1 has been found to be altered in lung, liver, renal cell, breast, cervical, col-
orectal and bladder cancers (reviewed in Gutschner, Hämmerle, and Diederichs 2013).
According to the competing endogenous RNA (ceRNA) hypothesis, RNAs compete for
binding sites intracellularly (Salmena et al. 2011). In the traditional sense, microRNAs re-
duce protein expression as discussed in subsection 1.2.1.1; however, the ceRNA hypoth-
esis predicts that the levels of available microRNAs deflate once they have bound to their
cognate sites, probably in the order of their strengths, and, consequently, a subset of mR-
NAs escape from microRNA-mediated gene silencing. A number of lncRNAs in the cyto-
plasm have been shown to work as ceRNAs or, informally, ‘microRNA sponges’. Upregu-
lation of lncRNA Highly Upregulated in Liver Cancer (HULC) has been shown to work as
a microRNA sponge for miR-372 in hepatocellular carcinoma (HCC), rescuing the miR-
372 target mRNA PRKACB from suppression (Wang et al. 2010). e PTEN pseudogene
1 (PTENP1) absorbs levels of microRNAs such as miR-21 that usually target the PTEN
mRNA. Overexpression of PTENP1 negated actions of miR-21 and reduced cell prolifera-
tion, invasion, tumuor growth, andmetastasis, which are hallmarks of the functional PTEN
protein (Poliseno et al. 2010; Yu et al. 2014a). As expected from its tumour-suppressive
functions, PTENP1 was found to be downregulated in clear cell renal carcinoma by pro-
moter methylation (Yu et al. 2014a) and deletion in melanoma (Poliseno, Haimovic, Chris-
tos, et al. 2011). HOTAIR has also been found to work as ceRNA for miR-29b, miR-1, and
miR-141 (Bian et al. 2016; Liu et al. 2014; Su et al. 2016; Xu and Zhang 2017; Yu et al. 2017).
Recently, a species of lncRNAsknowns as circular RNAs (circRNAs) have been proposed
to function as ceRNAs. A covalent bond between the 5’ and 3’ ends of an RNA closes the
loop, forming a circle (Rong et al. 2017). In particular, circRNA-7 was found to have 70
binding sites for miR-7 (Hansen et al. 2013). Surprisingly, miR-671 could cleave circRNA-7
using Ago2, releasing miR-7 into the cellular pool (Hansen et al. 2011). us, circRNA-
7 was referred as a buﬀer for miR-7, ensuring its rapid release when needed (Hansen,
Kjems, and Damgaard 2013). Genome-wide circRNA studies have already shown their
deregulation in gastric and colorectal cancers as well as squamous cell carcinoma since the
first demonstration of the mechanism in 2013 (Sand et al. 2016; Zhao and Shen 2016).
In a short period, lncRNAs have been proven to have crucial roles in promoting cancer
by diversemechanisms, and the field continues to advance rapidly. Although the diagnostic
potential of lncRNAs have been omitted from this discussion, the example of the lncRNA
prostate cancer antigen 3 (PCA3) is worth noting. A urine test based on PCA3 is already
in clinical use for detecting prostate cancer as PCA3 has been found to be superior to the
current prostate-specific antigen (PSA)-based methods and overcomes limitations of PSA
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such as dependency on the prostate volume (Chandra Gupta and Nandan Tripathi 2017).
A deeper understanding and appreciation of the role of lncRNAs in normal physiology
and disease aetiology is highly likely to lead to new avenues of diagnostics and therapeutic
treatments.
1.2.2.3 LncRNAs in OC and chemoresistance
Compared to other cancers, the research on the role of lncRNAs in OC has been relatively
sluggish. A number of lncRNAs have been predicted to have a role in OC, but many of
them are not functionally validated (Table 1.3). By identifying the microarray probes in
the TCGA-OV dataset corresponding to 10,207 lncRNAs, Du et al. 2013 reported that
expression of lncRNAs correlated with OS or PFS of patients with HGSOC. In addition,
expression of 1,749 lncRNAs were found to be specific to only one of the four subtypes of
HGSOC, reiterating the specificity of lncRNA expression (Du et al. 2013). An independent
analysis of the same dataset identified 455 deregulated lncRNAs in HGSOC versus the
normal ovary; however, the authors could not define a lncRNA signature that predicted
OS (Akrami et al. 2013). By applying principles of network analysis and ceRNA, Malat1,
HOTAIR and maternally expressed gene 3 (MEG3) were predicted to have a role in OC
(Zhou et al. 2015).
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Name Full Name In vivo and in vitro observations Mechanism Expression Reference
ZNF300P1 Zinc Finger Protein 300
Pseudogene 1
Downregulation decreases cell growth Not described Down Gloss et al. 2014
AB073614 NA Downregulation decreases prolifera-
tion,migration, invasion, andpromotes
apoptosis in vitro, and reduces tumour
size in vivo
Not described Up Cheng et al.
2015
HOST2 Human ovarian cancer spe-
cific transcript 2
Downregulation decreases prolifer-
ation and migration in vitro, reduces
tumour growth in vivo
microRNA sponge for let-7b Up Gao et al. 2015
LSINCT5 Long Stress-Induced Non-
Coding Transcript 5
Downregulation reduces proliferation Not described Up Silva et al. 2011
FAL1 Focally Amplified Long
Non-Coding RNA In Epithe-
lial Cancer
Overexpression suppresses senes-
cence and expression of p21
Chromatin modification
through PRC1
Up Hu et al. 2014
PVT1 Plasmacytoma Variant
Translocation 1
Downregulation decreases prolifera-
tion and promotes apoptosis
Myc protein stablisation Up Guan et al. 2007
XIST X Inactive Specific Tran-
script
Downregulation decreases resistance
to paclitaxel
Chromatin modification
through PRC2
Down Huang et al.
2002a
HOTAIR HOX transcript anti-sense
RNA
Overexpression increases migration
and invasion and promotes EMT
Chromatin modification
through PRC2
Up Qiu et al. 2014
Downregulation induces cell-cycle ar-
rest in vitro and in vivo
Up Qiu et al. 2015a
Overexpression sensitises cells to car-
boplatin
Up Teschendorﬀ et
al. 2015
HOXA11-
AS
HOXA11 Antisense RNA Overexpression decreases prolifera-
tion, migration, invasion in vitro, and
reduces tumour size in vivo
Not described Down Richards et al.
2015
CDKN2B-
AS1
CDKN2B Antisense RNA 1
(also known as ANRIL)
Overexpression increases metastasis Chromatin modification
through PRC2
Up Qiu et al. 2015a
MEG3 Maternally expressed gene
3
Expression suppresses proliferation
and promotes apoptosis
Chromatin modification
through PRC2, activation of
wt-p53
Down Sheng et al.
2014
H19 H19, Imprinted Maternally
Expressed Transcript
Codes miR-675 associated with EMT
and chemoresistance
Chromatin modification
through PRC2/microRNA
production
Up Matouk et al.
2014; Tanos
et al. 1999
Table 1.3: LncRNAs in OC
‘Expression’ refers to expression of a lncRNA in OC tissues compared to normal ovary/surface epithelia (Adapted fromMeryet-Figuière et al. 2016)
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As discussed in subsection 1.2.2.2, Malat1 has been implicated in multiple cancers.
Malat1 was found to be diﬀerentially expressed in SKOV-3.ip1 cells with an increased
metastatic potential compared to the parental SKOV-3 cell line (Liu et al. 2013a). However,
this was a preliminary in vitro study without any in vitro or in vivo validation of the invasive
capabilities of the cells by siRNA knockdown or othermethods. A recent study showed that
Malat1 expression was stimulated by TGF-β, and siRNA knockdown ofMalat1 reduced cell
viability, proliferation, migration and invasion of SKOV-3 cells by regulating the MAPK
pathway (Zou, Liu, and Wu 2016). Expression of MEG3 reduced levels of MDM2, leading
to accumulation of wt-p53 (Zhou et al. 2007), but it is commonly lost or silenced by
hypermethylation of its promoter in OC (Sheng et al. 2014).
XIST, H19 and HOTAIR have been implicated in OC biology as well as drug resistance.
XIST was found to be downregulated in OC, leading to reactivation of some of the genes
on the X chromosome, and correlated with a shorter PFS period (Huang et al. 2002b).
Interestingly, decreased XIST expression was linked to increased resistance to paclitaxel,
but not cisplatin (Huang et al. 2002b). A ‘classic’ lncRNA, H19, discovered in the 1990s
(Brannan et al. 1990) was found to be overexpressed in cisplatin-resistant A2780cisR cells
compared to its sensitive counterpart A2780 (Matouk et al. 2014). By acting as a pri-miRNA
for miR-675, H19 promoted epithelial-mesenchymal transition (EMT), a phenomena that
oen promotes drug resistance in cancers (Singh and Settleman 2010), through the actions
of miR-675 (Matouk et al. 2014). Silencing of HOTAIR reduced migration and invasion
of EOC cells in vitro, and inhibited metastasis of OC to the peritoneum in mice (Qiu et
al. 2014). e expression of HOTAIR was higher in serous OC samples compared to the
normal ovary and correlated with stage and grade of the tumour (Kogo et al. 2011; Qiu et
al. 2015b). Additionally, patients with elevated levels of HOTAIR had a shorter OS period
(Qiu et al. 2015b). Like H19, HOTAIR was overexpressed in A2780cisR versus A2780 cells
(Ozes et al. 2013). Mechanistically, HOTAIR promoted cisplatin resistance by activating
the wnt/β-catenin pathway (Li et al. 2016).
1.2.3 The eﬀect of p53 on lncRNAs
p53 is a well-studied transcription factor influencing the expression of a plethora of protein-
coding genes. He et al. 2007 first demonstrated that p53 also aﬀects expression of non-
coding RNAs, namely the miR-34 family of microRNAs. Notably, tumour-suppressive
functions of p53 were partially mediated through miR-34 (He et al. 2007). Within five
years, JohnRinn’s laboratory at theHarvardUniversity, USA, showed that p53 also regulates
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lncRNAs, by identifying lincRNA-p21 transcribed from a locus upstreamofCDKN1A (p21)
on chromosome 17 inmouse (Huarte et al. 2010). lincRNA-p21 was shown to be associated
with heterogeneous nuclear ribonucleoprotein K (hnRNP-K) to suppress a subset of genes
that are usually suppressed by p53 (Huarte et al. 2010). Global transcription factor-binding
analysis (ChIP-seq) showed that half of theDNA regions bound by p53were located outside
the protein-coding genes (Idogawa et al. 2014). Consequently, the list of lncRNAs directly
aﬀected by p53 is growing. PANDA (Hung et al. 2011), Pint (Huarte et al. 2010), PR-
lncRNA-1 (Sánchez et al. 2014), PR-lncRNA-10 (Sánchez et al. 2014), NORAD (Lee et al.
2016), TUG1 (Guttman et al. 2009; Khalil et al. 2009), PVT1 (Barsotti et al. 2012), LINP1
(Zhang et al. 2016c), DDSR1 (Sharma et al. 2015) andDINO (Schmitt et al. 2016) have been
reported to be transcribed directly or indirectly by p53, aiding the ‘guardian of the genome’
in its tumour-suppressive functions.
Despite the remarkable progress in understanding the eﬀect of p53 on ncRNAs, eﬀects
of mutant-p53 on lncRNAs remain largely unexplored. As discussed in subsection 1.1.2.3,
mutant-p53 can inactivate members of the p53 family of proteins as well as may oﬀer new
capabilities that significantly enhance carcinogenesis. erefore, it is likely that mutant-
p53 orchestrates a dramatically diﬀerent transcriptomic ‘symphony’ than its wild-type
counterpart, and expression of lncRNAs could be a significant part of it.
1.3 Thesis aims
e overall goal of this thesis is to apply the power of non-coding RNAs, both microRNAs
and lncRNAs, to OC with the following aims:
1. To assess the diagnostic role of serummicroRNAs in separating patientswithHGSOC
from healthy women as well as predict their surgical outcome.
2. To assess whether lncRNAs have a role in promoting cisplatin resistance.
3. To investigate the influence of themutant-p53 targeting drug APR-246 on coding and
non-coding RNAs.
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Materials & methods
2.1 Detection of serummicroRNAs
2.1.1 Collection of cell-free serum
Written informed consent was obtained and blood collected from 56 women with HGSOC
(64.1  3.4 years) and 30 healthy females age matched within 5 years (61.0  4.7 years)
under a protocol approved by the Northern Sydney Local Health District Human Research
Ethics Committee (Protocol # 0310-209B). For women undergoing surgical resection of
their tumour, blood was collected from the peripherally inserted central catheter (PICC
line) prior to the induction of anaesthesia. Blood from healthy volunteers was collected
using a 21 gauge needle. In both cases, samples were transferred or collected into a 9 ml
BD Vacutainer serum tube (BD). Blood was allowed to clot for 15 - 30 minutes at 4 C and
centrifuged at 3000 rpm for 15 minutes at 4 C. Serum was carefully withdrawn without
disturbing the buﬀy coat and immediately stored at -80 C in 500 μl aliquots as part of
the Kolling Institute Gynaecological Tumour Bank. Samples were rapidly thawed in a 37
C water bath as required. Additional centrifugation at 3000 g for 5 minutes resulted in
the cell-free fraction. Samples were randomised and remaining procedures performed in a
single-blind manner to avoid bias.
Table 2.1: List of chemicals and reagents
Name Supplier Catalogue number City State Country
4-12% NuPAGE® Novex Bis-Tris gel ThermoFisher Scientific NP0321BOX Scoresby Victoria Australia
Acetic Acid (Glacial) Bacto Laboratories A1-2.5L GL Mt Pritchard NSW Australia
Agarose, molecular biology grade Bio-Rad 1613102 Gladesville NSW Australia
AllStars Negative Control Qiagen SI03650318 Chadstone Vic Australia
Ampicillin Sodium Salt Sigma-Aldrich A9518-5G Castle Hill NSW Australia
APR-246/PRIMA-1MET Cayman Chemicals 9000487 Ann Arbor Michigan USA
BD Horizon Fixable Viability Stain 450 (FVS450) BD 562247 North Ryde NSW Australia
Bromophenol blue Sigma-Aldrich 114391-25G Castle Hill NSW Australia
Chloroform:Isoamyl alcohol (24:1) Sigma-Aldrich 25666-100ML Castle Hill NSW Australia
Cisplatin Sigma-Aldrich P4394-25MG Castle Hill NSW Australia
DMEM, high glucose HyClone/GE life sciences SH30243.01 Logan Utah USA
dimethyl sulfoxide (DMSO) Sigma-Aldrich D8418-50ML Castle Hill NSW Australia
DpnI enzyme New England BioLabs R0176S Ipswich MA USA
Ethylenediaminetetraacetic acid (EDTA) Astral Scientific 0105-5009 Caringbah NSW Australia
Electroporation cuvettes Bio-Rad 1652086 Gladesville NSW Australia
Fetal bovine serum (FBS) AusGeneX FBS500-S Molendinar QLD Australia
Glycerol Sigma-Aldrich 15524 Castle Hill NSW Australia
Glycine Sigma-Aldrich VWRC10119CU-5KG Castle Hill NSW Australia
HiPerFect Transfection Reagent Qiagen 301707 Chadstone Vic Australia
Amersham Protran Supported 0.45 Nitrocellulose
membrane
Sigma-Aldrich GE10600016 Castle Hill NSW Australia
LoBind microcentrifuge tubes Sigma-Aldrich Z666548-250EA Castle Hill NSW Australia
Methanol ThermoFisher Scientific 5005-10L Scoresby Victoria Australia
3 (N-Morpholino) propanesulfonic acid (MOPS) Sigma-Aldrich M1254-1KG Castle Hill NSW Australia
Sodium chloride Astral Scientific BIOSB0476-5kg Caringbah NSW Australia
Opti-MEM® Reduced Serummedia ThermoFisher Scientific 31985-062 Scoresby Victoria Australia
Name Supplier Catalogue number City State Country
PfuUltra II Fusion HS DNA Polymerase Agilent Technologies 600670 Mulgrave Vic Australia
Pierce ECL Dura reagent ThermoFisher Scientific 32106 Scoresby Victoria Australia
Pierce ECL Pico reagent ThermoFisher Scientific 34080 Scoresby Victoria Australia
Ponceau S Bio-Rad P7170-1L Gladesville NSW Australia
Propan-2-ol (isopropanol) ThermoFisher Scientific 425-2.5L Scoresby Victoria Australia
QIAzol lysis reagent Qiagen 79306 Chadstone Vic Australia
RNA 6000 Nano Assay Agilent Technologies 5067-1511 Mulgrave Vic Australia
RNA fromMS2 bacteriophage Sigma-Aldrich 10165948001 Castle Hill NSW Australia
RNaseZap® RNase Decontamination Solution ThermoFisher Scientific AM9780 Scoresby Victoria Australia
ROX reference dye ThermoFisher Scientific 12223-012 Scoresby Victoria Australia
RPMI-1640 HyClone/GE life sciences SH30027.01 Logan Utah USA
Sodium dodecyl sulfate (SDS) Sigma-Aldrich L3771-500G Castle Hill NSW Australia
SeeBlue® Plus2 protein standard (range 4-250
kDa)
ThermoFisher Scientific LC5925 Scoresby Victoria Australia
SeeBlue® Plus2 Pre-stained Protein Standard ThermoFisher Scientific LC5925 Scoresby Victoria Australia
Sucrose Sigma-Aldrich S0389-1KG Castle Hill NSW Australia
SYBR Safe Nucleic Acid Stain ThermoFisher Scientific S33102 Scoresby Victoria Australia
SYBR safeDNA gel Stain ThermoFisher Scientific S33102 Scoresby Victoria Australia
Tris Astral Scientific 77-86-1/0497-1KG Caringbah NSW Australia
Trypsin-EDTA Sigma-Aldrich T4049 Castle Hill NSW Australia
Tryptone Bacto Laboratories 211705 Mt Pritchard NSW Australia
Tween-20 Sigma-Aldrich P5927-500ML Castle Hill NSW Australia
Vacutainer serum tube BD 455092 North Ryde NSW Australia
X-tremeGENE 9 DNA Transfection Reagnt Sigma-Aldrich 6365809001 Castle Hill NSW Australia
Yeast extract Bacto Laboratories 212750 Mt Pritchard NSW Australia
Table 2.2: List of commercial kits
Name Supplier Catalogue number City State Country
Cell Line Nucleofector® Kit T Lonza VCA-1002 Mt Waverley Victoria Australia
CellTiter 96® AQueous One Solution Promega G3581 Alexandria NSW Australia
DNA High Sensitivity Reagent Kit PerkinElmer CLS760672 Notting Hill Victoria Australia
ExiLENT SYBR Green master mix Exiqon 203420 Vedbaek Denmark
iTaqTM Universal Probes Supermix Bio-Rad 1725134 Gladesville NSW Australia
Maxima H Minus Reverse Transcription kit ThermoFisher Scientific K1652 Scoresby Victoria Australia
miRCURY RNA Isolation Kit - Biofluids Exiqon 300112 Vedbaek Denmark
miRNeasy Mini Kit Qiagen 217004 Chadstone Vic Australia
mirVanaTM PARISTM RNA isolation kit ThermoFisher Scientific AM1556 Scoresby Victoria Australia
MitoProbeTM DiIC1(5) Assay Kit ThermoFisher Scientific M34151 Scoresby Victoria Australia
NucleoBon‘d® Plasmid Purification Kit Clontech PC100 Mountain View CA USA
Pick-&-Mix microRNA PCR panel Exiqon 203802 Vedbaek Denmark
PureYieldTM Plasmid Miniprep System Promega A1222 Alexandria NSW Australia
Quant-iTTM RNA Assay Kit, broad range ThermoFisher Scientific Q10213 Scoresby Victoria Australia
RNA Spike-In Kit Exiqon 203203 Vedbaek Denmark
SensiMixTM SYBR® Hi-ROX Kit Bioline QT605-05 Alexandria NSW Australia
Serum/Plasma Focus microRNA PCR panel Exiqon 203843 Vedbaek Denmark
SuperScript® III First-Strand Synthesis System ThermoFisher Scientific 18080051 Scoresby Victoria Australia
The LncProfiler qPCR Array Kit System Biosciences RA910A-1 Palo Alto CA USA
TruSeq Stranded Total RNA Library Prep Kit Illumina RS-122-2201 Scoresby Victoria Australia
Universal cDNA Synthesis kit Exiqon 203301 Vedbaek Denmark
Universal KAPA Library Quantification Kit for Illu-
mina Sequencing Platforms
KAPA Biosystems KK4824 North Ryde NSW Australia
Table 2.3: List of software and equipments
Name Supplier City State Country
Applied Biosystems 7900HT Fast Real-Time PCR System ThermoFisher Scientific Scoresby Victoria Australia
Agilent 2100 Bioanalyzer Agilent Technologies Mulgrave Vic Australia
DNA Engine®Peltier Thermal Cycler Bio-Rad Gladesville NSW Australia
FACS Diva software V8.0.1 BD North Ryde NSW Australia
epMotion 5070 liquid handling system Eppendorf North Ryde NSW Australia
ExpressionSuite V1.1 ThermoFisher Scientific Scoresby Victoria Australia
Fujifilm LAS-4000 imaging system Fujifilm Brookvale NSW Australia
Gene Pulser Electroporator Bio-Rad Gladesville NSW Australia
GenEX software V6 Exiqon Vedbaek Denmark
LabChip GX PerkinElmer Notting Hill Victoria Australia
Moxi Z Gene Target Solutions Dural NSW Australia
NanoDropTM 1000 spectrophotometer ThermoFisher Scientific Scoresby Victoria Australia
NucleofectorTM 2b Device Lonza Mt Waverley Victoria Australia
QuantStudioTM 7 Flex Real-Time PCR System ThermoFisher Scientific Scoresby Victoria Australia
Qubit® 2.0 Fluorometer ThermoFisher Scientific Scoresby Victoria Australia
SDS RQManager software V2.4 ThermoFisher Scientific Scoresby Victoria Australia
SmartView Pro 2100 Gel Documentation System Major Science Saratoga CA USA
Synergy HT Microplate Reader BioTek Winooski VT USA
2.1. Detection of serum microRNAs
2.1.2 RNA extraction
RNAwas extracted from 200 μl serum using themiRCURYRNA isolation kit for Biofluids
(Exiqon) according to themanufacturer’s instructions. Low nucleic acid binding (marketed
as ‘LoBind’) 1.5 ml eppendorf tubes were used to minimise loss of RNA due to adsorption
to tube walls (Sigma-Aldrich). All centrifugation steps were performed at 11,000 g at room
temperature for the indicated period. e RNA Spike-in kit consisted of two parts: spike-
into be added during RNA extraction (UniSp2, 4 and 5) and for reverse transcription (RT)
(UniSp6 and cel-miR-39-3p).
Briefly, the designated bench for RNA work was cleaned using RNaseZap® RNase
Decontamination Solution (ermoFisher). Lysis was performed by adding 60 μl Lysis
Solution for BioFluids (BF), 1μl (1 μg) RNA Spike-In Kit (UniSp2, 4 and 5; Exiqon) and
2.5 μl (1 μg) MS2 bacteriophage carrier RNA (Sigma-Aldrich). To remove proteins, 20
μl Protein Precipitation Solution BF was added to the sample, vortexed for 5 seconds,
incubated for 1 minute at room temperature and centrifuged for 3 minutes. e clear
lysate was transferred to an eppendorf tube, 270 μl isopropanol was added and mixed by
vortexing for 5 seconds. e mixture was transferred to microRNA mini spin column BF,
incubated for 2minutes at room temperature and centrifuged for 30 seconds. Flow through
was discarded. e column was washed by adding 100 and 700 μl wash solutions 1 and
2, respectively, with a centrifugation step of 30 seconds aer addition of each solution. An
additional wash was performed by adding 250 μl wash solution followed by centrifugation
for 2 minutes. Next, the columnwas transferred to a fresh eppendorf tube. RNAwas eluted
in 25 μl nuclease-free water twice (final volume 50 μl) and stored at -80 C in aliquots.
2.1.3 RT-qPCR
e study was split into the ‘Discovery’ phase using the Serum/Plasma Focus microRNA
PCR panel (Exiqon) containing locked nucleic acid (LNA) primers for 186 microRNAs,
of which 170 were target microRNAs, while the rest were primers to measure various
factors such haemolysis thatmay influence the accuracy of RT-qPCR.e ‘Validation’ phase
was designed using a miRCURY LNA Universal RT microRNA PCR Ready-to-Use PCR
panel with custom selection of LNA microRNA primer sets (Exiqon). For the Validation
phase, 48microRNAsweremeasured for each sample including the controls. Because fewer
microRNAs were measured in the Validation phase, RT for this phase was performed in 10
μl volume, and the RT-qPCR master mixed was scaled down without changing the ratio
of the constituents.
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RT was performed in either 20 μl or 10 μl for the Discovery and Validation phase,
respectively, using 2 μl RNA template per 10 μl RT reaction as instructed by the Universal
cDNA Synthesis kit (Exiqon). A 20 μl RT reaction contained 4 μl of 5X reaction buﬀer,
9 μl nuclease-free water, 4 μl RNA, 2 μl Enzyme mix and 1 μl Spike-in synthetic RNAs
(UniSp6 and cel-miR-39-3p). RTwas performed on aDNAEngine® Peltierermal Cycler
(Bio-Rad) according to the following programme: 42 C for 60 minutes followed by 95 C
for 5 minutes. e sample was first cooled at 4 C , followed by storage at -20 C. ree
independent RT reactions were performed for each sample, and one PCR conducted for
each RT.
e RT-qPCR master mix suﬃcient to run one sample on a Discovery Panel contained
1.04 ml of 2X ExiLENT SYBR Green master mix (Exiqon), 20 μl cDNA, 42 μl of 50X
ROX dye (ermoFisher) and 980 μl nuclease-free water. Ten μl of the master mix was
transferred to each well of a Serum/Plasma Focus microRNA PCR panel or Pick-&-Mix
microRNA PCR panel using the epMotion 5070 liquid handling system (Eppendorf). RT-
qPCR was performed on a 7900HT Fast Real-Time PCR System (ermoFisher) according
to the following conditions: 95 C for 10 minutes; 40 amplification cycles of 95 C for 10
seconds and 60 C for 1 minute, followed by melting curve analysis.
2.1.4 Data processing and analysis
Data was imported into the GenEx soware V6 (Exiqon). An experimental design
table containing grouping information for each sample was also imported into GenEx.
In GenEx, plate-to-plate variations in RT-qPCR was normalised to the expression of
UniSp3, an interplate calibrator present on each plate. Data points that diﬀered in
standard deviation by >1 for each gene per sample were removed. In addition, microRNAs
amplified in no template control (NTC) or amplified at Ct > 37 were removed. Following
the manufacturer’s guidelines missing data was filled with the averages of the biological
replicates. In cases where technical replicates for a microRNA in a sample were missing,
the missing data were filled with averages of the remaining technical replicates. Global
normalisation was applied to the Discovery panel. e NormFinder algorithm was used to
identify reference microRNAs to normalise data in the Validation phase or when both sets
were pooled and processed together. Missing data on a gene in patients were filled with
averages of the biological group for that gene. No microRNA was consistently absent or
not amplified in any particular biological group. Technical replicates (3 RTs) were averaged
for each gene/patient. e normalised data now resembledCt of the widely used 2-Ct
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method to analyse RT-qPCR data (Livak and Schmittgen 2001). Data was normalised to
‘nothing’, i.e. no specific biological group, which was calculated in GenEx by evaluating
2-Ct . Finally, the data was log2-transformed and used for subsequent analysis. us, last
two steps of the processing was essentially log2 (2-Ct) = -Ct. As a result of this, most of
the data were negative.
2.2 Cell culture experiments
2.2.1 Cell lines and culture protocols
All cell lines were available in the laboratory upon commencement of this thesis. eir
histology, origin and culture methods are listed in Tables 2.4 and 2.5. For passaging, cells
were cultured in humidified incubators at 37 C with 5% CO2 and passaged at 70 - 90%
confluency. Cells were washed once with warm PBS, treated with 0.25% Trypsin/EDTA
solution (usually 1 ml) at 37 C until detached. Approximately 10-times volume of the
trypsin of pre-warmed culture media (usually 10 ml) containing FBS was added to the tube
to neutralise trypsin followed by centrifugation at 300 g for 5 minutes at room temperature.
Supernatant was replacedwith fresh pre-warmedmedia, and cells were plated in cell culture
flasks according to the split ratio. Cells weremaintained for up to 10 passages aer thawing.
2.2.2 Cryopreservation of cells
Cells were harvested at the confluency of 70 - 90% as described above. Aer neutralising
trypsin, cells were preserved in their respective culture media containing a final concentra-
tion of 10% DMSO and aliquotted into 2 ml cryovials depending on the doubling time and
the split ratio. Cryovials were transferred to the freezing containers and stored at -80 C
for at least 24 hours, aer which they were transferred to liquid nitrogen vessels for long
term storage. To revive frozen cells, the aliquots were rapidly thawed at 37 C, washed once
with warm culture media containing FBS, and plated in suitable cell culture flasks.
2.2.3 Mycoplasm testing
Cells were routinely tested for Mycoplasma contamination by using 1 ml of conditioned
media from cultured cells on the MycoAletTM Mycoplasma detection kit. is detection
system relies on an enzyme produced by Mycoplasma to convert ATP to ADP, giving a
luminescent signal which was read on the VeritasTM Microplate luminometer.
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2.2.4 Cell typing
Cell typing to confirm their authenticity was performed on a fee-for-service basis at
CellBank Australia (Children’s Medical Research Institute, Westmead, Australia) using an
AmpFLSTR® Identifiler® PCR Amplification Kit.
44
Table 2.4: Ovarian cancer cell lines used in this study
Cell line Histology Origin Morphology Reference
A2780 Undiﬀerentiated carcinoma Tumour Epithelial Bohrens et al. 1987
A2780CISR Undiﬀerentiated carcinoma; derived from A2780
by gradually increasing exposure to cisplatin in
vitro
Tumour Epithelial Bohrens et al. 1987
CAOV4 Papillary serous adenocarcinoma ovary; derived from metastatic site:
subserosa of the fallopian tube
Epithelial Karlan et al. 1988
COV318 Serous adenocarcinoma Ascites Epithelial Berg-Bakker et al. 1993
H1299 Large cell carcinoma lung; derived from metastatic site:
lymph node
Epithelial Giaccone et al. 1992
KURAMOCHI Ovarian carcinoma Ascites Epithelial-like Motoyama 1982
OAW28 Ovarian cystadenocarcinoma Ascites Epithelial Hills et al. 1989
OVCAR-3 Poorly diﬀerentiated papillary epithelial ovarian
cancer
Ascites Epithelial Hamilton et al. 1983
OVCAR4 Adenocarcinoma Ovary Epithelial Hamilton, Young, and
Ozols 1984
OVKATE Adenocarcinoma Ovary Epithelial-like Gorai et al. 1995
OVSAHO Adenocarcinoma Ovary Epithelial-like Gorai et al. 1995
PEO1 Poorly diﬀerentiated serous adenocarcinoma Ascites Epithelial Cooke et al. 2010; Lang-
don et al. 1988
PEO4 Poorly diﬀerentiated serous adenocarcinoma; de-
rived from the same patient as PEO1 after she de-
veloped resistance to cisplatin, 5-fluorouracil and
chlorambucil
Ascites Epithelial-like Cooke et al. 2010; Lang-
don et al. 1988
SKOV-3 Serous adenocarcinoma Ascites Epithelial Andre et al. 2002
Table 2.5: Cell culture conditions
Cell line Medium Culture method TP53mutation
A2780 RPMI-1640 + 10% FCS 1:20 split every 3-5 days wt
A2780CISR RPMI-1640 + 10% FCS 1:20 split every 3-5 days wt
CAOV4 RPMI-1640 + 10% FCS 1:2 to 1:3 split every 6-8 days p.V147D
COV318 DMEM + 10% FCS 1:4 to 1:10 split every 4-7 days p.I195F
H1299 RPMI-1640 + 10% FCS 1:10 every 4 days p53 deletion
KURAMOCHI RPMI-1640 + 10% FCS 1:10 every 7 days p.D281Y
OAW28 DMEM + 20 IU/l Insulin + 10% FCS 1:3 to 1:6 every 4-7 days p.P152fs
OVCAR-3 RPMI-1640 + 10% FCS 1:3 to 1:8 split every 3-5 days p.R248Q
OVCAR4 RPMI-1640 + 10% FCS 1:4 to 1:5 split every 4 days p.L130V
OVKATE RPMI-1640 + 10% FCS 1:4 to 1:10 every 4-7 days p.R282W
OVSAHO RPMI-1640 + 10% FCS 1:4 to 1:10 every 4-7 days p.R342*
PEO1 RPMI-1640 + 10% FCS 1:4 to 1:8 every 4-7 days p.G244D
PEO4 RPMI-1640 + 10% FCS 1:4 to 1:8 every 4-7 days p.G244D
SKOV-3 RPMI-1640 + 10% FCS 1:3 to 1:8 split every 3-5 days c.267del1
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2.2.5 Cell proliferation assays using MTS reagent
MTS assays were performed in 96 well plates with all 4 sides filled with sterile water to
avoid the ‘edge eﬀect’. Cells were seeded in 100 μl culture media, plated for 8 - 24 hours,
and treated with 100 μl media containing 2X of the intended drug concentration. ree
technical replicates were performed for at each data point. In addition, each plate contained
wells filled onlywith the culturemedia (blanks) and cells treatedwith the solvent of the drug
(vehicle control) for normalisation (3 technical replicates). At the end of the treatment
period, 100 μl media was removed and 20 μl of CellTiter 96® AQueous MTS solution
(Promega) was added to each well. Plates were incubated for 1 - 3 hours in the dark at
37 C, ensuring the produced brown colouration remained in the quantitative range of the
assay. Air bubbles were removed, the plate was gently shaken and absorbance at 490 nm
was read on a Synergy HT Microplate Reader (BioTek). For data analysis, the average of
technical replicates was calculated, absorbance of the ‘blank’ well was removed from each
well, and data were normalised to the vehicle control (TreatmentVehicle  100%). Data analysis
was automated by a custom programming script written by the candidate in the statistical
language R (Appendix C).
2.2.6 Determination of IC50
Cell proliferation datawas normalised to the vehicle control inR asmentioned in subsection
2.2.5. e ‘drc’ package (Ritz et al. 2015) was used to calculate IC50 using the 4-parameter
(minimum, maximum, the point of inflection and Hill’s slope) logistic regression model
(see Appendix C for the code). In addition, the ‘compParm()’ function of the package
was used to test whether IC50 values of two dose response curves (DRCs) were statistically
diﬀerent using non-linear regression. Cells treated with at least 5 drug concentrations in
serial dilutions were used in the calculations.
2.2.7 Transfection of plasmids into mammalian cells
Cells were seeded in a 6 well plate in 2 ml culture media for 18 - 24 hours according to the
seeding density required by the experiment. In general, cells were 70 - 90% confluent on the
day of transfection. X-tremeGENE 9 DNA Transfection Reagent (Sigma-Aldrich), Opti-
MEM media (ermoFisher) and plasmid DNA were warmed at room temperature. e
ratio of 3 μl X-tremeGENE to 1 μg plasmid DNA was used unless stated. X-tremeGENE
was diluted with Opti-MEM to a total of 100 μl in an eppendorf tube, 1 μg of DNA
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was added, the solution gently mixed by pipetting and incubated for 15 minutes at room
temperature. e transfection mixture was added to the wells in a drop-wise manner and
swirled gently to mix.
2.3 Molecular biology experiments
2.3.1 RNA
2.3.1.1 RNA extraction using the miRNeasy Mini kit
A maximum of 1 107 adherent cells were washed once with warm PBS and harvested
in 700 μl QIAzol lysis reagent (Qiagen) with a scraper. e sample was transferred
to an eppendorf tube and mixed thoroughly by vortexing. e lysate was incubated at
room temperature for 5 minutes, 140 μl chloroform:isoamyl alcohol (24:1) was added
and vigorously mixed by vortexing for 15 seconds. e sample was briefly (2-3 minutes)
incubated at room temperature followed by centrifugation at 12,000 g for 15 minutes at 4
C. e mixture separated into a clear aqueous phase containing RNA (at top), a middle
interphase containing DNA and a bottom pink organic phase containing proteins and
lipids. e aqueous phase containing RNA was carefully transferred to a 2 ml eppendorf
tube, and total RNA was extracted using the miRNeasy Mini kit (Qiagen) on a QIAcube
robotic workstation according to manufacturer’s instructions. RNA was eluted in 30 - 50 μl
nuclease-free water and stored at -80 C.
2.3.1.2 RNA extraction using the RNeasy Mini kit
A maximum of 1 107 adherent cells were washed once with warm PBS and harvested in
350 μl RLT buﬀer (Qiagen) with a scraper. e lysate was transferred to a 2ml eppendorf
tube, and total RNA was extracted using the manufacturer’s protocol for the RNeasy Mini
kit on a QIAcube robotic workstation. RNA was eluted in 30 - 50 μl nuclease-free water
and stored at -80 C.
2.3.1.3 Assessment of RNA concentration and quality using the
NanoDropTM spectrophotometer
epedestal of the NanoDropTM spectrophotometer (ermoFisher) was washed once and
blanked with 2 μl nuclease-free water prior to use. Two μl RNA was used to measure
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its concentration and quality. A sample with both 260/280 and 260/230 ratios of > 2 was
accepted as “pure” with negligible amounts of proteins and salts that may interfere with
downstream analyses.
2.3.1.4 Assessment of RNA integrity using The Bioanalyzer
e integrity of RNA was checked using the RNA 6000 Nano Assay (Agilent Technologies)
according to the manufacturer’s instructions. Briefly, 1 μl Nano dye was mixed with 65 μl
filtered Nano gel. Nine μl of the dye-gel mixture was pipetted into corresponding wells
on the chip, and the chip was primed as described in the protocol*. One μl of total RNA
(25–500 ng/μl) and the ladder were loaded into their respective wells on the chip, and the
gel was run on an Agilent 2100 Bioanalyzer (Agilent Technologies). e virtual RNA gel
and the RNA Integrity Numbers (RINs) are reported in this when appropriate.
2.3.2 RT-qPCR
2.3.2.1 Reverse transcription using the Maxima HMinus kit
RT was performed a final volume of 10 μl using the Maxima HMinus Reverse Transcrip-
tion kit (ermoFisher). Up to 2.5 μg total RNA, 0.5 μl random hexamers and 0.5 μl
dNTP were adjusted with nuclease-free water to a total volume of 7.5 μl. e mixture was
incubated at 65 C for 5 minutes on a DNA Engine® Peltier ermal Cycler (Bio-Rad) to
denature secondary structures followed by 2-3 minutes of incubation on ice. Next, 2 μl
of 5X RT buﬀer and 0.5 μl of the Maxima H Minus reverse transcriptase were added to
the tube, resulting in the final volume of 10 μl. e final concentrations of the RT primers
and dNTP were 5 μM and 0.5 mM, respectively. e sample was incubated at 25 C for
10 minutes followed by 50 C for 30 minutes. cDNA was diluted 10X with nuclease-free
water and stored at 4 C for short term or -20 C for long term storage.
2.3.2.2 Reverse transcription using SuperScript® III First-Strand Synthe-
sis System
e following components were added into a PCR tube: up to 5 μg of total RNA, 1 μl
random hexamers, 1 μl 10 mM dNTPs and nuclease-free water to 10 μl. e tube was
heated at 65 C followed by >1 minute incubation on ice. Next, 10 μl of master mix
*http://www.agilent.com/cs/library/usermanuals/public/G2938-90034_RNA6000Nano_KG.
pdf
49
2.3. Molecular biology experiments
Stage Temp (C ) Time
1 95 10 minutes
2
(40 cycles)
95 15 seconds
60 30 seconds
72 30 seconds
3
(melt curve)
95 30 seconds
60 60 seconds
95 30 seconds
Table 2.6: Conditions for RT-qPCR using SYBR green dye
containing 2 μl 10X RT buﬀer, 4 μl 25 mMMgCl2, 2 μl DTT, 1 μl RNaseOUTTM and
1 μl SuperScript III enzyme (ermoFisher) were added to the same tube. e tube was
briefly centrifuged, and incubated according to the following programme: 25 C for 10
minutes, 50 C for 50 minutes and 85 C for 5 minutes. e cDNA was usually diluted at
10X and stored at 4 C when usage was anticipated for short-term, with long-term storage
-20 C.
2.3.2.3 RT-qPCR using SYBR green dye
RT-qPCR was performed in 10 μl reactions in 384 well plates on an Applied Biosystems
7900HT Fast Real-Time PCR System (ermoFisher). Typically, 8 μl of master mix
was prepared for each primer pair followed by addition of 2 μl diluted template. e
composition of the 8 μl master mix was as follow: 5 μl of 2X SensiMix SYBR Hi-ROX
master mix (Bioline), 1.33 μl of forward and reverse primers (final concentration = 0.4
μM) and 1.67 μl nuclease-free water. PCR conditions are shown in Table 2.6.
2.3.2.4 RT-qPCR using TaqMan probes
RT-qPCR was performed in 10 μl reactions in 384 well plates on an ABI7900 PCR system
(ermoFisher). Typically, 8 μl of master mix was prepared for each TaqMan probe
followed by addition of 2 μl of diluted template. e composition of the 8 μl master
mix is as follow: 5 μl of 2X iTaqTM Universal Probes Supermix (Bio-Rad), 0.5 μl of 20X
TaqMan probe and 2.5 μl nuclease-free water. PCR conditions are shown in Table 2.7, and
TaqMan probes used in this thesis are shown in Table 2.8.
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Stage Temp (C ) Time
1 95 1 minute
2
(40 cycles)
95 15 seconds
60 60 seconds
Table 2.7: Conditions for RT-qPCR using TaqMan probes
TaqMan
Probe Supplier Cat. No City State Country
GAPDH-FAM ThermoFisher Scientific Hs02758991_g1 Scoresby Victoria Australia
TP53-FAM ThermoFisher Scientific Hs01034249_m1 Scoresby Victoria Australia
UCA1-FAM ThermoFisher Scientific Hs01909129_s1 Scoresby Victoria Australia
Table 2.8: TaqMan probes used in this study
2.3.2.5 Analysis of the RT-qPCR data
On completion of the RT-qPCR run, plates were added to a project in the SDS RQmanager
soware V1.2.2. e baseline and the Ct were manually adjusted for each gene if required.
Further analyses were performed in the GenEX V6 or ExpressionSuite V1.1 sowares.
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) was used as a reference gene for
relative quantification of genes using the 2 Ct method (Livak and Schmittgen 2001). For
each sample,Ct was calculated by subtracting the Ct of the GAPDH from each gene of
interest. eCt was calculated by subtracting theCt of the calibrator sample from
each sample. Since Ct was measured on the log2 scale, 2 Ct operation transformed it
back to the linear scale in terms of fold-changes.
Table 2.9: SYBR Green primers used for RT-qPCR.
Gene Forward Reverse Catalogue Number Gene ID RefSeq ID
BAX aac tgg aca gta aca tgg ag ttg ctg gca aag tag aaa ag H_BAX_1 581 NM_004324
BBC3 gta aga tac tgt ata tgc gct g ttt tcc act gtt cca atc tg H_BBC3_1 27113 NM_001127240
C12orf5 aag gac aag gag tag atg aac ctg gag aaa gca tga gta aac H_C12orf5_1 57103 NM_020375
CDKN1A cag cat gac aga ttt cta cc cag ggt atg tac atg agg ag H_CDKN1A_1 1026 NM_000389
GAPDH aca gtt gcc atg tag acc ttt ttg gtt gag cac agg H_GAPDH_1 2597 NM_002046
GCLC tta tta gag acc cac tga cac ttc tca aaa tgg tca gac tc H_GCLC_1 2729 NM_001197115
MDM2 cct tag ctg act att gga aat g tgt tga gtt ttc cag ttt gg H_MDM2_1 4193 NM_002392
TP53I3 atc ttg tgg gaa atg ttc ag cat ttg aag ctt ctt ctg gg H_TP53I3_1 9540 NM_001206802
UCA1 agg aac atc tca cca att tc tct tca tat ggc tgg gaa tc H_UCA1_1 652995 NR_015379
Note: All primers were pre-designed by Sigma-Aldrich, Castle Hill, NSW, Australia
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2.3.3 DNA
2.3.3.1 Gel electrophoresis
Agarose (Bio-Rad) was dissolved in Tris-acetate-EDTA (TAE) buﬀer by heating in a
microwave (see Table 2.10 for composition of the buﬀer). When the solution was cold
enough to touch by hand, a 1:10,000 dilution of SYBR safe DNA gel stain (ermoFisher)
was added and poured immediately into a molding plate. DNA was mixed with 6X DNA
loading dye and electrophoresed at 100 V for 30-60 minutes in TAE buﬀer. e gel was
visualised on a SmartView Pro 2100 Gel Documentation System (Major Science).
2.3.3.2 Precipitation of DNA using ethanol
Milli-Qwater was added to the sample to give a final volume of 50 μl. Next, 5 μl (10% of 50
μl) of 3M sodium acetate (pH 5.2) and 120 μl (~2X volume) were added. e sample was
gently mixed by pipetting and incubated at -20 C overnight. e tube was centrifuged at
maximum speed for 15minutes and the supernatant removed. eDNA pellet was washed
once with 500 μl of cold (-20 C ) 80% ethanol, and dried at room temperature by keeping
the lid open for ~15minutes. e pellet was then dissolved in the desired volume ofMilli-Q
water.
2.3.4 Protein
2.3.4.1 Western blotting
Buﬀer composition is shown in Table 2.10. Cells were washed once with ice-cold PBS, lysed
on ice in Laemmli buﬀer and transferred to an eppendorf tube. e lysate was sonicated for
30 seconds by directly submerging a metal probe in the sample and heating at 95 C for 5
minutes. 10-20 μl of the lysate and SeeBlue® Plus2 protein standards (range 4-250 kDa)
were run on a pre-casted 4-12%NuPAGE® Novex Bis-Tris gels for 1 hour inMOPS running
buﬀer. Protein was transferred on to a nitrocellulose membrane for 90 minutes at 100 V in
cold blotting buﬀer. emembranewas blocked for at least 30minutes at room temperature
in 5% (w/v) skim milk dissolved in the blocking buﬀer followed by incubation with the
primary antibody overnight at 4 C. e membrane was washed 3 times (10 minutes each
time) with washing buﬀer, incubated with secondary antibody for at least 2 hours at room
temperature followed by 3  10 minute washes. Finally, chemiluminescence was detected
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Table 2.10: Composition of buﬀers
Name Constituents Final concentration
TAE Tris-Base 40 mM
Acetic acid 20 mM
EDTA (pH 8.0) 1 mM
(in Milli-Q water)
6X DNA loading dye Bromophenol blue 0.25% (v/v)
Sucrose 40% (v/v)
(in Milli-Q water)
Luria broth (LB) Bacto-tryptone 10 g/L
Bacto-yeast extract 5 g/L
NaCl 10 g/L
(in Milli-Q water)
(Adjust pH to 7.5 with NaOH. Auto-
clave.)
For LB agar plates, add 15 g/L agar be-
fore autoclaving.
MOPS running buﬀer MOPS 50 mM
Tris-Base 50 mM
SDS 0.1% (w/v)
EDTA 1 mM
(pH 7.7)
Blotting buﬀer Tris-Base 25 mM
Glycine 152 mM
Methanol 20% (v/v)
Blocking buﬀer Tris, pH 7.4 40 mM
Tween-20 0.1% (v/v)
Wash buﬀer Tris, pH 7.4 20 mM
Tween-20 0.1% (v/v)
NaCl 150 mM
using Pierce ECL Pico or Dura reagent (ermoFisher) on a LAS-4000 imaging system
(FujiFilm).
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Table 2.11: Primary and secondary antibodies used in this study
Antibody Host Dilution Diluent Molecular
mass (KDa)
Type Catalogue
number
Supplier City State Country
GAPDH (14C10) Rabbit 1:10,000 5% skimmilk 37 Primary 2118 Cell Signaling Danvers MA USA
p53 (1C12) Mouse 1:2,000 5% skimmilk 53 Primary 2524 Cell Signaling Danvers MA USA
Phospho-p53 (Ser15) Rabbit 1:1,000 5% BSA 53 Primary 9284 Cell Signaling Danvers MA USA
p21 (WAF1-
C1P1)(DCS60)
Mouse 1:2,000 5% skimmilk 21 Primary 2946 Cell Signaling Danvers MA USA
anti-mouse IgG HRP Sheep 1:2,500 5% skimmilk NA Secondary NA931 GE Healthcare
Life Sciences
Parramatta NSW Australia
anti-rabbit IgG HRP Donkey 1:2,500 5% skimmilk NA Secondary NA934 GE Healthcare
Life Sciences
Parramatta NSW Australia
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2.4 Bacterial work
2.4.1 Growing bacteria
Small amounts of Escherichia coli (E.coli) from the frozen glycerol stocks were transferred
to a starter culture of ~5 ml LB in a 50 ml Falcon tube, and grown overnight at 37 C at
roughly 225 rpm in a shaking incubator. Ampicillin was used at a final concentration of 0.1
mg/ml as a selectionmarkerwhen required, i.e growingE.coli carrying a plasmid containing
a transgene. All steps were performed under aseptic conditions using a bunsen burner.
2.4.2 Bacterial transformation using the heat shockmethod
Aliquots of commercially available α-Select Chemically Competent Cells were thawed
on ice, and mixed with gentle flicking. Plasmid DNA (1-5 μl) was added, cells were
mixed by gentle flicking and incubated on ice for 30 minutes. e heat shock treatment
was performed for 45 seconds in a pre-warmed water bath set at 42 C, and cells were
immediately returned to ice for ~2 minutes. One ml LB without antibiotics was added to
each tube, and incubated for 1 hour in a shaking incubator set at 225 rpm at 37 C to allow
expression of the antibiotic resistance gene. A small volume (50-100 μl) of this culture was
spread on LB agar plates containing antibiotics (usually ampicillin at 0.1 mg/ml), inverted
and incubated overnight at 37 C. Resistant colonies were selected for future work on the
following day.
2.4.3 Bacterial transformation using electroporation
Electroporation cuvettes (Bio-Rad) were cooled on ice. e electrocompetent E.coli strain
JM109 was thawed on ice, and 1-2 μl (50-100 ng) plasmid DNA was added to the cells
and mixed gently. Cells were electroporated on a Gene Pulser Electroporator (Bio-Rad)
using default settings. Immediately aer electroporation, 1 ml LB was added to the cuvette
and pipetted up and down to mix cells. is solution was transferred to a 1.5 ml eppendorf
tube. As described in the previous subsection, the tube was incubated for 1 hour in a shaker
incubator set at 225 rpm at 37 C, spread on LB agar plates containing antibiotics (usually
ampicillin at 0.1 mg/ml), grown overnight and colonies were picked for future work.
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2.4.4 Plasmid isolation from bacterial cells
Plasmids from 3 ml bacterial cultures grown overnight in the presence of ampicillin were
isolated using PureYieldTM Plasmid Miniprep System (Promega) according to manufac-
turer’s protocol. Briefly, bacteria were centrifuged at the maximum speed, the supernatant
was discarded and the bacterial pellet was re-suspended in 600 μl of water. Cells were
lysed by adding 100 μl Lysis buﬀer and mixed by gently inverting the tube 6 times. ree
hundred and fiy μl cold of Neutralisation solution was added and mixed by inverting.
e eppendorf tube was centrifuged at the maximum speed for 3 minutes, and the clear
lysate was transferred to a PureYieldTM Minicolumn. e minicolumn was placed inside
a collection tube and centrifuged at the maximum speed for 15 seconds. Two hundred μl
of Endotoxin removal solution was added to the minicolumn followed by centrifugation at
the maximum speed for 15 seconds. Next, the minicolumn was washed by adding 400 μl
Column wash solution followed by centrifugation at the maximum speed for 30 seconds.
Finally, the minicolumn was transferred to a fresh eppendorf tube, DNA was eluted in 30
μl Elution buﬀer by centrifugation and stored at -20 C.
2.5 Flow cytometry
2.5.1 Cell viability using DilC1(5)/FVS450 dyes
All centrifugation steps were performed at 300 g for 3 minutes at room temperature.
e MitoProbeTM DilC1(5) dye (ermoFisher) was re-constituted at 1 mg/ml in DMSO.
DilC1(5) accumulates in the mitochondria with active membrane potential, a hallmark of
viable cells, whereas FVS450 (BD) is amembrane impermeable dye analogous to propidium
iodide.
Supernatant was transferred to a round bottom flow cytometry tube and centrifuged to
collect dead cells and debris. Adherent cells were washed once with PBS, and harvested
with trypsin as described in subsection 2.2.1. Supernatant and the adherent fractions were
pooled and washed 2 times with PBS. Samples were suspended in 250 μl PBS, 50 μl of
staining buﬀer [44.5 μl PBS + 5 μl 1X DilC1(5) + 0.5 μl FVS450] was added and the
sample was incubated in the dark at room temperature for 15 minutes.
Flow cytometry analyses were performed using the BD Fortessa cell analyser (BD).
FVS450 and DilC1(5) were excited with violet (405 nm) and red (640 nm) lasers, respec-
tively, and their emission was measured by 450/50 and 670/14 filters, respectively. Com-
pensation was calculated by staining an identical sample, comprising both dead and live
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cells, with both dyes individually. Technically, compensation was found to be unnecessary
due to little overlap in emission spectra of both dyes as well as diﬀerent lasers, which were
spatially separated, used for excitation; however, it was occasionally used for improving
visualisation of the populations. Data was analysed on FACS Diva soware V8.0.1 (BD).
DilC1(5) and FVS450 mark viable (DilC1(5)+/FVS450-; top le quadrant), late
apoptotic/dead (DilC1(5)-/FVS450+; bottom right quadrant) or early apoptotic
(DilC1(5)-/FVS450-; bottom le quadrant) cells. e DilC1(5)+/FVS450+ cells (top right
quadrant) represent artefact of trypsin digestion where cell membrane became permeable
while the mitochondrial membrane potential remained intact. In majority of cases, this
fraction remained unchanged up on various drug treatments.
2.5.2 Statistical analysis
All statistical analyses were performed in R. e student’s t-test was usually two-tailed
assuming equal variance in the two biological groups. Analysis of variance (ANOVA) was
followed by Tukey’s honest significance post-hoc test. Error bars in all Figures represent
standard error of mean (SEM). A P-value < 0.05 was considered significant unless stated.
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Chapter 3
Prediction of surgical outcome of patients
with HGSOC using serum microRNAs
3.1 Introduction
Size of the residual tumour at the conclusion of cytoreductive surgery remains one of the
most important factors influencing the overall survival (OS) and progression-free survival
(PFS) of ovarian cancer (OC) patients (Bristow et al. 2002; Fader and Rose 2007; Griﬃths
1975). Bristow et al. 2002 reported a 5.5% increase in median OS for every 10% increase
in maximal cytoreduction*. Historically, ‘optimal’ cytoreduction status of the surgery was
defined as <1.5 cm of residual disease at the conclusion of the surgery because residual
tumour size beyond this cut-oﬀ, i.e. suboptimal cytoreduction, did not improve OS
significantly (Griﬃths 1975). Although ‘optimal’ is currently defined as <1 cm of residual
tumour, recent evidence suggests that achieving ‘no macroscopic’ residual disease (0 mm;
also known as R0 resection) improves OS even further compared to the presence of any
visible tumour mass aer the completion of surgery (>0 mm) (du Bois et al. 2009; Winter
et al. 2008). Specifically,Winter et al. 2008 reported a doubling inmedianOS of the patients
achieving R0 status (median OS: 64 months) compared to any residual disease (0.1 - 5 cm;
median OS: 30 months). As a result, R0 resection is increasingly becoming recognised
*maximal cytoreduction eﬀort was graded from 0-100%, with >2 cm residual tumour as 0% and <0.5 cm
as 100%.
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as ‘optimal’, and surgeons are encouraged to be aggressive in the cytoreductive surgery to
achieve R0 resection when possible (Chang et al. 2013; Horowitz et al. 2015; Jayson et al.
2014; Nick et al. 2015).
Prediction of surgical outcome is critical as it helps with timing of the surgery. Patients
with >1 cm of residual disease may experience little to no overall benefits from the primary
cytoreductive surgery considering the possible significant morbidity resulting from the
extensive surgery (Bristow 2006; Bristow et al. 2007). In fact, it may be better to avoid
surgery all together and rely purely on chemotherapy in cases with extensive disease
(Bowtell et al. 2015). Neoadjuvant chemotherapy (NACT) could be a suitable option for
patients likely to have suboptimal cytoreduction (Kehoe et al. 2015; Morice et al. 2003;
Schwartz et al. 1999; Vergote et al. 2010). Although OS remains unchanged for these
patients (Kehoe et al. 2015; Morice et al. 2003; Schwartz et al. 1999; Vergote et al. 2010),
they tend to have less morbidity, improving the quality of their lives.
Computed tomography, laparoscopy, aberrant expression of certain genes in tumour
tissue, measurement of serum proteins CA-125 and HE4, machine learning/artificial
intelligence and obtaining a two-surgeon opinion on the resectability of ovarian tumours
(e Anderson Algorithm) have been used to predict surgical outcome (see subsection
1.1.1.6); however, a reliable method remains elusive. Serum microRNAs have not yet
been tested to address this challenge. microRNAs are a class of small RNAs with a
profound biological role in normal physiology as well as diseases such as cancer (Hayes,
Peruzzi, and Lawler 2014; Lin and Gregory 2015; Lu et al. 2005; Schickel et al. 2008).
Notably, microRNAs are present in a variety of biological fluids, and can withstand extreme
conditions such as boiling, multiple freeze-thaw cycles and extended storage (Cortez et al.
2011; McDonald et al. 2011; Wang et al. 2014; Weber et al. 2010), making them a strong
choice for biomarkers. e overall aim of this chapter was to assess the diagnostic role
of serum microRNAs by testing whether pre-operative levels of certain serum microRNAs
could identify patients with HGSOC from healthy women as well as predict their surgical
outcome.
Since serummicroRNAs are influenced by a number of pre-analytical factors (McDon-
ald et al. 2011; Witwer 2015), development and implementation of a thorough quality con-
trol protocol was necessary prior to the microRNA profiling. Traditional predictive tools
such as logistic regression (LR) were tested against modern machine learning (ML) meth-
ods † for their predictive power. As proof-of-principle, the analytical pipeline was first ap-
†LR was performed by the candidate whereas ML was conducted by Professor Jean Yang of the School of
Mathematics and Statistics, University of Sydney, Australia.
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plied to identify microRNAs that could separate HGSOC patients from healthy women,
followed by an assessment of these models to predict surgical outcome.
3.2 Materials andmethods
Since this work is presented over Chapters 3 and 4, common methodologies for both
chapters, such as collection of cell-free serum, RNA extraction, RT-qPCR, data processing
and analysis, can be found in Chapter 2, section 2.1.
3.2.1 Cohort Information
As detailed in Chapter 2, subsection 2.1.1, blood was collected from all individuals accord-
ing to a protocol approved by the Northern Sydney Local Health District Human Research
Ethics Committee (Protocol # 0310-209B). e composition of the cohort is shown in Ta-
ble 3.1. Optimal cytoreduction was defined as R0 resection, i.e. no macroscopic residual
tumour, whereas suboptimal was defined as >1 cm residual tumour. Patients achieving 1
- 10 mm residual tumour were excluded from analyses to potentially observe clear diﬀer-
ences in serum microRNA profiles of a relatively small number of optimally/suboptimally
cytoreduced patients (N = 56).
3.2.2 Quantification of CA-125 levels in serum
CA-125 (also known as MUC16) concentrations were determined using the Quantikine®
ELISA Human CA-125/MUC16 Immunoassay kit (R&D Systems #DCA125, Minneapolis,
United States) according to the manufacturer’s instructions. Serum was diluted 5 – 5000
times in Calibrator Diluent RD5P supplied with the kit. One hundred μl of Assay Diluent
RD1X was added to each well followed by addition of 100 μl of the diluted samples, 7
standards (0.5 to 32 U/ml in a 2-fold dilution series) or zero controls. e plates were
incubated for 2 hours at room temperature on a plate shaker set at 500 rpm, and washed
4 times with Wash Buﬀer. Next, 200 μl of the CA-125 conjugate was added to each well,
incubated for 2 hours at room temperature on a plate shaker set at 500 rpm and washed
4 times. To develop colouration 200 μl of Substrate Solution was added to each well,
incubated for 30 minutes at room temperature followed by the addition of 50 μl of Stop
Solution. All samples were performed in 2 technical replicates. Absorbance was read at 450
nm on a VICTOR3 1420 multilabel plate reader (PerkinElmer). For each plate absorbance
the average of the zero controls was removed from all wells and the averages of technical
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Discovery (N= 43) Validation (N= 43)
Cohort information (N = 86)
Healthy* 15 15
Optimally cytoreduced 15 15
Suboptimally cytoreduced 13 13
Mean age (yr)* SEM
Healthy 61.1 3.4 61 3.3
Optimally cytoreduced 60.5 3.8 59.13.1
Suboptimally cytoreduced 68.7 2.5 67.9 2.8
FIGO Stage
I 1 (3.6%) 3 (10.7%)
II 1 (3.6%) 4 (14.3%)
III 21 (75%) 17 (60.7%)
IV 1 (3.6%) 0 (0%)
Unknown 4 (14.3%) 4 (14.3%)
Interval Debulking
Suboptimally cytoreduced 4 (14.3%) 3 (10.7%)
Table 3.1: Cohort information
*: Samples from healthy women were age-matched within 5 years to samples from women with
ovarian cancer. ‘Interval debulking’: patients underwent primary surgery followed by a few cycles of
chemotherapy. A secondary surgery was performed to excise more tumour mass prior to resuming
additional cycles of chemotherapy. Optimal: R0 resection; suboptimal >1 cm residual disease.
Patients achieving 1 - 10 mm residual tumours were excluded
FIGO Stage Optimal (N=30) Suboptimal (N=26)
I 3 (10%) 1 (3.8%)
II 3 (10%) 2 (7.7%)
III 22 (73.3%) 16 (61.5%)
IV 1 (3.3%) 0 (0%)
Unknown 1 (3.3%) 7 (26.9%)
Table 3.2: Tumour Stage according to the surgical outcome.
replicates were calculated. e standard curve was constructed and the concentrations of
the samples were read oﬀ. All standard curves were of high quality (R2 > 0.99). Log2-
transformed CA-125 values were used in calculations.
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3.2.3 Data analysis
3.2.3.1 Empirical Bayesian test
A typical high-throughput experiment in ‘omic’ technologies measures a much greater
number of variables, ie genes, than the number of samples. e empirical Bayes test (also
known as the moderated t-test) proposed by Smyth 2004 and oﬀered by the R (R Core
Team 2016) package ‘limma’ (Ritchie et al. 2015) modifies the SEM of the student’s t-test by
applying the Baye’s rule on the observed variance of all genes, resulting in a robust estimate
of the SEM.
A matrix containing gene expression values in ‘genes  samples’ format and a design
matrix specifying grouping of the samples to treatments groups were constructed in R. A
linearmodelwas built using ‘lmFit()’ function of ‘limma’ based on the twomatrices followed
by ‘eBayes()’ with the ‘trend’ option set to ‘TRUE’. Benjamini–Hochberg (BH) procedure
was applied to control for false discovery rate (FDR) at 5% unless stated otherwise.
3.2.3.2 Feature selection and evaluating their performances
Using the R package MASS (Venables and Ripley 2002), the ‘stepAIC()’ function was em-
ployed for performing stepwise logistic regression in both directions as a feature selection‡
method identifying predictive biomarkers. A threshold thatmaximised the sum of sensitiv-
ity and specificity was used to calculate the area under curve (AUC) of the receiver operator
characteristic (ROC) curve as well as the accuracy of prediction using the R package pROC
(Robin et al. 2011). A 1000 bootstraps with replacement was calculated using the R pack-
age boot (Davison and Hinkley 1997), and the median values of AUC or accuracy were
reported.
3.2.3.3 Machine learning
e applications of ML algorithms for this thesis were established by Professor Jean Yang
of University of Sydney, and were modified extensively by the candidate. Machine learning
was performed using the R package ClassifyR (Strbenac et al. 2015). In addition, ‘dlda()’
and ‘svm()’ functions of R package sparsediscrim (Ramey 2016) and e1071 (Meyer et
al. 2015) were used to run diagonal linear discriminatory analysis (DLDA) and support
‡‘feature selection’ is the technical term to describe the process of identifying themost important variables
in predicting an outcome.
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vector machine (SVM) algorithms, respectively— both were implemented in the ClassifyR
package.
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3.3 Results
Overview of the experimental design is presented in Figure 3.1.
Optimisation of RT-qPCR 
Assessment of haemolysis 
RT-qPCR 
Data analyses in GenEx and R 
Logistic regression Machine learning 
DE predictors  
using eBayes test 
Feature selection/ 
Stepwise regression 
Performance of the model  
using AUC and accuracy 
Select a suitable algorithm 
based on error rate 
100-times 4-fold cross validation 
Feature selection based on  
inclusion frequencies 
Performance of the model  
using accuracy 
Effect of haemolysis on candidate microRNAs 
Compare 
CA-125 
(pooled data) 
• Discovery phase (186 miRs) 
• Validation phase (48 miRs) 
Figure 3.1: Overview of the study design
‘DE’ refers to diﬀerentially expressed and ‘miRs’ refer to microRNAs
3.3.1 Optimisation and quality control
3.3.1.1 Optimisation of RT-qPCR
First, the selection of small or total RNA was addressed. Since separate buﬀers are required
for extracting total versus small RNAs, it was not clear whether to follow protocols to extract
total RNA, which may not enrich for small RNAs, compared to specific protocols designed
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to enrich small RNAs such as microRNAs but may compromise the levels of large RNAs.
e choice of enriching for small RNAs seemed obvious for a microRNA study. However,
ours and the adjacent laboratory (Cancer Genetics, Kolling Institute) that works on serum
microRNAs have traditionally used total RNA for quantifying serum microRNA. I also
contacted Dr. Kai Wang of the Institute for Systems Biology, Seattle, Washington, United
States of America, who has co-authored 8 studies on circulating microRNAs since 2013, to
ask his opinion on small versus total RNA for serummicroRNAprofiling. He also suggested
using total RNA for profiling. Based on the experience of researchers in our and the adjacent
laboratory, as well as an external researcher, total RNA from serum was used in this study.
Our laboratory had previously used themirVanaTM PARISTM RNA isolation kit to quan-
tify microRNAs from serum (Kan et al. 2012). However, a recent study reported that
the Exiqon miRCURYTM Biofluid RNA Isolation kit was superior in terms of yield of
RNA extracted and removal of inhibitors of PCR out of five commercially available kits
tested: miRCURYTM RNA Isolation Kit – Cell and Plant, miRCURYTM RNA Isolation Kit
– Biofluid, mirVanaTM PARISTM, Qiagen miRNeasy Serum/Plasma Kit and TRIzol reagent
LS for Liquid Samples (McAlexander, Phillips, and Witwer 2013). To compare the per-
formance of mirVanaTM PARISTM and Exiqon miRCURYTM Biofluid RNA extraction kits,
RNA from 200 μl of serum pooled from three HGSOC patients was extracted using both
kits, and the yields were measured using a NanoDropTM 1000 spectrophotometer. e
mirVanaTM PARISTM kit resulted in a higher yield of RNA (1.68 μg/200 μl serum) com-
pared to the miRCURYTM Biofluid kit (150 ng/200 μl serum). eNanoDropTM measure-
ments are known to be inaccurate for serum microRNAs due to their low concentrations;
therefore, RT-qPCR was used to measure the abundance of endogenous hsa-miR-103 (Kan
et al. 2012) as a stable surrogate marker of microRNA levels in RNA extracted from serum.
Haemoglobin, immunoglobin G and lactoferrin tend to be co-purified in low levels
with RNA extracted from serum, which can significantly inhibit reverse transcriptase or
Taq polymerase when high amounts of RNA is used for RT-qPCR (Akane et al. 1994;
Al-Soud, Jönsson, and Rådström 2000; Al-Soud and Rådström 2001). To identify the
maximum amounts of RNA that could be used for RT-qPCRwithout aﬀecting its eﬃciency,
six diﬀerent amounts of RNAwere reverse transcribed in a total of 20 μl using theUniversal
cDNA Synthesis kit (Exiqon), and levels of miR-103 was quantified using RT-qPCR. RNA
extracted using miRCURYTM Biofluid andmirVanaTM PARISTM kits as well as pooled RNA
from both kits in a 1:1 ratio was used. As shown in Figure 3.2A, miR-103 extracted using
the miRCURYTM Biofluid kit consistently resulted in a lower Ct than from the mirVanaTM
PARISTM kit and pooled RNAof both kits, suggesting that themiRCURYTM Biofluid kit was
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Figure 3.2: Selection of RNA extraction kit and RT protocol for serummicroRNA profiling
Two questions were answered by one experiment: (1) identifying themaximum amount of RNA that
does not inhibit RT-qPCR as inhibitors of RT-qPCR tend to be co-purified with RNA, and (2) Selection
of a superior RNA extraction kit between miRCURYTM Biofluid and mirVanaTM PARISTM kits. (A)miR-
103 extracted using the miRCURYTM Biofluid kit consistently resulted in a lower Ct than from the
mirVanaTM PARISTM kit and pooled RNA of both kits, suggesting that the miRCURYTM Biofluid kit was
indeed better for RT-qPCR. Additionally, a linear decrease in the Ct of hsa-miR-103 was observed
when up to 4 μl of RNA extracted using the miRCURYTM Biofluid kit was used as template for RT. (B)
Spike-in RNA UniSp6 was equally added to each RT reaction; therefore, it should be amplified at the
same level in all reaction, whichwas the casewhenup to 4 μl RNAwas used for RT. BothmiR-103 and
UniSp6 indicated that RT-qPCR was not aﬀected using up to 4 μl of serum RNA. Error bars represent
SEM of 3 technical replicates.
indeed better for RT-qPCR. Next, a linear decrease in the Ct of hsa-miR-103 was observed
when up to 4 μl of RNA extracted using themiRCURYTM Biofluid kit was used as template
for RT, indicating an insignificant amount of inhibitors of RT and PCR up to this point.
Furthermore, the spike-in RNA UniSp6, which was utilised to monitor eﬃciency of RT
(subsection 2.1.2), was added to all RT reactions in equal amounts, and amplified using
RT-qPCR. e Ct values of UniSp6 also remained unchanged for up to 4 μl of serum
RNA (Figure 3.2B), which is consistent with results obtained on miR-103.
RT was performed in 20 μl volumes using 4 μl RNA for the Discovery phase where
186 microRNAs (170 candidates + 16 controls) were profiled. Because a small number
of microRNAs (N = 48) were amplified in the Validation phase, we proposed to conduct
RT in a 10 μl volume using 2 μl RNA. To assess the applicability of both protocols to a
large number of samples prior tomicroRNAprofiling, three and two samples were prepared
according to the protocol for the Discovery and Validation phases, i.e 20 μl or 10 μl RT
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Figure 3.3: Testing of the RT protocol in multiple biological samples
(A) Confirming lack of inhibitors for the RT protocol for the Discovery phase. RT was performed in a
total of 20 μl volume using 4 μl RNA as template. No inhibition in miR-103 and UniSp6 levels was
observed, suggesting that this protocol was applicable to a large number of samples. (B) Due to the
smaller number of microRNAs amplified in the Validation phase relative to the Discovery phase, RT
was carried out in a 10 μl volume using 2 μl RNA. Again, no significant inhibition was observed
using this protocol in 2 samples. Error bars represent SEM of 3 technical replicates.
volume using varied amounts of RNA, respectively, and hsa-miR-103 and UniSp6 were
amplified. As shown in Figure 3.3, no inhibition was seen when 4 μl (Figure 3.3A) and
2 μl (Figure 3.3B) of RNA were used in a total of 20 and 10 μl RT reactions, respectively.
3.3.1.2 Assessment of haemolysis
Release of the microRNA content of RBC upon haemolysis has the potential to interfere
with screening processes (Kirschner et al. 2011, 2013; McDonald et al. 2011; Pritchard et al.
2012). As an essential quality control step for this study, I compared sensitivities of four
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diﬀerent methods to detect low levels of haemolysis: Coulter® AcT diﬀTM Analyzer, visual
inspection, the absorbance of haemoglobin measured by spectrophotometry at 414 nm
and the ratio of red blood cell-enriched miR-451a to the reference microRNA miR-23a-3p
(referred to as the ‘miR ratio’). esemethods have been described in the literature (Blondal
et al. 2013; Kirschner et al. 2011, 2013), but a direct study comparing their sensitivities was
missing. is work has been described in detail in Chapter 4 and is published in Plos One
(Shah, Soon, and Marsh 2016).
e ‘miR ratio’ was found to be the most sensitive method to measure low levels of
haemolysis (Shah, Soon, and Marsh 2016), and was used to measure haemolysis in this
cohort. A ‘miR ratio’ of <5, 5-7 and >7 indicate a sample with low, moderate or high risk,
respectively, of being aﬀected byhaemolysis (Blondal et al. 2013). Next, haemolysis amongst
the three biological groups was assessed by one-wayANOVA.No diﬀerences were observed
and no further samples were excluded from the study (P = 0.365; Figure 3.10A). Finally,
diﬀerentially expressed microRNAs was tested to see if they are aﬀected by haemolysis
(subsection 3.3.4; Figure 3.10).
3.3.2 Using logistic regression to identify predictive
biomarkers
3.3.2.1 Predictors of HGSOC from healthy women
e levels of 27 of 170 (16%) microRNAs measured in the Discovery phase using the
Serum/Plasma Focus microRNA panel were found to be significantly diﬀerent between
healthy and HGSOC serum samples (P < 0.05; Figure 3.4A and marked with ‘{’ in
Supplementary Table B.1), of which the 10most highly (5.9%) diﬀerentially expressed (DE)
microRNAs were selected for independent validation in the Validation phase (Table 3.3).
Table 3.4 summarises candidate microRNAs when Discovery and Validation phases were
analysed separately or as a single pooled dataset. In the pooled dataset, levels of CA-125
were approximately 40-fold higher (log2 FC = 5.5) in HGSOC compared to healthy samples
(P = 4.24 10-14, Figure 3.4D and Table 3.4). Overall, miR-375, miR-150-5p, miR-210
and miR-181a-5p were amongst the most DE microRNAs between healthy and HGSOC
samples in the pooled data aer selection based on 5% FDR (Figure 3.4A-C, E and Table
3.4). miR-200c-3pwas found to be strongly upregulated by approximately 5-fold inHGSOC
compared to healthy samples in the Discovery phase (P = 3.5510-9; Figure 3.4A), but this
was not confirmed in theValidation phase (P = 0.116, Figure 3.4E andTable 3.4). miR-200c-
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Figure 3.4: Identification of the predictors separating HGSOC patients from healthy
women.
Volcano plots showing DE predictors identified from (A) Discovery, (B) Validation and (C) Pooled
phases (N=86; Table 3.4 and Supplementary Table B.1). Vertical and horizontal dashed linesmark the
absolute fold-change of 1.5 and P value of 0.05, respectively. Blue and red circles represent predictors
with > 1.5 absolute fold-change with either unadjusted P < 0.05 or were significant after 5% false
discovery rate (FDR), respectively. Only ‘red circles’ are labelled for simplicity. (D, E) Levels of CA-125
and candidate microRNAs in Discovery, Validation and the Pooled dataset. The expression of miR-
375, miR-210, miR-150-5p andmiR-181a-5p are shown in (E) because they were found to be DE after
FDR-correction in the pooled data whereas miR-200c-3p is shown as it was DE only in the Discovery
phase (Table 3.4). * P <0.05, ** P < 0.005 and *** P < 0.0005. Biomarkers that remained significant
after FDR-correction are marked with a red asterisk according to the criteria above.
3p, as a result, was not found to be significant at 5% FDR in the pooled dataset (FDR-P value
= 0.7; Table 3.4).
Given the relatively small cohort sizes of Discovery and Validation phases, data was
pooled and stepwise regression analysis was employed to determine microRNA levels in
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Purpose microRNAs N
Haemolysis miR-451a, miR-16-5p, miR-15b-3p, miR-142-3p, miR-
146a-5p
6
Healthy versus OC miR-200c-3p, miR-92b-3p, miR-150-5p, miR-210, miR-
181a-5p, miR-200b-3p, miR-200a-3p, miR-99b-5p, miR-
141-3p
10
Optimal versus suboptimal cy-
toreduction
miR-34a-5p, miR-145-5p, miR-551b-3p, miR-629-5p, miR-
20b-5p, let-7i-3p, miR-361-3p, miR-505-3p, miR-122-5p,
miR-605, miR-29a-5p, miR-222-3p, miR-29b-2-5p, miR-
30a-5p
15
References miR-93-5p, miR-106b-5p, miR-106a-5p, miR-20a-5p, miR-
144-3p, miR-22-3p, miR-101-3p, miR-29c-3p, miR-19a-3p,
miR-103a-3p, miR-29a-5p
11
Eﬃciency of RT-qPCR UniSp2, UniSp4, UniSp5, UniSp6, cel-miR-39-3p 6
Table 3.3: microRNAs tested in the Validation Phase.
healthy versus HGSOC cohorts. is analysis was undertaken to determine whether data
from Validation and Discovery phases analysed separately could be replicated, and/or
new DE microRNAs identified. Akaike information criterion (AIC) is oen used to rank
competing statistical models. AIC computes loss in information by a given model, and
the model minimising AIC usually represents the best prediction model (Burnham and
Anderson 2004; Kuha 2004; Lindsey and Jones 1998; Symonds and Moussalli 2011).
Stepwise regression, a feature selection method, identified CA-125, miR-375 and miR-210
as the most important predictors of all 10 possible predictors identified with P < 0.05 in
the pooled data (log2 CA-125, miR-150-5p, miR-375, miR-210, miR-181a-5p, miR-141-
3p, miR-200c-3p, miR-106b-5p, miR-551b-3p and miR-629-5p; Table 3.4), reducing the
initial AIC of 48.22 to 37.12 When compared individually, log2 CA-125 had the highest
median AUC of 0.929 in the ROC curve followed by miR-375 (0.765) and miR-210 (0.750;
Figure 3.5A and Table 3.5). Similarly, log2 CA-125 alone had a higher accuracy (0.895) of
prediction whereas both miR-375 and miR-210 alone resulted in the identical accuracy of
0.756 (Figure 3.5C). AUC and accuracy of the prediction model comprising log2 CA-125,
miR-375 andmiR-210 were found to be 0.984 and 0.965, respectively (Figure 3.5B, D; Table
3.5).
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Figure 3.5: Performance of predictors separating HGSOC patients from healthy women.
Area under curve (AUC) and accuracy of the most significant markers identified from stepwise
regression from the pooled data (N=86; 30 healthy + 56 HGSOC samples) to predict healthy versus
HGSOC status: (A, B)whenmarkers are used individually, or (C, D) in combination. Boxplots represent
values of 1000 bootstraps with replacement.
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Discovery Validation Pooled
logFC P FDR-P logFC P FDR-P logFC P FDR-P
Log2 CA-125 5.494 1.79E-09 3.02E-07 5.105 1.97E-07 9.46E-06 5.300 4.24E-14 2.00E-12
150-5p -0.780 0.001 0.034 -1.455 1.83E-06 4.40E-05 -1.118 2.63E-06 6.19E-05
375 -1.288 3.09E-04 0.018 -1.954 5.55E-05 0.001 -1.514 5.50E-05 0.001
210 0.734 0.001 0.036 0.619 0.002 0.019 0.648 1.54E-04 0.002
181a-5p -0.650 0.005 0.079 -0.577 0.025 0.201 -0.602 0.003 0.024
141-3p 1.315 0.001 0.034 0.749 0.154 0.466 1.060 0.010 0.070
200c-3p 2.332 3.55E-09 3.02E-07 0.855 0.116 0.47 1.014 0.013 0.07
92b-3p 0.572 0.001 0.034 0.064 0.815 0.910 0.124 0.619 0.873
200a-3p 1.108 0.002 0.045 0.406 0.384 0.596 0.566 0.121 0.472
99b-5p 0.829 0.003 0.063 -0.197 0.610 0.818 0.290 0.351 0.720
Identified from Pooled Data
106b-5p -0.267 0.361 0.748 -0.337 0.008 0.075 -0.304 0.007 0.058
551b-3p -0.676 0.005 0.080 -0.561 0.061 0.416 -0.573 0.035 0.168
629-5p 0.585 0.014 0.159 0.236 0.263 0.525 0.357 0.036 0.168
Table 3.4: Summary statistics of microRNAs that can separate healthy women from HGSOC patients
Predictors with absolute FC > 1.5-fold are filled with background colour while thosemeeting FDR-corrected P < 0.05 are shown in bold face. FC:
fold-change, FDR: false discovery rate.
3.3. Results
AUC Accuracy
Log2 CA-125 0.929 0.884
miR-375 0.765 0.756
miR-210 0.751 0.756
Log2 CA-125 + miR-375 0.956 0.907
Log2 CA-125 + miR-210 0.952 0.895
miR-375 + miR-210 0.946 0.919
Log2 CA-125 + miR-375 + miR-210 0.984 0.965
Table 3.5: Performance of biomarkers that can separate healthy women from HGSOC patients
Log2 CA-125, miR-375 and miR-210 were found to be the most significant predictors of disease
status, i.e. patients with HGSOC or healthy women, from stepwise regression. Their performances
in predicting the binary outcome was tested by systematically adding additional features in the
predictive model. A model comprising Log2 CA-125, miR-375 and miR-210 resulted in a higher AUC
and accuracy compared to each predictor individually. AUC: area under curve
3.3.2.2 Predictors of the surgical outcome
irteen microRNAs of 170 tested (7.6%) were found to be DE between sera of optimally
and suboptimally cytoreduced (abbreviated as Opt and Subopt hereaer) patients in the
Discovery phase (unadjusted-P < 0.05; Table 3.6 and marked with ‘x’ in Supplementary
Table B.2). In addition to the 13 microRNAs, we included 5 predictors (Log2 CA-125,
miR-222-3p, miR-30a-5p, miR-29a-5p and miR-29b-2-5p), which failed to reach statistical
significance but showed a trend (P between 0.05 and 0.17), for the Validation phase only
(Table 3.6). Log2 CA-125 levels were elevated in Subopt compared to Opt samples by
approximately 4.4 fold (log2 FC = 2.1) in the pooled data; however, this biomarker failed
to achieve statistical significance at 5% FDR (Figure 3.6D and Table 3.6). In contrast, miR-
34a-5p was consistently found to be at a higher level in Subopt versus Opt samples when
Discovery andValidation phases were analysed separately or pooled, satisfying the criterion
of 5% FDR in the pooled data (Figure 3.6C, E and Table 3.6).
Eight of 18 (13 miRs with P < 0.05 + 5 miRs showing a trend) predictors (log2 CA-125,
let-7b-3p, miR-34a-5p, 222-3p, 141-3p, 30a-5p, 29a-5p and 29b-2-5p) were found to be
statistically significant in the pooled data (P < 0.05; Table 3.6). ree additionalmicroRNAs
(miR-92b-3p, 200a-3p and 200c-3p), which were not found to be statistically significant in
the Discovery or Validation data tested individually, also reached the P-value of 0.05 in the
pooled data, resulting in a total of 11 predictors for the feature selection (Table 3.6). Stepwise
regression analysis on the pooled data identified miR-34a-5p and log2 CA-125 as the most
74
3.3. Results
í í 0  
0.
0
0.
5








3.
0
/RJFROGFKDQJH
íO
RJ

3
ív
DO
XH
í 0   3 4
0.
0
0.
5






/RJFROGFKDQJH
íO
RJ

3
ív
DO
XH
í 0   3
0.
0
0.
5








3.
0
3.
5
/RJFROGFKDQJH
íO
RJ

3
ív
DO
XH
DíS
íS
(bOXHSRLQWV 3UHGSRLQWV )'5DGMXVWHG3
Discovery Validation Pooled
Pooled
Test
Training
Log2 CA−125
0
5
10
15
0
5
10
15
0
5
10
15
Predictor
E
xp
re
ss
io
n
Treatment OptSubopt
Pooled
Validation
Discovery
&$í
0



0



0



Predictor
Lo
g 
 (U
/m
l)
Treatment OptSubopt
Pooled
Validation
Discovery
DíS íS íS íS OHWíEíS
í
í
í
í

í
í
í
í

í
í
í
í

microRNA Predictor
(
[S
UH
VV
LR
Q
Treatment 2SW 6XERSW
E
xp
re
ss
io
n
(A) (B) (C)
(D) (E)
**
**
***
*
**
*
*
*
*
*
*
Log2 CA-125
Log2 CA-125
Log2 CA-125
222-3p
222-3p
34a-5p 34a-5p
Figure 3.6: Identification of the markers that predict surgical outcome for women with
HGSOC.
Volcanoplots showingdiﬀerentially expressedpredictors identified from (A)Discovery, (B)Validation
or (C) Pooled set. Vertical and horizontal dashed lines mark the absolute fold-change of 1.5 and P
value of 0.05, respectively. Blue and red circles represent predictors with > 1.5-fold absolute change
with either unadjusted P < 0.05 or were significant after 5% false discovery rate (FDR), respectively.
Only CA-125, miR-34a-5p and miR-222-3p are labelled for simplicity. (D, E) Levels of CA-125 and
candidatemicroRNAs in Discovery, Validation and the Pooled dataset. microRNAs in (E)were chosen
based on their DE (Table 3.6). * P <0.05, ** P < 0.005 and *** P < 0.0005. Biomarkers that remained
significant after FDR-correction are marked with a red asterisk according to the criteria above.
important predictors of surgical outcome out of all 11 predictors, reducing the AIC from
78.04 to 65.64. miR-34a-5p also had a slightly higher bootstrapped median AUC (0.779)
and accuracy (0.750) compared to CA-125 (AUC: 0.700 and accuracy: 0.714, Figure 3.7 and
Table 3.7). A prediction model comprising both predictors resulted in AUC and accuracy
of 0.818 and 0.786, respectively (Figure 3.7 and Table 3.7).
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Discovery Validation Pooled
logFC P FDR-P logFC P FDR-P logFC P FDR-P
34a-5p 0.928 0.001 0.202 1.269 0.004 0.192 1.298 3.31E-04 0.016
222-3p 0.431 0.083 0.755 0.600 0.011 0.241 0.700 0.002 0.042
Log2 CA-125 1.886 0.063 0.755 2.359 0.040 0.321 2.123 0.010 0.150
141-3p 1.037 0.037 0.578 1.161 0.081 0.351 1.244 0.017 0.155
let-7b-3p 0.471 0.025 0.578 0.433 0.157 0.402 0.577 0.020 0.155
30a-5p 0.549 0.074 0.755 0.518 0.117 0.351 0.733 0.025 0.155
29a-5p 0.346 0.162 0.905 0.448 0.159 0.402 0.620 0.025 0.155
29b-2-5p 0.369 0.102 0.773 0.303 0.265 0.427 0.475 0.044 0.187
145-5p -0.698 0.018 0.578 0.472 0.273 0.427 0.345 0.452 0.766
551b-3p -0.631 0.014 0.578 0.200 0.560 0.656 0.083 0.797 0.946
629-5p -0.593 0.026 0.578 0.208 0.444 0.547 -0.072 0.722 0.946
20b-5p -0.657 0.023 0.578 0.063 0.814 0.850 0.021 0.902 0.953
let-7i-3p -0.733 0.019 0.578 0.321 0.175 0.409 0.065 0.813 0.946
361-3p -0.483 0.032 0.578 0.266 0.347 0.484 0.101 0.736 0.946
505-3p 0.509 0.047 0.610 0.284 0.353 0.484 0.558 0.076 0.248
122-5p 0.890 0.027 0.578 0.595 0.251 0.427 0.774 0.084 0.248
605 -1.361 0.036 0.578 0.400 0.324 0.472 -0.140 0.815 0.946
375 0.809 0.044 0.610 0.430 0.391 0.521 0.679 0.110 0.305
Identified from Pooled Data
92b-3p 0.046 0.837 0.966 0.733 0.032 0.310 0.666 0.026 0.155
200a-3p -0.057 0.903 0.973 0.727 0.202 0.421 0.978 0.030 0.156
200c-3p 0.231 0.608 0.962 1.414 0.049 0.339 1.070 0.043 0.187
Table 3.6: Summary statistics of microRNAs that could predict Optimal/Suboptimal cytoreduction
Predictors with absolute FC > 1.5-fold are filled with background colour while thosemeeting FDR-corrected P < 0.05 are shown in bold face. FC:
fold-change, FDR: false discovery rate.
3.3. Results
AUC Accuracy
Log2 CA-125 0.693 0.714
miR-34a-5p 0.777 0.750
Log2 CA-125 + miR-34a-5p 0.818 0.786
Table 3.7: Performance of biomarkers that can separate Optimal/Suboptimal samples
miR-34a-5p and log2 CA-125 were found to be the most significant predictors of the surgical
outcome from stepwise regression. Their performances in predicting the binary outcomewas tested
by systematically adding additional features in the predictive model. A model comprising both
predictors resulted in a higher AUC and accuracy compared to each predictor individually. AUC: area
under curve
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Figure 3.7: Performance of predictors that predict the surgical outcome of women with
HGSOC.
(A) Area under curve (AUC) and (B) accuracy of themost significant markers identified from stepwise
regression from the pooled data to predict the optimal versus suboptimal cytoreduction (N=56; 30
Opt + 26 Subopt samples) whenmarkers are used individually or in combination. Boxplots represent
values of 1000 bootstraps with replacement.
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3.3.3 Usingmachine learning to identifypredictivebiomark-
ers
3.3.3.1 Predictors of HGSOC from healthy women
Two ML algorithms were used to separate patients with HGSOC from healthy women:
DLDA and SVM. Both algorithms were trained on the Discovery dataset and tested on
the Validation dataset by incrementally increasing the number of features§ used for the
classification. Error rates (1 - accuracy) for both algorithms were calculated as a function of
the number of features (Figure 3.8A). Compared to SVM,DLDA showed less fluctuations in
the error rate for predicting healthy or HGSOC status; therefore, was subsequently selected
for 100-times 4-fold¶ cross validation (CV). e top 10 features from each round of CV
were pooled into a frequency table. Ranking the inclusion frequencies of the features from
CV suggested their order of importance for the binary classification (Figure 3.8B). For
example, if a feature is strongly predictive of an outcome, it will tend to be selected more
oen compared to others in the CV and present with a high inclusion frequency.
CA-125 had the highest inclusion frequency followed by microRNAs when both phases
were pooled, suggesting that CA-125 was superior to microRNAs in predicting HGSOC
(Figure 3.8B). Performance of DLDA by incrementally adding more features is shown in
Figure 3.8C, startingwith a combination of Log2CA-125 andmiR-150-5p asDLDA requires
at least two features. Overall, the median accuracy of DLDA using a combination of 10
microRNAs with the highest inclusion frequencies was 0.883 and Matthews correlation
coeﬃcient (MCC), a measure of quality of binary classification with a value of 1 for perfect
prediction, was 0.770 (Figure 3.8C).
§‘features’ is the technical term to refer to predictor variables in machine learning
¶4-fold means that the data was split into 4 equal parts or ‘folds’; 3 folds were used for training the
algorithm and the remaining 1 fold was used to test the performance of the model. is procedure was
repeated 100-times with randomisation, ultimately using all data for training and testing the algorithm.
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Figure 3.8: Applyingmachine learning algorithms to separate patients with HGSOC from
healthy women
(A) Selectionof twoMLalgorithms, diagonal lineardiscriminatory analysis (DLDA) and support vector
machine (SVM), to separatepatientswithHGSOC fromhealthywomen. DLDAwas selected for further
analyses as it resulted in a lower error rate than SVM. (B) Inclusion frequencies of features using 100-
times 4-fold cross validation (CV). (C) Accuracy of prediction using DLDA and multiple features.
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3.3.3.2 Predictors of the surgical outcome
DLDA was also found to have less fluctuations in the error rate of predicting the surgical
outcome compared to SVM, and was selected for 100-times 4-fold CV (Figure 3.9A).
Both miR-34a and miR-222 had higher inclusion frequencies compared to Log2 CA-
125, indicating that microRNAs were superior to Log2 CA-125 in predicting the surgical
outcome (Figure 3.9B). Performance of DLDA by incrementally adding more features is
shown in Figure 3.9C, starting with a combination of miR-34a-5p and miR-222-3p. e
median accuracy of DLDA using a combination of the top 10 microRNAs with highest
inclusion frequencies was 0.688 with MCC of 0.362 (Figure 3.9C).
3.3.4 The eﬀect of haemolysis on DEmicroRNAs
Numerous microRNAs are found to be aﬀected by haemolysis due to the emptying of
microRNA content of red blood cells into serum (Kirschner et al. 2011, 2013; Pritchard et al.
2012). We have previously shown that the ratio of miR-451a tomiR-23a-3p (delta Cq (miR-
23a-3p - miR-451a)), referred to as the ‘miR ratio’, is the most sensitive method to monitor
low levels of haemolysis in serum (Shah, Soon, and Marsh 2016). As discussed previously,
the miR ratio of <5, 5-7 and >7 is indicative, respectively, of a sample at a low, moderate
or high risk of being aﬀected by haemolysis (Blondal et al. 2013). We tested whether
the microRNAs identified to predict surgical outcome or diﬀerentiate serum from healthy
women or ovarian cancer patients were aﬀected by haemolysis. No significant diﬀerences
in haemolysis levels in the three groups (Healthy, Opt and Subopt) were found in pooled
data (one-way ANOVA, P = 0.365; Figure 3.10A). One-way ANOVA also suggested that
miR-210 was significantly aﬀected by haemolysis (P < 0.05) whereas log2 CA-125, miR-375
and miR-34a-5p remained unaﬀected (P > 0.05; Figure 3.10B-F).
3.4 Discussion
Prediction of surgical outcome forHGSOCwomen prior to surgery has a potentially crucial
role in personalising therapeutic options yet remains diﬃcult to achieve. is study used
serummicroRNAs to predict the completeness of surgical resection. As proof-of-principle
that serum microRNAs could potentially diﬀerentiate disease state, we also employed our
analytical pipeline to identify diﬀerentially expressed (DE)microRNAs in HGSOC patients
compared to healthy age-matched women
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Figure 3.9: Applying machine learning algorithms to predict surgical outcome
(A) Selection of two ML algorithms, DLDA and SVM, to predict surgical outcome for women with
HGSOC. DLDA was selected for further analyses as it resulted in a lower error rate than SVM. (B)
Inclusion frequencies of features using 100-times 4-fold CV. (C) Accuracy of prediction using DLDA
and multiple features.
3.4.1 Identifying HGSOC patients from healthy women
Serum microRNAs miR-375 and miR-210 were consistently found to be diﬀerentially
expressed in HGSOC patients versus healthy women in this study. To our knowledge,
these microRNAs have not previously been reported to discriminate healthy women from
patients with ovarian cancer (Table 3.8). miR-375 levels in circulation has been found to be
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Figure 3.10: Eﬀect of haemolysis on candidate predictors.
(A) Haemolysis levels in the three biological groups (Healthy, Optimally and Suboptimally cytore-
duced) in this cohort measured by the ‘miR ratio’ (delta Cq (miR-23a-3p—miR-451a)), the most sen-
sitive method of detecting low levels of haemolysis (Shah, Soon, and Marsh 2016) (B-F) Eﬀect of
haemolysis on the candidate predictors including log2 CA-125. Log2 CA-125, miR-375, miR-34a-5p
andmiR-222-3pwere not aﬀectedbyhaemolysis, suggesting that they are suitable for routine clinical
use where haemolysis is frequent (Hawkins 2010; Lippi et al. 2009).
altered in patients with prostate (Cheng et al. 2013; He et al. 2015; Kachakova et al. 2015;
Selth et al. 2012; Wach et al. 2015), breast (Huo et al. 2016), gastric (Zhang et al. 2012b),
pancreatic (Carlsen et al. 2013) and non-small-cell lung cancers (Yu et al. 2014b) compared
to healthy individuals. Circulating miR-210 has also been suggested as a biomarker of early
recurrence of melanoma (Ono et al. 2015), colorectal (Wang et al. 2016b), pancreatic (Ho
et al. 2010; Yingxia et al. 2015) and clear cell renal cancers (Iwamoto et al. 2014).
Serum protein CA-125 levels had a higher AUC (0.929) and accuracy (0.884) for
predicting theHGSOC status compared to eithermiR-375 ormiR-210 alone that hadAUCs
and accuracies of approximately 0.750 each. A combination of CA-125, miR-375 and miR-
210 increased AUC and the accuracy of prediction to 0.984 and 0.965, respectively. Since
we and others (Kirschner et al. 2013) have shown that miR-210 was aﬀected by haemolysis,
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it may not be suitable for clinical use where haemolysis is common (Hawkins 2010; Lippi
et al. 2009). In contrast, miR-375 was not aﬀected by haemolysis, and a combination of CA-
125 and miR-375 marginally improved AUC (0.953) and accuracy (0.907) of prediction of
HGSOC patients versus healthy women compared to CA-125 alone.
e performance of miR-375 is comparable with the previous study published by our
group that reported a combination of miR-200b and miR-200c in predicting HGSOC from
healthy women (AUC: 0.784; Kan et al. 2012), and by other laboratories (summarised in
Table 3.8). Hausler et al. 2010 reported that miR-343-3p could separate OC patients from
healthy women with an AUC of 0.86. Assuming that a diagnostic test would be unlikely
to rely on a single biomarker, the authors used a panel of 40 microRNAs using SVM that
resulted in an AUC of ~0.85. Nonetheless, microRNA predictive of OC from the study of
Hausler et al. 2010 and others (Table 3.8) were found to be inferior to CA-125, which, in
our study, could predict HGSOC with an AUC of 0.929.
Currently, a population-wide screening test for OC is missing due to high sensitivity
(>0.75) and specificity (0.996) required of the test to attain a PPV of 0.10, a minimum value
for a screening test (Clarke-Pearson 2009; Hennessy, Coleman, and Markman 2009). CA-
125 is also known to be nonspecific and its levels in blood are aﬀected by multiple factors
such as menopausal status, uterine fibroids, ovarian cysts and liver disease (Felder et al.
2014; Matulonis et al. 2016; Verheijen et al. 1999). Any biomarker that is likely to replace
CA-125 in the diagnosis of OC should at least perform as well as CA-125 before being
tested in wider settings that could overcome its limitations. HE4 is increasingly becoming
a promising biomarker with performance reported to be equivalent to CA-125 (Chen et al.
2016; Ferrarow et al. 2013; Hu et al. 2016). A meta-analysis of 9 published studies (N =
1,807;Wu et al. 2012) reported thatHE4 could separateOC fromhealthy samples withAUC
of 0.927, sensitivity of 0.83 and specificity of 0.90, which is comparable with a sensitivity of
0.80 and specificity of 0.75 reported by an earlier meta-analysis performed on CA-125 (17
studies, N = 2,374; Medeiros et al. 2009)￿.
Serum microRNAs have, so far, been unable to match the performance of CA-125 or
HE4 in identifying OC from healthy samples. Most reviews in this field only report the
diﬀerentially expressed microRNAs, not their performance in predicting the healthy/OC
status. A meta-analysis evaluating predictive power of reported microRNAs (similar to
Table 3.8) is needed to identify microRNAs reported from independent studies and to
￿Medeiros et al. 2009 reported AUC of 0.888 for CA-125’s ability to diﬀerentiate malignant versus benign
lesions; however, a healthy versus OC comparison was missing, making it diﬃcult to compare AUCs of HE4
and CA-125 directly. Nonetheless, HE4 outperformed CA-125 in sensitivity and specificity in this study,
making it at least comparable, if not superior, to CA-125.
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evaluate their predictive potential in a large cohort. miR-200a, -b or -c have been reported
for their predictive power fromat least three independent studies (Kan et al. 2012; Selth et al.
2012; Taylor and Gercel-Taylor 2008). Diﬀerences in cohort compositions, methodologies
to quantify serum microRNAs as well as choice of the quality control protocols may
explain why miR-200a, -b or -c were not discovered in other studies. is study and
the study conducted by Kan et al. 2012 — both from our laboratory — had numerous
methodological diﬀerences. e current study used miRCURY RNA isolation kit for
Biofluids (Exiqon) whereas Kan et al. 2012 used miRVANA PARIS kit (Ambion, Applied
Biosystems). Additionally, LNA primers were used in qPCR in the current study versus
pre-amplification using the Taqman PreAmp Master Mix (Applied Biosystems) used by
Kan et al. 2012. Of the samples analysed in the current study, 19 HGSOC and 3 healthy
volunteer serums were also included in this earlier study conducted by Kan et al. 2012. In
this study, miR-200c displayed a strong upregulation in HGSOC sera (FC: ~5-fold, FDR-P
= 3.0210-7) in the Discovery phase, but this diminished when all data were pooled (FDR-
P = 0.07; Table 3.4). miR-200a was not found to be DE in the pooled data, and miR-200b
was present only in the Validation phase at a statistically non-significant level (FDR-P = 0.8;
Supplementary Table B.1). It remains to be tested whether other ncRNAs such as lncRNAs
or circular RNAs could improve or outperform CA-125 or HE4 in diagnosing OC.
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Highest value
microRNA Source Volume AUC Acc Sens Spec FC Reference Comments
miR-200b + miR-200c Serum 500 μl 0.784 0.786 0.464 2.5 Kan et al. 2012
miR-343-3p Whole
blood
5 ml 0.86 Hausler et al. 2010
A panel of 40 miRs 0.85* 0.85* 0.85* miR-375 and miR-210 were not
present on this list.
miR-21, -141, -200a, -
200b, -200c, -203, -205
and -214
Exosomes 2.5ml
serum
Taylor and Gercel-
Taylor 2008
Reported 8 DE miRs, but diagnostic
statistics were missing
miR-21, -92, -93, -126
and -29a (upregulated)
Serum 250 μl 5.4* Resnick et al. 2009 miR-92 had the highest FC of 5.4*.
miR-155, -127 and -99b
(downregulated)
-9.2* miR-99b had the highest FC of -9.2*.
miR-21 Plasma 400 μl 3.4 Xu et al. 2013 Investigated early diagnosis of OC
miR-92 Serum 200 μl 0.803 1.3* Guo et al. 2013 Although miR-92 was DE in EOC ver-
sus healthy samples (P <0.05; N =
100), the FC seemed low (read-oﬀ the
graph). Haemolysis-sensitive miR-16
used as reference.
miR-205 + let-7f Plasma 250 μl 0.726 -
0.831
0.62 -
0.64
0.72 -
0.929
Zheng et al. 2013 Statistics on multiple validation sam-
ple reported, but a pooled analysis
was lacking.
miR-132, -26a, -143, -145
and let-7b
Plasma 500 μl >-2 Chung et al. 2013 All 5 miRs were downregulated. Diag-
nostic statistics were missing
miR-1290 Plasma 1 ml 0.87 14.57 Shapira et al. 2014
miR-92a Urine ex-
osomes
31.97 Záveský et al. 2015
miR-106b -3.7
miR-100 -3.3
miR-206 Plasma 21.26 Ayaz et al. 2014 Used plasma of 3 ml blood
miR-200c Serum 0.79 0.72 0.7 1.8* Gao and Wu 2015
miR-141 0.75 0.69 0.72 1.7*
Table 3.8: Summary of microRNAs predictive of OC
Only highest values of performance indicators are reported. * exact values were not reported in the manuscript, but they were read-oﬀ the graphs. AUC: Area under curve,
Acc: accuracy, Sens: sensitivity, Spec: specificity, FC: fold-changes. Positive and negative FC represent up- or down-regulation of a miR in OC compared to healthy controls.
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3.4.2 Prediction of surgical outcome
Serum levels of miR-34a-5p and log2 CA-125 were found to be predictive of surgical
outcome for women with HGSOC, with miR-34a-5p performing slightly better than log2
CA-125 (AUC: 0.779 versus 0.700, and accuracy: 0.750 versus 0.714, respectively). e
final AUC and accuracy of 0.818 and 0.786, respectively, were achieved by combining both
markers (Figure 3.7 and Table 3.7).
e identification of miR-34a-5p in predicting surgical outcome is intriguing. Indepen-
dent studies have established that miR-34a-5p is a potent tumour suppressor microRNA
and a direct transcriptional target of the wild-type (wt) p53, resulting in cell cycle arrest
and apoptosis upon induction (Adams, Parsons, and Slack 2016; He et al. 2007; Hermek-
ing 2012; Rokavec et al. 2014). Several pre-clinical studies have demonstrated the eﬃcacy
of restoring expression of the miR-34 family of microRNAs in inhibiting tumour growth
in mouse models of lung (Kasinski and Slack 2012; Wiggins et al. 2010), pancreatic (Pra-
manik et al. 2011) and prostate cancers (Liu et al. 2011a). In fact, restoring expression of the
miR-34 family of microRNAs is currently being tested as a cancer therapy in a clinical trial
(NCT01829971). miR-34a-5p was found to be downregulated in late versus early stages of
EOC (Eitan et al. 2009; Zhang et al. 2008) as well as EOC compared to the normal ovarian
surface epithelial cells by promoter hypermethylation (Corney et al. 2010; Schmid et al.
2016). Of note, these studies were conducted in EOC, of which HGSOC is the most com-
mon subtype (Matulonis et al. 2016) and their findings should translate well to HGSOC.
Given the downregulation of miR-34a-5p in EOC, it remains unlikely that miR-34a-5p is
released at elevated levels from presumablymore aggressive suboptimally cytoreducedHG-
SOC.
Besides cancer, miR-34a-5p has been shown to play a crucial role in normal physiology
and diseases such as metabolic syndromes (Lovis et al. 2008; Rottiers and Näär 2012; Yang,
Cappello, and Wang 2015), senescence of endothelial cells (Qin, Yang, and Xiao 2012),
aging of cardiac cells (Boon et al. 2013) and platelet production (Gatsiou et al. 2012).
erefore, the observed elevation in miR-34a-5p could be a result of the body’s response
to suboptimally cytoreduced tumours.
e current study highlights ongoing challenges in predicting the surgical outcome. A
range of modalities such as CT, laparoscopy, expression of mRNAs from tissues, surgical
management using the two-surgeon opinion approach (eAnderson Algorithm), circula-
tory proteins CA-125 andHE4 have been attempted as well as the use of serummicroRNAs
as conducted in this study. A reliable method of predicting surgical outcome to identify pa-
tients that are either likely, or unlikely, to respond well to the primary cytoreductive surgery
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remains elusive. e challenge could partly be attributed to variations in skills of surgeons,
attitudes as well as policies of institutes towards aggressive surgeries. Modalities such as
CT have been found to be promising in predicting the surgical outcomes in single centre
studies (Bristow et al. 2000; Dowdy et al. 2004) but failed to attain suﬃcient performance
in multicentre trials (Axtell et al. 2007; Borley et al. 2015; Mackintosh et al. 2014), partially
due to variability in radiologists’ skills (Mackintosh et al. 2014). us, inconsistencies in
patient management are a significant hurdle to overcome.
Standardised patient care is the crux of ‘e Anderson Algorithm’ which uses la-
paroscopy with at least 2 surgeons’ opinions on the surgical resectability of the tumour
(Nick et al. 2015). Although the study has not been oﬃcially published yet, the initial results
reported in a review by Nick et al. 2015 have been promising, with the rate of R0 increasing
from 20% to 84% since implementation of the protocol. e eﬀect of laparoscopy combined
with either one surgeon or multiple surgeons’ opinions on the likelihood of R0 resection
also remains to be seen, which would indicate the eﬀect of unstandardised protocols on the
rate of R0 resection. Given the low prevalence of OC, implementing a two-surgeon opinion
approach may be diﬃcult to achieve in smaller centres. However, if approaches such ase
Anderson Algorithm are proven to be eﬀective in multicentre studies, they would represent
strong evidence for streamlining the surgical management of OC patients.
3.4.3 A commentary on statistical methods
Traditional methods such as LR and ML algorithms originated as diﬀerent branches of
statistics with their own jargon to oen describe the same concepts (Iterson, Haagen,
and Goeman 2012). Briefly, traditional statistics put significant emphasis on accuracy of
the probability distribution function, such as the Gaussian (‘normal’) distribution, and
estimates of the parameters (e.g. mean and standard deviation); performance measures
are calculated aerwards. In contrast, ML algorithms aim to maximise accuracy of the
prediction based on linear or non-linear functions that separate the binary outcomes (Wale
2011). I have used accuracies predicted by LR and ML to compare their performances.
e consulting statistician, Professor Jean Yang of e University of Sydney, Australia,
found it appropriate to use two ML algorithms (DLDA and SVM) to model the data.
SVM resulted in significantly more variations in the accuracy of prediction than DLDA for
classifying healthy/HGSOC and Opt/Subopt outcomes. In both predictions, LR resulted
in a higher accuracy of the prediction than DLDA. However, this is not a criticism of ML
algorithms. DLDA performed reasonably well in separating HGSOC from healthy samples
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(median accuracy: 0.883), where there were obvious diﬀerences between the two biological
groups. In addition, only 2 algorithms were attempted in this study whereas ML consists
of an exhaustive number of algorithms, with >200 algorithms implemented in a single R
package ‘caret’ (Jed Wing et al. 2016).
3.5 Conclusions
Pre-operative prediction of surgical outcome has the potential to improve clinical man-
agement of patients with HGSOC by optimising the timing of the surgery, i.e. before
chemotherapy (current standard treatment) or aer ‘shrinking’ tumours with a few rounds
of chemotherapy (neoadjuvant chemotherapy). Although prediction of the surgical out-
come using serum microRNAs was the primary aim of this study, a thorough quality con-
trol protocol, including measurements of low levels of haemolysis, was first developed for
reliable quantification of serummicroRNAs (Chapter 4). is study identified that levels of
miR-375 and miR-210 in serum can separate patients with HGSOC from healthy women,
both have not been reported in the literature for this purpose previously to our knowledge.
In addition, serum miR-34a-5p was found to be slightly superior to CA-125 in predicting
the surgical outcome. Finally, miR-375 and miR-34a-5p were not aﬀected by haemolysis,
suggesting their suitability for routine use as circulating biomarkers.
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Chapter 4
Detecting low levels of haemolysis in serum
4.1 Introduction
Since serummicroRNAs and their extracellular carriers (exosomes,microvesicles and high-
density lipoproteins) bathe in blood, the microRNA content of blood cells could interfere
with analyses of disease-associated microRNA profiles due to haemolysis. Leakage of the
content of RBC is potentially a grave source of contamination given the vast abundance of
RBCs in blood compared to other blood cells such as leukocytes, although lymphocyte-
derived microRNAs such as miR-150 could also be aﬀected by haemolysis to a lesser
extent (Pritchard et al. 2012). Recent studies have shown that 58% (46/79) of proposed
microRNA biomarkers for solid cancers were highly expressed in one or more blood
cell types (Pritchard et al. 2012), and up to 65% of detectable microRNAs in plasma
were aﬀected by haemolysis (Kirschner et al. 2013). Although certain diseases such as
chronic lymphocytic leukaemia can cause haemolysis in vivo, blood collection protocols
andprocessing seem to be a common cause of haemolysis (Kirschner et al. 2013). According
to a study on 111,780 clinical samples, up to 43% of the clinical samples were found to
be haemolysed based on free haemoglobin levels >0.5 g/L (Hawkins 2010). On the other
hand, only 5.6% manifested the pink discolouration visible to the naked eye (Lippi et al.
2009). Taken together, haemolysis has the potential to lead to inaccurate quantification
of microRNAs in a significant proportion of samples, including the current study. As an
example, the reference miR-16 used for normalising data in some serum/plasma studies
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was found to be severely aﬀected by haemolysis, questioning its suitability as a reference
microRNA (Kirschner et al. 2013; McDonald et al. 2011).
Determining robust methods to enable sensitive detection of haemolysis that may
aﬀect the identification of disease-associated microRNA was essential for the microRNA
studies presented in Chapter 3 of this thesis. Earlier studies by others employed the
presence of pink discolouration of serum as a marker of haemolysis; however, it was later
discovered that plasma samples can already be aﬀected by haemolysis before manifesting
this discolouration (Kirschner et al. 2011, 2013). For example, Kirschner et al. 2011
established that RBC concentration of up to 0.125% (v/v) of plasma could be detected as
visually pink indicating that haemolysis had occurred. e levels of haemolysis-sensitive
miR-16 andmiR-451; however, could be detected at just 0.031% (v/v) haemolysis in plasma
(Kirschner et al. 2011). Alternative methods, such as measuring the peak absorbance
of haemoglobin at 414 nm by spectroscopy, or quantifying levels of miR-451a, the most
abundant microRNA in RBC, compared to the reference microRNA miR-23a (the ‘miR
ratio’) were proposed in the literature, but a direct comparison to determine the sensitivities
of these was lacking (Blondal et al. 2013; Kirschner et al. 2011).
In this chapter, I present a detailed analysis of diﬀerent methods to detect haemolysis,
including use of a cohort of serum collected fromhealthywomen andwomenwithHGSOC.
e utility of routinely used equipment to determine haemoglobin levels in the clinic such
as the Coulter®AcT diﬀTM Analyzer as well as visual inspection for pink discolouration
in serum were investigated to determine their ability to robustly detect low levels of
haemolysis.
Declaration: is study has been published (see Shah, Soon, andMarsh 2016). e text
in Materials & Methods, Results, Discussion and Conclusion of this chapter is identical to
the work originally published in American English, but has been re-formatted to Australian
English for this thesis. In-text citations have been updated to match the references in the
bibliography. American English has been retained within the published figures.
The followingmethodologydescribed in thepublishedpaper is expanded
elsewhere:
• Blood collection and ethics information: Chapter 2, subsection 2.1.1, p. 36
• RNA extraction from serum: Chapter 2, subsection2.1.2, p. 41
• RT-qPCR for detecting serum microRNAs: Chapter 2, subsection 2.1.3, p. 41
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• Data analysis: Chapter 2, subsection 2.1.4, p. 42
Complete citation: Shah JS, Soon PS and Marsh DJ. Comparison of Methodologies to
Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs,
PloS One (2016). doi: http://dx.doi.org/10.1371/journal.pone.0153200
4.2 Materials andmethods
4.2.1 Haemolysis dilution series
Whole blood, 0.5ml collected from a healthy volunteer, was allowed to clot in an eppendorf
tube, and sonicated until the sample was completely fluid and bright red, indicative of
a high degree of haemolysis. Serum was isolated from the blood of a healthy volunteer
as per the healthy volunteers’ protocol. is sample, collected under optimal conditions,
was classified as unhaemolysed for the purpose of this study. A haemolysis dilution series
comprising 100%, 20%, 4%, 1%, 0.25%, 0.062%, 0.016%, 0.004%, 0.001% haemolysed
and unhaemolysed samples (v/v) was prepared by serial dilution of the 100% haemolysed
sample with unhaemolysed serum.
4.2.2 Assessment of haemolysis
Haemolysis in serum samples was measured using 4 methods. e first method mea-
sured haemoglobin concentration using the Coulter® AcT diﬀTM Analyzer and the Tainer
Reagent Kit (Beckman Coulter Inc # 8547135, Lane Cove, NSW, Australia). ree tech-
nical replicates were performed for each sample. e second method to assess haemolysis
was simple visual inspection of serum samples for pink discolouration indicative of free
haemoglobin against a white background. Visual discolouration of each sample was scored
from 0 (unhaemolysed serum) to 5 (100% haemolysed serum). e thirdmethod wasmea-
surement of the absorbance of haemoglobin at 414 nm using a NanoDropTM 1000 spec-
trophotometer (ermo Scientific, Scoresby, Victoria, Australia), averaging two technical
replicates per sample. Lastly, the fourth method used determined the ratio of miR-451a
to miR-23a-3p (delta Ct (miR-23a-3p - miR-451a)) referred to hereon as the “miR ratio”),
with RT-qPCR. ree RT reactions were performed for each sample followed by one PCR
per RT.
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Figure 4.1: Sensitivities of four methods to detect haemolysis.
(A) A haemolysis series was prepared by diluting 100% haemolysed sample with unhaemolysed
serum (0%), and the sensitivity of each method determined by its ability to detect haemolysis
(indicated by arrows). (B - E) Detection of haemolysis using four methods. For visual inspection,
samples were scored from 0 (unhaemolysed sample) to 5 (100% haemolysis). Averages of technical
replicates are shown where appropriate. ‘Unhem’ denotes unhaemolysed serum. Absorbance
measures (D) and miR ratios (E) are noted on the graphs.
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4.3 Results
4.3.1 Sensitivities of four methods to detect haemolysis
Four methods for the detection of haemolysis were compared using the haemolysis dilu-
tion series as described. e Coulter® AcT diﬀTM Analyzer measurement of haemoglobin
could detect down to 1% haemolysis, while the 0.25% haemolysed and the unhaemolysed
sample remained indistinguishable (Figure 4.1B). By visual inspection alone, the pink dis-
colouration of free-haemoglobin could be detected down to 0.25%haemolysis (Figure 4.1A,
C). In contrast, the spectrophotometric method could detect down to 0.004% haemolysis
(Figure 4.1D).e calculatedmiR ratio could detect down to 0.001% haemolysis, the lowest
point tested, making it the most sensitive method (Figure 4.1E). e Coulter® AcT diﬀTM
method was excluded from further analyses due to its low sensitivity. erefore, in order of
decreasing sensitivity, the methods used can be ranked as miR ratio > spectrophotometry
> visual inspection > Coulter® AcT diﬀTM Analyzer.
Next, we determined the haemolysis levels of 86 samples (56 women with ovarian
cancer and 30 age-matched, healthy females) using visual inspection, spectrophotometric
absorbance and the miR ratio. Using the miR ratio as the ‘gold standard’, 16% (14/86), 48%
(41/86) and 36% (31/86) of the samples were found to have low (miR ratio <5), moderate
(miR ratio between 5 and 7) or severe (miR ratio >7) haemolysis, respectively, according
to the criteria defined by Blondal et al. 2013, highlighting haemolysis as potentially a
problematical factor, even when serum samples are collected under optimal conditions
(Figure 4.2A). e miR ratio of the unhaemolysed sample used to construct the dilution
series was 4.59  0.10. In contrast, the miR ratio for the 0.25% haemolysed sample, the
limit of visual inspection, was 7.67  0.14. Furthermore, 100% of the samples with pink
discolouration (8/8) had a miR ratio >7, suggesting that any samples with visible pink
discolouration were already severely aﬀected by haemolysis (Figure 4.2A).
4.3.2 Identification of severely haemolysed samples using
visual inspection and the absorbance of haemoglobin
Since the majority of the severely haemolysed samples based on the miR ratio (74%; 23/31)
were visually undetectable, we investigated whether the absorbance of haemoglobin could
be utilised to detect additional severely haemolysed samples, i.e miR ratio >7. e samples
93
4.3. Results
Figure 4.2: Comparison ofmethodologies for determining haemolysis in serum samples.
(A) Serum samples (N=86) categorised by low (miR ratio <5; N=14), moderate (miR ratio 5-7; N=41)
and severe (miR ratio >7; N=31) haemolysis. Results of visual inspection are recorded for each
category as the proportion of samples that are clear, cloudy or visibly pink. (B)Absorbance at 414 nm
and themiR ratio of the cohort (N=86). Thedotted line represents the threshold abovewhich samples
are considered to be severely haemolysed according to themiR ratio (>7). Samples are colour-coded
according to their visual appearance (clear, cloudy or visibly pink).
with pink discolouration had both higher absorbance (0.46 0.11) and miR ratios (8.29
0.51; Figure 4.2B).
No significant diﬀerences were observed between the absorbance of low and moderate
haemolysed samples as classified by the miR ratio (P = 0.13; Figure 4.3A); however,
low and moderately haemolysed samples were significantly diﬀerent from the severely
haemolysed samples (P <0.001 & <0.0001, respectively). In other words, the miR ratio
could further quantify haemolysis in the samples that were indistinguishable by absorbance.
Severely haemolysed samples (miR ratio >7) had 1.85-fold higher absorbance than low
and moderately haemolysed samples combined together (miR ratio <7; P <0.0001;Figure
4.3B), indicating that the absorbance of haemoglobin could have predictive value in
discriminating severely haemolysed (miR ratio >7) samples. e ROC curve separated
severely haemolysed samples from the rest with an AUC of 0.8038 (P <0.0001; Figure
4.3C). e cut-oﬀ absorbance of 0.3 identified 48.4% (15/31) of haemolysed samples,
of which 8 were visually undetectable. e accuracy of prediction using this cut-oﬀ
(True Positive + True NegativePositive+Negtive ) was 0.779.
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Figure 4.3: Identification of samples with low or severe haemolysis by spectrophotomet-
ric absorbance
(A) Cohort (N=86) is grouped by low (miR ratio <5; N=14), moderate (miR ratio 5-7; N=41) and severe
(miR ratio >7; N=31) predicted risk of haemolysis, and absorbance at 414 nmwas compared between
groups. No significant diﬀerences in absorbance of samples were observed between the low and
moderate groups; however, both were significantly diﬀerent to the severe haemolysis group. (B-C)
Absorbance of samples with miR ratio >7 was 1.85-fold higher than those with miR ratio <7. ROC
analysis suggested that absorbance could predict severely haemolysed samples (miR ratio >7). The
cut-oﬀ for absorbance of 0.3 identified by ROC is shown as a dotted red line. (D-E) ROC analysis
revealed a cut-oﬀ for absorbance of 0.072 (depicted as a dotted red line) belowwhich sampleswould
be predicted to have low levels of haemolysis (miR ratio <5). ** P < 0.001, *** P < 0.0001 and ##Mann-
Whitney U test P < 0.001. ‘TPR’ and ‘FPR’ refer to true and false positive rates, respectively.
We tested whether a similar analysis could identify an absorbance cut-oﬀ below which a
sample is likely to have low levels of haemolysis (miR ratio <5; Figure 4.3D). Despite similar
median values between the two groups (miR ratio <5 and >5), the cut-oﬀ absorbance of
0.072 could identify sampleswith a low risk of haemolysiswithAUCof 0.7173 (Figure 4.3E).
In general, absorbance-based tests to predict haemolysis suﬀered from low sensitivity, but
oﬀered high specificity and moderate positive and negative predictive values (Table 4.1 and
Figure 4.5).
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Low risk (miR ratio <5) Severe risk (miR ratio >7)
All samples
(N=86)
Clear samples*
(N=77)
All samples
(N=86)
Clear samples*
(N=77)
Cut-oﬀ absorbance 0.072 0.072 0.300 0.300
AUC 0.717 0.733 0.804 0.756
Accuracy 0.849 0.831 0.779 0.779
Sensitivity 0.250 0.250 0.484 0.333
Specificity 0.986 0.984 0.946 0.981
PPV 0.800 0.800 0.833 0.889
NPV 0.852 0.833 0.765 0.765
Table 4.1: Assessment of performance of the spectrophotometric absorbance of haemoglobin at
414 nm for predicting the miR ratio.
Absorbancemeasurements of samples were split into two groups for each comparison: (I) prediction
of low risk of haemolysis (miR ratio<5): <5 versus>5, and (II) predictionof high risk of haemolysis (miR
ratio >7): >7 versus <7. ROC analysiswas performed for each comparison, and the cut-oﬀ absorbance
that maximised the accuracy of prediction was selected. Sensitivity, specificity, PPV and negative
predictive value (NPV) were calculated based on the chosen cut-oﬀ. *refers to samples that did not
have a pink discolouration or were cloudy.
4.3.3 Impact of haemolysis on haemolysis-sensitivemicroR-
NAs
Since the microRNAs aﬀected by haemolysis originate predominantly from the rupture of
RBC, the extent to which a specific microRNA is altered may depend on its abundance in
RBC. Using RBC-derived miR-16-5p and miR-15b-3p surrogates for haemolysis-sensitive
high and low abundant microRNAs based on Ct values in the cohort as a whole (Figure
4.4), we calculated diﬀerences in their levels across the 3 categories defined by the miR
ratio, especially for miR-15b-3p as most microRNAs in serum are likely to be present at
moderate or low levels. e levels of miR-16-5p and miR-15b-3p increased as the miR
ratio increased (Figure 4.4A, B). miR-16-5p and miR-15b-3p were found to be altered by
5.9-fold (P <0.0001) and 4.5-fold (P <0.0001), respectively, in the samples at severe risk of
haemolysis (miR ratio >7) compared to those at low risk (miR ratio <5). Both microRNAs
were also found to be elevated by approximately two-fold between miR ratio categories
<5 compared to 5-7, as well as 5-7 compared to >7. us, both high and low abundant
microRNAs susceptible to haemolysis are significantly altered amongst 3 categories defined
by the miR ratio. miR-23a-3p was present at a similar level in each of the 3 categories as
expected (Figure 4.4C).
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Figure 4.4: Haemolysis-sensitive high and low abundant microRNAs are significantly
altered between categories defined by the miR ratio.
(A) Levels of haemolysis-sensitive highly abundant serum microRNA miR-16-5p was found to be
significantly altered across low, moderate and severely haemolysed serum samples defined by miR
ratios (B) Levels of a haemolysis-sensitive low abundant microRNA miR-15b-3p were also diﬀerent
across allmiR ratio categories. (C)miR-23a-3pwas present at a similar level amongst three categories,
supporting its use as a reference microRNA in determining the miR ratio. * P <0.05, ** P < 0.001 and
*** P < 0.0001.
4.4 Discussion
SerummicroRNAs are attractive non-invasive biomarkers because of their disease-specific
expression and stability in a wide range of conditions. However, a series of pre-analytical
and analytical variables must be considered in the development of robust and reliable
microRNA-based tests (Becker and Lockwood 2013; Calin and Croce 2006; Cortez and
Calin 2009; Cortez et al. 2011; Lin and Gregory 2015; Lu et al. 2005; McDonald et al. 2011;
Schickel et al. 2008; Witwer 2015). e eﬀect of release of the microRNA content of blood
cells upon haemolysis dramatically alters the level of specific serum microRNAs. Recent
studies have shown that 58% (46/79) of proposed microRNA biomarkers (Pritchard et al.
2012) for solid cancers were highly expressed in one or more blood cell types, and up to
65%of detectablemicroRNAs in plasmawere aﬀected by haemolysis (Kirschner et al. 2013).
Haemolysis in clinical samples is common. Reports have suggested that approximately 43%
of clinical samples are haemolysed as determined by free haemoglobin >0.5 g/L, whereas
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Figure 4.5: Assessment of haemolysis in serum samples.
All serum samples exhibiting pink discolouration were found to be strongly aﬀected by haemolysis
for microRNA profiling according to themiR ratio. After exclusion of the visibly haemolysed samples,
samples with absorbance at 414 nm of >0.3 are also likely to be have miR ratio >7, predicting severe
haemolysis. In contrast, samples with an absorbance at 414 nm of <0.072 are predicted to have a
miR ratio <5. Samples meeting these criteria may be excluded from miR ratio for the purpose of
determining haemolysis; however, the miR ratio should be determined for samples with absorbance
between 0.072 and 0.3. PPV and NPV refer to positive and negative predictive values after removal
of visibly haemolysed or cloudy samples, respectively.
visual detection indicated by the presence of a pink discolouration is seen in less than
6% of samples (Hawkins 2010; Lippi et al. 2009). erefore, quantifying haemolysis is an
essential step for any procedure measuring circulatory microRNAs for diagnostic purposes
or biomarker discovery. A number of methods to measure haemolysis in serum have been
described; however, a direct comparison assessing their sensitivities has not been reported.
In our study of serum, using a 4-fold dilution series, visual inspection could only detect
down to 0.25% haemolysis (v/v). is is comparable to the detection limit of 0.125% (v/v)
identified by Kirschner et al. 2011 using a 2-fold dilution series of plasma (Kirschner et al.
2013). We and others have shown that visual inspection, i.e. identification of visible pink, as
a measure of haemolysis is insuﬃcient as levels of haemolysis-sensitive microRNA such as
miR-451a are already compromised prior to visual detection (Blondal et al. 2013; Kirschner
et al. 2013).
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e ratio of miR-451a to miR-23a-3p was found to be the most sensitive method
that could detect down to 0.001% haemolysis in serum. We quantified haemolysis levels
of 86 samples using the miR ratio, and discovered that haemolysis-sensitive microRNAs
miR-15b-3p and miR-16-5p were significantly aﬀected in the categories of haemolysis
(low, moderate and severe) defined by Blondal et al. 2013. In particular, the levels of
low abundant, haemolysis-sensitive miR-15b-3p were approximately 4.5-fold higher in the
samples with low (miR ratio <5) versus severe (miR ratio >7) risk of haemolysis. e
diﬀerences were greater for the more abundant miR-16-5p between the same groups (5.9-
fold).
While the miR ratio was the most sensitive method to detect low levels of haemolysis,
it may not be suitable for all large-scale screening for haemolysis due to additional cost
and a relatively large requirement for starting material (200 μl serum). e absorbance of
haemoglobin at 414 nm, on the other hand, is a suitable alternative as it overcomes these
restrictions and was found to be more sensitive than visual inspection in our dataset. We
tested whether absorbance could identify samples that are at a severe risk of haemolysis
(miR ratio >7) but remained undetectable by visual inspection. ROC analysis revealed that
absorbance at 414 nm >0.3 (water as blank) identified severely haemolysed samples with
accuracy, PPV andNPV of approximately 80% (Figure 4.5). Over half (8/15) of the samples
were visually undetectable. Similarly, Kirschner et al. 2013 suggested use of absorbance at
414 nm>0.2 (unhaemolysed plasma as blank) to identify haemolysis in plasma as it reduced
variability in miR-451 levels (Kirschner et al. 2013). e diﬀerent choices of blanks and
serum versus plasma may have led to the diﬀerences observed. Interestingly, some samples
in our study had lower absorbance than the unhaemolysed serumused in the dilution series;
therefore, water seemed to be an appropriate choice of blank. Similarly, based on our data,
samples with absorbance less than 0.072 are likely to be at low risk of haemolysis (miR ratio
<5).
Given that a substantial number of circulatory microRNAs are known to be aﬀected by
haemolysis, the miR ratio is recommended as the final quality control step unless clearly
indicated in the literature that the microRNA of interest is not aﬀected by haemolysis, for
examplemiR-122 (Ding et al. 2012;McDonald et al. 2011; Qiu andDai 2014). If a promising
microRNA is found to be sensitive to haemolysis, clinical interpretation of the test should
evaluate the extent to which it is modified by the underlying condition or disease as well
as haemolysis. Since haemolysis is common in clinical samples, this comparison will also
help identify levels of haemolysis that are acceptable in the samples without significantly
aﬀecting the performance of a given test. Failure tomeet quality standardswould jeopardise
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accuracy of measurement in the context of a disease specific relationship of any microRNA
known to be aﬀected by haemolysis. Measuring absorbance of haemoglobin at 414 nm can
identify samples that are likely to be at either a low or severe risk of haemolysis, reducing the
total number of samples that would require testing by miR ratio to determine haemolysis.
Despite high specificity, we have shown that the absorbance-basedmethod is inaccurate for
predicting haemolysis between absorbance readings at 414 nmof 0.3 and 0.072, and suggest
that themiR ratio should be used to test for haemolysis in samples that fall within this range.
Further, bilirubin is known to interfere with the absorbance of haemoglobin, rendering this
method inaccurate in conditions such as jaundice where serum bilirubin levels are elevated
(Noe, Weedn, and Bell 1984).
4.5 Conclusions
e pivotal role of haemolysis as a quality control measure in any serum microRNA
profiling cannot be underestimated. e ratio of miR-451a to miR-23a-3p proposed by
Blondal et al. 2013 was found to be the most sensitive method to detect low levels of
haemolysis, and should be routinely employed. High and low abundant microRNAs
sensitive to haemolysis are significantly altered in the three categories of haemolysis
(low, moderate and severe) defined by Blondal et al. 2013. Visual inspection to detect
haemolysis is insuﬃcient as microRNA in serum samples that do not display a visible pink
discolouration can still show eﬀects of haemolysis, as shown by a miR ratio >7. Measuring
haemoglobin’s absorbance at 414 nm can identify samples that are likely to be at a low or
high risk of haemolysis, therefore reducing the total number of samples that should be
further analysed for haemolysis using the miR ratio test.
4.6 Additional conclusions
e finding that the ‘miR ratio’ is the most sensitive method to detect low levels of
haemolysis has been integrated as an essential quality control step for all experiments
analysing serummicroRNAs in this thesis (Chapter 3, subsection 3.3.1.2). e expression of
candidatemicroRNAs identified inChapter 3was tested against the ‘miR ratio’ to determine
that candidate microRNAs were not influenced by haemolysis (Chapter 3, subsection
3.3.4).
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Chapter 5
Role of lncRNAs in promoting cisplatin
resistance
5.1 Introduction
Cisplatin was the first platinum-containing drug approved for treatment of cancers by
the FDA in 1978. Although second- and third- generation platinum-containing agents
such as carboplatin and oxaliplatin were subsequently developed to reduce toxicities
associated with cisplatin (McWhinney, Goldberg, and McLeod 2009; Rabik and Dolan
2007), platinum-containing agents still remain crucial for treatment of some cancers nearly
forty years aer their first application. Primary cytoreductive surgery followed by platinum
and taxane-based chemotherapy remains the standard therapy for patients with OC, with
carboplatin-paclitaxel being the most common combination (Coleman, Ramirez, and
Gershenson 2017; Matulonis et al. 2016; Raja, Chopra, and Ledermann 2012). OC is
initially sensitive to chemotherapy; however, most patients develop resistance within two
years of the treatment (Agarwal and Kaye 2003; Hennessy, Coleman, and Markman 2009;
Romero and Bast 2012), resulting in recurrent disease that is diﬃcult to treat (Coleman,
Ramirez, and Gershenson 2017).
Small noncoding RNAs such as the miR-200 family of microRNAs are known to
promote cisplatin resistance in OC (Samuel et al. 2016); however, the roles of long non-
coding RNAs (lncRNAs) remain poorly understood. To address this gap, ninety lncRNAs
5.2. Materials & methods
were profiled by the candidate in two independent cell lines that model the development of
cisplatin resistance. Functional studies assessing the role of a lncRNA known as Urothelial
Cancer Associated 1 (UCA1) discovered from these profiling experiments is presented in
this chapter.
5.2 Materials & methods
5.2.1 lncRNA profiling
LncRNA profiling was conducted using the LncProfiler qPCR Array Kit (System Bio-
sciences). e kit contained reagents for reverse transcription (RT) and SYBR-green
primers for 90 lncRNAs.
5.2.1.1 Reverse transcription
RNA was extracted from cells using the miRNeasy Mini kit (subsection 2.3.1.1), and
reconstituted at the final concentration of 400 ng/μl. Addition of poly(A) tails to 3’ ends
of the RNAs was performed in a PCR tube by incubating the following constituents at 37
C for 30 minutes: 5 μl total RNA (2 μg) + 2 μl 5X polyA buﬀer + 1 μl 25 mMMnCl2
+ 1.5 μl 5 mM ATP + 0.5 μl PolyA polymerase. Next, 0.5 μl oligo-dT adapters were
added to the PCR tube and incubated at 60 C for 5minutes followed by 2minutes at room
temperature. eRTmixture was prepared as follows: 4 μl 5X RT buﬀer + 2 μl dNTPmix
+ 1.5 μl 0.1M DTT + 1.5 μl random primer mix + 1 μl reverse transcriptase, incubated
at 42 C for 60 minutes followed by 95 C for 10 minutes.
5.2.1.2 Real-time RT-qPCR
Lyophilised primers were purchased in a 96 well-plate format (System Biosciences). e
plate was briefly centrifuged and the primers were reconstituted in 132 μl nuclease-free
water. RT-qPCR was performed in 384 well-plates in a total of 10 μl reactions. Eight μl
of the master mix containing cDNA was transferred to each well followed by addition of
2 μl of the reconstituted primers. Composition of the master mix was as follows: 3.125
ml 2X SensiMix SYBR Hi-ROX master mix (Bioline) + 40 μl cDNA + 1.835 ml nuclease-
free water. RT-qPCR was performed on an ABI7900 PCR system using the standard PCR
program (Table 2.6).
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Gene Supplier Catalogue Number
UCA1, siRNA #13 Qiagen SI05450340
UCA1, siRNA #17 Qiagen SI05463353
TP53, siRNA #9 Qiagen SI02655170
AllStars Negative Control Qiagen SI03650318
AllStars Negative Control-Alexa Fluor 488 Qiagen 1027292
Table 5.1: List of siRNAs
ree biological replicates were used for each cell line, and 1 RT-qPCR was performed
for each lncRNA. GAPDH, Hydroxymethylbilane Synthase (HMBS) and β-actin (ACTB)
were tested for their potential use as the reference gene. However, they all performed equally
well (data not shown) and GAPDH was chosen as the reference gene. Data was analysed
using the 2-Ct method using the ExpressionSuite soware (ermoFisher).
5.2.2 siRNA transfection
5.2.2.1 siRNA transfection using HiPerFect Reagent
siRNA were transfected using HiPerFect reagent (Qiagen) according to the ‘fast-forward’
protocol. Cells were seeded in a 6 well plate in 2 ml culture media for 18 - 24 hours prior
to the transfection. Cells were approximately 50-80% confluent on the day of transfection.
siRNA (usually 100 nmol) were diluted with Opti-MEM media (ermoFisher) to 100 μl
in an eppendorf tube and 12 μl of HiPerFect reagent was added. Reagents were mixed by
vortexing, incubated for 10 minutes at room temperature and added to the well in a drop-
wise manner. e plate was swirled gently and returned to the incubator. e AllStars
Negative Control (Qiagen) was included as a control (Table 5.1).
5.2.2.2 siRNA transfection using electroporation
Cells were harvested from T75 flasks using trypsin as described. 1 106 cells underwent
electroporation using Nucleofactor (Lonza). Cells were centrifuged and resuspended in
100 μl Opti-MEM media, and 10 μl (100 nmol) siRNA was added. Cells were mixed
gently by pipetting, transferred to an electroporation cuvette and electroporated using
the Nucleofactor program X-005 for epithelial cells. Following electroporation, cells were
immediately transferred to an eppendorf tube containing warm media and plated in 6 well
plates. AllStars Negative Control (Qiagen) was included as a control.
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Cell line Cells/well for MTS assay Cells/well for clonogenic assay
PEO1 4000 1000
PEO4 10,000 1000
OVCAR-3 6000 2000
OVCAR4 5000 500
Kuramochi 10,000 NA
Table 5.2: Seeding densities for MTS and clonogenic assays
MTS and clonogenic assays were performed in 96 and 6 well-plates, respectively.
5.2.3 Clonogenic assays
Cells were seeded at low density in a 6 well plate to allow colonies to grow from single cells
as described in subsection 2.2.1. Seeding density and growth period were optimised for
each cell line (Table 5.2). For drug treatments, cells were seeded in 1.5 ml media and 0.5 ml
media containing 4X drug concentration was added aer 18-24 h. Media was replaced at
the end of drug treatment (usually 3 days), and cells were grown for 10-21 days with weekly
addition of 1 ml of fresh media. Colonies were stained with crystal violet for 5 minutes.
Excess stain was removed by washing the plates 2-3 times with water. e plates were dried
and colonies were counted. A cluster of at least 50 cells was considered as a colony.
5.2.4 Determining siRNA transfection eﬃciency using flow
cytometry
Cells were seeded and transfected with 100 nmol AllStars Negative Control siRNA labelled
with Alexa Fluor 488 (AS-488) (Qiagen) usingHiPerFect reagent as described in subsection
5.2.2.1. Unlabelled AllStars Negative Control siRNA (AS-UNL) (Qiagen) was used as a
control. Cells were cultured for 24 h aer the siRNA transfection and harvested using
trypsin. Cells were washed once in PBS and suspended in 300 μl PBS. Flow cytometry
was conducted as described in subsection 2.5. Alexa Fluor 488 was excited with a blue (488
nm) laser and its emission was measured using a 530/30 filter.
5.2.5 Site-directed mutagenesis
e wt TP53 was isolated from HEK293 cells and cloned into the mammalian expression
vector pcDNA4/To by Dr. Michael Hahn, a previous postdoctoral fellow in our laboratory.
To introduce a desired mutation, PCR was conducted using forward and reverse primers of
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TP53mutation Direction Primer sequence (5’! 3’)
C176Y Forward gac gga ggt tgt gag gcg cta ccc cca cca tga gcg ctg ctc ag
C176Y Reverse ctg agc agc gct cat ggt ggg ggt agc gcc tca caa cct ccg tc
H179R Forward ggt tgt gag gcg ctg ccc cca ccg tga gcg ctg ctc aga tag cga tgg
H179R Reverse cca tcg cta tct gag cag cgc tca cgg tgg ggg cag cgc ctc aca acc
I195T Forward ctg gcc cct cct cag cat ctt acc cga gtg gaa gga aat ttg cgt g
I195T Reverse cac gca aat ttc ctt cca ctc ggg taa gat gct gag gag ggg cca g
R175H Forward cat gac gga ggt tgt gag gca ctg ccc cca cca tga gcg ctg c
R175H Reverse gca gcg ctc atg gtg ggg gca gtg cct cac aac ctc cgt cat g
R248Q Forward cct gca tgg gcg gca tga acc aga ggc cca tcc tca cca tca tc
R248Q Reverse gat gat ggt gag gat ggg cct ctg gtt cat gcc gcc cat gca gg
R248W Forward cct gca tgg gcg gca tga act gga ggc cca tcc tca cca tca tc
R248W Reverse gat gat ggt gag gat ggg cct cca gtt cat gcc gcc cat gca gg
R273C Forward gac gga aca gct ttg agg tgt gtg ttt gtg cct gtc ctg gga g
R273C Reverse ctc cca gga cag gca caa aca cac acc tca aag ctg ttc cgt c
R273H Forward gac gga aca gct ttg agg tgc atg ttt gtg cct gtc ctg gga g
R273H Reverse ctc cca gga cag gca caa aca tgc acc tca aag ctg ttc cgt c
V157F Forward cac ccc cgc ccg gca ccc gct tcc gcg cca tgg cca tct aca agc
V157F Reverse gct tgt aga tgg cca tgg cgc gga agc ggg tgc cgg gcg ggg gtg
Y220C Forward cga cat agt gtg gtg gtg ccc tgt gag ccg cct gag gtt ggc tct g
Y220C Reverse cag agc caa cct cag gcg gct cac agg gca cca cca cac tat gtc g
Table 5.3: Primer sequences to introduce mutations into TP53 using site-directed mutagenesis
This work was equally shared with Mr. Alexander Cole, a PhD student in the laboratory. The
introduced mutation is shown in slightly larger fonts in bold face.
30-44 nucleotides in length harbouring the desired mutation roughly in the middle (Table
5.3). High fidelity DNA polymerase Pfu Ultra II (Agilent) was used for amplification. Final
composition of the 50 μl PCR reaction was as follows: 5 μl of 10X reaction buﬀer + 6 μl
of 2.5 mM dNTPs + 1 μl (100 ng) DNA template + 5 μl of 2 μM forward primer + 5 μl
of 2 μM reverse primer + 2.5 μl of 100 % molecular grade DMSO + 24.5 μl nuclease-
free water + 1 μl Pfu Ultra II polymerase. PCR cycling conditions: 95 C for 30 seconds
and 16 cycles of 95 C for 30 seconds + annealing temperature of 62-65 C for 1 minute +
extension at 68 C for 7 minutes, roughly 1 minute/kb of the insert length. Amplification
of the product was confirmed using electrophoresis on a 1% agarose gel.
Since the template DNA was isolated from E.coli strain JM109, it was methylated by
the bacteria to mark it as ‘self ’ compared to a foreign piece of DNA such as bacteriophage
during infection. e templateDNAwas digested using themethylation-specific restriction
enzyme Dpn I (New England BioLabs) by incubating 40 μl PCR product with 1 μl Dpn
I at 37 C for 1 hour. DNA was purified using the ethanol precipitation method described
105
5.3. Results
0 5 10 15
0
5
10
15
ΔCt measured in 30 µl reactions in 96 well-plates
Δ
C
t m
ea
su
re
d 
in
 1
0 
µl
 re
ac
tio
ns
R2 = 0.986
in
 3
84
 w
el
l-p
la
te
s
Figure 5.1: Strong correlation between lncRNA profiling performed in 96 and 384 well
plates
in subsection 2.3.3.2. Competent JM109 bacteria were transformed using electroporation,
selected based on resistance to Ampicillin and propagated as described in section 2.4.
Finally, mutation status was confirmed using Sanger sequencing commercially performed
at the Australian Genome Research Facility (AGRF), Westmead, NSW, Australia.
5.3 Results
5.3.1 lncRNA profiling
5.3.1.1 Optimisation
e LncProfiler qPCR Array Kit (System Biosciences) was used to evaluate expression of
90 lncRNAs from 4 cell lines. e 90 lncRNAs measured by the kit were selected by the
supplier based on their association with cancer (see lncRNAdb,Amaral et al. 2010). e
manufacturer advised to conduct RT-qPCR in a 30 μl volume in a 96 well plate format,
which would limit the number of biological replicates for profiling due to the large amount
of SYBR green required. I first tested whether the profiling performed equally in a 10 μl
volume in a 384 well plate using cDNA from A2780 cells (Figure 5.1). e manufacturer
suggested to reconstitute the lncRNA primers in 44 μl of nuclease-free water, transferring
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(A)
Well Cell line Replicate RIN
1 A2780 1 10
2 A2780 2 9.8
3 A2780 3 10
4 A2780cisR 1 10
5 A2780cisR 2 10
6 A2780cisR 3 10
7 PEO1 1 9.8
8 PEO1 2 9.9
9 PEO1 3 9.8
10 PEO4 1 9.8
11 PEO4 2 9.7
12 PEO4 3 9.9
(B)
Figure 5.2: Assessment of RNA integrity of the samples used for lncRNA profiling
(A) RNA quality of each sample. Three biological replicates were profiles for each cell line. (B) Virtual
RNA gel exported from the Bioanalyzer 2100 (Agilent). RIN: RNA Integrity Number.
2 μl of primers to the 28 μl master mix comprising cDNA and RT-qPCR master mix
comprising SYBR-green dye. Scaling this ratio down to a 10 μl total reaction volume
corresponded with pipetting 0.67 μl primers/well, which would be too low for accurate
pipetting. To overcome this limitation, primers were reconstituted in 132 μl (scaled up
3 times) water instead, and 2 μl (3  0.67 μl) and 6 μl (3  2 μl) were used in a total
volume of 10 μl and 30 μl RT-qPCR reactions. e final concentration of primers in both
reactions was 600 nM. A strong correlation (R2 = 0.986) was seen in Ct generated from
30 μl or 10 μl volume, suggesting that both protocols were comparable in performance
(Figure 5.1).
5.3.1.2 lncRNAprofilingof2pairsof cisplatin sensitive/resistant cell lines
A2780/A2780cisR and PEO1/PEO4 cell lines were used for identifying lncRNAs that could
be promoting drug resistance. e A2780 and PEO1 cells were derived from untreated
patients with HGSOC. A2780cisR was developed from A2780 by gradual exposure to
cisplatin in vitro (Bohrens et al. 1987) whereas the PEO4 cell line was established from
the same patient as PEO1 aer she naturally acquired resistance to cisplatin (Langdon et
al. 1988). RNA was extracted using the miRNeasy kit and integrity was checked using
a Bioanalyzer 2100 (Agilent) as described in subsections 2.3.1.1 and 2.3.1.4, respectively.
All RNA had a RNA Integrity Number (RIN) >9.5, indicating an excellent quality of
RNA (Figure 5.2). Ninety lncRNAs were profiled from a total of twelve samples (three
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(A) (B) (C)
Figure 5.3: Representative melt curves used for grading the quality of lncRNA primers
(A) Excellent melt curve with only one peak;UCA1 amplified from in A2780/A2780cisR cells, (B)
Acceptable melt curve with one major peak and additional 1-2 small peaks; Gas5 amplified from
A2780/A2780cisR cells, and (C) Poor melt curve with multiple peaks of significant heights; HOTAIR
amplified from A2780/A2780cisR cells
biological replicates/cell line), and one RT-qPCR was performed for each lncRNA/sample.
e reference gene GAPDHwas amplified in three technical replicates/sample for accurate
quantification. In addition, a no template control (NTC) was included using GAPDH
primers to monitor contaminants in the reagents.
GAPDHwas amplified at a Ct of 34.04 0.42 in the NTC compared to the Ct of 20.25
 0.11 for the actual samples, indicating lack of contamination in water and the PCRmaster
mix. e data was normalised to the sensitive cell line of each cisplatin resistant counterpart
using the 2-Ct method. e following selection criteria were used to identify candidate
lncRNAs for further analysis.
1. Each primer pair must display only one peak in the melt curve.
emelt curve of each primer pair was graded as excellent (only one peak), acceptable
(one major peak with 1-2 additional smaller peaks) or poor (multiple peaks of
significant heights). A representative melting curve for each grade is shown in Figure
5.3. In addition, the proportion of each grade of melting curves in the cell lines are
shown in Table 5.4. Roughly, 40% of the lncRNA primers exhibited excellent melt
curves; the rest displayed acceptable or poor quality of the melt curves, which could
be due to generally low abundance of lncRNAs compared to mRNAs (Derrien et al.
2012).
A2780 A2780cisR PEO1 PEO4
Excellent 41 (42.7%) 41 (42.7%) 37 (38.5%) 37 (38.5%)
Acceptable 28 (29.2%) 30 (31.3%) 36 (37.5%) 37 (38.5%)
Poor 27 (28.1%) 25 (26.0%) 23 (24.0%) 22 (22.9%)
Total primer pairs 96 96 96 96
Table 5.4: Quality of primer pairs based on their melt curves
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2. A lncRNA must amplify at Ct < 35 as RT-qPCR tends to be unreliable at late cycles.
3. A lncRNA must be altered by at least 1.5-fold in at least one out of two resistant cell
lines.
4. A lncRNA must be significantly diﬀerent (P < 0.05) in at least one out of two drug
resistant cell lines.
5. A lncRNAmust show the same trend of diﬀerential expression in both drug resistant
cell lines.
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Figure 5.4: Overviewof lncRNAexpression in twopairs of cisplatin resistant/sensitive cell
lines.
LncRNAs meeting criteria 1 (excellent melt curve) and 2 (Ct < 35) are shown as a heatmap diagram
to provide an overview of lncRNA expression in two pairs of cisplatin resistant/sensitive cell lines.
LncRNAs highlighted in blue met all five criteria (Table 5.5). RQ: relative quantification.
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Five lncRNAs shown in Table 5.5 and Figure 5.4 satisfied the above selection criteria.
LncRNA HOTAIR* was excluded from further analyses at it presented with a poor melt
curve (Figure 5.3C). Urothelial Cancer Associated 1 (UCA1) was selected for further
biological validation based on its emerging role in promoting cisplatin resistance in bladder
cancer, as described in the next subsection.
A2780cisR normalised to A2780 PEO4 normalised to PEO1
Melt curve RQ P Mean Ct Melt Curve RQ P Mean Ct
SNHG1 Excellent 1.35 0.59 30.14 Acceptable 3.71 0.02 30.60
SNHG6 Excellent 2.32 0.10 27.66 Excellent 6.19 0.04 27.53
Malat1 Excellent 1.58 0.41 28.61 Excellent 4.62 0.03 27.32
Y RNA-1 Excellent 2.47 0.04 20.20 Excellent 3.68 0.07 21.62
UCA1 Excellent 2.04 0.03 32.64 Acceptable 4.35 0.14 30.01
Table 5.5: Candidate lncRNAs that were diﬀerentially expressed between drug resistant and non-
drug resistant cell line pairs.
Excellent melt curve: only one peak; acceptable: one major peak with 1-2 additional smaller peaks.
RQ: relative quantification
5.3.1.3 LncRNAs identified by profiling resistant/sensitive pairs of cell
lines
is project started in 2013 and many things that are known now were unknown at that
time. However, the following information reflects the current knowledge on the candidate
lncRNAs.
5.3.1.3.1 SNHG1 & SNHG6
Role in cancer: Both snoRNAs and snoRNA host genes (SNHGs) have been implicated
in cancer biology (reviewed in Stepanov et al. 2015; Williams and Farzaneh 2012).
SNHG1was found to be upregulated in non-small cell lung cancer (NSCLC) cell lines
and its knockdown reduced the ability of the cells to form colonies in clonogenic
assays (You et al. 2014). Similarly, SNHG1 was also found to be upregulated in
HCC, and its overexpression enhanced proliferation, invasion andmigration of HCC
cells through suppressing levels of miR-195 (Zhang et al. 2016a; Zhang et al. 2016b).
Higher expression of SNHG1 in neuroblastoma was found to be associated with poor
patient survival as well as an independent prognostic marker for progression-free
*e names of the lncRNA are not italicised when referring to as the expressed RNA form, whereas they
are italicised when referring to the gene on the DNA, as in mutations in HOTAIR.
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survival (Sahu et al. 2016). SNHG6 was also found to be upregulated in HCC (Chang
et al. 2016).
Role in promoting cisplatin resistance: Unknown.
Mechanism: snoRNAs and SNHGs encode noncoding transcripts that predominantly
associate with the nucleolus where they play a vital role in maturation of rRNA. By
directly base-pairing with the rRNA, snoRNAs guide the enzymes that catalyse 2’-O-
ribose methylation or pseudouridylation to their target sites on the rRNA (Williams
and Farzaneh 2012).
5.3.1.3.2 Malat1
Role in cancer: e role of Malat1 in cancer is relatively well-studied (reviewed in
Gutschner, Hämmerle, and Diederichs 2013 and Dhamija and Diederichs 2016).
Briefly, the expression of Malat1 was found to be associated with late stages and
metastasis in NSCLC (Ji et al. 2003), enhanced cell migration and tumour growth
in mouse models (Schmidt et al. 2011). Malat1 is highly expressed in pancreatic
cancer and its expression was found to correlate with clinical stage, tumour size,
lymph node and distant metastases (Jiao et al. 2014; Pang et al. 2015). In pancreatic
cancer cells, knockdown of Malat1 inhibited cell proliferation and invasion through
downregulation of EMT and induction of G2/M cell cycle arrest (Jiao et al. 2014).
Malat1 also induced EMT in NSCLC, enhancing metastasis to the brain (Shen et al.
2015). Malat1 has been reported to increase cell proliferation in clear cell renal
carcinoma (Zhang et al. 2015), multiple myeloma (Cho et al. 2014) and osteosarcoma
(Dong et al. 2015). Malat1 expression is correlated with poor outcome in multiple
cancers from a meta-analysis (Wei and Niu 2015).
Role in promoting cisplatin resistance: A study reported that cisplatin suppressedMalat1
expression in laryngeal squamous cell carcinoma (Chen et al. 2014). HIF-2 has
been found to stimulateMalat1 expression under hypoxic conditions. As described in
Chapter 1, subsection 1.2.2.2, many lncRNAs can act as competing endogenous RNAs
(ceRNAs) and absorb levels of microRNAs. Working as a ceRNA, Malat1 absorbs the
levels of miR-216b, a negative regulator of autophagy in HCC, promoting multidrug
resistance by upregulating autophagy that resulted from the downregulation of miR-
216b (Mimeault and Batra 2013). Malat1 was found to be overexpressed in cisplatin
resistant tumours as well as cancer stem cells of NSCLC (Lopez-Ayllon et al. 2015).
112
5.3. Results
Interactions between Bcl-2 andMalat1 in NSCLC have also been proposed, implicat-
ing its potential role in regulating apoptosis (Schmidt et al. 2014).
Mechanism: Malat1 binds to the serine/arginine (SR) splicing factors, aﬀecting their
distribution in the nuclear speckle domains and regulating splicing of a subset of
mRNAs (Tripathi et al. 2010). In addition, Malat1 has been found to interact with
Polycomb proteins and control gene expression of cell cycle genes (Yang et al. 2011).
5.3.1.3.3 YRNA-1 YRNAs are technically considered as small ncRNAs given their length
of 83-112 nucleotides (Christov, Trivier, and Krude 2008).
Role in cancer: Y RNA-1 to 5 have been found to be over-expressed in solid cancers,
of which Y RNA-1 and 3 were the most upregulated Y RNAs in bladder, cervix,
colon, kidney, lung and prostate cancers (Christov, Trivier, and Krude 2008). siRNA
knockdown of Y RNA-1 reduced the proportion of replicating cells (Christov et al.
2006).
Role in promoting cisplatin resistance: Unknown.
Mechanism: Y RNAs are required for initiation of the chromosomal DNA replication
by interacting with components of the pre-replicative complex (Hall, Turnbull, and
Dalmay 2013; Zhang et al. 2011a). Y RNAs have been found to be associated with
autoantigen protein Ro60, influencing its subcellular localisation (Sim and Wolin
2011). Y RNAs have been proposed as potential sources of microRNAs such as miR-
1975 from Y RNA-5 andmiR-1979 from Y RNA-3 (Hall, Turnbull, and Dalmay 2013;
Verhagen and Pruijn 2011).
5.3.1.3.4 UCA1
Role in cancer: A study in 2006 reported upregulation of UCA1 in bladder cancer com-
pared to the adjacent normal tissue. In addition, levels of UCA1 in urine were found
to be predictive of bladder transitional cell carcinoma (Wang et al. 2006). Subse-
quently, UCA1 was found to be associated with multiple cancers including breast
cancer, colorectal cancer, lung squamous cell carcinoma, oesophageal sqamous cell
carcinoma, gastric cancer, HCC and ovarian cancer (Xue, Chen, and Li 2016). A
pan-cancer analysis, incorporating RNA-seq data on 2,878 tumour samples of 8 can-
cer types as well as 349 matched normal tissues, confirmed overexpression of UCA1
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in colorectal cancer and lung squamous cell carcinoma (Cabanski et al. 2015). No-
tably, ovarian cancer was excluded from this analysis due to missing RNA-seq data
on normal ovaries. UCA1 was also one of the 5 diﬀerentially expressed lncRNAs
between SKOV-3 and its derivative cell line with enhanced metastatic capabilities
(SKOV-3.ip1) (Liu et al. 2013a).
Role in promoting cisplatin resistance: Multiple studies have confirmed that overexpres-
sion of UCA1 promotes cisplatin resistance in bladder cancer (Fan et al. 2014; Pan
et al. 2016; Wang et al. 2008). A report in 2015 showed that UCA1 was upregulated
in ovarian cancer compared to normal ovaries, and its forced overexpression pro-
moted migration, invasion and cisplatin resistance of SKOV-3 cells through inter-
actions with SR Protein Kinase 1 (SRPK1) (Wang et al. 2015). Knockdown of UCA1
restored cisplatin sensitivities of 2 cell lines of tongue squamous cell carcinoma (Wang
et al. 2016a).
Mechanism: UCA1 promoted cell proliferation by inducing cAMP response-element
binding protein (CEBP) and phosphoinositide-3-kinase (PI3K)/Akt pathways (Yang
et al. 2012). Further, activated transcription factor CEBP induced expression of
miR-196a-5p in bladder cancer cells, which then suppressed the expression of
the cell cycle inhibitor p27kip1 through microRNA-miRISC axis (Pan et al. 2016).
Overexpression of UCA1 was found to downregulate regulators of apoptosis Fas and
ataxia telangiectasia mutated (ATM) (Wang et al. 2012).
5.3.1.4 Selection of UCA1 for further investigations
All 5 candidate lncRNAs have been implicated in cancer biology. Further, Malat1 and
UCA1 were found to have roles in promoting cisplatin resistance. Malat1 has been studied
extensively as it is normally present at a high level compared to other lncRNAs whereas
UCA1 remains understudied. While Malat1 could be knocked down using siRNA or
similar technologies for functional studies, its long size of ~8 kb could pose diﬃculties in
conducting rescue experiments involving transfection of cloned expression vector or virus-
mediated transduction. In contrast, all 3 isoforms ofUCA1 (1.4, 2.2 and 2.7 kb) (Xue, Chen,
and Li 2016) are much shorter thanMalat1 . As described above, UCA1 has been shown to
work through the PI3K/Akt pathway — a pathway that has been extensively studied in our
laboratory previously with antibodies and TaqMan probes for its key members available for
further downstream investigation. erefore, UCA1 was selected for further studies. e
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1.4 kb isoform of UCA1 is most abundant, and has been the focus of most studies (Xue,
Chen, and Li 2016) including the current one.
5.3.2 Investigating the role of UCA1 in promoting cisplatin
resistance in PEO1 and PEO4 cells
To provide an overview of the experimental approach, the expression of UCA1 in A2780,
A2780cisR, PEO1 and PEO4 quantified from the lncRNA profiling was validated using
sensitive TaqMan probes. Next, the transfection eﬃciencies of the cells were tested using
labelled-siRNAs in flow cytometry. Finally, the eﬀect of UCA1 knockdown on cisplatin
sensitivities was determined using MTS and clonogenic assays.
5.3.2.1 Validation of UCA1 expression using TaqMan probes
One μg RNA was reverse transcribed using SuperScript III enzyme, and the expression of
UCA1 quantified in 4 cell lines using TaqMan probes (N = 6/cell line; Figure 5.5). GAPDH
was used as the reference gene. In contrast to the SYBR green primers used for lncRNA
profiling, no significant diﬀerences were observed in UCA1 levels between A2780 and
A2780cisR cells (P = 0.07). However, UCA1 was found to be elevated by approximately
3-fold in PEO4 compared to PEO1 cells (P = 0.0005). It remains unclear why conflicting
results were obtained using the SYBR-green primers and the TaqMan probes. All three
biological replicates used in the lncRNA profiling were used when quantifying expression
of UCA1 using the TaqMan probes and passaged less than ten times since revival from
the liquid nitrogen stocks. e manufacturer of the LncProfiler qPCR Array Kit (System
Biosciences) did not disclose the sequence ofUCA1 SYBR-green primers, making it diﬃcult
to compare the regions of UCA1 amplified with the SYBR-green primers and the TaqMan
probes. Nevertheless, results obtained using the TaqMan probes should be more reliable
because TaqMan-based RT-qPCR is much more sensitive than SYBR green-based assays.
Given that UCA1 levels did not diﬀer in the A2780/A2780cisR paired cell lines, they were
excluded from further validation.
5.3.2.2 Testing siRNA transfection eﬃciency in PEO4 and PEO1 cells us-
ing flow cytometry
esiRNA transfection eﬃciency of PEO4 cells was tested by transfecting 100 nmolAllStars
Negative Control siRNA labelled with Alexa Fluor 488 (AS-488) using the HiPerFect
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Figure 5.5: TaqMan Validation of UCA1 in 4 ovarian cancer cell lines
** P < 0.005.
reagent. Unlabelled AllStars Negative Control siRNA (AS-UNL) was transfected as a
control. Cells were prepared for flow cytometry as described in subsection 5.2.4. When
compared to the AS-UNL cells, approximately 80% of the single cells (gate P1 in Figure 5.6
B and E) transfected with AS-488were positive for Alexa Fluor 488 at 24 h post-transfection
(N = 3; Figure 5.6 A and D; gate Q4 in Figure 5.6 C and F), suggesting a high transfection
eﬃciency of PEO4 cells. Similarly, PEO1 cells also exhibited a high transfection eﬃciency
using HiPerFect reagent (N = 1; Figure 5.7 A and B).
5.3.2.3 Optimising UCA1 knockdown in PEO4 and PEO1 cells
Although the flow cytometry experiment above used 100 nmol siRNA, the levels of siRNA
used to knockdown an actual gene should be kept to a minimum in order to avoid possible
oﬀ-target eﬀects. Two independent siRNAs (#13 and #17) targeting diﬀerent regions of
the 3’ UTR of UCA1 were used to knockdown UCA1. Fiy nmol of siRNAs #13 and #17
each was transfected into PEO4 cells using 12 μl HiPerFect reagent (as for flow cytometry
experiments described above), but UCA1 levels, quantified by TaqMan probes using RT-
qPCR, were not significantly reduced at 16 and 88 h post-transfection (N = 3; Figure
5.8 A). ese time points mimic start and end points of a typical experiment involving
cisplatin treatments for 3 days. To reduce UCA1 levels further, the siRNA concentration
was increased to 100 nmol as well as transfected with two diﬀerent volumes (12 or 18 μl) of
the HiPerFect reagent (N = 3), and UCA1 levels were measured at 24 h post-transfection.
As shown in Figure 5.8B, increasing the siRNA concentration indeed further reduced the
UCA1 levels compared to the 50 nmol siRNA regardless of the amount of HiPerFect used
for transfection; however, the final knockdown levels of ~40% in PEO4 cells were still found
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Figure 5.6: Determining siRNA transfection eﬃciency using HiPerFect reagent in PEO4
cells measured by flow cytometry
(A) Transfection eﬃciency of PEO4 cells using HiPerFect measured by flow cytometry (N=3), (B-C)
PEO4 transfected with AS-UNL, (D) Typical transfection eﬃciencies achieved in PEO4 cells using
HiPerFect reagent measured by flow cytometry, and (E-F) PEO4 transfected with AS-488. FCS-A and
SSC-A represent areas of the forward and side scatter, respectively. B_530-A represents area for the
fluorescence of Alexa Fluor 488. AS-UNL: unlabelled AllStars Negative Control siRNA, AS-488: AllStars
Negative Control siRNA labelled with Alexa Fluor 488.
to be unsuitable for functional validation. UCA1 levels were found to be even less aﬀected
upon siRNA treatment in PEO1 cells (100 nmol siRNA + 12 μl HiPerFect; N = 3; Figure
5.9), suggesting that other methods to knockdown UCA1 should be investigated.
In contrast to HiPerFect reagent that utilises lipid-based chemistry to deliver siRNA-
infused complexes to the cell, electroporation relies on momentary generation of holes in
the cell’s lipid bilayer upon electric shock, during which siRNAs enter the cell because of
its high extra-cellular concentration. Nucleofactor Kit T (Lonza) for electroporation was
tested for it suitability to knockdown UCA1 in PEO4 cells. In addition, serum-free Opti-
MEM media was also tested for the purpose of cost-eﬃciency. Kit T resulted in 86% and
83% knockdown at 24 and 48 h post-electroporation using 100 nmol siRNA, respectively
(N=1; data not shown). A similar knockdown eﬃciency of 87% at 24 h post-electroporation
was achieved just by using Opti-MEM media (N=1; data not shown); therefore, Opti-
MEMmedia was used in electroporation for the rest of the study. Electroporation resulted
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Figure 5.7: Determining siRNA transfection eﬃciency using HiPerFect reagent in PEO1
cells measured by flow cytometry
(A) PEO1 cells transfectedwith AS-UNL or AS-488 usingHiPerFect reagent, and transfection eﬃciency
was measured using flow cytometry (N=1). (B) Quantification of the transfection eﬃciency (N=1).
FCS-A and SSC-A represent areas of the forward and side scatter, respectively. B_530-A represents
area for the fluorescence of Alexa Fluor 488. AS-UNL: unlabelled AllStars Negative Control siRNA,
AS-488: AllStars Negative Control siRNA labelled with Alexa Fluor 488.
in slightly higher cell death compared to the HiPerFect reagent, which was compensated
by increasing seeding densities in experiments. e knockdown eﬃciencies of UCA1 by
electroporation in PEO1 and PEO4 cells are depicted in Figure 5.10A (N = 3).
5.3.2.4 The eﬀect of UCA1 knockdown on cisplatin sensitivity of PEO4
and PEO1 cells
Cisplatin sensitivity of PEO1 and PEO4 cells following UCA1 knockdown was determined
by MTS and clonogenic assays. One million cells were electroporated with 100 nmol
AllStars (AS) Negative Control and UCA1 siRNAs #13 and #17 using Opti-MEM media
(Figure 5.10 A), seeded overnight for MTS or clonogenic assays at the densities outlined in
Table 5.2, subsections 2.2.5 and 5.2.3. Cells were treatedwith cisplatin for 3 days (N= 3). No
diﬀerence in cisplatin DRCs were observed using the MTS assay upon UCA1 knockdown
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Figure 5.8: Knockdown of UCA1 in PEO4 cells using the HiPerFect reagent
(A) Fifty nmol of siRNAs #13 or #17 were transfected using 12 μl of HiPerFect reagent, and UCA1
expression was measured at 16 and 88 h post-transfection using TaqMan RT-qPCR (N=3). (B) To
achieve a higher knockdown, 100 nmol siRNAswere transfected using 12 or 18 μl HiPerFect reagent,
andUCA1 levelsweremeasuredat 24hpost-transfectionusingTaqManRT-qPCR (N=3). In both cases,
UCA1 knockdown achieved using the HiPerFect reagent were unsuitable for functional assays. RQ:
relative quantification.
AS 13 17
PEO1
R
Q
0.
0
0.
6
Figure 5.9: siRNA transfection eﬃciency using HiPerFect reagent in PEO1 cells
One hundred nmol siRNAs were transfected using 12 μl HiPerFect reagent and UCA1 knockdown
was measured at 24 h post-transfection using by TaqMan RT-qPCR (N=3). RQ: relative quantification.
in both cells (Figure 5.10B and D). Further, the calculated IC50 also remained unchanged
(Figure 5.10C and E; N = 3; P > 0.05).
Long-term eﬀects of UCA1 knockdown on cell survival were measured by clonogenic
assays (Figure 5.11). is assay was initially seeded in N = 3 for both cell lines according
to the densities in Table 5.2, but some wells in one biological replicate for PEO1 cells were
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Figure 5.10: Cisplatin sensitivities of PEO1 and PEO4 cells upon UCA1 knockdown mea-
sured by MTS assay
(A) The eﬃciencies of UCA1 knockdown using electroporation (N=3). (B-C) Cisplatin dose response
curves (DRCs) and IC50 in PEO1 cells upon UCA1 knockdown, respectively. (D-E) Cisplatin DRCs and
IC50 in PEO4 cells upon UCA1 knockdown, respectively. ‘AS’: AllStars Negative Control, RQ: relative
quantification.
dried, resulting in inaccurate quantification andwere ignored. eonly statistical diﬀerence
was observed in PEO4 cells electroporated with AS control or siRNA #17 treated with
0.08 μM cisplatin; however, no diﬀerences were observed between AS and siRNA #13
treated at the same cisplatin concentration. Further, this diﬀerence disappeared at higher
concentrations, suggesting that the diﬀerence observed might be inconsistent. erefore,
we concluded that UCA1 does not aﬀect survival of PEO1 and PEO4 cells upon cisplatin
treatment.
5.3.3 Functional validation of UCA1 knockdown in addi-
tional HGSOC cells
5.3.3.1 UCA1 expression in 8 HGSOC cell lines
To broadly investigate the role of UCA1 in promoting drug resistance, 8 cell lines ranked as
‘likely high-grade serous’ according to Domcke et al. 2013 were chosen, representing rele-
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Figure 5.11: Long-term eﬀects of UCA1 on cell survival upon cisplatin treatment in PEO1
and PEO4 cells measured by clonogenic assays
(A) PEO1 cells (N=2; somewells in the 3rd biological replicate were dried out and excluded.) (B) PEO4
cells (N=3). * P < 0.05.
vant models to study drug resistance. UCA1 expression was determined using SYBR-green
primers (N = 3; Figure 5.12)†. GAPDHwas used as the reference gene whereas Kuramochi
cells were used as the calibrator cell line. Amongst the 8 cell lines, Kuramochi and OAW28
were excluded from the clonogenic assays as they did not form colonies upon 21 days of
growth in vitro. Nonetheless, Kuramochi cells were selected for investigation by the MTS
assay as it is arguably the closest match to primary HGSOC patient samples (Domcke et al.
2013). CaOV4, COV318 and OVKATE had a doubling time of approximately 6 days, mak-
ing them diﬃcult to grow. OVSAHO was a suitable cell line but it was excluded because
its abilities to form colonies had not been tested previously. Kuramochi, OVCAR-3 and
†e UCA1 primers used in this experiment were pre-designed by Sigma-Aldrich (Table 2.9) whereas
UCA1 primers used for lncRNA profiling were supplied by the kit. Results obtained using primers from
Sigma-Aldrich were comparable to UCA1 Taqman probes (data not shown)
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Figure 5.12: UCA1 levels relative to the Kuramochi cells in 8 HGSOC cell lines
OVCAR4 were chosen for further validation due to their ease of handling and amenability
for drug sensitivity assays.
5.3.3.2 Eﬀect of UCA1 knockdown on cisplatin sensitivity in additional
HGSOC cell lines
eoverall approach in investigating the eﬀects ofUCA1 knockdown in additionalHGSOC
cell lines was similar to the experiments conducted in PEO1/PEO4 cells: optimisation of
UCA1 knockdown inKuramochi, OVCAR-3 andOVCAR4 cell lines followed by functional
assays to determine sensitivities to cisplatin uponUCA1 knockdown. Like PEO1 and PEO4
cells, ~80% of Kuramochi, OVCAR-3 and OVCAR4 cells were found to be positive for AS-
488 following its transfection usingHiPerFect reagent (Supplementary Figure A.1). Despite
a high level of transfection capabilities, UCA1 knockdown inOVCAR-3 andOVCAR4 cells
using HiPerFect reagent was found to be insuﬃcient (~40-60%) for functional experiments
(Supplementary Figure A.2). It was empirically observed that Kuramochi cells were
diﬃcult to transfect using HiPerFect reagent (data not shown), and were excluded from
this experiment.
Kuramochi, OVCAR-3 and OVCAR4 cells were tested for electroporation to knock-
down UCA1. Electroporation resulted in an excellent UCA1 knockdown in OVCAR-3 and
OVCAR4 cells that was sustained for up to 4 days post-electroporation, indicating that the
knockdown persisted throughout the experiment (Figure 5.13A. Unfortunately, UCA1 was
not found to be knocked down in Kuramochi cells even using electroporation.
One million OVCAR-3, Kuramochi and OVCAR4 cells were electroporated with 100
nmol siRNAs, seeded for MTS and clonogenic assays, and treated with cisplatin for 3
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Figure 5.13: Eﬀect of UCA1 knockdown on cisplatin sensitivity in 3 additional HGSOC cell
lines
(A) UCA1 knockdown using electroporation. (B, D and F) Cisplatin DRC upon UCA1 knockdown
in OVCAR-3, Kuramochi and OVCAR4 cells, respectively. (C, E and G) IC50 of cisplatin upon UCA1
knockdown in OVCAR-3, Kuramochi and OVCAR4 cells, respectively. Kur: Kuramochi cells. * P < 0.05.
days as previously described. Despite an excellent UCA1 knockdown in OVCAR-3 and
OVCAR4 cells (Figure 5.13A), cisplatin DRCs and IC50 remained relatively unchanged.
A statistical diﬀerence between IC50 values of AS and siRNA #17 in OVCAR-3 cells was
observed (Figure 5.13C); however, this translated into a marginal increase of 12.4% in the
IC50. Similarly, a statistically significant diﬀerence of 21% in IC50 of AS and siRNA #13
was observed in OVCAR4 cells (Figure 5.13G). e observed diﬀerences, however, were
not replicated in the second siRNA treatment despite the excellent knockdown using both
siRNAs individually. No diﬀerences in IC50 values upon siRNA treatments were observed
in Kuramochi cells (Figure 5.13D, E), which is expected because these cells were resistant to
siRNA electroporation (Figure 5.13A). Nonetheless, this experiment could be interpreted
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Figure 5.14: Long-term eﬀects of UCA1 on cell survival upon cisplatin treatment in
OVCAR4 cells measured by clonogenic assays
* P < 0.05.
as a scenario where the null hypothesis is true, and, indeed, no diﬀerences were observed,
reflecting robustness of the assay.
OVCAR-3 and OVCAR4 cells were seeded to perform clonogenic assays following
siRNA electroporation (N = 3). Kuramochi cells were not seeded for clonogenic assays
as they lacked an ability to form colonies. Unfortunately, media of some wells, including
the vehicle control used for normalisation, in all 3 biological replicates for OVCAR-3 cells
were dried out, making them unusable. e data on OVCAR4, on the other hand, were
reliable and have been presented in Figure 5.14. A statistically significant diﬀerence was
observed betweenAS and siRNA #13 treated with 0.1 μM cisplatin. However, no statistical
diﬀerence was observed between AS and siRNA #17 under the same conditions. us, no
consistent diﬀerence upon UCA1 knockdown in cisplatin sensitivity was observed.
5.3.4 Eﬀect of p53 on UCA1
Mr. Alexander Cole, a fellow PhD student in the lab, studied transcriptome-wide eﬀects
of wt p53 upon cisplatin treatment in the A2780 cells. UCA1 was found to be induced by
~20-fold in the A2780 cells treated at the IC75 value of cisplatin (9.9 μM) for 24 hours in his
dataset (FDR-adjusted P = 0.0001). CDKN1A encoding p21, a canonical downstream target
of wild-type p53, was also found to be upregulated by 21.4-fold under the same conditions
(FDR-adjusted P = 0.0001). Since A2780 harboured wt p53 that was stabilised by cellular
stressors such as cisplatin and given the induction of p21 upon cisplatin treatment, I tested
whether UCA1 was a downstream target of wt p53 and, further, whether it was aﬀected by
mutant-p53.
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Figure 5.15: Frequency of types of TP53mutation observed in the TCGA-OV dataset
(FS = frame shift, IF = in-frame, ins = insertion and del = deletion)
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Figure 5.16: Prioritising the p53 mutations based on their evolutionary conservation
predicted by the algorithm PROVEAN and their observed frequency in the TCGA-OV
dataset
5.3.4.1 Identifying high priority TP53mutations in TCGA-OV dataset
Information on the TP53 mutations in a total of 302 patients of the TCGA-OV dataset
were downloaded from cBioportal on June 6, 2013. Missense mutations were found to
be the most common type (~62%; Figure 5.15). ere were 94 unique missense mutations
reported in the TCGA-OV dataset, and it was important to prioritise a small number of
TP53mutations for further studies.
Algorithms, such as SIFT, polyphen2 and mutation assessor, based on evolutionary
conservation of amino acids have been employed to predict whether mutations are neutral
or could be disease-causing (Rebbeck, Spitz, and Wu 2004). In general such algorithms
first identify evolutionary conserved residues because of their essential role in protein
functions. In addition, these algorithms also compare the chemical properties (electric
charge, hydrophobicity and so on) of thewild-type versus themutated residue in calculating
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Figure 5.17: Validating protein expression of mutant-p53 constructs in p53-null SKOV- 3
cells
(A) Comfirming that SKOV-3 are p53-null by stimulating these cells with cisplatin for up to 24 h and
blotting for phospho-p53, as its antibody was more sensitive than the total p53. OVCAR-3 cells were
stimulated with doxorubicin for 18 h as a positive control. GAPDH was used as reference. ‘Dox’
refers to doxorubicin. (B) Protein expression of mutant-p53 transfected into SKOV-3 cells to show
that the transfected plasmids carryingmutant-p53 were expressed in the cells. (B) was generated by
Mr. Alexander Cole.
a score (Rebbeck, Spitz, and Wu 2004). When the SIFT algorithm was run on the
TP53 mutations reported in the TCGA-OV dataset, almost all of them were predicted
to be disease-causing (data not shown), rendering this soware incapable in prioritising
mutations. A recent algorithm known as Protein Variation Eﬀect Analyzer (Provean) could
evaluate the eﬀects of up to 6 mutations in a given protein (Choi et al. 2012). Importantly,
the Provean scores could segregate the disease-causingmutations into a broader range than
SIFT, making this an appropriate algorithm for this purpose.
Since a lethal mutation would be less tolerated by the cell, it was hypothesised that
lethality of a mutation should inversely correlate with its observed frequency. Surprisingly,
the data revealed this not to be the case, and certain mutations stood out distinctively from
the rest (highlighted in blue in Figure 5.16). eir higher frequency in independent patients
ascertain favourable outcomes for the cancer cell. In fact, the TP53 mutations R175H,
R273H and R248Q are amongst the most frequently occurring mutations and have been
reported as ‘gain-of-function’ mutations (Bieging, Mello, and Attardi 2014).
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Using the pcDNA4/TOmammalian expression vector harbouring the wt-p53 cloned by
a previous laboratorymember as template, the following 10mutations were generated using
site-directed mutagenesis‡: R175H, R273H, R273C, R248Q, R248W, I195T, V157F, Y220C,
R282W and C176Y. All mutations were confirmed by Sanger sequencing. Several attempts
were made to synthesise R282W; however, the mutated p53 also showed extra unintended
mutations in addition to R282W, leading us to exclude this mutation from further studies.
e expression vector containing wild-type or mutant-p53 was transfected into the
functionally p53-null ovarian cancer cell line SKOV-3 (c.267del1, resulting in a frame-shi
(Bamford et al. 2004)). To confirm that SKOV-3 cells are bona fide p53-null, 5105 SKOV-3
cells were treated with 16.6 μM (5 μg/ml) cisplatin for 2, 4 or 24 h and blotted for phospho-
p53. A treatment of stressors such as cisplatin would be expected to increase phospho-
rylation and subsequent accumulation of p53, if present. OVCAR-3 cells harbouring the
TP53mutation R248Q were treated with 1 μM doxorubicin for 18 h as a positive control.
GAPDH was used as the reference. Either total p53 or phospho-p53 could be blotted to
answer the question. However, the phospho-p53 antibody was used because it was found
to be more sensitive than total p53 antibody in our experience. Phospho-p53 was not de-
tected in SKOV-3 cells upon the cisplatin treatment (Figure 5.17A), confirming that they
are p53-null.
Next, 1 μg of plasmid containingwild-type ormutant-p53were transfected into SKOV-
3 cells using X-tremeGENE 9 DNA Transfection Reagent, and total protein was harvested
48 h post-transfection. As shown in Figure 5.17B, most mutants produced the protein in
SKOV-3 cells. Interestingly, the levels of R175H, R273H, R273C, R248Q, R248Q, I195T and
V157F were higher than the wt-p53, similar to the clinical HGSOC samples where mutant-
p53 is expressed at a higher level. e levels of Y220C mutations were undetectable, and
the mutation was excluded.
5.3.4.2 Eﬀect of p53 on UCA1
In a 6 well-plate 2.5105 SKOV-3 cells were seeded overnight, and transfected with 1 μg
plasmid harbouring empty vehicle (pcDNA4), wt-p53 or 4 mutant-p53 (R175H, R248Q,
R248WANDR273H). RNAwas harvested 48 h post-transfection using the Qiazol reagent.
Expression of UCA1 and p53 mRNA was quantified by TaqMan probes using RT-qPCR,
and was normalised to the vehicle control (Figure 5.18A). As expected, the levels of wt-
p53 and mutant-p53 were more than 500-fold higher compared to the vehicle control (P <
0.05). Interestingly, the levels of mutant-p53 were also higher than the wt-p53 (P < 0.05),
‡is work was shared equally with Mr. Alexander Cole.
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Figure 5.18: Eﬀect of p53 on UCA1
(A) SKOV-3 cells were transfected with 1 μg empty pcDNA4 (V0) or pcDNA4 containing wild-type
or mutant-p53, and the expression of TP53 (to confirm successful transfection) and UCA1 were
determined 48 h post-transfection using TaqMan RT-qPCR.Note: The levels of all 4 mutant-p53 were
statistically higher than wt-p53, but the figure has not been marked with ‘*’ for simplicity. (B) The
eﬀect of p53 knockdown in OVCAR-3 cells naturally harbouring the TP53mutation R248Q. UCA1was
not aﬀected despite ~80% knockdown in p53 levels.
consistent with the protein expression of mutant-p53 shown in Figure 5.17B.e statistical
significance of p53 expression was not marked with ‘*’ on Figure 5.18A to focus on UCA1.
When compared to the vehicle control, UCA1 was found to be upregulated only by
the wt-p53 by 3.2-fold (N = 3; P = 0.01; Figure 5.18A). Importantly, the UCA1 expression
induced by wt-p53 remained higher than the mutant-p53 R175H, R248Q and R248W (P <
0.05). Although UCA1 expression upon wt-p53 transfection was statistically not diﬀerent
compared with the R273Hmutation, it was found to be upregulated in wt-p53 with a trend
(P = 0.077; Figure 5.18A). is experiment was repeated in an independent p53-null cell
line H1299 (lung cancer), but it was not fruitful as UCA1 was not found to be expressed
at the basal level in H1299 cells as well as upon transfection of wild-type and mutant-p53
(data not shown).
To confirm that UCA1 was not induced by mutant-p53, TP53 was knocked down
in OVCAR-3 cells endogenously harbouring mutant-p53 R248Q (Figure 5.18B). 2105
OVCAR-3 cells were transfected with 100 nmol p53 siRNA #9 using HiPerFect reagent,
RNA was harvested 48 h post-transfection followed by quantification of gene expression
using TaqMan probes. Intriguingly, the p53 mRNA was found to be reduced by 80% (P
= 0.001), which contradicted the previous experiments attempted to knockdown UCA1
in OVCAR-3 cells (Supplementary Figure A.2). Nonetheless, UCA1 levels remained
unchanged upon p53 knockdown (P = 0.7).
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5.4 Discussion
Adjuvant chemotherapy based on the agents containing platinum and taxane, such as
a combination of carboplatin and paclitaxel, remain the cornerstone for treatment of
patients withOC. AlthoughOC is responsive to these agents initially, most patients develop
resistance to chemotherapy within the first two years of the treatment (Agarwal and Kaye
2003; Hennessy, Coleman, and Markman 2009; Romero and Bast 2012). erefore,
understanding the mechanisms of drug resistance is crucial. e possible role of lncRNAs
in promoting cisplatin resistance was investigated in this chapter.
e experimental approach utilised two independent pairs of cisplatin sensi-
tive/resistance cell lines, A2780/A2780cisR and PEO1/PEO4, to identify candidate lncR-
NAs. e sensitive cell lines A2780 and PEO1 cells were derived from untreated HGSOC
patients. A2780cisR was developed from A2780 by gradual exposure to cisplatin in vitro
(Bohrens et al. 1987) whereas the PEO4 cell line was established from the same patient
as PEO1 aer she naturally acquired resistance to cisplatin (Langdon et al. 1988). A total
of 90 lncRNAs were profiled using SYBR-green primers in RT-qPCR. By optimising the
RT-qPCR conditions, we were able to profile each cell line in three biological replicates
for the amount of one. In addition, five types of selection criteria, ranging from assessing
the qualities of the lncRNA primers to consistent diﬀerential expression of lncRNAs in
both pairs of cell lines, were implemented to identify the robust candidates for functional
studies.
Five of 90 lncRNAs (SNHG1, SNHG6, Y RNA-1, Malat1 and UCA1) satisfied the
selection criteria. Notably, the prominent lncRNA HOTAIR was excluded as it manifested
poor melt curves. Amongst the 5 candidates, both SNHG1 and SNHG6 were previously
demonstrated to have a role in promoting NSCLC (You et al. 2014), HCC (Chang et al.
2016; Zhang et al. 2016a; Zhang et al. 2016b) and neuroblastoma (Sahu et al. 2016), but
their potential role in promoting cisplatin resistance remains unknown. Y RNA-1 was
found to be a small ncRNA given its length of 83-112 nucleotides (Christov, Trivier, and
Krude 2008). In comparison, Malat1 is a relatively well-studied lncRNA in promoting
cancer (Dhamija andDiederichs 2016; Gutschner, Hämmerle, and Diederichs 2013) as well
as dug resistance by mechanisms such as increasing autophagy (Mimeault and Batra 2013).
Interactions between Bcl-2 and Malat1 in NSCLC have also been proposed, implicating its
potential role in regulating apoptosis (Schmidt et al. 2014). e role of UCA1 in promoting
cancer and cisplatin resistance began to emerge recently. It was found to be upregulated in
bladder cancer compared to the adjacent healthy tissue, and its level in urine could predict
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bladder transitional cell carcinoma (Wang et al. 2006). Subsequently, UCA1was found to be
associated with multiple cancers including breast cancer, colorectal cancer, lung squamous
cell carcinoma, oesophageal squamous cell carcinoma, gastric cancer, HCC and ovarian
cancer (Xue, Chen, and Li 2016), and to promote cell proliferating by inducing CEBP
and PI3K/Akt pathways (Yang et al. 2012). Furthermore, Wang et al. 2008 showed that
overexpression of UCA1 promoted cisplatin resistance in bladder cancer. Based on these
pieces of evidence in bladder cancer, especially its role in promoting cisplatin resistance,
as well as novelty in OC, UCA1 was chosen to investigate its possible role in promoting
cisplatin resistance in OC when the project started in 2013. Importantly, the PI3K/Akt
pathway had been extensively studied in our laboratory previously with antibodies and
TaqMan probes for key members of the pathway available for further investigation.
Prior to the functional analyses, we validated the overexpression of UCA1 observed
in the resistant cell lines from the lncRNA profiling conducted using SYBR-green-based
RT-qPCR with more sensitive TaqMan probes. In the lncRNA profiling, UCA1 was found
to be diﬀerentially expressed only in the A2780/A2780cisR pair. However, this finding
was reversed when TaqMan probes were used to quantify UCA1 expression, and UCA1
was found to be overexpressed in PEO4 compared to PEO1 cells. According to a study
published in 2013, A2780/A2780cisR ranked as ‘unlikely HGSOC’ when their various ‘-
omic’ profiles were compared to the primary HGSOC tissues of the TCGA-OV cohort (Bell
et al. 2011; Domcke et al. 2013) whereas the PEO1/PEO4 pair remain untested as models
that strongly mimic HGSOC. Based on the functional evidence of UCA1 in promoting
cisplatin resistance in bladder cancer, we continued the investigation in the PEO1/PEO4 cell
lines, and subsequently three additional cell lines (Kuramochi, OVCAR-3 and OVCAR4)
that closely matched primary HGSOC tissues (Domcke et al. 2013).
Eﬃcient knockdown of UCA1 was challenging. Roughly 80% of the cells were found
to be positive for fluorescently labelled AllStars Negative Control (AS-488) 24 h post-
transfection, suggesting high transfection eﬃciencies of the cell lines using HiPerFect
reagent. In contrast, transfection of two independent siRNAs targeting separate regions
of the 3’ UTR of UCA1 reduced its levels by only ~50% in most cell lines at 16 - 24 h
post-transfection, which was insuﬃcient for functional assays. Additionally, TP53 was
found to be knocked down at higher levels (~80%) in OVCAR-3 cells 48 h post-HiPerFect
transfection, whereas UCA1 levels were mildly aﬀected under the same conditions at 24
h post-transfection in the same cell line, pointing to the fact that OVCAR-3 cells were
adequately transfected using the HiPerFect reagent. is led us to question whether both
UCA1 siRNAs were functional in vitro. Approximately 80% of knockdown in UCA1 levels
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was achieved using electroporation of the same siRNAs in all cell lines except Kuramochi
24 h post-electroporation, suggesting that both siRNAs were functional. erefore, it
appears that the time-point of 24 h was perhaps too early to measure knockdown in UCA1
when HiPerFect Reagent was used for transfection, but it was necessary to quantify the
knockdown levels prior to further experiments.
Electroporation proved to be surprisingly eﬃcient and cheap (cost in addition to
siRNAs: Opti-MEM media and recycled electroporation cuvettes) in knocking down
UCA1, and was used for the rest of experiments. UCA1 levels were measured on 1 and 4
days post-electroporation to confirm the knockdown throughout the experiment. A slightly
higher cell death was observed using electroporation compared to the HiPerFect reagent,
which was adjusted by empirically increasing the seeding densities.
UCA1 knockdown did not aﬀect cisplatin resistance in PEO1, PEO4, OVCAR-3 and
OVCAR4 cells as tested by MTS assays (N=3). Specifically, the IC50 values remained
unchanged when UCA1 was knocked down compared to the AS control. e IC50 values
were statistically diﬀerent between treatments in some cases, but the diﬀerences in absolute
fold-changes were marginal (~1.2-fold). No significant diﬀerences were observed upon
UCA1 knockdown in the clonogenic assays performed on PEO1, PEO4 and OVCAR4 cells
investigating the long-term eﬀects of UCA1 knockdown on cell survival. Kuramochi cells
were found to be unable to form colonies, and results of the clonogenic assays onOVCAR-3
cells were excluded from the analyses because the culture media in some wells evaporated
during the experiment.
e conclusion of this study contradicts (Wang et al. 2015) who reported that overex-
pression of UCA1 promoted cisplatin resistance of SKOV-3 cells. e choice of knocking
down UCA1 using siRNA in our case versus a forced overexpression from an expression
vector performed byWang et al. 2015 could have led to diﬀerent conclusions. A key limita-
tion of their study is the use of only one HGSOC cell line SKOV-3, which has already been
found to be ‘unlikely’ to be representative of HGSOC according to Domcke et al. 2013. Al-
though the similarities between PEO1/PEO4 and HGSOC patient samples were not tested
by Domcke et al. 2013, OVCAR-3 and OVCAR4 model HGSOC well in vitro, therefore,
results obtained from these cell lines should immediately be able to be translated.
Transcriptional regulation ofUCA1 also remains largely unknown. Transcription factor
Ets-2 was found to induce UCA1 expression by directly binding to its promoter in bladder
cancer cell lines (Wu et al. 2013b). In addition, a bioinformatic analysis suggested c-Myb
can bind to the promoter of UCA1 (Xue, Li, and Chen 2013). In the dataset generated by
Mr. Alexander Cole, a fellow PhD student, UCA1 was induced by roughly 20-fold upon
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cisplatin treatment in A2780 cell lines harbouring wt-p53. Remarkably, this induction
was as high as CDKN1A/p21, a direct transcriptional target of wt-p53, prompting us to
investigate whether UCA1 could be downstream of p53.
A functional approach was undertaken to test whether UCA1 expression was aﬀected
by wt-p53 as well as four TP53 mutations. Ten high priority mutations in TP53, identi-
fied based on evolutionary approaches, were synthesised using site-directed mutagenesis.
UCA1 was found to be induced by ~3-fold in the p53-null cells transfected with wt-p53
compared to the empty vector whereas three (R175H, R248Q and R248W) of the four
mutant-p53 tranfected had no significant eﬀect on UCA1 levels (P < 0.05). e fourth
mutant-p53 (R273H) also showed the same eﬀect with a trend (P = 0.077).
To confirm that mutant-p53 was unable to induce UCA1, mutant-p53 was downreg-
ulated in OVCAR-3 cells endogenously harbouring the TP53 mutation R248Q. As shown
in Figure 6.2, OVCAR-3 cells express a high level of mutant-p53 and an additional stimu-
lus such as cisplatin treatment was unnecessary. UCA1 levels were not aﬀected by ~80%
knockdown in the TP53mRNA.us, there is some indirect evidence to support the role of
wt-p53 in regulation of UCA1, which could have been lost upon TP53mutation. However,
more experiments are needed to confirm this. In particular, if the hypothesis is correct,
downregulation of the mutant-p53 in cells, such as Kuramochi, CaOV4 and OV202 ex-
pressing high basal levels of mutant-p53, should not aﬀect levels of UCA1. Knocking down
p53 in the cell lines harbouring wt-p53 (HEY andMCF7) in the absence of a DNA damage-
type stimulus would probably be unfruitful since the levels of wt-p53 are usually kept low by
the E3 ligase MDM2. UCA1 might be induced in these cells upon treatment with stressors
such as cisplatin, as shown in A2780 cells. In fact, the A2780 cell line could be a goodmodel
to investigate eﬀects of UCA1 following activation of wt-p53. e expression of UCA1 was
found to be higher in PEO4 versus PEO1 cells. Both cell lines carry the identical TP53
mutation G244D (Cooke et al. 2010) as well as harbouring a germline mutation in BRCA2;
however, PEO4 cells gained an additional mutation in BRCA2 that restores the wild-type
protein sequence (Cooke et al. 2010). While the identical mutation in TP53 in PEO1/PEO4
may not be responsible for the overexpression of UCA1 seen in PEO4 cells, the possible in-
fluence of BRCA2 status on UCA1 expression remains unclear. Besides cisplatin resistance,
a wider role of UCA1 in promoting multiple cancer remains unknown. In the context of
OC, UCA1 was also one of the five diﬀerentially expressed lncRNAs between SKOV-3 and
its derivative cell line with enhancedmetastatic capabilities (SKOV-3.ip1) (Liu et al. 2013a),
and the potential role of UCA1 in promoting invasiveness remains to be tested in other cell
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line models. Finally, if additional evidence supports that UCA1 is a transcriptional target
of wt-p53, its role in the p53 network should be investigated.
5.5 Conclusions
Ninety lncRNAs were profiled in two cell line models of cisplatin resistance, and five
lncRNAs were found to be diﬀerentially expressed between resistant and sensitive cell lines.
UCA1 was selected for functional validation given its emerging role in promoting cisplatin
resistance in bladder cancer, as well as its association with multiple cancers including
ovarian, bladder and breast cancers. However, no diﬀerences in cell proliferation and
survival were observed upon UCA1 knockdown in a pair of cisplatin sensitive/resistant cell
line originally used in the lncRNA profiling as well as two additional HGSOC cell liness.
UCA1 was significantly induced, as much as CDKN1A, in A2780 cells harbouring wt-p53
treated with cisplatin, indicating that it could be a downstream target of wt-p53. In support
of this hypothesis, UCA1 was induced in the p53-null cells transfected with wt-p53, but not
mutant-p53, and downregulating mutant-p53 in OVCAR-3 cells did not aﬀect the levels of
UCA1. However, further experiments are needed to confirm a potential role for UCA1 in
the wild-type p53 network.
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Chapter 6
Investigating the eﬀects of mutant-p53 on
lncRNAs by using the p53-activating drug
APR-246
6.1 Introduction
p53 is a well-studied transcription factor regulating expression of a large number of protein-
coding genes. Recently, p53 has also been found to transcribemicroRNAs, such as themiR-
34 family of microRNAs, (He et al. 2007) and lncRNAs such as lincRNA-p21 (Huarte et al.
2010), PANDA (Hung et al. 2011), Pint (Huarte et al. 2010), PR-lncRNA-1 (Sánchez et al.
2014), PR-lncRNA-10 (Sánchez et al. 2014), NORAD (Lee et al. 2016), TUG1 (Guttman et
al. 2009; Khalil et al. 2009), PVT1 (Barsotti et al. 2012), LINP1 (Zhang et al. 2016c), DDSR1
(Sharma et al. 2015) andDINO (Schmitt et al. 2016). In fact, half of theDNA regions bound
by p53were found to be located outside the protein-coding genes by a recentChIP-seq study
(Idogawa et al. 2014). us, p53 is likely to dramatically influence transcription of lncRNAs.
TP53 is mutated at a high frequency in cancers (Muller and Vousden 2013; Oren and Rotter
2010; Strano et al. 2007b) and almost universally mutated in HGSOC (Bell et al. 2011). e
eﬀect of mutant-p53 on the lncRNA landscape remains largely unexplored.
Mutations in most tumour suppressors result in loss of their functions, which can
eventually lead to cancer. Most mutations in p53 aremissensemutations that are frequently
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expressed at a high protein level. e p53 protein is a tetramer consisting of two dimers.
Mutant-p53/wt-p53 heterodimers are considerable impaired in the ability to bind to the
p53-response element and transcribe wt-p53-response genes(Goh, Coﬃll, and Lane 2010;
Weinberg et al. 2004). Mutant-p53 can inactivate wt-p53 as well as other members of the
p53 family of proteins such as p63 and p73 due to dominant-negative eﬀects (Martynova
et al. 2012). In addition, mutant-p53 was found to interact with transcription factors
and proteins that do not influence transcription directly, enhancing or preventing their
activities, depending on the mutant-p53 and interacting partners (Muller and Vousden
2013). Based on these pieces of evidence, it has been proposed that mutations in p53 do not
always equate to the loss of the protein but oﬀer new capabilities that significantly enhance
carcinogenesis. In support of this theory, genetically engineered mouse models harbouring
mutant-p53 were found to have more aggressive and metastatic tumours than p53-wild-
type or p53-null mice (Doyle et al. 2010; Lang et al. 2004; Morton et al. 2010; Olive et al.
2004). Furthermore, patients of Li–Fraumeni syndrome harbouring germline p53missense
mutations developed tumours 9-15 years earlier than those with mutations that resulted in
a loss of p53 expression (Bougeard et al. 2008; Zerdoumi et al. 2013).
e aim of the research described in this chapter was to investigate the eﬀects ofmutant-
p53 on lncRNAs using a small compound known asAPR-246 that has been shown to induce
wt-p53 activity from mutant-p53 in multiple cancers and is currently undergoing phase
Ib/II clinical trial for treatment of recurrent HGSOC (NCT02098343 2014). Furthermore,
APR-246 was found to be synergistic with cisplatin in ovarian cancer cell lines and primary
cells derived from patients’ ascites (Fransson et al. 2016; Mohell et al. 2015). erefore, we
also aimed to investigate mechanisms of synergy between APR-246 and cisplatin.
A combination of two drugs is called synergistic when their combined eﬀect is signif-
icantly greater than their addition; therefore, the calculation of the additive eﬀect is of ut-
most importance and remains complex (see the 60-page review authored by Chou 2006
devoted to this topic). More than 300 mechanism-specific equations have been derived to
predict the additive eﬀect (Chou 2010). A simple graphical technique known as an isobolo-
gram is oen used to interpret drug interactions since its first employment by Loewe 1953.
An abridged description of an isobologram is provided in Figure 6.1, and details on its
construction can be found in Tallarida 2001 and Grabovsky and Tallarida 2004. Assuming
the potency ratio, R, is constant, the additive eﬀect of both drugs results in a linear line
(‘isobole’) connecting the IC50 values of both drugs (Figure 6.1). When concentration of
drug B is zero (b = 0), the equation for the isobole shown in Figure 6.1 results in a = A,
which is the IC50 and the x-intercept of drug A. If a pair of doses is synergistic, the fixed
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Figure 6.1: Analysis of drug interactions using isobolograms
A specified eﬀect level observed upon a drug treatment, such as IC50, is fixed for an experiment.
The IC50 of each drug represents x and y intercepts of the isobologram. Next, the potency ratio,
R, is calculated by dividing IC50 of drug A and B. The potency ratio enables the calculation of the
equivalent dose of drug B to observe the same eﬀect, such as a reduction in cell viability by half,
using dose of drug A. When R is constant, the isobole is linear otherwise it is curved. Interaction
points below and outside the isobole represent synergism and antagonism, respectively (Grabovsky
and Tallarida 2004; Tallarida 2001). P: synergistic drug combinations, Q: sub-additive or antagonistic
drug interactions.
eﬀect level, i.e. IC50, is reached using a lower amount of the total dose and the interaction
falls below the isobole (point P in Figure 6.1). A drug interaction such as point Q in Figure
6.1 represents sub-additivity or antagonism, where a higher dose than the predicted additive
eﬀect is required to observe the eﬀect level. e ‘Additive model’ (explained in subsection
6.2.1) was employed in this study to identify synergistic drug interaction, as advised by the
developers of APR-246 (Mohell et al. 2015).
6.2 Materials andmethods
6.2.1 Calculations of synergy between two treatments
e additive model (Jonsson et al. 1998) was used to calculate synergy between two
drugs. For example, if drug A and B individually resulted in cell viabilities of 0.4 and 0.6,
respectively, the additive model predicts the viability of 0.24 (0.4 0.6) for their combined
eﬀect. e ratio of the observed to the predicted viabilities (ObservedPredicted ; also known as the
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Survival Index (SI)) dictates whether an interaction is additive (0.8 SI 1.2), synergistic
(SI < 0.8) or sub-additive/antagonist (SI > 1.2).
6.2.2 RNA-seq
RNA-seq was performed at the Garvan Institute of Medical Research, Sydney, Australia, by
our collaborators on bioinformatics, Dr. Nenad Bartonicek and Mr. James Torpy. A short
description is provided below.
6.2.2.1 RNA quality control prior to cDNA library construction
RNA quality was assessed on a LabChip GX instrument (Perkin Elmer) with the Standard
RNA Assay kit according to the manufacturer’s instructions (Perkin Elmer). RNA con-
centration was measured using a Qubit 2.0 spectrophotometer (ermo Fisher) and RNA
Broad Range (BR) assay (ermo Fisher).
6.2.2.2 cDNA library construction
250 ng of total RNA was used as input material for library preparation using the TruSeq
Stranded Total RNA Sample Prep Kit (Illumina) according to the manufacturer’s instruc-
tions. Individual libraries were indexed as recommended by Illumina.
6.2.2.3 Quantification and quality control of cDNA libraries
Indexed DNA libraries were analysed individually using a LabChip GX instrument (Perkin
Elmer) with the DNA High Sensitivity Assay kit according to the manufacturer’s instruc-
tions (Perkin Elmer). Libraries were diluted and pooled to a final concentration of 3 nM
in Resuspension Buﬀer (Illumina). Pooled libraries were analysed using a LabChip GX
instrument and DNA High Sensitivity Assay kit according to the manufacturer’s instruc-
tions. PCR-competent library DNA concentration was verified using the universal KAPA
Library Quantification Kit for Illumina Sequencing Platforms according to manufacturer’s
instructions (KAPA Biosystems). An Applied Biosystems QuantStudio 7 Real-Time PCR
machine (Life Technologies) was used for RT-qPCR.
6.2.2.4 Processing of RNA-seq data
e sequenced sample libraries were assessed for quality control and trimmed by Trim
Galore (v.0.41). Next, the sequences were mapped to the human genome (hg38) and
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transcriptome (Gencode human, v.24) using STAR (v.2.5.0b) and counted with RSEM
(v.1.2.25). e counts reported with RSEM were normalised with the R package ‘edgeR’
(Robinson, McCarthy, and Smyth 2010). Only those genes that had at least 5 reads in at
least 3 samples were reported. Diﬀerentially expressed genes were calculated as those with
FDR <0.05.
6.2.3 Gene Set Enrichment Analysis
Gene Set Enrichment Analysis (GSEA) was performed by the candidate under supervi-
sion of the bioinformaticians. e java application for performing GSEA (v.2.2.4) was
downloaded from the Broad Institute’s website (http://software.broadinstitute.org/
gsea/downloads.jsp). e ‘Hallmarks’ and ‘C2’ gene sets used in this thesis were provided
by MSigDB v.6.0, also available through the Broad Institute (Subramanian et al. 2005). A
1000 permutations were performed using themedian values of the ranked list L to calculate
the P values of a gene set.
6.3 Results
6.3.1 Selection of cell line models
Since APR-246 is thought to work by reactivating wt-p53 activity from the mutant-p53, we
hypothesised that the cell line with high basal levels of mutant-p53 might respond well to
APR-246. Measurements of basal levels of mutant-p53 were conducted by Mrs. Kristie
Dickson and Ms. Joa Manoudian in our laboratory (Figure 6.2). OVCAR-3 cells were
selected based on their high basal mutant-p53 expression as well as TP53mutation R248Q,
which is a gain-of-function and hotspot p53 mutation (Bieging, Mello, and Attardi 2014;
Walerych, Lisek, and Del Sal 2015).
6.3.2 Establishing synergistic conditionsof the combination
of cisplatin and APR-246 at 72 hours post-treatment
Synergistic drug combinations can be determined at any given time point. Our laboratory
has routinely treated cells with cisplatin for 72 hours to allow the drug to manifest its
eﬀects; therefore, this time period was chosen to determine the synergy between APR-246
and cisplatin. Once synergistic conditions were established, transcript levels of selected
138
6.3. Results
p53
GAPDH
Ku
ra
m
oc
hi
 (D
28
1Y
)
C
aO
V
4 
(V
14
7D
)
O
V
C
A
R
−3
 (R
24
8Q
)
P
E
O
1 
(G
24
4D
)
P
E
O
4 
(G
24
4D
)
O
V
20
2 
(S
24
1F
)
O
V
K
AT
E
 (R
28
2W
)
O
V
C
A
R
−4
 (L
13
0V
)
C
O
V
31
8 
(I1
95
F)
C
O
V
50
4 
(P
32
2f
s)
O
V
S
A
H
O
 (R
34
2*
)
C
aO
V
3 
(Q
13
6*
)
O
AW
28
 (P
15
2f
s)
p5
3/
G
A
P
D
H
0
5
10
15
20
Figure 6.2: Protein expression of mutant-p53 in OC cell lines
Cell lines were grown as described in subsection 2.2.1. Three biological replicates were used
for quantifying levels of mutant-p53 using western blotting. TP53 mutation status is shown in
parenthesis after a cell line’s name. GAPDH was used for normalisation. A representative western
blot is shown in this figure. This data was generated by Mrs. Kristie Dickson and Ms. Joa Manoudian.
p53 target genes were measured as early as 4 hours post-treatment to capture the cellular
response to the drugs whose eﬀects were determined to be synergistic aer 72 hours.
6.3.2.1 Optimising drug doses using the MTS assay
IC50 values of APR-246 and cisplatin were calculated in OVCAR-3 cells. Briefly, 3000
cells were seeded in 96 well-plates overnight, treated with the drugs individually for 72
hours and the MTS assay was performed to assess cell viabilities as described in subsection
2.2.5. As shown in Figure 6.3, the IC50 values for APR-246 and cisplatin were found to be
11.7 and 3.31 μM, respectively (N=3). Next, OVCAR-3 cells were treated with a range of
combinations ofAPR-246 and cisplatin in terms of varied ratios of their IC50 concentrations.
e DRC was calculated for each ratio of IC50. For simplicity, the concentration of APR-
246 was fixed at 60 μM whereas the amount of cisplatin was varied to achieve the desired
ratio. For example, to prepare the master mix for the IC50 ratio of 1:1 for APR-246 and
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Figure 6.3: Dose response curves (DRCs) and IC50s of APR-246 and Cisplatin in OVCAR-3
cells
OVCAR-3 cells were seeded into 96well plates overnight and treatedwith the drugs for 72 hours. The
MTS assay was used to infer cell viability. Data was normalised to vehicle controls. A total of 8 drug
dilutions were used in calculating IC50 values (N = 3).
cisplatin (11.7/3.3 = 3.54), 16.9 μM cisplatin (60/3.54) was added to 60 μM APR-246.
Cells were treated with 8 concentrations, in 1.5-fold dilutions from the master mix, for
each IC50 ratio to obtain the DRC. Cells were treated with the following ratios of APR-246
to cisplatin IC50s: 0.8:1, 1:1, 1:2, 1:2.5, 1.2:1 and 1.4:1. In addition, drug combinations in
the format ‘10 μM APR-246+various concentrations of cisplatin’ were also tested. ese
combinations culminated in a total of 8 96 well-plates for each biological replicate. ree
biological replicates were performed and each biological replicate included theDRC of each
drug treated individually to account for inter-plate variability.
Data analysis was automated by a custom R script written by the candidate (Appendix
C). For each biological replicate, the treatment dose was broken down into its APR-246 and
cisplatin constituents, and cell viability at the concentrations for each drug was estimated
from their respective DRCs. e Additive model was applied to each drug combination to
determinewhether the drug combinationwas additive, synergistic or sub-additive (outlined
in subsection 6.2.1). Finally, the SEM was calculated for each data point from three
biological replicates (Figure 6.4). To visually identify the synergistic drug combinations, the
size of the coloured ‘bubble’ was plotted inversely proportional to the SI whereas SEM was
colour-coded. Data points with both small SI and SEM (large bubbles in red, blue or green
colour) close to the IC50 values of each drug were given a priority. ree points of interest
were validated for synergy using the alternative methodology of flow cytometry: 10 μM
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Figure 6.4: Overview of interactions between APR-246 and cisplatin measured using the
MTS assay in OVCAR-3 cells.
OVCAR-3 cells were treated with a range of APR-246 and cisplatin concentrations for 72 hours, and
the eﬀects on cell viability were measured by MTS assay (N = 3). The size of the coloured bubble
is inversely proportional to the SI, hence, larger bubbles represent stronger synergies. Only data
matching SI < 1 are shown to put an emphasis on the synergistic conditions. The colour of the
bubbles represents SEM of the biological replicates. The bubbles marked with arrows were selected
for validating synergy using flow cytometry as their total drug dose was higher compared to other
drug interactions. The notation ‘A+C’ refers to drug combination of APR-246 (A) and cisplatin (C).
APR-246+2.2 μM cisplatin (shortened as 10A+2.2C hereon), 10A+3.3C and 13.8A+3.9C
(marked with arrows in Figure 6.4).
6.3.2.2 Validating the synergistic drug interactionsusingflowcytometry
e synergistic conditions identified from MTS assays were upscaled to T25 flasks to
provide suﬃcient cells to perform flow cytometry. 2.25 105 OVCAR-3 cells were seeded
into T25 flasks and treated with 10A+2.2C, 10A+3.3C and 13.8A+3.9C, either both drugs
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Figure 6.5: Validating synergistic conditions established byMTS assay using flow cytom-
etry at 24 hours and 72 hours post-treatment
Three synergistic drug combinations (10A+2.2C, 10A+3.3C and13.8A+3.9C) identified fromFigure 6.3
were tested for synergy using flow cytometry. OVCAR-3 cells were treatedwith APR-246 and cisplatin
aloneor in combination for 24 or 72 hours, and cell viabilitieswere determinedusingDilC1(5)/FVS450
dyes (subsection 2.5)
individually or in combination (Figure 6.5). Cells were prepared for flow cytometry
to determine cell viability using DilC1(5)/FVS450 dyes at 24 hours and 72 hours post-
treatment (subsection 2.5). As shown in Figure 6.5, cell viability at 24 hours post-treatment
of all samples treated with drugs was similar to the vehicle control. Although the cell
viability was markedly reduced in some drug treated samples for 72 hours, the viability in
the dual drug combinations such as 13.8A+3.9C did not seem to be synergistic compared
to cells treated with both drugs individually. is simple experiment (N = 1) suggested that
the conditions used previously to assess cell viability by MTS assays may not be scalable
to T25 flasks. Out of the 3 drug combinations found to be synergistic based on the MTS
data, ‘13.8A+3.9C’ contained the highest concentrations of both drugs compared to other
combinations and it was tested for synergy in further experiments (N = 4).
Optimising conditions in T25 flasks was also found to be cumbersome, requiring
excessive numbers of cells, amount of the drugs and tissue culture consumables; therefore, 6
well-plates were used for subsequent experiments. e seeding density was fixed at 1.5105
OVCAR-3 cells/well, which was found to be suﬃcient for downstream analyses without
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overgrowing the cells. Cells were treated with 20A+4C, 20A+6C, 20A+8C, 30A+4C,
30A+6C or 30A+8C for 72 hours, and cell viability was measured using flow cytometry
(Figure 6.6; N = 3). e drug combination 13.8A+3.9C found to be synergistic at 72 hours
post-treatment identified from the MTS assays was also tested (N=4).
In standard hypothesis testing procedures, the null hypothesis states that no diﬀerence
between two treatments is observed, i.e. H0: average (treated samples) - average (untreated
samples) = 0. A P < 0.05 is considered as suﬃcient evidence to reject the null hypothesis.
Because the synergistic drug interactions have SI < 0.8, the null hypothesis for this
experiment was: H0: SI < 0.8*, statistical analyses were preformed using a one-tailed one-
sample student’s t-test. e following drug combinations were found to be synergistic (P >
0.05, insuﬃcient evidence to reject the null hypothesis): 20A+4C, 20A+6C and 30A+4C.
When assessed alone, the 30A treatment resulted in a more variable cell viability compared
to 20A and was excluded from further analyses. e variability in cell viability was similar
between 4C and 6C treatments; however, 20A+6C was found to be more synergistic than
20A+4C and was chosen for subsequent experiments.
6.3.2.3 Assessing drug response under synergistic conditions
Since APR-246 is proposed to activate wt-p53 activity, SYBR green primers were used to
quantify the expression of canonical p53-regulated genes (CDKN1A,BBC3/PUMA,MDM2,
TP53-Induced Gene 3 (TP53I3), BAX and C12orf5 aer APR-246 treatment (N = 3; Figure
6.7). In addition, Glutamate-Cysteine Ligase Catalytic Subunit (GCLC) induced upon
oxidative stress was also measured. Data was normalised to the vehicle control, which
was omitted from the graphs aer normalisation. As shown in Figure 6.7, CDKN1A,
BBC3/PUMA, BAX and C12orf5 were not significantly induced (absolute FC > 2 and P
< 0.05) upon 20A and 30A treatments. In contrast to p53-response genes, GCLC was
significantly induced upon 20A and 30A treatments (Figure 6.7). Although CDKN1A and
BBC3/PUMA were induced at a higher level upon treatment with 30 μM compared to 20
μM APR-246, this treatment was not statistically significant.
Western blotting was performed to test whether APR-246 induced p21 at the protein
level regardless of the doses that were found to be synergistic. Since western blotting
required more cells than RT-qPCR and significant cell death was observed upon APR-
246 treatments, both seeding densities and drug doses were increased for the following
*e H0: SI = 1 (absence of synergy) was considered. However, a P < 0.05 would indicate that the drug
interactions are either synergistic (SI < 1) or sub-additive (SI > 1), requiring a one-tailed t-test for further
confirmation. Importantly, a synergistic interaction is defined as SI < 0.8, not SI < 1, justifying H0: SI < 0.8
for this experiment
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Figure 6.6: Optimisation of synergistic conditions at 72 hours post-treatment using flow
cytometry
OVCAR-3 cells were treated with either both drugs alone or in combination for 72 hours, and cell
viabilities weremeasured using DilC5/FVS450 dyes on a flow cytometer. P values represent evidence
against the null hypothesis H0: SI < 0.8, whichwas acceptedwhen P > 0.05. The short horizontal lines
above ‘A+C’ combinations indicate predicted viability of the drug combination based on theAdditive
model, and cell viabilities under the lines usually represent synergy. The notation ‘A+C’ refers to drug
combination of APR-246 (A) and cisplatin (C).
experiment to obtain enough starting material. Briefly, 3105 OVCAR-3 cells were treated
with 30 - 50 μM APR-246 for 24 - 48 hours, and both the floating and the adherent fractions
were collected in 200 μl Laemmli buﬀer (N = 1; Figure 6.8A). TP53-null H1299 cells
(Mitsudomi et al. 1992) transfected with wt-p53 plasmid, which were found to express the
wt-p53 and the downstream protein p21, were used as a positive control. OVCAR-3 cells
expressedmutant-p53 basally as well as uponAPR-246 treatment, although this experiment
would not discriminate between wild-type or mutant-p53 upon APR-246 treatment in
this experiment. e expression of p21 remained undetectable with or without APR-246
treatment for 24 or 48 hours (Figure 6.8).
If treatment withAPR-246was able to reactivate wt-p53 activity frommutant-p53, there
was an expectation that levels of p53-target genes such asCDKN1A/p21would be increased,
which would be detectable by RT-qPCR. Plus, RT-qPCR also requires lower amounts of
starting material for analysis; therefore, RT-qPCR was used for further experiments. In
conclusion, canonical p53-response genes, measured by RT-qPCR and western blotting,
were not significantly induced in OVCAR-3 cells following treatment with APR-246,
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Figure 6.7: Expression of p53- and ROS-responsive genes in OVCAR-3 cells after treat-
ment with APR-246 or cisplatin.
Horizonal dashed lines represent fold-change (FC) of 1, i.e. the vehicle control. Diﬀerentially
expressed data points (absolute FC > 2 and P using student’s t-test < 0.05) are decorated with an
asterisk. p53-responsive genes TP53I3, BAX and C12orf5 were not measured in cisplatin-treated
samples.
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Figure 6.8: Screening for p21 induction in OVCAR-3 cells following APR-246 treatment.
OVCAR-3 cells treated with APR-246 for 24 and 48 hours. H1299 (p53-null) cells transfected with wt-
p53 plasmid were used as a positive control for detecting wt-p53 and p21 proteins.
suggesting that the selected APR-246 dose, despite causing a reduction in cell viability as
measured by flow cytometry experiments, may not be enough to elicit a strong wt-p53
response, or the drug might be operating through other pathways.
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6.3.3 Establishing synergistic conditionsof the combination
of cisplatin and APR-246 at 48 hours post-treatment
OVCAR-3 cells were treated with higher concentrations of APR-246 to ensure that the
dose was suﬃciently high to induce a potential p53-response upon treatment. Induction
of p21 protein was observed in published studies using ~50 μM APR-246 at 12 - 24
hours post-treatment (Bykov et al. 2005a; Liu et al. 2015; Zandi et al. 2011). Previous
experiments showed that ~50 μM APR-246 treatment killed virtually all OVCAR-3 cells
at 72 hours post-treatment, and synergistic conditions were optimised at an earlier time
point. However, 24 hours of drug treatments may be too early to observe the full extent of
cell death; therefore, synergy was optimised at 48 hours post-treatment using higher drug
doses. Furthermore, Kuramochi cells, which express mutant-p53 (D281Y) at high levels
(Figure 6.2), were also included to investigate eﬀects of APR-246 on a separate cell line.
OVCAR-3 cells were seeded at 4 105 cells/well in 6 well-plates, treated with high
concentrations of APR-246 (50, 60 and 70 μM APR-246) and cell viability was measured
at 48 hours post-treatment using flow cytometry (Figure 6.9). Similar experiments were
performed on Kuramochi cells (seeding density: 3 105 cells/well; Figure 6.10). Multiple
drug combinations were found to be synergistic in each cell line, amongst which 70A+8C
and 80A+20C were chosen for further investigations in OVCAR-3 and Kuramochi cells,
respectively (marked with red arrows in Figure 6.11A; N = 3). Next, cell viabilities of
OVCAR-3 and Kuramochi cells were measured at 12, 24 and 48 hours post-treatment
(Figure 6.11B; N = 3). A reduction in cell viability was evident as early as 12 hours
post-APR-246 treatment in OVCAR-3 cells, confirming that cells were responding to the
drug dosage. Kuramochi cells, on the other hand, did not show significant reduction in
cell viability when treated with both drugs individually for up to 48 hours, but a marked
reduction in cell viability was observed in ‘A+C’ dual drug treatments at 24 and 48 hours.
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Figure 6.9: Synergistic conditions in OVCAR-3 cells at 48 hours post-treatment
Representativedataof the conditions for synergypreviously established (Figure 6.11B).OVCAR-3 cells
were treatedwith the vehicle, 70 μM APR-246, 8 μM cisplatin and 70 μM APR-246+8 μM cisplatin
for 48 hours. Debris were excluded (Gate P1). Cell viabilities were measured using DilC1(5)/FVS450
dyes in flow cytometry (Gate Q1). Additive model was used to calculate the predicted viability:
viability obtained using 70 μM APR-246 viability obtained using 8 μM cisplatin = 0.607 0.303
= 0.183. Survival Index (SI): 0.064 (observed viability of 70 μM APR-246 + 8 μM cisplatin)/0.183
(predicted viability) = 0.350, which is less than 0.8, i.e. synergistic.
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Figure 6.10: Synergistic conditions in Kuramochi cells at 48 hours post-treatment
Representative data of the conditions for synergy previously established (Figure 6.11B). Kuramochi
cells were treated with the vehicle, 80 μM APR-246, 20 μM cisplatin and 80 μM APR-246+20
μM cisplatin for 48 hours. Debris were excluded (Gate P1). Cell viabilities were measured using
DilC1(5)/FVS450 dyes in flow cytometry (Gate Q1). Additive model was used to calculate the
predicted viability: viability obtained using 80 μM APR-246  viability obtained using 20 μM
cisplatin = 0.824  0.672 = 0.554. Survival Index (SI): 0.03 (observed viability of 80 μM APR-246
+ 20 μM cisplatin)/0.554 (predicted viability) = 0.054, which is less than 0.8, i.e. synergistic.
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Figure 6.11: Optimisation of synergistic conditions inOVCAR-3 andKuramochi cells at 48
hours post-treatment using higher drug doses
(A) Screening for synergistic conditions at 48 hours post-treatment in OVCAR-3 and Kuramochi cells
using higher APR-246 and cisplatin doses. Red arrows highlight drug combinations that were chosen
for further studies in OVCAR-3 (70A+8C) and Kuramochi (80A+20C) cells (N = 3). Dashed lines
represent SI of 0.8, below which drug interactions are classified as synergistic. (B) Quantification of
cell viabilities in OVCAR-3 and Kuramochi cells treated at synergistic combinations for 12, 24 and 48
hours (N = 3).
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Expression of CDKN1A/p21, BBC3 and GCLC were measured 4, 8, 12, 16 and 24 hours
post-treatment (Figure 6.12; N = 3). Again, the p53-responsive gene CDKN1A was barely
induced by 2-fold whereas BBC3 remained relatively unaﬀected in both cell lines treated
with APR-246 for up to 24 hours. In contrast, ROS-responsive GCLC was induced by ~3-
fold following treatment with APR-246 as early as 8 hours in OVCAR-3 cells. ese data
were consistent with the earlier results optimised at 72 hours for drugs treatments using
lower doses (Figure 6.7), supporting the hypothesis that APR-246 failed to activate wt-p53
activities in OVCAR-3 cells. Interestingly, p21 was found to be DE in Kuramochi cells
treated with cisplatin for 16 and 24 hours (Figure 6.12), suggesting that transcription of
CDKN1Amay not be entirely exclusive to wt-p53.
RNA-seq was employed to gain a transcriptome-wide overview of the cellular response
to the drugs and identify pathways resulting in the synergy observed. OVCAR-3 and
Kuramochi cells treated for 12 and 24 hours were selected for RNA-seq, respectively, as
they represented the earliest time point where diﬀerences in gene expression were observed
in the corresponding cell lines. In addition, the viability of OVCAR-3 cells treated for 12
hours was comparable with Kuramochi cells treated for 24 hours (Figure 6.11), representing
functionally equivalent points. Both cells were also equivalent in cell viabilities at 48 hours
post-treatment where synergy was optimised.
151
6.3. Results
*
*
*
*
*
**
* *
CDKN1A BBC3 GCLC
O
V
C
A
R
−3
Kuram
ochi
4 8 12 16 24 4 8 12 16 24 4 8 12 16 24
0
2
4
6
0
1
2
3
4
Treatment period (h)
R
Q
Treatment A C A+C
Figure 6.12: Assessing whether higher drug concentrations induced p21 using a time-
course
OVCAR-3 and Kuramochi cells were treatedwith 70A+8C and 80A+20C, respectively, with both drugs
individually as well as their indicated combinations. RNA was collected at 4, 8, 12, 16 and 24 hours
post-treatment (N=3), and levels of p53-responsive genes CDKN1A/p21 and BBC3/PUMA as well as
ROS-responsiveGCLCwerequantifiedusingRT-qPCR. Vehicle controlwas used for normalisation, and
excluded from plots since its RQ = 1. RQ: relative quantification, ‘*’ denotes absolute RQ > 2 and P <
0.05, ‘A’ APR-246, ‘C’ cisplatin and ‘A+C’ APR-246 + cisplatin
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6.3.4 Investigating transcriptome-wide eﬀects of APR-246
using RNA-seq
RNA-seq was employed to investigate the global changes in transcription in OVCAR-3 and
Kuramochi cells following treatment with APR-246 for 12 and 24 hours, respectively. is
work was conducted in collaboration with bioinformaticians Dr. Nenad Bartonicek and
Mr. James Torpy of e Garvan Institute of Medical Research, Sydney, Australia. Quality
control, library preparation, RNA-seq andprocessing of the datawas performat theGarvan.
Analyses presented in this section were conducted by the candidate following consultation
with the bioinformaticians.
6.3.4.1 Comparison of RNA-seq results with RT-qPCR
RT-qPCR remains the ‘gold standard’ to validate results of RNA-seq experiments, and
expression of CDKN1A, BBC3 and GCLC in OVCAR-3 and Kuramochi cells in a time-
course as determined previously could be used as positive controls to validate the results
obtained from RNA-seq (Figure 6.12). Expression of CDKN1A, BBC3 and GCLC based on
RNA-seq (Figure 6.13) were comparable with RT-qPCR, and only GCLC was found to be
diﬀerentially expressed at 12 hours post-APR-246 treatment in OVCAR-3 cells using both
methods.
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Figure 6.13: Validation of RNA-seq results with RT-qPCR
mRNA levels of BBC3/PUMA, CDKN1A and GCLC were measured by RT-qPCR following 12 and
24 hours of APR-246 treatment in OVCAR-3 and Kuramochi cells, respectively (Figure 6.12). The
expression of the three genes quantified by RNA-seq in terms of Fragments Per Kilobase of transcript
per Millionmapped reads (FPKM). Higher FPKM indicate a higher number of sequencesmapped to a
gene, hence, higher abundance of a transcript in a sample. Amongst the threemRNAs, onlyGCLCwas
found to significantly (absolute fold-changed > 2 and P < 0.05) induced upon 12 hours of APR-246
treatment in OVCAR-3 cells, which is comparable with results of the RT-qPCR experiment, suggesting
that RNA-seq was comparable to RT-qPCR. Identical RNA samples were used in RT-qPCR and RNA-
seq.
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Figure 6.14: Overview of Gene Set Enrichment Analysis
Gene Set Enrichment Analysis (GSEA) calculates whether genes in a pre-determined gene set S
behave significantly diﬀerent between two conditions or biological states. More specifically, it
measures whether the position of S in a ranked list L (ordered by Fold-change (FC) or log2-FC) is
non-random and significantly shifted towards upregulated, downregulated genes or both. In our
case, S and L could represent known genes downstream of p53 and FC of all genes measured in an
experiment, respectively. A score is calculated by walking down the list L. The score of the running-
sum statistic is increased upon encountering a member of S and decreased when the encountered
gene is not in S. The Enrichment score (ES) is themaximumdeviation from0 (Subramanianet al. 2005).
Genes at or immediately before the ES constitute the leading edge subset (LES) which identifies the
genes contributing to the ES.
6.3.4.2 Investigation of the p53-response in the RNA-seq dataset
GSEA (Subramanian et al. 2005) was used to calculate enrichment of the p53 pathway
following treatment with APR-246. e calculation of ES is straight forward (explained
in Figure 6.14). Numerous pre-designed gene sets representing canonical pathways and
the soware are available through the Broad Institutes’s MSigDB database†. Gene sets are
grouped into several categories. e ‘Hallmark’ gene sets summarise and represent well-
defined biological states or processes. e ‘C2’ gene sets are curated from various sources
such as online pathway databases, the biomedical literature and knowledge of experts in
the field. p53 gene sets from four well-known sources were used for further analyses: one
from the ‘Hallmark’ and three from the ‘C2’ categories (Biocarta, KEGG and the protein
interactions database (PID)).
Since APR-246 was proposed to work by alkylating the cysteine residues irrespective
of the missense mutations in TP53 (Lambert et al. 2009), the expression data from both
†http://software.broadinstitute.org/gsea/msigdb
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cell lines were combined to test if the potential induction of the p53 pathway was common
between both cell lines following APR-246 treatment (Table 6.1A). Combining data from
both cell lines simplified the analysis and increased the number of biological replicates (N),
which then improved the statistical power to detect a change. If a phenomenon, such as
enrichment of the p53 pathway, is not consistent in both cell lines, the combined data should
have a higher variance and likely to result in statistically non-significant results (P > 0.05).
In addition, these analyses was repeated on both cell lines individually (Table 6.1B-C).
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(A) Both cell lines combined
Weighted-FC Weighted-Log2-FC
Name Size (S) ES NES P LES % (LES/S) ES NES P LES % (LES/S)
Biocarta 16 0.32 0.82 0.56 13 81% 0.45 1.09 0.37 7 38%
KEGG 64 0.26 0.73 0.70 11 16% 0.30 0.99 0.47 15 22%
PID 125 0.62 1.85 0.05 13 10% 0.39 1.44 0.00 19 15%
Hallmark 194 0.25 0.77 0.76 24 12% 0.27 1.05 0.34 32 16%
(B) OVCAR-3
Weighted-FC Weighted-Log2-FC
Name Size (S) ES NES P LES % (LES/S) ES NES P LES % (LES/S)
Biocarta 16 0.26 0.56 0.76 4 19% 0.42 1.03 0.38 4 19%
KEGG 64 0.20 0.43 0.94 8 11% 0.28 0.91 0.63 9 13%
PID 125 0.67 1.52 0.11 4 3% 0.33 1.18 0.13 23 18%
Hallmark 194 0.29 0.66 0.85 16 8% 0.26 0.96 0.59 20 10%
(C) Kuramochi
Weighted-FC Weighted-Log2-FC
Name Size (S) ES NES P LES % (LES/S) ES NES P LES % (LES/S)
Biocarta 16 0.37 0.64 0.76 12 75% 0.50 1.14 0.26 7 38%
KEGG 64 0.28 0.51 0.97 13 20% 0.26 0.76 0.91 13 20%
PID 125 0.56 1.07 0.35 15 12% 0.36 1.17 0.14 38 30%
Hallmark 194 0.30 0.60 0.99 16 8% 0.26 0.88 0.82 51 26%
Table 6.1: GSEA on four p53 pathways using weighted-FC and weighted-log2-FC
FC: fold-change, Size (S): size of the gene set, ES: enrichment score, NES: normalised ES, LES: number
of genes in the leading edge set, %(LES/S): percentage of genes used to calculate the ES.
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Figure 6.15: Enrichment plots for the p53 gene set from the Protein InteractionDatabase
(PID) using various parameters in GSEA
Gene Set Enrichment Analysis (GSEA) performed using the p53 downstream genes provided by
the protein interactions database (PID) weighted by their (A) fold-change (FC) or (B) log2-FC in our
experiment. Using log2-FC resulted inmore uniform changes in fold-changes as seen in thewaterfall
plots under the ‘barcode’-like plots in (A-B). (C) GSEA was performed on the PID-p53 gene set using
unweighted-FC.
e list L could be sorted by FC, log2-FC or simply by the rank or position of a gene in L.
Preliminary analysis showed that ‘weighted’ analysis, which used a magnitude of FC/log2-
FC in calculating the ES, was superior to unweighted analysis based purely on ranking of
the genes in L (Figure 6.15C). Weighted GSEA using four gene sets was performed on the
combined data and each cell line individually as well as FC or log2-FC (Table 6.1).
As shown in Table 6.1, only one gene set (the PID p53 gene set; shortened as PID-p53
hereaer) out of four was found to be significantly upregulated when GSEAwas performed
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Weighted-Log2-FC
Cells Size (S) ES NES P LES % (LES/S)
Combined 114 0.31 1.12 0.179 15 13%
OVCAR-3 114 0.32 1.16 0.169 18 15%
Kuramochi 114 -0.32 -1.01 0.429 36 31%
Table 6.2: p53 pathway eEnrichment scores for cell lines treated with APR-246 based on a
published consensus list of p53-responsive genes (Fischer 2017).
on the combined dataset using FC or log2-FC; none of the gene sets were statistically
enriched when cell lines were analysed individually. Enrichment plots for PID-p53 are
shown in Figure 6.15A, B. Although GSEA based on FC and log2-FC gave similar results,
results of log2-FC should bemore reliable because (1) log-transformation is oen employed
to convert skewed data to normally-distributed data, (2) the waterfall plots for ranked list
L under the gene set S (‘barcode’-like plots in Figure 6.15A, B) look more uniform using
log2-FC, and (3) on average, a higher number of genes were used to calculate the ES using
log2-FC versus FC (compare LES/S in Table 6.1), making the analysis more robust.
6.3.4.3 Meta-analysis of p53-target genes
Fischer 2017 curated a list of potential 3,509 p53-target genes from13 genome-wide studies.
Interestingly, a majority of the genes (2261 out of 3509; 64.4%) were specific to only one
dataset, even when multiple studies were analysed under the same conditions, i.e. HCT116
cells treated with 5-Fluorouracil or MCF-7 cells treated with Nutlin-3a (Fischer 2017).
is variance suggests the presence of false positive and false negative results when relying
on only one dataset. To identify a consensus list of p53-responsive genes, Fischer 2017
suggested a list of 116 genes that were found to be upregulated by p53 in at least six datasets.
Canonical p53-response genes CDKN1A/p21, RRM2B, BAX andMDM2 were included in
the list (see Table 6.3 for their general role in the p53 pathway). e candidate created a
custom gene set consisting of these genes, and performed GSEA using weighted log2-FC
on the data from both cell lines combined or treated individually (Table 6.2). Two genes
out of 116 were not detected in our dataset, resulting in the size of the gene set of 114 genes.
e p53 pathway was not found to be enriched in all combinations tested (Table 6.2 and
Figure 6.16).
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Figure 6.16: Enrichment plots for the 114 p53-responsive genes present in at least six
studies curated by Fischer 2017.
Fischer 2017 identified116genes thatwerepresent in at least six genome-side studies that quantified
cellular response to activation ofwt-p53. 114 out of 116 geneswere present in our dataset. GSEAwas
performed usingweighted log2-FC on the data from both cell lines combined or treated individually.
(A) OVCAR-3 and Kuramochi cells combined, (B) OVCAR-3 cells and (C) Kuramochi cells.
Gene Function
RRM2B DNA repair by supplying pre-cursors
CDKN1A/p21 p53-dependent downregulation of cell cycle genes
MDM2 E3 ligate, mediates degradation of p53
GDF15 member of TGF-B family, inflammation and apoptosis
GADD45A controls G2/M progression
BAX control mitochondria membrane permeabilisation
BBC3/PUMA regulator of apoptosis
PMAIP1/NOXA regulator of apoptosis
Table 6.3: Functions of some of the canonical p53-response genes
RRM2B: ribonucleotide reductase regulatory TP53 inducible subunit M2B, CDKN1A/p21: Cy-
clin Dependent Kinase Inhibitor 1A, MDM2: Mouse double minute 2 homologue , GDF15:
Growth/diﬀerentiation factor 15, GADD45A: Growth Arrest And DNA Damage Inducible Alpha,
BAX : BCL2 Associated X, BBC3/PUMA: BCL2 Binding Component 3 and PMAIP1/NOXA: Phorbol-12-
Myristate-13-Acetate-InducedProtein 1. Data for this tablewas supplied by Bieging andAttardi 2012;
Zilfou and Lowe 2009 and Fischer 2017.
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Weighted-Log2-FC
Cells Size (S) ES NES P LES % (LES/S)
Combined 181 0.42 1.65 0 51 28%
OVCAR-3 181 0.32 1.24 0.025 46 25%
Kuramochi 181 0.42 1.43 0.003 51 28%
Table 6.4: Enrichment of genes downstream of NRF2, a ROS-responsive transcription factor
Figure 6.17: Enrichment plot for NRF2-pathway upon APR-246 treatment
Note: Combined data of both cell lines were used in this analysis.
6.3.4.4 Testing upregulation of ROS upon APR-246 treatment
Transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) plays a central
role in sensing oxidative stress (Gorrini, Harris, and Mak 2013). Analogous to the p53-
MDM2 axis, NRF2 is present at low levels in resting conditions due to actions of the
Kelch-like ECH-associated protein 1 (KEAP1)-Cullin 3 E3 ligase complex thatmarksNRF2
for ubiquitin-mediated protein degradation (Gorrini, Harris, and Mak 2013). KEAP1
is modified under oxidative conditions and unable to bind to NRF2, leading to the
stabilisation and translocation of NRF2 to the nucleus where it transcribes key genes
responsible for glutathione (GSH) biosynthesis (Gorrini, Harris, and Mak 2013). NRF2
directly transcribes GCLC and the Glutamate-Cysteine Ligase Modifier Subunit (GCLM)
necessary for formation of the glutamate–cysteine ligase — an enzyme conducting the
rate-limiting step of GSH synthesis, reaction of glutamate with cysteine (Gorrini, Harris,
and Mak 2013). In addition, NRF2 also transcribes cysteine transporter XCT coded by
solute carrier family 7member 11 (SLC7A11) to increase intracellular abundance of cysteine
(Gorrini, Harris, and Mak 2013).
Using transcription of genes downstream of NRF2 as a proxy for ROS response, GSEA
was attempted to test for enrichment of the ROS response followed by quality control check
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by visualisation of FPKMusing bar plots. Only the Biocarta collection on theMSigDBhad a
gene set available for ROS compared to other well-known sources such as KEGG. However,
the Biocarta NRF2 gene set had only 13 members, which was inadequate for performing
GSEA. Some gene sets such as ‘HOUSTIS_ROS’ had >15 genes but were specific to diseases
such as type 2 diabetes, and were excluded for GSEA. A study conducted by Chorley
et al. 2012 used ChIP-seq to identify direct transcriptional targets of NRF2 in human
lymphoblastoid cells treated with the ROS-inducing agent sulforaphane. Normalised ChIP-
seq data was available in Supplementary File 1 of the publication, and a custom gene set
was built by selecting 181 genes with high confidence ChIP-seq peaks that had at least
one antioxidant responsive element (ARE) in the vicinity. Importantly, GCLC, GCLM and
SLC7A11 were present in this gene set.
As show in Table 6.4 and Figure 6.17, the NRF2 pathway was found to be significantly
upregulated following treatment with APR-246 in OVCAR-3 and Kuramochi cells analysed
individually as well as in combination, suggesting a presence of high intracellular levels of
ROS. FPKM values of 51 genes comprising the LES in the combined dataset are shown in
Figure 6.18 in the order of their ranking used inGSEA.A number of top ranked upregulated
genes following APR-246 treatment, shown in the ‘le’ side of the enrichment plot in Figure
6.17, were genuinely found to be DE (absolute FC >2 and FDR-P < 0.05), validating the
result of GSEA.
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Figure 6.18: Expression of the genes in the leading edge subset (LES) used for calculating enrichment score (ES) for NRF2 pathway.
Genes shown from left to right are sorted in the order of ranking as used by GSEA for a custom gene set of NRF2-responsive genes identified according to the ChIP-seq study
by Chorley et al. 2012. ‘*’ absolute FC >2 and FDR-P < 0.05
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6.3.4.5 Eﬀect of APR-246 on noncoding RNAs
In addition to protein coding genes, p53 also influences expression of microRNAs such as
miR-34a (Figure 6.19A), (He et al. 2007) and lncRNAs such as lincRNA-p21 (Huarte et al.
2010), PANDA (Hung et al. 2011), Pint (Huarte et al. 2010), PR-lncRNA-1 (Sánchez et al.
2014), PR-lncRNA-10 (Sánchez et al. 2014), NORAD (Lee et al. 2016), TUG1 (Guttman
et al. 2009; Khalil et al. 2009), PVT1 (Barsotti et al. 2012), LINP1 (Zhang et al. 2016c),
DDSR1 (Sharma et al. 2015) andDINO (Schmitt et al. 2016). Since the field is still evolving,
only seven lncRNAs downstream of p53 (PANDA, Pint, NORAD, TUG1, LOC105371267,
PVT1, LINP1) were specific to the human species with annotated sequences on the Ensembl
genome browser‡, of which five were detectable in our dataset (Figure 6.19B). Only PVT1
out of five lncRNAswas found to be DE; however, it does not appear DE upon examining its
FPKM in Figure 6.19B. e bioinformaticians advised that FPKM and statistics (FC and P
values) were determined using separate algorithms, and the algorithm calculating statistics
(edgeR) was more accurate in their opinion. Even thoughmiR-34a was found to be a direct
target of wt-p53 by He et al. 2007, it was not found to be DE following APR-246 treatment
in OVCAR-3 (P = 0.071) and Kuramochi cells (P = 0.098).
6.3.5 Testing the specificity of APR-246 for mutant-p53
p53-null SKOV-3 cells (c.267del1, resulting in a frame-shi (Bamford et al. 2004)) were
transfected with 0.25, 0.5 or 1 μg of empty vector (V0) or plasmid harbouring wt-p53 or
the R248Q mutation (harboured in OVCAR-3 cells), seeded into 96 well plates at 24 hours
post-transfection and treated with a range of APR-246 concentrations for 72 hours to test
whether the IC50 values, measured by the MTS assay, were dependent on the wild-type or
mutant status of p53 as well as the amounts of plasmid transfected. If eﬀects of APR-246
are specific to mutant-p53, higher levels of transfected plasmid should result in a dose-
dependent reduction in IC50 specific to the R248Qmutation. In contrast, cell death due to
other eﬀects such as induction of ROS would be common in all plasmid transfections.
Levels of wild-type and mutant-p53 in SKOV-3 cells at 24 hours post-transfection is
shown in Figure 6.20A. As expected, p53 remained undetected in untransfected (UT)
cells or cells transfected with diﬀerent amounts of the empty vector, whereas transfection
with wt-p53 or mutant-p53 resulted in higher levels of p53. In the case of wt-p53, the
expression of p53 was dependent on the amount of plasmid transfected for all biological
replicates (N=3). e same trend was observed in 2 out of 3 replicates of cells transfected
‡last checked on 9th June 2017.
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Figure 6.19: Eﬀect of APR-246 on noncoding RNAs
Eﬀect of APR-246 treatment onwt-p53-responsive (A)miR-34a and (B) five lncRNAs. PVT1 was found
to be DE following APR-246 treatment in both cell lines. Although mean FPKM values for PVT1 look
similar in both cell lines, bioinformaticians advised that FPKM and FC values were determined using
separate algorithms, and the algorithm calculating FC (edgeR) wasmore accurate in their opinion. ‘*’
absolute FC >2 and FDR-P < 0.05.
with mutant-p53. Both wild-type and mutant-p53 had identical molecular weights. p21
downstream of wt-p53 was immunoblotted to confirm that the mutant-p53 was indeed
mutant, and p21 was detected only in the cells transfected with wt-p53. Remarkably, p21
was detectable in the cells transfected with 0.25 μg of wt-p53, in which the wt-p53 itself
remained undetectable (Figure 6.20A).us the positive controls of the experiment showed
results as expected. No diﬀerences were observed in background-corrected absorbance
values for the transfected cells treatedwith vehicle (one-wayANOVA;P=0.252), suggesting
that transfection of V0, wt-p53 ormutant-p53 by itself did not result in significant cell death
(Figure 6.20B).
Processed data from the MTS assay used for calculating the IC50 values are shown
in Figure 6.21. Data was normalised to the vehicle control prior to the calculations. A
significant decrease in IC50 was observed between cells transfected with 0.25 versus 1 μg
of empty vector V0 (P < 0.05, marked with the red line over the bar graph in Figure 6.22A).
To normalise the reduction in IC50 due to the amount of plasmid transfected, IC50 for
wild-type or mutant-p53 were divided by the IC50 of the V0 for a given amount of plasmid
(Figure 6.22B).
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Figure 6.20: Eﬀect of plasmid transfections on the levels of p53 and p21 as well as cell
viabilities.
(A)Protein expressionof p53 andp21 at 24hours post-transfection in threebiological replicates upon
varied amounts of plasmid transfected. (B) Background-corrected absorbance values of the MTS
assay for transfected cells treated with the vehicle. No diﬀerence amongst treatments was observed
(one-way ANOVA; P = 0.252). UT: untransfected, V0: empty vector.
edegree of wt-p53-like activities restored frommutant-p53 uponAPR-246 treatment
could be roughly inferred by matching the IC50 values of mutant-p53 to wt-p53 obtained
using diﬀerent amounts of transfected plasmid. SKOV-3 cells transfected with 1 μg of
plasmid harbouring wt-p53 had a significantly lower IC50 compared to V0 for the same
amount of plasmid (P < 0.05), reflecting the tumour-suppressive actions of wt-p53 and
benchmarking the expected IC50 if 100% of the transfected 1 μg of mutant-p53 was
converted to wt-p53. A statistically significant diﬀerence in 1 μg wild-type versus mutant-
p53 was observed (P < 0.05; highlighted in red lines above the bar plot in Figure 6.22B).
However, the IC50 of cells transfected with 1 μg mutant-p53 was not only higher than
1 μg wt-p53 but also 0.25 μg mutant-p53 (highlighted in the blue line), which strongly
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Figure 6.21: DRCs of SKOV-3 cells transfected with varied amounts of empty vector (V0)
or plasmid harbouring wt-p53 or the TP53 R248Qmutation and treated with APR-246.
contradicted the hypothesis that a dose dependent decrease in IC50 should be observed by
increasing the amounts of mutant-p53 if APR-246 is specific to mutant-p53. Intriguingly,
the IC50 of 1 μg mutant-p53 was not found to be statistically diﬀerent to that of 1 μg V0
by one-way ANOVA (P = 0.10), but a t-test indicated that this comparison was statistically
significant (P = 0.037). Nonetheless, an increase of ~30% in IC50 values of 0.25 μg and 1
μg mutant-p53 is key evidence that APR-246 is not specific for mutant-p53. Mutant-p53
is likely to promote cellular growth and/or drug resistance, explaining the dose-dependent
increase in IC50.
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Figure 6.22: Eﬀects of wild-type or mutant-p53 on the IC50 of APR-246 in the p53-null
SKOV-3 cell line.
(A) IC50 obtained by normalising the data with vehicle-treated cells. As marked with red lines, a
statically significant diﬀerence in IC50 values of 0.25 versus 1 μg V0 was observed, suggesting that
higher amounts of V0 had a detrimental eﬀect on IC50. (B) IC50 values for wild-type or mutant-p53
were divided by the IC50 of the V0 for a given amount to account for a reduction in IC50 due to the
amount of plasmid transfected. All statistically significant comparisons (P < 0.05) are marked with
lines above the graph for completeness whereas key comparisons are marked in red and blue lines
above the bar plot.
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6.4 Discussion and future directions
e transcription factor p53 influences a myriad numbers of protein-coding and ncRNAs.
Given that p53 is mutated at a high frequency in multiple cancers, and almost universally
mutated in HGSOC, it is likely that the transcriptomic signature of mutant-p53 is markedly
diﬀerent than wt-p53 and its eﬀects on lncRNAs remain largely unknown. In this chapter,
we investigated transcriptome-wide eﬀects of a drug knowns as APR-246 that has been
reported to restore wt-p53 activities frommutant-p53 (Bykov et al. 2016; Bykov et al. 2005b;
Lambert et al. 2010; Rkaeus et al. 2010; Zache et al. 2008a).
6.4.1 Activation ofwt-p53 activity inOC cell lines uponAPR-
246 treatment
Because APR-246 has been reported to be synergistic with cisplatin in ovarian cancer
(Mohell et al. 2015), we reasoned that mechanisms of synergy could be studied using
transcriptome-wide analysis by carefully selecting time-points and drug doses. Synergistic
conditions were optimised several times to accommodate diﬀerent end-points and drugs
doses. Initially, cells were treated for 72 hours to allow suﬃcient time for the drugs to exert
their eﬀects and cell viability was measured byMTS assays, allowing testing of a wide range
of drug combinations to identify synergistic combinations. Although convenient, material
extracted from 96 well plates used for MTS assays would not be suﬃcient for downstream
analyses. Further, since cells were cultured for 72 hours, they were seeded at low densities
to avoid excessive growth, and the tissue culture vessels had to be large enough to harvest
suﬃcient cells at an earlier point, such as 24 hours post-treatment, to test activation of p53-
responsive genes. Both factors led to validating theMTS conditions in T25 flasks using flow
cytometry, an independent method. However, the combination of 13.8A+3.9C found to be
synergistic at 72 hours post-treatment by MTS assays was not found to be synergistic when
tested using flow cytometry, which could be attributed to upscaling the conditions by ~75-
times or to diﬀerences in methodologies. Optimising conditions in T25 flasks was already
found to be cumbersome in these preliminary experiments, requiring excessive numbers
of cells, amount of the drugs and tissue culture consumables; therefore, 6 well-plates were
used for subsequent experiments. Moreover, only flow cytometry was used to test synergy
as it allowed a direct measure of cell viability in cultures treated in 6 well-plates.
e doses of drugs were increased in the next round of experiments, and three com-
binations were found to by synergistic at 72 hours post-treatment: 20A+4C, 20A+6C and
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30A+4C. None of the 6 canonical p53-downstream genes (CDKN1A, BAX, BBC3/PUMA,
MDM2, c12orf5 and TP53I3) were found to be diﬀerentially expressed (DE; absolute FC >
2 and P < 0.05) using RT-qPCR when cells were treated with 20 and 30 μM APR-246 in a
time-course experiment. In contrast, ROS-responsive GCLC was found to be DE as early
as 10 hours following APR-246 treatment.
In published studies p53-responsive genes were found to be upregulated by 15 - 100
μM of APR-246 (15-60 μM in Li et al. 2015, 25 μM in Bykov et al. 2005b, 35 μM in
Tessoulin et al. 2014 and 100 μM in Zandi et al. 2011). We considered the possibility
that 20 - 30 μM APR-246 may not be suﬃcient to fully activate wt-p53-functions from
mutant-p53. Furthermore, the study by Mohell et al. 2015 conducted using APR-246 in
OVCAR-3 found that APR-246 was synergistic with cisplatin at 48 hours post-treatment
whereas the interaction was only additive at 24 h. erefore, synergy was optimised again
at 2 d post-treatment using drug dose. We also included Kuramochi cells as an additional
cell line for subsequent analyses. Much higher doses of drugs (70A+8C for OVCAR-3
and 80A+20C for Kuramochi) were required to observe synergy between APR-246 and
cisplatin at 48 h. Consistent with previous results, the p53-responsive genes CDKN1A and
BBC3 were not found to be DE at 70 and 80 μM APR-246 treatment in OVCAR-3 and
Kuramochi cells, respectively, while GCLC was found to be DE at 8 hours post-treatment.
A concurrent increase in seeding densities and drug doses may nullify the eﬀect of using a
higher drug dose; however, insuﬃcient activation of wt-p53 due to lower drug doses was
not a factor contributing to the lack of induction of p53-responsive genes. In addition, we
also monitored cell viabilities at 12, 24 and 48 hours and showed that cells were responding
to the drugs.
RNA-seq was employed through collaborations with bioinformaticians at the Garvan
Institute of Medical Research, Sydney, Australia to investigate transcriptome-wide eﬀects
of APR-246. Although OVCAR-3 and Kuramochi responded diﬀerently to the drugs, the
drug treatments for 12 hours in OVCAR-3 was functionally equivalent to that of 24 hours
in Kuramochi cells in terms of cell viability. In addition, both time-points were reasonably
early to capture direct changes in gene expression. Enrichment of the p53-responsive genes
was tested by Gene Set Enrichment Analysis (GSEA) using the lists/gene sets of canonical
p53-responsive genes from four well-known sources: KEGG, Biocarta, PID and ‘Hallmark’
pathways of MSigDB database maintained by the Broad Institute, USA. Only the PID-
p53 gene set was found to be enriched in our data set. Recently, Fischer 2017 identified
116 genes that were commonly induced by wt-p53 in at least six high-throughput studies.
GSEA performed using these p53-responsive genes showed that the p53 pathway was not
170
6.4. Discussion and future directions
statistically enriched in both cell lines treated with APR-246. KEGG, Biocarta, PID and
‘Hallmark’ gene sets shared only six members and Fischer 2017 reported a majority of the
genes (2261 out of 3509; 64.4%) were specific to only one dataset, indicating a considerable
amount of variation in p53-responsive genes between studies. In short, the p53 pathway
was not found to be significantly induced upon APR-246 treatment in 4 out of 5 gene sets.
To directly assess the specificity of APR-246 towardsmutant-p53, p53-null SKOV-3 cells
were transfected with 0.25, 0.5, 1 μg of empty vector, wt-p53 or p53-R248Q and treated
with APR-246 to determine the IC50 values. A dose-dependent reduction in IC50 of cells
transfected with mutant-p53 was predicted if APR-246-dependent cell death was mediated
bymutant-p53. Remarkably, the IC50 of cells transfectedwith 1 μg mutant-p53was higher
than cells transfected with 0.25 μg mutant-p53, strongly contradicting the hypothesis. An
increase in IC50 upon transfecting 1μg mutant-p53 could be attributed to its potential
eﬀect on promoting cellular growth and/or drug resistance. us, our results consistently
showed that APR-246 was not inducing wt-p53 activities in HGSOC cell lines harbouring
mutant-p53.
Despite being in phase Ib/II clinical trials (NCT02098343), there are only three pub-
lished studies, to the best of the candidate’s knowledge, testing the eﬀects of APR-246 in OC
(Fransson et al. 2016; Mohell et al. 2015; Yoshikawa et al. 2016). None of these studies tested
whether p53-response genes such as p21 were induced following APR-246 treatment. p21
was found to be upregulated by more than 2-fold in Kuramochi cells (p53 status: D281Y)
upon 16 hours of cisplatin treatment in our time-course experiment, suggesting that its
expression was not exclusive to wt-p53. In studies such as Liu et al. 2015, the induction of
p21 upon APR-246 was confirmed to be dependent on p53 since siRNA knockdown of p53
demolished activation of p21. However, such experiments did not have much value in our
case where p21 was simply not induced by APR-246.
APR-246 has been shown to induce high levels of ROS and kill cells regardless of the p53-
status in multiple cancers (Deben et al. 2016; Grellety et al. 2015; Peng et al. 2013; Tessoulin
et al. 2014) including OC (Yoshikawa et al. 2016). Our preliminary GSEA consistently
showed enrichment of the genes downstream of the ROS-sensitive transcription factor
NRF2 upon APR-246 treatment in OVCAR-3 and Kuramochi cells individually as well as
their combination, suggesting that APR-246 was inducing oxidative stress. However, this
needs to be confirmed in functional assays such as rescue of the APR-246-mediated cell
death by the antioxidant/ROS scavenger NAC.
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6.4.2 Calculations of synergy
Despite commonly used in publications, the term ‘synergy’ remains profusely littered with
technical terms that are not always clearly defined (Berenbaum 1977). In the absence of a
clear understanding of synergy amongst researchers, experiments were found to be poorly
designed to detect synergy even if it existed or the cases of additivities, in fact, represented
antagonisms (Berenbaum 1977). A recent meta-analysis that evaluated reported cases of
synergies between drugs in clinical trials for multiple cancers found that inappropriate
methods for evaluation of synergy was common in pre-clinical publications (43% and 56%
of phase I and II studies, respectively) (Ocana et al. 2012). Only ~32% of the studies used
formal methods to validate synergies between agents using tools such as isobolograms
(Ocana et al. 2012). Clearly, the biomedical community should be more vigorous and
specific when reporting synergies between compounds.
Isobolograms were not employed to test the synergies between APR-246 and other
compounds in the original or subsequent reports describing PRIMA-1 andAPR-246 (Bykov
et al. 2002, 2005b; Fransson et al. 2016; Mohell et al. 2015). In particular, the potency ratio
R (see Figure 6.1) is oen not constant in practice, leading to curved isoboles representing
drug additivities, which is oen mistaken for synergy or antagonism if the fundamental
assumptions are not tested (Foucquier and Guedj 2015; Tallarida 2006). e developers
of APR-246 chose to use the ‘Additive model’ to evaluate synergies. According to this
model, if drug A and B individually results in cell viabilities of 0.4 and 0.6, respectively,
the additive model predicts the viability of 0.24 (0.4  0.6) for their combination (Jonsson
et al. 1998). While this model may be applicable, it only requires two data points to predict
the expected additive eﬀect and appears to be too simplistic given that more than 300
mechanism-specific equations have been derived to predict the additive eﬀect (Chou 2006,
2010). Importantly, the developers the APR-246 generally discarded the Chou-Talalay
Method, a widely used method to calculate synergies, because the DRC of APR-246 was
found to be too steepwhen comparedwith agents such as cisplatin and doxorubicin (Mohell
et al. 2015). e Chou-Talalay Method based on the mass-action law has been called the
‘the unified theory’ because fundamental equations of biochemistry and biophysics, such
as the Michaelis-Menten equation of enzyme kinetics, Henderson-Hasselbalch equation
for estimating pH of a buﬀer system and Hill and Scatchard equations for describing ligand
binding to the receptor, can be derived from this method (Chou 2006, 2010). Most studies
in the field also have used the Additive model for calculating synergies, with exceptions
such as Sobhani et al. 2015, Synnott et al. 2017 and Liu et al. 2015 who have employed the
Chou-Talalay method. Evaluation of the pharmacological basis for choosing a model to
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predict synergy remains outside of the expertise of the candidate. e Additive model may
well be superior to the Chou-Talalay method. Legitimate synergistic interactions should
be proven by multiple methods. Furthermore, such studies should be made available for
researchers who search for them in scientific databases. It is also unclear whether such
studies are conducted at all or remain unpublished due to the commercial nature of the
drug companies.
6.5 Conclusions
e aim of this study was to investigate eﬀects of mutant-p53 on the expression of lncRNAs
using a small molecule known as APR-246, which had been reported to restore wt-p53
activities from mutant-p53 by stabilising its structure. APR-246 is currently undergoing
phase Ib/II trials for recurrent HGSOC and an induction of p53-activities in the context
of HGSOC has not been tested. Using RT-qPCR and global transcriptomic analysis, we
conclude that APR-246 does not induce a robust wt-p53-response in the models tested,
and, as a result, we could not use this system to identify a broad range of lncRNAs aﬀected
by mutant-p53. We observed that the IC50 of APR-246 in p53-null cells transfected with
varied amounts of mutant-p53 expression vector increased in a dose-dependent manner,
which is in sharp contrast to the hypothesis that APR-246 is specific to mutant-p53.
Preliminary analysis suggests that APR-246 could act by increasing ROS levels.
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Chapter 7
Final discussion and future directions
7.1 Final discussion
Ovarian cancer (OC) is the seventh most common form of cancer and eighth cause of
death from cancer in women worldwide. Approximately 152,000 women succumb to OC
annually (Ferlay et al. 2015). e overall aim of the research presented in this thesis was to
address three challenges facing the clinical management of OC by applying the recently
emerging field of noncoding RNAs. Noncoding RNAs are a widely transcribed species
of RNA that does not code for proteins but can play a crucial role in normal physiology
as well as disease progression. Specific aims of the thesis were as follows: (1) to test the
utility of serum microRNAs, a class of small noncoding RNAs, in predicting the surgical
outcome, (2) to investigate the role of long non-coding RNAs (lncRNAs) in promoting
cisplatin resistance, and (3) to investigate the eﬀects ofmutant-p53 on lncRNAs and general
gene expression by using a small compound known as APR-246 that has been published to
function by restoration of wild-type p53 activity in mutant-p53 cells.
7.1.1 Importance of thorough quality control in serum mi-
croRNA profiling
Anumber of analytical and pre-analytical factors can aﬀect accurate quantification of serum
microRNAs (McDonald et al. 2011; Witwer 2015). Release of the microRNA contents of
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red blood cells upon haemolysis can dramatically influence the profile of serummicroRNAs
(Kirschner et al. 2011, 2013; Pritchard et al. 2012). Unfortunately, haemolysis is common in
routine diagnostic samples, potentially confounding the use of serummicroRNA as robust
biomarkers of disease (Hawkins 2010).
A significant contribution of this thesis to the field is to recommend a methodology
to detect low levels of haemolysis in serum to identify, and potentially exclude, samples
that are severely aﬀected by haemolysis. In our publication in Plos One, we suggested a
flowchart to assist researchers to choose appropriate methodologies to detect haemolysis
in their studies (Shah, Soon, and Marsh 2016). Although the ‘miR ratio’ was found to
be the most sensitive method to detect low levels of haemolysis, it may be impractical in
reality due to time-consuming procedures and associated costs. We showed that serum
samples exhibiting spectroscopic absorbance at 414 nm > 0.3, typically measured on a
NanodropTM spectrophotometer, compared to water used as a ‘blank’ identified samples
that were likely to be severely aﬀected by haemolysis. is detection method based on
spectroscopic absorbance is cost-eﬀective and has low sample requirements (5-10 μl).
is work has already been cited four times within a year of its publication in April,
2016 (Scopus). Furthermore, this research has been practice changing, as spectroscopic
absorbance of serum samples is now being recorded by the Kolling Institute Tumour Bank
to allow researchers the option of excluding potentially haemolysed samples in their serum
microRNA studies.
7.1.2 Separating patients of HGSOC from healthy women
using serummicroRNAs
OC is termed the ‘silent killer’ due to vague symptoms such as constipation, diarrhoea,
nausea and vomiting that are also manifested by aging, menopause, weight gain and other
benign conditions of the gastrointestinal tract (Bankhead et al. 2008; Goﬀ et al. 2000; Jayson
et al. 2014). Serum protein CA-125 is the only biomarker routinely used for the diagnosis of
OC. However, the level of CA-125 is known to be influenced by factors such as pregnancy,
menstruation, race and presence/history of other cancers (Medeiros et al. 2009; Pauler et al.
2001; Verheijen et al. 1999).
Serum levels of the miR-200 family of microRNAs were found to be predictive of OC
from a previous study conducted in our laboratory (Kan et al. 2012); however, the current
study examined amuch greater number ofmicroRNAs. Before proceeding to the prediction
of surgical outcome using serummicroRNAs, a proof-of-principle analysis was directed to
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test whether serummicroRNAs can separate patients ofHGSOC fromhealthywomenusing
the identical platform as the current study. A total of 170 serummicroRNAs were profiled,
which seems a fraction of the currently known >3,500 microRNAs (Londin et al. 2015).
However, a significant proportion of these microRNAs may not be detectable in serum or
plasma whereas the 170 microRNAs used in the profiling were found to be present in the
majority of serum samples in a study conducted by Exiqon, the platform used for serum
microRNAprofiling in this thesis (Blondal et al. 2013). miR-375 andmiR-210were found to
be predictive of HGSOC in our study. Although serum levels of miR-375 andmiR-210 were
reported to be predictive of cancers of pancreas (Carlsen et al. 2013; Ho et al. 2010; Yingxia
et al. 2015), prostate (Cheng et al. 2013; He et al. 2015; Kachakova et al. 2015; Selth et al.
2012; Wach et al. 2015), breast (Huo et al. 2016) and, gastric cancers (Zhang et al. 2012b),
neither microRNA have been reported to predict HGSOC to our knowledge. miR-210 was
found to be aﬀected by haemolysis, suggesting that it may not be suitable for routine clinical
use, whereas miR-375 remained unaﬀected. Despite its novelty, the predictive power of
miR-375 alone to distinguish healthy women from those with ovarian cancer was inferior
to that of CA-125 (AUC: 0.765 versus 0.929; accuracy: 0.756 versus 0.884). A combination
ofmiR-375 andCA-125 increased the accuracy of CA-125 in separating patients of HGSOC
from healthy women. e potential of measurement of both CA-125 and serum miR-375
to discriminate healthy women from those with HGSOC needs to be confirmed in a larger
cohort.
A number of circulatory microRNAs in the literature have been reported for their pre-
dictive power to separate patients with OC from healthy women. To prioritise microRNAs
that could improve the predictive power of CA-125, the candidate summarised currently
known microRNAs predictive of OC in Table 3.8. Surprisingly, many studies failed to re-
port the performance of the predictive power to separate patients with OC from healthy
women even though samples from healthy women were used in the studies as controls. e
predictive power of miR-375 was found to be comparable with a previous study from our
laboratory (Kan et al. 2012) and others (Table 3.8). miR-200a, -b or -c have been reported
for their predictive power fromat least three independent studies (Kan et al. 2012; Selth et al.
2012; Taylor and Gercel-Taylor 2008), suggesting that they should be prioritised for vali-
dation in large cohorts. Although levels of miR-1290 in plasma and miR-343-5p in whole
blood were found to have a higher AUC of ~0.85 compared to miR-375 identified from the
current study as well as miR-200 family members from multiple studies, microRNAs, in
general, were found to be inferior to CA-125. is indicates that microRNAs by themselves
would probably be unable to replace CA-125 in routine practice, but they could improve
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the predictive power of CA-125 when combined together. A panel of serum microRNAs
might be valuable in identifying patients of OC from healthy women if they are shown
to be resistant to the factors that are known to influence CA-125 levels. Since microRNAs
themselves are aﬀected by pre-analytical factors, it is currently unclear whethermicroRNAs
could overcome the limitations of CA-125 without imposing a diﬀerent set of limitations.
7.1.3 Prediction of surgical outcome using serum microR-
NAs
Pre-operative prediction of surgical outcome has the potential to customise timing of the
surgery. Integration of tools to predict the surgical outcome was identified as one of the
seven priorities likely to improve outcomes for women with advanced OC in the consensus
of the most recent ‘Ovarian Cancer Action’ meeting held in 2015 (Bowtell et al. 2015).
e current study is the first study, to our knowledge, to investigate the utility of serum
microRNAs to predict surgical outcome. miR-34a-5p was found to be superior to CA-125
for the prediction of surgical outcome. In fact, miR-34a-5p was the only biomarker out
of a total of 48 that remained significant at 5% FDR in the pooled dataset. is finding
was confirmed by the machine learning algorithm DLDA, where miR-34a-5p was found
to have a higher inclusion frequency than CA-125 in 100-times 4-fold cross validation.
Additionally, miR-34a-5p was not aﬀected by haemolysis. It remains intriguing why miR-
34a-5p, which was found to be downregulated in late versus early stages of EOC (Eitan et al.
2009; Zhang et al. 2008) as well as in EOC compared to the normal ovarian surface epithelial
cells (Corney et al. 2010; Schmid et al. 2016), is upregulated in serum of suboptimally
cytoreduced patients. Should patient material have been available, it would have been
interesting to assess the levels of miR-34a-5p in normal secretory epithelial cells of the
fallopian tube given the likely site of origin of these tumours (discussed in subsection
1.1.2.1).
7.1.4 Investigating the role of lncRNAs in promoting cis-
platin resistance
Investigation of the role of lncRNAs in promoting cisplatin resistance in OC was novel in
the field when this project commenced in 2013. Five lncRNAs (SNHG1, SNHG6, Y RNA-
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1*, Malat1 and UCA1) out of ninety were found to be diﬀerentially expressed in the cell line
models of cisplatin resistance. Only Malat1 and UCA1 were reported to promote cisplatin
resistance inmultiple cancers (Fan et al. 2014; Lopez-Ayllon et al. 2015; Mimeault and Batra
2013; Pan et al. 2016; Schmidt et al. 2014; Wang et al. 2008); however, both had not been
implicated in promoting drug resistance inOC.UCA1was selected for further investigation
due its role in promoting cisplatin resistance in bladder cancer as well as cell proliferation
through the PI3K pathway (Yang et al. 2012), which had been extensively studied in our
laboratory previously.
Coincidentally, UCA1 was one of the earliest lncRNAs reported, by a separate group,
for its potential role in promoting drug resistance in the OC cell line SKOV-3 (Wang et
al. 2015). We discovered that the sensitivity of OC cells to cisplatin remained unchanged
upon siRNA-mediated knockdown of UCA1, which contradicted the findings of Wang et
al. 2015. ere were significant diﬀerences in methodologies which could have led to a
diﬀerent conclusion. Wang et al. 2015 overexpressed UCA1 in SKOV-3 cells, which is
‘unlikely’ to be representative of HGSOC according to Domcke et al. 2013, whereas we
downregulated UCA1 in two cell line models, OVCAR-3 and OVCAR4, representative of
HGSOC (Domcke et al. 2013) as well as the PEO1/PEO4 cell lines that were not tested
by Domcke et al. 2013. Further experiments modulating UCA1 expression by siRNA-
mediated gene silencing as well as forced overexpression in additional OC cell lines are
needed to assess the potential role of UCA1 in promoting drug resistance in OC. Since
lncRNAs exhibit a remarkable tissue-specific expression (Derrien et al. 2012), it is likely
that the eﬀects of UCA1 are restricted to bladder cancer. In addition, indirect evidence
that UCA1 might be downstream of p53 should be validated in future studies, probably in
bladder cancer because of the known functional role of UCA1 in this cancer.
7.1.5 Investigating the eﬀects ofmutant-p53 on lncRNAs by
using the p53-activating drug APR-246
p53 is perhaps themost investigated of all transcription factors which is universallymutated
in HGSOC. Mis-sense mutations are the most common type of mutations in TP53 and
are expressed at a higher level in cancer cells (Bieging and Attardi 2012; Muller, Vousden,
and Norman 2011; Walerych, Lisek, and Del Sal 2015). Mutant-p53 can inhibit activities
of wt-p53 as well as other members of the p53 protein family such as p63 and p73 by
*Y RNA-1 is technically a small noncoding RNA (length: 83-112 nucleotides), but it is included in this
discussion for simplicity.
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dominant-negative mechanisms (Goh, Coﬃll, and Lane 2010; ukral et al. 1995). In
addition, by binding to other transcription factors and proteins, some mutant-p53 can
activate or prevent gene expression, depending on interacting partners and the nature of
the mutations (Muller and Vousden 2013). Recently, wt-p53 has been found to influence
expression of both small and noncoding RNAs. Since half of all p53-binding sites on the
DNAwere found to be outside protein coding regions, aberrant transcription of noncoding
RNAs upon mutations could be a significant part of carcinogenesis promoted by mutant-
p53 (Idogawa et al. 2014).
Experiments conducted as part of this thesis aimed to examine the eﬀect of mutant-p53
on lncRNA transcription using a small molecule known as APR-246. APR-246 has been
reported to activate wt-p53 functions frommutant-p53 by stabilising the protein structure,
resulting in expression of typical p53-response genes such as CDKN1A/p21 (Liu et al. 2015;
Zandi et al. 2011), GADD45α (Liu et al. 2015), Bax (Bykov et al. 2005b; Izetti et al. 2014;
Zandi et al. 2011), BBC3/PUMA (Bykov et al. 2005b; Liu et al. 2015) and MDM2 (Izetti
et al. 2014; Zandi et al. 2011) in a range of cancer cell lines harbouring mutant-p53, their
xenogras, and, in selected cases, patient-derived xenogras transplanted in to immuno-
incompetent mice. Moreover, APR-246 was found to synergise with cisplatin in OC cell
lines as well as other cancers (Bykov et al. 2005a; Fransson et al. 2016; Izetti et al. 2014;
Liu et al. 2015; Mohell et al. 2015). Importantly, APR-246 is currently being evaluated in a
phase Ib/II clinical trial for the treatment of recurrent OC (NCT02098343 2014).
Despite the current clinical trial, there are only three reports (Fransson et al. 2016;
Mohell et al. 2015; Yoshikawa et al. 2016), to the candidate’s knowledge, on the use of APR-
246 in OC, and none have tested activation of p53-response genes upon the drug treatment.
Instead, it appears that activation of wt-p53 activities upon the drug treatment have been
assumed in OC based on evidence from other cancers. erefore, by studying APR-246 in
OC, the candidate also aimed to investigate: (1) transcriptome-side eﬀects of APR-246 in
OC cell lines, and (2) possible mechanisms of synergy between APR-246 and cisplatin in
OC cell lines.
Synergy between APR-246 and cisplatin in OVCAR-3 cells was reported by Mohell et
al. 2015, and this study supports this finding. In addition, we also report synergy between
these two compounds in Kuramochi cells, which is novel. ree of four gene sets from
well-known sources (KEGG, Biocarta, PID and the Broad Institute’s ‘Hallmark’ gene sets)
did not show enrichment of the p53 pathway in our dataset. e four gene sets had only
six members in common, indicating variability between resources as well as under the p53-
response in experimental conditions used. Fischer 2017 compiled a list of 116 genes that
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were activated by p53 in at least six genome-wide studies. ese genes were also not found
to be enriched following APR-246 treatment in OVCAR-3 and Kuramochi cells. miR-34a
directly transcribed by p53 was also not found to be induced in both cells. Moreover, only
PVT1 was induced following ARP-246 treatment in both cell lines out of seven lncRNAs
(PANDA (Hung et al. 2011), Pint (Huarte et al. 2010), NORAD (Lee et al. 2016), TUG1
(Guttman et al. 2009; Khalil et al. 2009), LOC105371267/PR-LncRNA-1 (Sánchez et al.
2014), PVT1 (Barsotti et al. 2012) and LINP1 (Zhang et al. 2016c)) reported to be activated
by wt-p53. Although only two OC cell lines were used, both models were found to be
representative of HGSOC according to a study by Domcke et al. 2013. Experiments using
additionalOC cell lines are needed to confirm the eﬀects of APR-246 on p53-response genes
and lncRNAs.
Because APR-246 was proposed to act onmutant-p53, we hypothesised that the IC50 of
the p53-null SKOV-3 cells transfected with varied amounts of the mammalian expression
vector harbouringmutant-p53 R248Qwould be inversely proportion to the amount of plas-
mids transfected. However, a dose-dependent increase in IC50 was observed, contradicting
this hypothesis.
Results presented in this thesis consistently indicated that APR-246 could work inde-
pendently of mutant-p53. In contrast, according to our bioinformatics analysis, APR-246
could function by inducing high levels of ROS.Modulation of ROS levels has been an attrac-
tive therapeutic option for treatment of cancer (Gorrini, Harris, and Mak 2013; Pelicano,
Carney, and Huang 2004; Sosa et al. 2013). Glutathione (GSH) and thioredoxin are the key
components in neutralising ROS. Cancer cells have re-wired metabolic pathways to sustain
rapid growth. A shi towards aerobic glycolysis (the Warburg eﬀect) for rapid production
of energy oen results in a high oxidative stress (Liberti and Locasale 2016). As a result,
cancer cells are muchmore prone to an imbalance in ROS compared to healthy cells, which
is exploited by the therapies targeting ROS (Gorrini, Harris, and Mak 2013). Critical genes
responsible for de novo glutathione synthesis such as SLC7A11,GCLC andGCLM (Gorrini,
Harris, and Mak 2013) were strongly induced by APR-246. ese genes are a direct tran-
scriptional target of NRF2, a ROS-sensitive transcription factor (Gorrini, Harris, and Mak
2013), suggesting induction of ROS upon APR-246 treatment, which is in agreement with
a study by Yoshikawa et al. 2016.
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7.2 Future directions
7.2.1 Biomarker potential of noncoding RNAs
e detection of microRNAs in as many as twelve biofluids despite the presence of potent
RNases has been unexpected and potentially revolutionary when it comes to identifying
new diagnostic and prognostic biomarkers (Weber et al. 2010). An ease of access and
stability of circulating microRNAs make them appealing biomarkers (Cortez et al. 2011).
We anticipate that wider implementation of stringent quality control protocols in clinical
laboratories, such as monitoring levels of haemolysis in serum as discussed in Chapter 4,
should ultimately lead to reliable quantification of serum microRNAs, and subsequently,
promote their routine use as biomarkers. Recently, lncRNAs have been emerging as
novel biomarkers. For example, levels of the lncRNA PCA3 in urine has been shown
to be superior to the current PSA-based tests to detect early prostate cancer (Chandra
Gupta and Nandan Tripathi 2017). Combined measurements of the lncRNAs CCAT1 and
HOTAIR in serum have been suggested as an eﬀective screening tool for colorectal cancer
(Zhao et al. 2015). While increasing accessibility of technologies such as RNA-seq should
greatly enhance the biomarker discovery process, much remains to be learnt about the
presence of lncRNAs in a range of biofluids as well as appropriate quality control protocols.
Nevertheless, the number of lncRNAshas been currently estimated to as high as 58,000 (Iyer
et al. 2015), and investigation of the biomarker potential of lncRNAs remains a promising
avenue of research.
7.2.2 Detection of OC using noncoding RNAs
A population-wide screening test to detect OC has remained elusive, partly because of the
low incidence rate of OC, demanding a test with a sensitivity of >0.75 and a specificity
of >0.996, criteria that are extremely diﬃcult to meet (Clarke-Pearson 2009; Hennessy,
Coleman, and Markman 2009). As discussed in Chapter 3, serum levels of miR-375
identified from this thesis could improve the accuracy of CA-125 in detecting OC, but a
number of microRNAs will probably be required to meet the performance criteria required
for population-wide screening. e miR-200 family of microRNAs have been found to
detect OC from healthy women from at least three independent studies, identifying them
as robust candidates to be tested in future studies in combination with CA-125. Emerging
evidence shows that the serum protein HE4 could be superior to CA-125 in detecting OC
(Chen et al. 2016; Ferrarow et al. 2013; Hu et al. 2016). Although HE4 is not routinely
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used in clinical practice currently, a test known as ROMA, comprising CA-125 and HE4,
is approved by the FDA to assess the risk of EOC in women with a pelvic mass (ROMA®
2011). It remains to be seen whether microRNAs can further improve the performance of
ROMA or predict patient response to first-line chemotherapy. e biomarker potential of
lncRNAs remains to be fully explored in future studies. Furthermore, future studies should
investigate the role of lncRNAs in pathogenesis of HGSOC in the context of fallopian tube
as its likely source.
7.2.3 Prediction of surgical outcome for HGSOC patients
Prediction of surgical outcome remains diﬃcult to achieve despite a range of tools such as
computed tomography (CT), laparoscopy, aberrant expression of certain genes in tumour
tissue, measurement of serum proteins CA-125 and HE4, machine learning/artificial
intelligence and obtaining a two-surgeon opinion on the resectability of ovarian tumours
(e Anderson Algorithm) have been attempted. miR-34a-5p was found to be superior to
CA-125 in predicting surgical outcome, and serum levels of CA-125, HE4 and miR-34a-5p
should be tested in combination in future studies.
e challenge of accurately predicting surgical outcome could partly be attributed to
variation in the skills and attitudes of surgeons, as well as policies of institutions regarding
aggressive surgeries. Although the study on ‘e Anderson Algorithm’ is yet to be oﬃcially
published, the initial results reported in a review by Nick et al. 2015 have been promising,
with the rate of R0 increasing from 20% to 84% since implementation of the protocol. A
2-surgeon opinion may be diﬃcult to achieve in smaller centres; however, if successful, the
study is likely to indicate whether prediction of surgical outcome could simply be improved
by implementing standard guidelines. ‘e Anderson Algorithm’ utilises laparoscopy in
predicting resectability of the tumours, which is minimally invasive but may be time-
consuming. A simple, accurate blood test to predict surgical outcome, by potentially
combining levels of CA-125, HE4, miR-34a-5p and lncRNAs if they are investigated for
this purpose in future studies, remains appealing.
7.2.4 Role of lncRNAs in promoting cisplatin resistance
e finding that our genome actively transcribes RNAs only became apparent by the appli-
cation of technologies such as RNA-seq, and lack of RNA-seq data still remains a significant
limiting factor to fully explore the biological roles of lncRNAs in disease. For example,
TCGA-OV study used microarrays for quantifying expression of mRNAs and microRNAs,
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which are biased towards the choice of hybridisation probes. A clever study in the field
identified the microarray probes corresponding to lncRNAs from existing microarray ex-
periments (Du et al. 2013). By applying ~10,000 ‘re-purposed’ lncRNAs reported by Du
et al. 2013 to the TCGA-OV dataset, Liu et al. 2017 identified eight diﬀerentially expressed
lncRNAs (ZFAS1, RP5-1061H20.5, LINC01514, TUG1, RP11-489O18.1, RP11-136I14.5,
RP11-16E12.1 and CTD-2555A7.3) between cisplatin sensitive and resistant HGSOC. e
role of most of these eight lncRNAs as well as four lncRNAs reported by the candidate
(SNHG1, SNHG6, Y RNA-1 and Malat1) remains to be investigated in future studies. Fur-
thermore, proteins involved in the key biological pathways regulated by these lncRNAs
could represent potentially novel drug targets.
7.2.5 Investigating the eﬀects ofmutant-p53 on lncRNAs by
using the p53-activating drug APR-246
Despite being widely reported as a p53-activating drug, APR-246 failed to induce a robust
p53-response, based on our bioinformatic analyses, in two representative cell line models
of HGSOC in this thesis. We also tested the specificity of APR-246 for mutant-p53 by
transfecting p53-null SKOV-3 cells with varied amounts of an expression vector harbouring
mutant-p53 R248Q, and observed a dose dependent increase in IC50 for this drug. e
developers of APR-246 showed induction of p21 and PUMA at a protein level upon APR-
246 treatment in the p53-null H1299 cells transfected with p53 mutants R175H or R273H
(Bykov et al. 2005a; Bykov et al. 2002) whereas we focused on the TP53 mutation R248Q
endogenously harboured in the OVCAR-3 cells. APR-246 has been shown to stabilise the
mutant-p53 by alkylating the cysteine residues independent of the mutation itself as long
as the entire mRNA is translated (missense mutations) (Lambert et al. 2009), hence, choice
of the actual missense mutation is, in theory, irrelevant. However, it is possible that APR-
246 was unable to restore wt-p53 activities from certain mutant-p53 such as R248Q. Future
experiments should test this by transfecting p53-null cell lines H1299 and SKOV-3 with
mutant-p53 R248Q as well as R273H and R175H serving as positive controls due to their
use by the developer of the drug.
ere was some evidence suggesting that APR-246 could potentially kill cancer cells
by inducing high levels of ROS. Future experiments should confirm this, potentially by
attempting to rescue cells from APR-246-induced ROS by treating with NAC, an antiox-
idant/ROS scavenger (Yoshikawa et al. 2016), especially in the OC cell lines harbouring
nonsense or frame-shi mutations of TP53. Platinum drugs such as cisplatin and carbo-
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platin also result in a high level of ROS (Conklin 2004b). APR-246 has been found to inhibit
thioredoxin reductase 1, an important enzyme for recycling thioredoxin to its normal state
(Peng et al. 2013). Interestingly, auranofin, an inhibitor of thioredoxin, was able to induce
apoptosis by increasing the release of cytochrome-c in cisplatin resistant OC cells (Marzano
et al. 2007). Buthionine sulphoximine (BSO) inhibiting GCL, a rate limiting enzyme in
GSH production, is currently in clinical use (Gorrini, Harris, andMak 2013). us, actions
of APR-246 may overlap with other ROS-modulating drugs. Future studies should clarify
whether the observed synergy between APR-246 and cisplatin is due to induction of ROS
at high levels by each drug individually. Furthermore, eﬃciencies of APR-246, BSO and
auranofin should be tested using drugs individually or in combination with drugs such
as cisplatin that could potentially synergise with ROS-modulating drugs. While multiple
modes of actions of a drug could de clinically desired, based on evidence presented in this
thesis and by Yoshikawa et al. 2016, the purpose of APR-246 as a reactivator of wt-p53
function from mutant-p53 should be questioned in OC.
We captured an early transcriptomic response to APR-246 and cisplatin alone as well as
their synergistic combinations in two cell lines representative of OC. A lack of induction
of p53-response genes in OVCAR-3 and Kuramochi cells upon APR-246 treatment was
unexpected, which led to a detailed investigation of mechanisms of APR-246 in these
cell lines. It would probably be diﬃcult to identify lncRNAs aﬀected by mutant-p53
in the absence of a clear p53-response as discussed above. Only lncRNA PVT1 out of
five p53-responsive lncRNAs was found to be diﬀerentially expressed in both cell lines
following APR-246 treatment from the RNA-seq experiment, but this should be confirmed
by RT-qPCR. Approaches such as ‘guilt-by-association’ could be utilised to predict putative
functions of diﬀerentially expressed lncRNAs based on their correlation with mRNAs
(Guttman et al. 2009). Nevertheless, further analyses of our dataset should identify
molecular pathways that work together to result in the synergy observed between the two
compounds, which will be of tremendous impact for identifying potential side eﬀects or
mechanism of resistance to the dual drug treatment.
In the absence of a robust induction of the p53-response following APR-246 treatment,
the original question of identifying lncRNAs aﬀected by mutant-p53 could be answered by
transfecting expression vectors harbouring wild-type or mutant-p53 in p53-null cell lines
such as SKOV-3 and H1299, followed by RNA-seq. In addition, genome-editing tools such
as Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated
protein 9 (Cas9) could be utilised to revert the endogenous missense TP53 mutations in
OC cell lines to wild-type TP53. Additionally, the same CRISPR/Cas9 approach could also
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be used to test the specificity of APR-246 for mutant-p53 in additional OC cell lines. It is
expected that lncRNAs downstream of mutant-p53 could be oncogenic, which should be
tested for their role in promoting OC. Modulating levels of oncogenic lncRNAs by tools
such as antisense oligonucleotides (ASO) could represent novel anti-cancer targets.
7.3 Concluding remarks
e potential of non-coding RNAs in the clinical management of women with ovarian
cancer remains to be fully explored. As discussed in Chapter 3, we identified novel
microRNA biomarkers miR-375 and miR-34a-5p that could separate patients of HGSOC
from healthy women and predict their surgical outcome, respectively. In addition, both
microRNAs were unaﬀected by haemolysis, which is common in diagnostic samples and
can dramatically alter the serum microRNA profile. Chapter 4 discussed methodologies
to detect low levels of haemolysis in serum, which should lead to discovery of robust
microRNA biomarkers suitable for routine clinical use. is work is published in Plos One
(Shah, Soon, and Marsh 2016). In Chapter 5, five lncRNAs were found to be associated
with promoting cisplatin resistance. Although UCA1, one of the five lncRNAs identified,
was found to promote cisplatin resistance in bladder cancer, this was not the case in cell line
models of ovarian cancer. We aimed to discover potential oncogenic lncRNAs aﬀected by
mutant-p53 by using the drug APR-246 that has been reported to activate wt-p53 activities
and is currently undergoing a clinical trial to treat recurrent OC. Evidence presented in
Chapter 6 suggested that APR-246 could act independently of mutant-p53 in cell line
models of ovarian cancer. ehuman genome is estimated to harbourmore than double the
number of non-coding RNAs than the protein-coding genes. A thorough understanding of
their functions has a potential to revolutionise the diagnosis and treatment ofmany diseases
that are currently diﬃcult to manage or cure.
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Figure A.1: Downregulation of UCA1 in Kuramochi, OVCAR-3 and OVCAR4 cells using
HiPerFect reagent measured by flow cytometry
(A) Cells were transfected with 100 nmol of unlabelled AllStars Negative Control siRNA (AS-UNL) and
AllStarsNegative Control siRNA labelledwithAlexa Fluor 488 (AS-488) using 12μl HiPerFect reagent,
and flow cytometry was performed 24 h post-transfection to test transfection eﬃciencies of the cells
(N = 1). More than 80% of the cells were found to be positive for AS-488, reflecting high transfection
eﬃciencies of these cells. (B) Quantification of transfection eﬃciency shown in (A).
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Figure A.2: Downregulation of UCA1 in OVCAR-3 and OVCAR4 cells using HiPerFect
reagent andmeasured by TaqMan RT-qPCR
UCA1 siRNA #13 and #17 were transfected into OVCAR-3 and OVCAR4 cells, and their eﬀect on
reducing UCA1 levels determined by TaqMan RT-qPCR 24 h post-transfection. Each siRNA resulted
in an average knockdown eﬃciency of ~40-60% in both cells, which was found unsatisfactory for
functional assays.
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Table B.1: Diﬀerentially expressed biomarkers in healthy versus HGSOC samples { : unadjusted-P < 0.05.
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
Log2 CA-125 { 5.49 1.8E-09 3.0E-07 5.11 2.0E-07 9.5E-06 5.30 4.2E-14 2.0E-12
150-5p { -0.78 1.0E-03 3.4E-02 -1.45 1.8E-06 4.4E-05 -1.12 2.6E-06 6.2E-05
375 { -1.29 3.1E-04 1.8E-02 -1.95 5.6E-05 8.9E-04 -1.51 5.5E-05 8.6E-04
210 { 0.73 1.5E-03 3.6E-02 0.62 1.6E-03 1.9E-02 0.65 1.5E-04 1.8E-03
181a-5p { -0.65 4.7E-03 7.9E-02 -0.58 2.5E-02 2.0E-01 -0.60 2.6E-03 2.4E-02
106b-5p -0.27 3.6E-01 7.5E-01 -0.34 7.8E-03 7.5E-02 -0.30 7.4E-03 5.8E-02
141-3p { 1.32 9.3E-04 3.4E-02 0.75 1.5E-01 4.7E-01 1.06 1.0E-02 7.0E-02
200c-3p { 2.33 3.6E-09 3.0E-07 0.86 1.2E-01 4.7E-01 1.01 1.3E-02 7.4E-02
551b-3p { -0.68 5.2E-03 8.0E-02 -0.56 6.1E-02 4.2E-01 -0.57 3.5E-02 1.7E-01
629-5p { 0.58 1.4E-02 1.6E-01 0.24 2.6E-01 5.3E-01 0.36 3.6E-02 1.7E-01
142-3p { -0.56 3.1E-02 2.6E-01 -0.51 1.5E-01 4.7E-01 -0.53 6.3E-02 2.7E-01
200a-3p { 1.11 2.1E-03 4.5E-02 0.41 3.8E-01 6.0E-01 0.57 1.2E-01 4.7E-01
103a-3p -0.36 1.6E-01 6.4E-01 -0.28 2.1E-01 5.1E-01 -0.23 1.8E-01 5.7E-01
16-5p 0.23 4.4E-01 8.2E-01 0.00 9.9E-01 9.9E-01 0.10 1.6E-01 5.7E-01
605 -0.67 2.0E-01 6.8E-01 -0.62 8.2E-02 4.7E-01 -0.64 1.9E-01 5.7E-01
let-7i-3p -0.22 4.6E-01 8.3E-01 -0.26 2.6E-01 5.3E-01 -0.32 1.8E-01 5.7E-01
222-3p { 0.40 4.5E-02 3.0E-01 0.12 5.5E-01 8.0E-01 0.25 2.1E-01 5.8E-01
122-5p -0.34 3.2E-01 7.5E-01 -0.43 3.4E-01 6.0E-01 -0.40 2.9E-01 7.0E-01
19a-3p 0.11 6.8E-01 9.2E-01 0.01 9.2E-01 9.6E-01 0.11 2.8E-01 7.0E-01
361-3p -0.36 5.9E-02 3.4E-01 -0.23 3.6E-01 6.0E-01 -0.27 3.0E-01 7.0E-01
144-3p -0.24 5.4E-01 8.5E-01 -0.12 6.1E-01 8.2E-01 -0.22 3.6E-01 7.2E-01
25-3p 0.15 6.1E-01 8.9E-01 0.07 5.9E-01 8.2E-01 0.10 3.7E-01 7.2E-01
29c-3p 0.00 1.0E+00 1.0E+00 -0.28 1.0E-01 4.7E-01 -0.16 3.6E-01 7.2E-01
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Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
99b-5p { 0.83 3.3E-03 6.3E-02 -0.20 6.1E-01 8.2E-01 0.29 3.5E-01 7.2E-01
UniSp2 -0.09 6.8E-01 9.2E-01 -0.45 1.6E-01 4.7E-01 -0.24 4.0E-01 7.6E-01
146a-5p -0.02 9.4E-01 9.8E-01 -0.34 2.4E-01 5.3E-01 -0.18 4.5E-01 7.9E-01
22-3p 0.00 9.9E-01 1.0E+00 0.15 2.6E-01 5.3E-01 0.12 4.7E-01 7.9E-01
34a-5p 0.11 6.9E-01 9.2E-01 0.35 3.8E-01 6.0E-01 0.25 4.6E-01 7.9E-01
29a-5p 0.03 8.8E-01 9.8E-01 -0.25 3.9E-01 6.0E-01 -0.17 4.9E-01 8.0E-01
20a-5p 0.06 8.2E-01 9.5E-01 0.01 9.0E-01 9.6E-01 0.02 5.5E-01 8.0E-01
UniSp4 -0.04 8.2E-01 9.5E-01 -0.33 3.1E-01 5.9E-01 -0.18 5.3E-01 8.0E-01
UniSp5 -0.37 1.8E-01 6.5E-01 -0.37 3.5E-01 6.0E-01 -0.21 5.4E-01 8.0E-01
106a-5p -0.01 9.6E-01 9.9E-01 0.02 8.0E-01 9.1E-01 -0.01 7.2E-01 8.7E-01
145-5p { -0.63 8.4E-03 1.1E-01 -0.12 7.3E-01 8.5E-01 -0.12 7.5E-01 8.7E-01
15b-3p 0.02 9.4E-01 9.8E-01 0.19 1.1E-01 4.7E-01 0.03 6.8E-01 8.7E-01
20b-5p 0.25 3.4E-01 7.5E-01 0.04 8.4E-01 9.2E-01 0.05 7.4E-01 8.7E-01
30a-5p -0.04 8.6E-01 9.7E-01 0.11 7.1E-01 8.5E-01 0.09 7.6E-01 8.7E-01
451a 0.10 7.8E-01 9.4E-01 -0.08 6.8E-01 8.5E-01 -0.04 7.6E-01 8.7E-01
505-3p 0.17 4.2E-01 8.1E-01 0.09 6.9E-01 8.5E-01 0.09 7.2E-01 8.7E-01
92b-3p { 0.57 1.2E-03 3.4E-02 0.06 8.2E-01 9.1E-01 0.12 6.2E-01 8.7E-01
let-7b-3p 0.15 3.8E-01 7.7E-01 -0.38 1.5E-01 4.7E-01 -0.09 6.9E-01 8.7E-01
UniSp6 0.13 5.1E-01 8.4E-01 -0.43 1.8E-01 4.7E-01 -0.12 8.2E-01 9.1E-01
23a-3p -0.09 6.4E-01 9.2E-01 -0.24 2.1E-01 5.1E-01 -0.11 8.7E-01 9.5E-01
29b-2-5p { 0.39 3.3E-02 2.6E-01 -0.32 1.5E-01 4.7E-01 0.03 9.0E-01 9.6E-01
93-5p 0.02 9.3E-01 9.8E-01 0.00 9.9E-01 9.9E-01 0.00 9.2E-01 9.6E-01
101-3p 0.22 4.5E-01 8.2E-01 -0.16 4.1E-01 6.1E-01 0.00 9.9E-01 9.9E-01
cel-39-3p 0.46 1.8E-01 6.5E-01 -0.44 1.7E-01 4.7E-01 0.01 9.7E-01 9.9E-01
106b-3p 0.19 3.0E-01 7.5E-01
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Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
107 -0.11 7.1E-01 9.2E-01
10b-5p { 0.53 3.4E-02 2.6E-01
125a-5p 0.10 6.8E-01 9.2E-01
125b-5p 0.24 2.7E-01 7.5E-01
126-3p -0.13 4.8E-01 8.3E-01
127-3p { -0.41 5.0E-02 3.0E-01
130a-3p 0.17 5.0E-01 8.4E-01
130b-3p -0.01 9.6E-01 9.9E-01
132-3p -0.20 2.8E-01 7.5E-01
133a -0.44 7.2E-02 3.8E-01
133b -0.36 9.5E-02 4.9E-01
136-5p { -0.83 8.7E-03 1.1E-01
139-5p -0.25 3.1E-01 7.5E-01
140-3p 0.37 2.1E-01 6.9E-01
140-5p 0.03 9.0E-01 9.8E-01
142-5p { -0.93 1.3E-02 1.5E-01
143-3p 0.14 5.9E-01 8.9E-01
144-5p 0.00 9.9E-01 1.0E+00
146b-5p -0.14 4.9E-01 8.3E-01
148a-3p 0.17 3.5E-01 7.5E-01
148b-3p 0.05 8.2E-01 9.5E-01
151a-3p 0.25 2.6E-01 7.5E-01
151a-5p -0.07 7.7E-01 9.4E-01
152 -0.07 7.4E-01 9.3E-01
154-5p 0.35 1.5E-01 6.2E-01
193
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
155-5p { -0.40 4.0E-02 3.0E-01
15a-5p 0.18 4.7E-01 8.3E-01
15b-5p 0.10 6.6E-01 9.2E-01
16-2-3p 0.17 6.0E-01 8.9E-01
17-5p -0.35 1.8E-01 6.5E-01
185-5p { 0.60 3.4E-02 2.6E-01
186-5p 0.23 3.2E-01 7.5E-01
18a-3p 0.02 9.1E-01 9.8E-01
18a-5p -0.09 7.1E-01 9.2E-01
18b-5p -0.01 9.6E-01 9.9E-01
191-5p 0.08 7.6E-01 9.4E-01
192-5p 0.00 9.8E-01 1.0E+00
193b-3p 0.08 7.9E-01 9.4E-01
194-5p 0.16 4.5E-01 8.2E-01
195-5p { -0.60 2.0E-02 2.1E-01
197-3p -0.22 3.5E-01 7.5E-01
199a-3p -0.11 6.2E-01 9.0E-01
199a-5p -0.43 2.9E-01 7.5E-01
19b-3p 0.28 3.5E-01 7.5E-01
200b-3p 0.23 6.4E-01 8.3E-01
204-5p 0.02 9.2E-01 9.8E-01
205-5p 0.18 6.0E-01 8.9E-01
20a-3p { -0.41 2.3E-02 2.3E-01
21-5p 0.28 1.2E-01 5.8E-01
215 -0.09 6.6E-01 9.2E-01
194
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
22-5p -0.20 4.8E-01 8.3E-01
221-3p 0.10 7.1E-01 9.2E-01
223-3p -0.29 2.4E-01 7.2E-01
223-5p -0.02 9.2E-01 9.8E-01
23b-3p -0.06 7.7E-01 9.4E-01
24-3p 0.04 8.3E-01 9.5E-01
26a-5p -0.24 2.9E-01 7.5E-01
26b-5p -0.35 1.8E-01 6.5E-01
27a-3p -0.12 5.3E-01 8.5E-01
27b-3p 0.01 9.8E-01 1.0E+00
28-3p -0.16 3.9E-01 7.7E-01
28-5p -0.16 5.7E-01 8.7E-01
296-5p 0.32 1.1E-01 5.2E-01
29a-3p -0.12 5.7E-01 8.7E-01
29b-3p -0.09 7.4E-01 9.3E-01
301a-3p -0.30 1.6E-01 6.4E-01
30b-5p -0.25 2.2E-01 7.0E-01
30c-5p -0.20 3.5E-01 7.5E-01
30d-5p { 0.41 4.2E-02 3.0E-01
30e-3p -0.05 7.7E-01 9.4E-01
30e-5p 0.08 7.0E-01 9.2E-01
32-5p -0.36 2.9E-01 7.5E-01
320a { 0.58 2.7E-02 2.6E-01
320b 0.45 6.3E-02 3.5E-01
324-3p -0.07 7.0E-01 9.2E-01
195
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
324-5p -0.04 8.6E-01 9.7E-01
326 -0.47 1.7E-01 6.5E-01
328 -0.28 2.1E-01 6.9E-01
331-3p 0.02 9.2E-01 9.8E-01
335-5p 0.13 4.5E-01 8.2E-01
338-3p -0.26 3.3E-01 7.5E-01
339-3p -0.15 4.5E-01 8.2E-01
33a-5p -0.59 6.1E-02 3.4E-01
342-3p -0.28 1.1E-01 5.2E-01
363-3p 0.20 5.4E-01 8.5E-01
365a-3p 0.20 4.3E-01 8.2E-01
374a-5p -0.37 1.4E-01 6.2E-01
374b-5p -0.27 3.0E-01 7.5E-01
378a-3p 0.28 1.3E-01 6.0E-01
382-5p 0.14 5.1E-01 8.4E-01
409-3p { -0.46 4.7E-02 3.0E-01
421 0.27 1.9E-01 6.7E-01
423-3p 0.20 3.8E-01 7.7E-01
423-5p 0.23 2.7E-01 7.5E-01
424-5p 0.18 4.7E-01 8.3E-01
425-3p 0.17 3.7E-01 7.6E-01
425-5p 0.09 7.4E-01 9.3E-01
484 0.29 2.6E-01 7.5E-01
485-3p -0.19 5.1E-01 8.4E-01
486-5p 0.39 2.4E-01 7.2E-01
196
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
497-5p { -0.55 4.9E-02 3.0E-01
500a-5p -0.25 3.4E-01 7.5E-01
501-3p -0.20 3.6E-01 7.5E-01
502-3p 0.36 1.4E-01 6.2E-01
532-3p 0.19 3.4E-01 7.5E-01
532-5p 0.13 5.8E-01 8.7E-01
574-3p 0.12 5.3E-01 8.5E-01
590-5p -0.22 3.4E-01 7.5E-01
652-3p -0.11 6.1E-01 8.9E-01
660-5p 0.04 8.4E-01 9.7E-01
766-3p 0.13 5.6E-01 8.7E-01
885-5p 0.29 3.0E-01 7.5E-01
92a-3p 0.32 2.5E-01 7.5E-01
93-3p -0.06 7.9E-01 9.4E-01
99a-5p 0.09 7.2E-01 9.3E-01
let-7a-5p 0.06 7.6E-01 9.4E-01
let-7b-5p 0.02 9.2E-01 9.8E-01
let-7c -0.14 5.3E-01 8.5E-01
let-7d-3p -0.03 8.5E-01 9.7E-01
let-7e-5p 0.34 2.1E-01 6.9E-01
let-7f-5p -0.04 8.7E-01 9.7E-01
let-7g-5p -0.33 1.5E-01 6.3E-01
let-7i-5p 0.11 6.7E-01 9.2E-01
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Table B.2: Diﬀerentially expressed biomarkers in Optimally versus Suboptimally cytoreduced samples x: unadjusted-P < 0.05
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
34a-5p x 0.93 0.00 0.20 1.27 0.00 0.19 1.30 0.00 0.02
222-3p 0.43 0.08 0.76 0.60 0.01 0.24 0.70 0.00 0.04
Log2 CA-125 1.89 0.06 0.76 2.36 0.04 0.32 2.12 0.01 0.15
141-3p x 1.04 0.04 0.58 1.16 0.08 0.35 1.24 0.02 0.15
29a-5p 0.35 0.16 0.91 0.45 0.16 0.40 0.62 0.02 0.15
30a-5p 0.55 0.07 0.76 0.52 0.12 0.35 0.73 0.02 0.15
92b-3p 0.05 0.84 0.97 0.73 0.03 0.31 0.67 0.03 0.15
let-7b-3p x 0.47 0.03 0.58 0.43 0.16 0.40 0.58 0.02 0.15
200a-3p -0.06 0.90 0.97 0.73 0.20 0.42 0.98 0.03 0.16
200c-3p 0.23 0.61 0.96 1.41 0.05 0.34 1.07 0.04 0.19
29b-2-5p 0.37 0.10 0.77 0.30 0.26 0.43 0.48 0.04 0.19
UniSp4 0.29 0.25 0.93 0.64 0.10 0.35 0.65 0.06 0.23
122-5p x 0.89 0.03 0.58 0.59 0.25 0.43 0.77 0.08 0.25
505-3p x 0.51 0.05 0.61 0.28 0.35 0.48 0.56 0.08 0.25
99b-5p 0.35 0.29 0.93 0.62 0.18 0.41 0.65 0.07 0.25
UniSp2 0.32 0.30 0.93 0.62 0.11 0.35 0.61 0.08 0.25
375 x 0.81 0.04 0.61 0.43 0.39 0.52 0.68 0.11 0.30
210 0.17 0.52 0.94 0.12 0.65 0.73 0.33 0.12 0.31
150-5p 0.12 0.67 0.96 0.34 0.32 0.47 0.40 0.13 0.31
UniSp5 0.30 0.39 0.93 0.49 0.27 0.43 0.56 0.15 0.36
181a-5p -0.09 0.75 0.96 0.27 0.41 0.54 0.34 0.17 0.38
146a-5p 0.07 0.79 0.96 0.24 0.52 0.62 0.32 0.27 0.57
UniSp6 0.34 0.19 0.91 0.79 0.06 0.34 0.64 0.28 0.57
198
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
145-5p x -0.70 0.02 0.58 0.47 0.27 0.43 0.34 0.45 0.77
16-5p -0.21 0.56 0.94 -0.08 0.63 0.72 0.07 0.43 0.77
25-3p -0.25 0.45 0.93 0.02 0.90 0.92 0.10 0.46 0.77
29c-3p -0.18 0.56 0.94 0.08 0.69 0.73 0.15 0.43 0.77
451a -0.33 0.44 0.93 -0.32 0.20 0.42 -0.12 0.44 0.77
106a-5p -0.24 0.44 0.93 -0.20 0.03 0.31 -0.01 0.83 0.95
106b-5p -0.12 0.73 0.96 -0.37 0.02 0.24 -0.07 0.64 0.95
142-3p 0.17 0.57 0.94 -0.04 0.93 0.93 0.15 0.66 0.95
144-3p -0.22 0.62 0.96 -0.47 0.11 0.35 -0.13 0.65 0.95
19a-3p -0.44 0.17 0.91 -0.25 0.11 0.35 0.04 0.77 0.95
22-3p -0.32 0.27 0.93 0.17 0.26 0.43 0.08 0.67 0.95
361-3p x -0.48 0.03 0.58 0.27 0.35 0.48 0.10 0.74 0.95
551b-3p x -0.63 0.01 0.58 0.20 0.56 0.66 0.08 0.80 0.95
605 x -1.36 0.04 0.58 0.40 0.32 0.47 -0.14 0.81 0.95
629-5p x -0.59 0.03 0.58 0.21 0.44 0.55 -0.07 0.72 0.95
93-5p -0.27 0.39 0.93 -0.12 0.28 0.43 0.01 0.74 0.95
cel-39-3p -0.68 0.09 0.76 0.72 0.07 0.34 0.21 0.63 0.95
let-7i-3p x -0.73 0.02 0.58 0.32 0.17 0.41 0.07 0.81 0.95
103a-3p -0.17 0.59 0.94 -0.13 0.68 0.73 0.04 0.85 0.95
20a-5p -0.28 0.40 0.93 -0.17 0.15 0.40 0.00 0.91 0.95
20b-5p x -0.66 0.02 0.58 0.06 0.81 0.85 0.02 0.90 0.95
23a-3p 0.19 0.42 0.93 -0.30 0.23 0.43 0.10 0.90 0.95
15b-3p -0.25 0.44 0.93 -0.17 0.28 0.43 0.01 0.96 0.98
101-3p -0.13 0.71 0.96 -0.18 0.44 0.55 0.00 0.99 0.99
106b-3p -0.06 0.79 0.96
199
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
107 -0.56 0.11 0.77
10b-5p 0.44 0.17 0.91
125a-5p 0.10 0.74 0.96
125b-5p 0.39 0.18 0.91
126-3p 0.20 0.41 0.93
127-3p 0.14 0.53 0.94
130a-3p -0.03 0.92 0.97
130b-3p -0.20 0.44 0.93
132-3p 0.06 0.81 0.97
133a 0.11 0.73 0.96
133b 0.03 0.92 0.97
136-5p -0.36 0.21 0.91
139-5p 0.29 0.32 0.93
140-3p -0.47 0.18 0.91
140-5p -0.11 0.68 0.96
142-5p -0.33 0.45 0.93
143-3p 0.21 0.53 0.94
144-5p 0.06 0.83 0.97
146b-5p 0.16 0.53 0.94
148a-3p -0.04 0.87 0.97
148b-3p -0.33 0.20 0.91
151a-3p 0.00 1.00 1.00
151a-5p 0.00 1.00 1.00
152 0.06 0.81 0.97
154-5p 0.03 0.92 0.97
200
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
155-5p 0.13 0.57 0.94
15a-5p -0.25 0.45 0.93
15b-5p -0.29 0.29 0.93
16-2-3p -0.60 0.11 0.77
17-5p -0.32 0.36 0.93
185-5p -0.23 0.48 0.94
186-5p -0.26 0.36 0.93
18a-3p 0.29 0.19 0.91
18a-5p -0.20 0.48 0.94
18b-5p -0.08 0.78 0.96
191-5p 0.06 0.85 0.97
192-5p 0.02 0.93 0.97
193b-3p 0.62 0.11 0.77
194-5p -0.08 0.77 0.96
195-5p 0.53 0.09 0.76
197-3p 0.04 0.88 0.97
199a-3p -0.05 0.86 0.97
199a-5p -0.38 0.41 0.93
19b-3p -0.29 0.40 0.93
200b-3p 1.16 0.07 0.34
204-5p -0.19 0.50 0.94
205-5p 0.82 0.08 0.76
20a-3p -0.07 0.73 0.96
21-5p 0.31 0.19 0.91
215 -0.08 0.74 0.96
201
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
22-5p -0.12 0.73 0.96
221-3p 0.09 0.78 0.96
223-3p -0.10 0.76 0.96
223-5p 0.19 0.52 0.94
23b-3p 0.02 0.93 0.97
24-3p 0.14 0.54 0.94
26a-5p 0.01 0.96 0.99
26b-5p 0.16 0.63 0.96
27a-3p 0.35 0.15 0.91
27b-3p 0.05 0.86 0.97
28-3p -0.08 0.74 0.96
28-5p -0.23 0.46 0.93
296-5p 0.11 0.64 0.96
29a-3p 0.20 0.44 0.93
29b-3p -0.36 0.29 0.93
301a-3p -0.22 0.39 0.93
30b-5p -0.01 0.96 0.98
30c-5p -0.14 0.58 0.94
30d-5p -0.09 0.71 0.96
30e-3p 0.11 0.64 0.96
30e-5p -0.14 0.58 0.94
32-5p -0.45 0.25 0.93
320a -0.18 0.57 0.94
320b -0.23 0.44 0.93
324-3p 0.07 0.76 0.96
202
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
324-5p 0.07 0.79 0.96
326 -0.36 0.41 0.93
328 0.09 0.75 0.96
331-3p -0.16 0.49 0.94
335-5p -0.10 0.67 0.96
338-3p -0.08 0.82 0.97
339-3p -0.14 0.57 0.94
33a-5p -0.46 0.24 0.93
342-3p 0.04 0.84 0.97
363-3p -0.31 0.43 0.93
365a-3p 0.03 0.91 0.97
374a-5p -0.01 0.97 0.99
374b-5p -0.26 0.40 0.93
378a-3p -0.09 0.69 0.96
382-5p 0.08 0.76 0.96
409-3p 0.53 0.07 0.76
421 0.02 0.94 0.98
423-3p -0.25 0.35 0.93
423-5p -0.38 0.12 0.81
424-5p 0.27 0.41 0.93
425-3p 0.30 0.22 0.92
425-5p -0.14 0.66 0.96
484 -0.27 0.37 0.93
485-3p -0.33 0.38 0.93
486-5p -0.37 0.33 0.93
203
Discovery Validation Pooled
Biomarker P <0.05 Log FC P Adj-P Log FC P Adj-P Log FC P Adj-P
497-5p 0.40 0.26 0.93
500a-5p -0.06 0.86 0.97
501-3p -0.02 0.93 0.97
502-3p -0.11 0.69 0.96
532-3p 0.25 0.35 0.93
532-5p -0.35 0.19 0.91
574-3p 0.06 0.79 0.96
590-5p -0.22 0.45 0.93
652-3p -0.11 0.69 0.96
660-5p -0.01 0.98 0.99
766-3p 0.06 0.84 0.97
885-5p 0.41 0.19 0.91
92a-3p -0.24 0.46 0.93
93-3p -0.19 0.49 0.94
99a-5p 0.39 0.22 0.92
let-7a-5p -0.06 0.82 0.97
let-7b-5p -0.33 0.26 0.93
let-7c -0.04 0.88 0.97
let-7d-3p 0.14 0.51 0.94
let-7e-5p -0.43 0.20 0.91
let-7f-5p 0.14 0.67 0.96
let-7g-5p -0.16 0.58 0.94
let-7i-5p -0.33 0.27 0.93
Appendix C
e R script to process data fromMTS
assays
Automatic processing of data from MTS assays and
calculation of synergy
Defining custom functions
Main interface: ‘easy.mts()’ function
This is the main function which is called from external file handling data to process. ‘KEYS’ instructs R
to manage biological replicates. In most cases, KEYS is a combination of ‘Treatment1’ (three technical
replicates) and ‘Treatment5’ (biological group).
rm(list = ls())
library(ggplot2)
## Warning: package 'ggplot2' was built under R version 3.2.5
library(plotrix)
## Warning: package 'plotrix' was built under R version 3.2.5
library(RColorBrewer)
library(drc)
## Warning: package 'drc' was built under R version 3.2.5
## Loading required package: MASS
## Warning: package 'MASS' was built under R version 3.2.5
##
## 'drc' has been loaded.
## Please cite R and 'drc' if used for a publication,
## for references type 'citation()' and 'citation('drc')'.
##
## Attaching package: 'drc'
## The following objects are masked from 'package:stats':
##
## gaussian, getInitial
## --- Processing of MTS data, Script V5
easy.mts <- function(INFO, plotTechRep = FALSE, NORMBY = "vehicle", KEYS,...){
## the main interaction function
final <- final.raw <- data.frame()
plots <- list()
INFO <- subset(INFO,!is.na(INFO$File_name))
for(i in 1:nrow(INFO)){
mts.list <- process_MTS(INFO, i, NORMBY, KEYS, ...)
mts.results <- mts.list[[1]]
mts.results <- transform(mts.results,
Treatment2 = as.numeric(Treatment2))
mts.results <- mts.results[order(mts.results$Treatment2),]
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if(plotTechRep){
require(drc)
keys <- na.omit(unique(mts.list[[2]]$Keys))
tech.ic50 <- sapply(1: length(keys), function(i){
temp2 <- subset(mts.list[[2]], Keys == keys[i])
if(length(unique(temp2$Treatment2)) <= 1){
print (paste("not enough data for", keys[i],
paste(unique(temp2$Keys),unique(temp2$FileName)), sep =" : "))
} else {
fit <- drm(Percent_control ~ Treatment2,
fct = LL.4(names = c("Slope", "Lower Limit", "Upper Limit", "ED50")),
data = temp2)
plot(fit, type = "all", xlab = unique(temp2$Treatment3),
main = keys[i], sub = "(Technical replicates only)", cex.main = 0.8)
ed50 <- coef(summary(fit))[4,1] # returns IC50/ED50
legend("bottomleft", paste("IC50:", signif(ed50,3)),bty = "n")
ED(fit, 50, interval = "delta", display = FALSE)
}
})
}
if (i == 1){
final <- mts.results
final.raw <- mts.list[[2]]
}else{
final <- rbind(final, mts.results)
final.raw <- rbind(final.raw, mts.list[[2]])
}
}
# Ensuring all data is in correct format.
final <- transform(final, Treatment2 = as.numeric(Treatment2))
return(list(processed_data = final, raw_data = final.raw))
}
Processing of each MTS plate by function ‘process_MTS()’
This functions is called by ‘easy.mts()’ and reads an Excel file, substracts background absorbance and
normalises cell viability to the vehicle control.
process_MTS <- function(infoDF, n, NORMBY, KEYS){
require(xlsx)
tempInfo <- infoDF[n,]
columns <- 1
plate <- as.numeric (unique(tempInfo$Plate))
if(plate == 96){columns <- 12} else {
stop(paste("Incorrect plate dimension in file:",
infoDF[1, "File_name"], ". \n Only 96 well plates are supported"))
}
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seq.cols <- seq(1, columns, 1)
seq.rows <- seq(1, (plate/columns),1)
#----
#Reading and preparing data
#----
wrkbk <- loadWorkbook(as.character(tempInfo[1, "File_name"]))
wrksheets <- names(getSheets(wrkbk))
## Reading data
trt1 <- read.xlsx(file = as.character(tempInfo[1, "File_name"]),
sheetName = as.character(tempInfo[1, "Treatment1_sheet"]),
row.names = TRUE)
trt1 <- wp2DF2.MTS(trt1[seq.rows, seq.cols],
colNames = c("Well", "Treatment1"),
origin = as.character(tempInfo[1, "File_name"]))
trt2 <- read.xlsx(file = as.character(tempInfo[1, "File_name"]),
sheetName = as.character(tempInfo[1, "Treatment2_sheet"]),
row.names = TRUE)
trt2 <- wp2DF2.MTS(trt2[seq.rows, seq.cols],
colNames = c("Well", "Treatment2"),
origin = as.character(tempInfo[1, "File_name"]))
if(is.na(match("Treatment3_sheet", colnames(tempInfo)))){
trt3 <- wp2DF2.MTS(getEmptyFrame = TRUE,
colNames = c("Well", "Treatment3"),
origin = as.character(tempInfo[1, "File_name"]))
} else{
trt3 <- read.xlsx(file = as.character(tempInfo[1, "File_name"]),
sheetName = as.character(tempInfo[1, "Treatment3_sheet"]),
row.names = TRUE,
origin = as.character(tempInfo[1, "File_name"]))
trt3 <- wp2DF2.MTS(trt3[seq.rows, seq.cols],
colNames = c("Well", "Treatment3"),
origin = as.character(tempInfo[1, "File_name"]))
}
if(is.na(match("Treatment4_sheet", colnames(tempInfo)))){
trt4 <- wp2DF2.MTS(getEmptyFrame = TRUE,
colNames = c("Well", "Treatment4"),
origin = as.character(tempInfo[1, "File_name"]))
} else{
trt4 <- read.xlsx(file = as.character(tempInfo[1, "File_name"]),
sheetName = as.character(tempInfo[1, "Treatment4_sheet"]),
row.names = TRUE, origin = as.character(tempInfo[1, "File_name"]))
trt4 <- wp2DF2.MTS(trt4[seq.rows, seq.cols],
colNames = c("Well", "Treatment4"),
origin = as.character(tempInfo[1, "File_name"]))
}
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if(is.na(match("Treatment5_sheet", colnames(tempInfo)))){
trt5 <- wp2DF2.MTS(getEmptyFrame = TRUE,
colNames = c("Well", "Treatment5"),
origin = as.character(tempInfo[1, "File_name"]))
} else{
trt5 <- read.xlsx(file = as.character(tempInfo[1, "File_name"]),
sheetName = as.character(tempInfo[1, "Treatment5_sheet"]),
row.names = TRUE, origin = as.character(tempInfo[1, "File_name"]))
trt5 <- wp2DF2.MTS(trt5[seq.rows, seq.cols],
colNames = c("Well", "Treatment5"),
origin = as.character(tempInfo[1, "File_name"]))
}
if(tempInfo[1, "Transform_Abs"] == "TRUE"){
abs <- read.xlsx(file = as.character(tempInfo[1, "File_name"]),
sheetName = as.character(tempInfo[1, "Abs_sheet"]),
row.names = TRUE)
abs <- wp2DF2.MTS(abs, colNames = c("Well", "Abs"))
}
else {
abs <- read.xlsx(file = as.character(tempInfo[1, "File_name"]),
sheetName = as.character(tempInfo[1, "Abs_sheet"]))
abs <- abs[, c(3,6)]
}
colnames(abs) <- c("Well", "Abs")
abs <- transform(abs, Abs = as.numeric(Abs))
df <- Reduce(function(x,y) merge(x,y, all = FALSE),
list(trt1, trt2, trt3, trt4, trt5,abs))
df <- subset(df, Treatment1 != "" | is.na(Treatment1)) # removing empty wells
#---
# All data read. Algorithm to remove background and normalise to the vehicle control.
#---
# Step 1: Remove background
blk <- mean(df[df$Treatment1 == tempInfo[1, "Blank_indicator"], "Abs"])
df[,"Background"] <- blk
df[,"Abs_corrected"] <- df[,"Abs"] - blk
df <- subset(df, Treatment1 != tempInfo[1, "Blank_indicator"])
#---
# Step 2: Defining Keys to handle biological groups etc
#---
if(length(KEYS) == 1){
df[,"Keys"] <- df[,KEYS]
}
else{
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df[,"Keys"] <- apply( df[,KEYS ] , 1 , paste , collapse = ";" )
}
u.keys <- unique(df$Keys)
for(i in 1:length(u.keys)){
if (NORMBY == "vehicle"){
control <-
mean(df[df$Keys == u.keys[i] & df$Treatment2 == tempInfo[1, "Vehicle_control"],
"Abs_corrected"])
df[df$Keys == u.keys[i], "Abs_Vehicle_control"] <- control
df[df$Keys == u.keys[i],"Percent_control"] <-
(100*df[df$Keys == u.keys[i],"Abs_corrected"])/control
} else{
df[df$Keys == u.keys[i], "Abs_Vehicle_control"] <- NA
df[df$Keys == u.keys[i],"Percent_control"] <-
df[df$Keys == u.keys[i],"Abs_corrected"]
}
}
## Step 3: Average and SEM
require(plotrix)
df.abs<- aggregate(df$Abs_corrected,
by = list(df$Treatment1, df$Treatment2, df$Treatment3,
df$Treatment4, df$Treatment5), mean)
colnames(df.abs) <- c("Treatment1", "Treatment2", "Treatment3",
"Treatment4","Treatment5" , "Abs_corrected")
df.mean <- aggregate(df$Percent_control,
by = list(df$Treatment1, df$Treatment2, df$Treatment3,
df$Treatment4, df$Treatment5), mean)
colnames(df.mean) <- c("Treatment1", "Treatment2", "Treatment3",
"Treatment4","Treatment5" , "Percent_control")
df.sem <- aggregate(df$Percent_control,
by = list(df$Treatment1, df$Treatment2, df$Treatment3,
df$Treatment4, df$Treatment5), std.error)
colnames(df.sem) <- c("Treatment1", "Treatment2", "Treatment3",
"Treatment4","Treatment5" , "Tech_rep_sem")
df.mean <- Reduce(function(x,y) merge(x,y, all =TRUE), list(df.mean, df.sem, df.abs))
df.mean[,"FileName"] <- tempInfo[,"File_name"]
if(length(KEYS) == 1){
df.mean[,"Keys"] <- df.mean[,KEYS]
}
else{
df.mean[,"Keys"] <- apply( df.mean[,KEYS ] , 1 , paste , collapse = ";" )
}
df.mean <- transform(df.mean, Treatment2 = as.numeric(as.character (Treatment2)))
df[,"FileName"] <-tempInfo[,"File_name"]
df <- transform(df, Treatment2 = as.numeric(as.character (Treatment2)))
return(list(df.mean, df))
}
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Calculating and plotting IC50
This performed using a four-parameter log-logistic model supplied by R pacakge ‘drc’.
plot.ic50 <- calculate.ic50 <-
function(myData, y="Percent_control", x = "Treatment2",
cat = c("Treatment1", "Treatment3"), plot = FALSE, compact = TRUE,
textX = 0.5, textY = 20 , ...){
## both name performs same because of compatibility with previous version
myData[,"tempKeys"] <- paste(myData[,cat[1]], myData[,cat[2]], sep = ";")
keys <- unique(myData$tempKeys)
ic50 <- sapply(1: length(keys), function(i){
temp <- subset(myData, tempKeys == keys[i])
temp <- transform(temp, Treatment2 = as.numeric(as.character(Treatment2)))
temp[,y] <- as.numeric(as.character(temp[,y]))
temp <- subset(temp, Treatment2 >0)
fit <- drm(temp[,y] ~ temp[,x],
fct = LL.4(names=c("Slope","Lower Limit","Upper Limit","ED50")))
ed50 <- coef(summary(fit))[4,1] #ED50
if(plot){plot(fit, main = paste(temp$Treatment1[1],
temp$Treatment3[1], sep = ", "), ...)
text(x=textX, y =textY, paste("IC50:", signif(ed50,3)))
}
ed50
})
myData2 <- data.frame(keys, ic50)
myData2 <- merge(myData, myData2, by.x = c("tempKeys"), by.y=c("keys"))
if(compact){
return(subset(myData2, !(duplicated(tempKeys)), select = c(cat, "ic50")))
}else{
return(myData2)
}
}
ic50 <- function(merged,plotType = "all", xlab = NULL, ylab = NULL,
main = NULL, showIC50 = TRUE, ...){
require(drc)
bioGroups <- na.omit(unique(merged$BioGroup))
biogroup.ic50 <- sapply(1: length(bioGroups), function(i){
temp2 <- subset(merged, BioGroup == bioGroups[i])
fit <- drm(Percent_control ~ Treatment2,
fct = LL.4(names = c("Slope", "Lower Limit", "Upper Limit", "ED50")),
data = temp2)
plot(fit, type = plotType, main = bioGroups[i], ann = FALSE, ...)
if(is.null(xlab)){
title(xlab = unique(temp2$Treatment3))
} else{
title(xlab = xlab)
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}
if(is.null(ylab)){
title(ylab = "% viability")
} else{
title(ylab = ylab)
}
if(is.null(main)){
title(main = bioGroups[i])
} else{
title(main = main)
}
ed50 <- coef(summary(fit))[4,1] #ED50
if(showIC50){
legend("bottomleft", paste("IC50:", signif(ed50,3)),bty = "n")
}
ED(fit, 50, interval = "delta", display = FALSE)
})
colnames(biogroup.ic50) <- bioGroups
rownames(biogroup.ic50) <- c("IC50", "SEM", "Lower", "Upper")
t(biogroup.ic50)
}
Extracting experimental design of a large experiment.
In an experiment with several MTS plates, it could become difficult to determine number of biological replicates
and their assignment to a biological/treatment group. The following function returns such information from
an experiment.
generate.ExpDesign <- function(temp, KEYS){
temp.expDesign <- temp
if(length(KEYS) == 1){
temp.expDesign[,"Keys"] <- temp.expDesign[,KEYS]
}
else{
temp.expDesign[,"Keys"] <- apply( temp.expDesign[,KEYS ],
1 , paste , collapse = ";" )
}
temp.expDesign <- subset(temp.expDesign, !duplicated(Keys),
select = c(1,3:5,10))
cbind(temp.expDesign, BioGroup = "", isAccurate = "", Comments = "")
}
Conversion of a layout of 96 well-plate (8 x 12) to a data frame (96 x 1)
This functions makes it easy to work with layouts of an MTS file. Typically, it is easier to assign treatment
groups and drug doses in an Excel file in 8 x 12 format (96 well-plates). The spectrophometer also displays
absorbances in 8 x 12 format. In contrast, operations are easier when performed in a table or data frame.
Following function convert information such as well A1 to corresponding numeric format of a data frame.
wp2DF2.MTS <- function (template, plate= 96, IsNA.empty = TRUE,
colNames = c("Well","Value"), getEmptyFrame = FALSE, origin=""){
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df <- data.frame()
columns <- NA
if(plate == 384){columns=24} else {columns=12}
if(getEmptyFrame)
{
for (i in seq(1, to = plate/columns, by =1)) # looping throuh rows
{
df [seq(columns * (i-1) + 1, columns * i),"Well"] <- seq(columns * (i-1) + 1, columns * i)
df [seq(columns * (i-1) + 1, columns * i),"Value"] <- ""
}
}
else{
## checking if correct dimensions
if(ncol(template) >= (columns + 1) | nrow(template) >= ((plate/columns)+1)){
print(paste("INCORRECT DIMENTSION IN FILE in file", origin, sep = ":"))
print(paste("dimension, R X C :",nrow(template) ,ncol(template), origin))
}
for (i in seq(1, to = plate/columns, by =1)) # looping throuh rows
{
temp.fill <- t(template[i,])
not.empty <- which(is.na(temp.fill) != TRUE) #
df [seq(columns * (i-1) + 1, columns * i),"Well"] <-
seq(columns * (i-1) + 1, columns * i)
if (!IsNA.empty){
df [seq(columns * (i-1) + 1, columns * i),"Sample Name"] <-
paste(LETTERS[i], seq(1:columns), sep="") #fills with A1 etc by default
df [columns * (i-1) + not.empty ,"Sample Name"] <- temp.fill[not.empty] #works
} else{
df [seq(columns * (i-1) + 1, columns * i),"Detector"] <- ""
df [columns * (i-1) + not.empty ,"Detector"] <- temp.fill[not.empty]
}
}
}
colnames(df) <- colNames
df
}
Calculation of synergy using the Additive model
get4parameters <- function(merged, ...){
bioGroups <- na.omit(unique(merged$BioGroup))
biogroup.ic50 <- sapply(1: length(bioGroups), function(i){
temp2 <- subset(merged, BioGroup == bioGroups[i])
fit <- drm(Percent_control ~ Treatment2,
fct = LL.4(names = c("Slope", "Lower Limit", "Upper Limit", "ED50")),
data = temp2)
a <- summary(fit)
rse <- a$rseMat
c(coef(a)[,1], a$rseMat)
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})
# # dev.off()
colnames(biogroup.ic50) <- bioGroups
rownames(biogroup.ic50) <- c("slope", "min", "max", "ic50", "rse", "df")
biogroup.ic50 <- as.data.frame(t(biogroup.ic50))
biogroup.ic50[,"BioGroup"] <- rownames(biogroup.ic50)
merge(merged, biogroup.ic50)
}
estimate.response <- function(x, min, max, slope, ic50){
min +((max - min)/(1+ (exp(slope * (log(x) - log(ic50))))))
}
additive.synergy <- function(merged, plotGraph = TRUE){
results <- subset(merged, select = c("Keys", "BioGroup","Treatment1", "Treatment2",
"Treatment3", "Treatment4", "Percent_control"))
results[,"Percent_control"] <- results[,"Percent_control"]/100 #Converted to fractions
results <- get4parameters(results)
results[, "Type"] <- with(results,
ifelse((Treatment4 == "" & Treatment3 !="") |
(Treatment3 == "" & Treatment4 !=""), "individual", "combination"))
results[,"Cisp"] <- as.numeric(results[,"Treatment3"])
results[,"APR"] <- as.numeric(results[,"Treatment4"])
results[,"Frac_Cisp"] <- results$Treatment2 *(results$Cisp/(results$Cisp + results$APR))
results[,"Frac_APR"] <- results$Treatment2 *(results$APR/(results$Cisp + results$APR))
#checking if all fractikons all up to Treatment2. used fussy logic
print("---Checking if drug fractions correspond to total dose---")
print(paste("Is difference > 0.01? :",
any(na.omit((results$Frac_APR + results$Frac_Cisp) - results$Treatment2) > 0.01)))
## -- expected values based on DRC
drugs <- unique(results[results$Type == "individual", "BioGroup"])
logic.string <- intersect(grep(toupper("drc"), toupper(results$BioGroup)),
grep(toupper("cisplatin"), toupper(results$BioGroup)))
temp <- unique(results[logic.string, c("min", "max", "slope", "ic50")])
results[,"Exp_cisp"] <- with(temp,
estimate.response(results$Frac_Cisp, min, max,slope,ic50))
logic.string <- intersect(grep(toupper("drc"), toupper(results$BioGroup)),
grep(toupper("apr-246"), toupper(results$BioGroup)))
temp <- unique(results[logic.string, c("min", "max", "slope", "ic50")])
results[,"Exp_APR"] <- with(temp,
estimate.response(results$Frac_APR, min, max,slope,ic50))
###-- Additive model of synergy
## Ref: Jonsson et al. Eur J Clin Pharmacol (1998) 54: 509 -514.
results[,"Expected_viability"] <- results[,"Exp_cisp"] * results[,"Exp_APR"]
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results[,"Ratio_obs_exp"] <- with(results, Percent_control/Expected_viability)
results[,"Comb_effect"] <- with(results,
ifelse(Ratio_obs_exp < 0.8, "Synergy",
ifelse(Ratio_obs_exp > 1.2, "subadditive", "additive")))
results <- results[order(results$Comb_effect, decreasing = TRUE),]
if(plotGraph){
plot(x = results$Expected_viability, y = results$Percent_control, pch = 1,
main = unique(results$Treatment1),
sub = "(Size of the points is inversely propotional to the SI)",
cex.sub = 0.7,
xlab = "Predicted viability", ylab="Observed viability",
cex = 1/results$Ratio_obs_exp,
col = ifelse(results$Comb_effect == "Synergy", "red",
ifelse (results$Comb_effect == "subadditive", "blue", "grey40")))
legend("topleft", legend = c("Synergy","Additive", "Subadditive"), pch = 1,
col = c("red", "grey40", "blue"))
}
return(results)
}
Miscellaneous functions for plotting graphs
custom.ic50 <- function(merged,plotType = "all", xlab = NULL, ylab = NULL,
main = NULL, showIC50 = TRUE, plot = TRUE, ...){
require(drc)
require(magicaxis)
bioGroups <- na.omit(unique(merged$BioGroup))
biogroup.ic50 <- sapply(1: length(bioGroups), function(i){
temp2 <- subset(merged, BioGroup == bioGroups[i])
fit <- drm(Percent_control ~ Treatment2,
fct = LL.4(names = c("Slope", "Lower Limit", "Upper Limit", "ED50")),
data = temp2)
ed50 <- coef(summary(fit))[4,1] #ED50
if(plot){
plot(fit, type = plotType, main = bioGroups[i], ann = FALSE,
axes = FALSE,
bty = "n", ...)
magaxis(tcl=-0.75, mgp = c(2,1,0))
if(is.null(xlab)){
title(xlab = unique(temp2$Treatment3))
} else{
title(xlab = xlab)
}
if(is.null(ylab)){
title(ylab = "% viability")
} else{
title(ylab = ylab)
}
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if(is.null(main)){
title(main = bioGroups[i])
} else{
title(main = main)
}
if(showIC50){
legend("topright", paste("IC50:", signif(ed50,3)),bty = "n")
}
}
ED(fit, 50, interval = "delta", display = FALSE)
})
colnames(biogroup.ic50) <- bioGroups
rownames(biogroup.ic50) <- c("IC50", "SEM", "Lower", "Upper")
t(biogroup.ic50)
}
multiplot <- function(..., plotlist=NULL, file, cols=1, layout=NULL) {
require(grid)
plots <- c(list(...), plotlist)
numPlots = length(plots)
if (is.null(layout)) {
layout <- matrix(seq(1, cols * ceiling(numPlots/cols)),
ncol = cols, nrow = ceiling(numPlots/cols))
}
if (numPlots==1) {
print(plots[[1]])
} else {
# Set up the page
grid.newpage()
pushViewport(viewport(layout = grid.layout(nrow(layout), ncol(layout))))
# Make each plot, in the correct location
for (i in 1:numPlots) {
# Get the i,j matrix positions of the regions that contain this subplot
matchidx <- as.data.frame(which(layout == i, arr.ind = TRUE))
print(plots[[i]], vp = viewport(layout.pos.row = matchidx$row,
layout.pos.col = matchidx$col))
}
}
}
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Running an experiment
Reading data
All appropriate runs were merged in to an Excel file ‘160130 all input’. These include 160111, 160121 and
160125. Each run was mentioned using ExpID column. Each run was normalised to vehicle (intra-plate
normalisation).
KEYS <- c("Treatment1","Treatment5")
library(xlsx)
## Loading required package: rJava
## Loading required package: xlsxjars
### ----------------------------
### --- PREPROCESSING CODE ---
### ----------------------------
INFO <- read.xlsx("160130_all_inputs.xlsx", sheetName = "Sheet1")
INFO<- INFO[INFO$Exclude != "Y",]
# read all files in INFO aka 160130_all_inputs.xlsx
df <- Reduce(function(f,i){
# print(paste (f, i))
temp <- easy.mts(subset(INFO, ExpID == i), plotTechRep = FALSE, KEYS= KEYS)[[1]]
if(i == unique(INFO$ExpID)[1]){
f <- temp
} else{
f <- rbind(f,temp)
}
}, unique(INFO$ExpID), init = unique(INFO$ExpID)[1])
ExpDesign <- generate.ExpDesign(df, KEYS = KEYS)
ExpDesign[,"BioGroup"] <- ExpDesign$Treatment5
### removing conditions with n = 1
temp <- table(ExpDesign$BioGroup)
temp <- temp[which(temp >1)]
ExpDesign <- subset(ExpDesign, ExpDesign$BioGroup %in% names(temp))
merged <- merge(df, ExpDesign[, c("Keys", "BioGroup", "isAccurate")], all = FALSE)
merged <- transform(merged, Treatment2 = as.numeric(as.character(Treatment2)))
merged <- droplevels(subset(merged, Treatment2 > 0))
merged <- transform(merged, Treatment2 = as.numeric (Treatment2))
### ----------------------------
### --- End of PREPROCESSING CODE ---
### ----------------------------
IC50s according to biological groups
Experimental design was generated using a function in MTS5 R file. Treatment5 was assigned at BioGroups.
ic50 <- try(custom.ic50(merged, xlab = "Total dose (uM)", plot = F))
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## Loading required package: magicaxis
## Warning: package 'magicaxis' was built under R version 3.2.5
## Loading required package: sm
## Warning: package 'sm' was built under R version 3.2.5
## Package 'sm', version 2.2-5.4: type help(sm) for summary information
##
## Attaching package: 'sm'
## The following object is masked from 'package:MASS':
##
## muscle
## Loading required package: mapproj
## Warning: package 'mapproj' was built under R version 3.2.5
## Loading required package: maps
## Warning: package 'maps' was built under R version 3.2.5
## Loading required package: celestial
## Warning: package 'celestial' was built under R version 3.2.5
## Loading required package: RANN
## Warning: package 'RANN' was built under R version 3.2.5
ic50 <- ic50[order(ic50[,"IC50"], decreasing = TRUE),]
library(gplots)
## Warning: package 'gplots' was built under R version 3.2.5
##
## Attaching package: 'gplots'
## The following object is masked from 'package:plotrix':
##
## plotCI
## The following object is masked from 'package:stats':
##
## lowess
par(mar= c(3,16,2,2), mgp = c(2,1,0), mfrow = c(1,1))
barplot2(ic50[,1], plot.ci = TRUE, ci.l = ic50[,"Lower"],
ci.u = ic50[,"Upper"],
las = 2, cex.names = 0.7, xlab = "IC50 (uM)",
main ="IC50 of all conditions", horiz = TRUE)
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DRC−APR−246
10uM APR−246 + Cisp
Cisp:APR IC50 ratio = 1:1.4 = 3.3:16.4uM_40uMAPR
8uM APR−246 + Cisp
Cisp:APR 1:1.2 = 3.3 uM : 14.0 uM_38uM_APR
Cisp:APR 1:1 = 3.3 uM : 11.7 uM_38uM_APR
Cisp:APR IC50 ratio = 1:1.2 = 3.3:14uM_40uMAPR
Cisp:APR IC50 ratio = 1:0.8 = 3.3:9.4uM_40uMAPR
Cisp:APR IC50 ratio = 1:1 = 3.3:11.7uM_40uM_APR
6uM APR−246 + Cisp
Cisp:APR IC50 ratio = 2:1 = 6.6:11.7uM_12uMCis
Cisp:APR IC50 ratio = 2:1 = 6.6:11.7uM_12.5uMCisp
Cisp:APR IC50 ratio = 2.5:1 = 8.3:11.7uM_12.5uM_cisplatin
Cisp:APR IC50 ratio = 2.5:1 = 8.3:11.7uM_12uMCisp
DRC−Cisplatin
Cisp2
IC50 of all conditions
IC50 (uM)
0 2 4 6 8 10 12 14
Synergy
Additive model was implimented in R. First, expected effect (death) was estimated using DRC of both
drugs and exptected additive effect was calculated, which was compared to the observed effect. Ratio of
observed/predicted indicates type of drug interaction. If ratio is < 0.8, it’s synergy and > 1.2 indicates
subaddtivity. Ratio between these values are considered additive because of error in measurements.
160103 and 160108 were exclused as it only has DRCs. This gives n = 3 for IC50 ratio dilutions and fixed
APR-246 + varied cisplatin.
Overview of synergies
Following code identifies synergistic combinations by calculating SI and SEM at each drug combination.
temp <- unique(merged$Treatment1)
par(mar=c(5.1,4.1,4.1,2.1))
synergy.df <- Reduce(function(f,i){
# print(i)
tempdf <- subset(merged, Treatment1 == i)
temp2 <- additive.synergy(tempdf, plotGraph = F)
if(i == temp[1]){
f <- temp2
} else{
f <- rbind(f,temp2)
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}
}, temp, init = temp[1])
## [1] "---Checking if drug fractions correspond to total dose---"
## [1] "Is difference > 0.01? : FALSE"
## [1] "---Checking if drug fractions correspond to total dose---"
## [1] "Is difference > 0.01? : FALSE"
## [1] "---Checking if drug fractions correspond to total dose---"
## [1] "Is difference > 0.01? : FALSE"
syn.mean <- aggregate(synergy.df$Ratio_obs_exp,
by = list(synergy.df$BioGroup,
synergy.df$Treatment3,synergy.df$Treatment4),
mean)
colnames(syn.mean) <- c("BioGroup", "Treatment3","Treatment4", "mean_ratio")
syn.sem <- aggregate(synergy.df$Ratio_obs_exp,
by = list(synergy.df$BioGroup,
synergy.df$Treatment3,synergy.df$Treatment4),
std.error)
syn.sem <- syn.sem[order(syn.sem$x, decreasing = TRUE),]
colnames(syn.sem) <- c("BioGroup", "Treatment3","Treatment4", "sem_ratio")
syn.summary <- merge(syn.mean, syn.sem)
syn.summary <- transform(syn.summary, Treatment3 = as.numeric(Treatment3),
Treatment4 = as.numeric(Treatment4))
master.syn.df <- syn.summary
plot(x= syn.summary$Treatment4, syn.summary$Treatment3,
cex = 1/syn.summary$mean_ratio,
xlab ="APR-246 (uM)", ylab = "Cisplatin (uM)",
main = "Synergy at different concentrations - All data",
sub = "Dotted line represent IC50 of each drug; size of bubbles represent strength of synergy")
abline(h = ic50["DRC-Cisplatin","IC50"], lty = 2)
abline(v = ic50["DRC-APR-246","IC50"], lty = 2)
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## Filtered data
All points with synergy ratio < 0 (some points have negative values) and those with >1 ratio were excluded.
This allows to focus on synergistic interactions, ie SI ratio < 0.8.
syn.summary <- subset(syn.summary, mean_ratio >0 & mean_ratio <1)
syn.summary <- syn.summary[order(syn.summary$sem_ratio),]
syn.summary$Col <- brewer.pal(9, "Set1")[as.numeric(cut(syn.summary$sem_ratio,breaks = 9))]
syn.summary <- syn.summary[order(syn.summary$sem_ratio, decreasing = FALSE),]
layout(matrix(c(1,2), 2,1), widths = c(1,1), heights = c(3,1))
par(mar = c(3, 3, 2,1), mgp = c(2,1,0))
range(syn.summary$sem_ratio)
## [1] 0.01692255 0.25010933
a <- seq(range(syn.summary$sem_ratio)[1],
range(syn.summary$sem_ratio)[2], length.out = 9)
plot(x= syn.summary$Treatment4, syn.summary$Treatment3,
cex = 1/syn.summary$mean_ratio, pch = 16,
xlab = bquote("APR-246 ("*mu*"M)"),
ylab = bquote("Cisplatin ("*mu*"M)"),
main = "Synergies at different concentrations - filtered data",
sub = "Dotted line represent IC50 of each drug; size of bubbles represent strength of synergy",
col = alpha(syn.summary$Col, 0.6))
abline(h = ic50["DRC-Cisplatin","IC50"], lty = 2, col = "grey50")
abline(v = ic50["DRC-APR-246","IC50"], lty = 2,col = "grey50")
par(mar = c(1,1,1,1))
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plot(1:2,1:2, type = "n", bty = "n", axes = FALSE, xlab = "", ylab = "")
legend("top", pch = 16, col = alpha(brewer.pal(9, "Set1"),0.6), cex = 1,
legend = round(seq(range(syn.summary$sem_ratio)[1],
range(syn.summary$sem_ratio)[2], length.out = 9),2),
ncol = 9, title = "Colour codes represent SEM")
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Synergies at different concentrations − filtered data
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APR−246 (µM)
Ci
sp
la
tin
 (µ
M
)
Colour codes represent SEM
0.02 0.05 0.08 0.1 0.13 0.16 0.19 0.22 0.25
17
Appendix C. e R script to process data fromMTS assays
221
Appendix D
Publications
RESEARCH ARTICLE
Comparison of Methodologies to Detect Low
Levels of Hemolysis in Serum for Accurate
Assessment of Serum microRNAs
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Abstract
microRNAs have emerged as powerful regulators of many biological processes, and their
expression in many cancer tissues has been shown to correlate with clinical parameters
such as cancer type and prognosis. Present in a variety of biological fluids, microRNAs
have been described as a ‘gold mine’ of potential noninvasive biomarkers. Release of
microRNA content of blood cells upon hemolysis dramatically alters the microRNA profile in
blood, potentially affecting levels of a significant number of proposed biomarker microRNAs
and, consequently, accuracy of serum or plasma-based tests. Several methods to detect
low levels of hemolysis have been proposed; however, a direct comparison assessing their
sensitivities is currently lacking. In this study, we evaluated the sensitivities of four methods
to detect hemolysis in serum (listed in the order of sensitivity): measurement of hemoglobin
using a Coulter1 AcT diff™ Analyzer, visual inspection, the absorbance of hemoglobin
measured by spectrophotometry at 414 nm and the ratio of red blood cell-enriched miR-
451a to the reference microRNAmiR-23a-3p. The miR ratio detected hemolysis down to
approximately 0.001%, whereas the Coulter1 AcT diff™ Analyzer was unable to detect
hemolysis lower than 1%. The spectrophotometric method could detect down to 0.004%
hemolysis, and correlated with the miR ratio. Analysis of hemolysis in a cohort of 86 serum
samples from cancer patients and healthy controls showed that 31 of 86 (36%) were pre-
dicted by the miR ratio to be hemolyzed, whereas only 8 of these samples (9%) showed visi-
ble pink discoloration. Using receiver operator characteristic (ROC) analyses, we identified
absorbance cutoffs of 0.072 and 0.3 that could identify samples with low and high levels of
hemolysis, respectively. Overall, this study will assist researchers in the selection of appro-
priate methodologies to test for hemolysis in serum samples prior to quantifying expression
of microRNAs.
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Introduction
A class of small non-coding RNAs known as microRNA plays a central role in almost all
known biological processes. microRNAs are approximately 17–22 nucleotides in length and
when bound to the 3' UTR of target mRNAs, repress gene expression by degradation of target
mRNA or suppressing translation [1–3]. The human genome is estimated to encode more than
1,000 microRNAs, which collectively regulate more than half of all protein coding genes [1–4].
Therefore, it is not surprising that aberrant microRNA expression is linked to development
and progression of many diseases including cancer [1–3, 5, 6]. Furthermore, microRNA signa-
tures of cancer tissues are associated with cancer types and subtypes as well as staging, progres-
sion, prognosis and response to treatments [3, 7–9].
Recently, microRNAs were identified in a range of body fluids including urine, serum,
plasma, tears and saliva, highlighting them as potential ‘gold mines’ of noninvasive disease bio-
markers [5, 6, 10–14]. Serum microRNAs can withstand extreme conditions such as extended
storage, multiple freeze-thaw cycles, high and low pH and even boiling [6, 15, 16]. The encap-
sulation of microRNA into vesicles (exosomes, microvesicles and high-density lipoproteins),
chemical modifications or association with protein complexes such as Ago2, an essential pro-
tein for RNA interference, are all currently thought to provide protection against potent endog-
enous ribonucleases present in the blood [5, 6, 14, 17–20].
The source of microRNAs, collection protocol, extraction and detection methods, as well as
inter-individual variables such as age, diet, race and even altitude have been shown to influence
the ability to robustly determine microRNA levels. These and other pre-analytical and analyti-
cal factors must be addressed in the development of reliable and reproducible microRNA-
based tests for clinical settings [15, 16, 21]. In addition, microRNA content released from
blood cells upon hemolysis can dramatically alter the expression of certain microRNA, and
may lead to false discovery of disease-associated biomarkers [22–24]. One study identified over
half of the proposed microRNA biomarkers of solid cancers have been identified at high levels
in one or more types of blood cells [25]. Further, up to 65% of detectable microRNAs in plasma
have been shown to be affected by hemolysis [23]. While a number of studies have suggested
that miR-16 is suitable as a reference microRNA for normalization of samples [26, 27], it is sig-
nificantly altered by hemolysis, raising some concern for its routine use as a reference micro-
RNA in serum or plasma studies [15, 23].
Currently, there is a lack of consensus on methods to detect low levels of hemolysis in
serum that has the potential to affect the accuracy of microRNA-based tests. Reports have
revealed that serum microRNA content is already altered due to hemolysis before samples
manifest pink discoloration that is visible to the naked eye [23, 24]. In search of methods to
detect low levels of hemolysis, Blondal et al. (2013) suggested that the ratio of red blood cell-
enriched miR-451a to miR-23a, the latter microRNA being unaffected by hemolysis, can be
used as a surrogate indicator of hemolysis [22]. miR-451a:miR-23a ratios of<5, 5–7 and>7
are, respectively, indicative of samples at low, moderate or severe risk of hemolysis [22]. The
spectrophotometric absorbance of hemoglobin has also been suggested as a measure of hemo-
lysis [22, 24]. A direct comparison of these methods has not been previously reported, nor have
their sensitivities to detect low levels of hemolysis in serum been determined.
In this study, we evaluated the sensitivities of four separate methods to detect hemolysis in
serum from healthy volunteers and women with ovarian cancer: (1) Coulter1 AcT diff™ Ana-
lyzer measurement of hemoglobin, (2) visual inspection, (3) spectrophotometric measurement
of absorbance of hemoglobin at 414 nm [22–24], and (4) the ratio of miR-451a to miR-23a
[22].
Detection of Low Levels of Hemolysis in Serum
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Materials and Methods
Blood collection, processing and storage
Written consent was obtained and blood collected from 56 women with high-grade serous
ovarian carcinoma (HGSOC; 64.1 ± 3.4 years) and 30 healthy females age matched within 5
years (61.0 ± 4.7 years) under a protocol approved by the Northern Sydney Local Health Dis-
trict Human Research Ethics Committee (Protocol #0310-209B). For women undergoing sur-
gical resection of their tumor, blood was collected from the peripherally inserted central
catheter (PICC line) prior to the induction of anesthesia. Blood from healthy volunteers was
collected using a 21 gauge needle. In both cases, samples were transferred or collected into a 9
ml BD Vacutainer serum tube (BD #455092, North Ryde, NSW, Australia). Blood was allowed
to clot for 15–30 minutes at 4°C and centrifuged at 3000 rpm for 15 minutes at 4°C. Serum was
carefully withdrawn without disturbing the buffy coat and immediately stored at -80°C in
500 μl aliquots as part of the Kolling Institute Gynecological Tumor Bank. Samples were rap-
idly thawed in a 37°C water bath as required.
Hemolysis dilution series
Whole blood, 0.5 ml collected from a healthy volunteer, was allowed to clot in an eppendorf
tube, and sonicated until the sample was completely fluid and bright red, indicative of a high
degree of hemolysis. Serum was isolated from the blood of a healthy volunteer as per the
healthy volunteers’ protocol described above. This sample, collected under optimal conditions,
was classified as unhemolyzed for the purpose of this study. A hemolysis dilution series com-
prising 100%, 20%, 4%, 1%, 0.25%, 0.062%, 0.016%, 0.004%, 0.001% hemolyzed and unhaemo-
lysed samples (v/v) was prepared by serial dilution of the 100% hemolyzed sample with
unhemolyzed serum.
Assessment of hemolysis
Hemolysis in serum samples was measured using 4 methods. The first method measured
hemogloblin concentration using the Coulter1 AcT diff™ Analyzer and the Tainer Reagent Kit
(Beckman Coulter Inc # 8547135, Lane Cove, NSW, Australia). Three technical replicates were
performed for each sample. The second method to assess hemolysis was simple visual inspec-
tion of serum samples for pink discoloration indicative of free hemoglobin against a white
background. Visual discoloration of each sample was scored from 0 (unhemolyzed serum) to 5
(100% hemolyzed serum). The third method was measurement of the absorbance of hemoglo-
bin at 414 nm using a NanoDrop™ 1000 spectrophotometer (Thermo Scientific, Scoresby, Vic-
toria, Australia), averaging two technical replicates per sample. Lastly, the fourth method used
determined the ratio of miR-451a to miR-23a-3p (delta Cq (miR-23a-3p—miR-451a)) referred
to hereon as the “miR ratio”), with real-time reverse transcription (RT)-PCR using a 7900HT
Fast Real-Time PCR System (Life Technologies, Scoresby, Victoria, Australia). Three RT reac-
tions were performed for each sample followed by one PCR per RT.
RNA extraction and real-time RT-PCR
RNA was extracted from 200 μl serum using the miRCURY RNA isolation kit for Biofluids
(Exiqon #300112, Vedbaek, Denmark) according to the manufacturer’s instructions. One μg
MS2 bacteriophage carrier RNA (Roche #10165948001, Castle Hill, NSW, Australia) was
added during the lysis step. RNA was eluted in 25 μl nuclease-free water twice (final volume
50 μl) and stored at -80°C. RT was performed using 2 μl RNA template per 10 μl RT reaction
using the Universal cDNA Synthesis kit (Exiqon #203301). Three independent RT reactions
Detection of Low Levels of Hemolysis in Serum
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were performed per sample, and one PCR conducted for each. The real-time RT-PCR master
mix contained 100-fold diluted cDNA, 1X ExiLENT SYBR Green master mix (Exiqon
#203420) and 1X ROX reference dye (Life Technologies #12223–012). Ten μl of the master mix
was transferred to each well of a Serum/Plasma Focus microRNA PCR panel (Exiqon #203843)
or Pick-&-Mix microRNA PCR panel (Exiqon #203802) containing locked nucleic acid (LNA)
primers using the epMotion 5070 liquid handling system (Eppendorf, North Ryde, NSW, Aus-
tralia). Real-time RT-PCR was performed on a 7900HT Fast Real-Time PCR System (Life
Technologies). PCR conditions were as follows: 95°C for 10 minutes; followed by 40 amplifica-
tion cycles of 95°C for 10 seconds and 60°C for 1 minute, followed by melting curve analysis.
Statistical analyses
Real-time RT-PCR data was exported and analyzed in GenEx software V6 (Exiqon #207016)
and adjusted for plate-to-plate PCR variability using the spike-in miR UniSP3. Further analyses
were performed in the statistical language R using ‘ggplot2’, ‘ROCR’, ‘verification’, ‘car’ and
‘plotrix’ packages. An average of the technical replicates was calculated for each sample. A P-
value of<0.05 using the student’s t-test assuming equal variance or Mann–Whitney U test was
considered as significant. Results are presented as mean ± 2 × S.E.M. Error bars in all Figs rep-
resent S.E.M.
Results
Sensitivities of four methods to detect hemolysis
Four methods for the detection of hemolysis were compared using the hemolysis dilution series
as described. The Coulter1 AcT diff™ Analyzer measurement of hemoglobin could detect
down to 1% hemolysis, while the 0.25% hemolyzed and the unhemolyzed sample remained
indistinguishable (Fig 1B). By visual inspection alone, the pink discoloration of free-hemoglo-
bin could be detected down to 0.25% hemolysis (Fig 1A and 1C; S1 File). In contrast, the spec-
trophotometric method could detect down to 0.004% hemolysis (Fig 1D). The calculated miR
ratio could detect down to 0.001% hemolysis, the lowest point tested, making it the most sensi-
tive method (Fig 1E). The Coulter1 AcT diff™method was excluded from further analyses due
to its low sensitivity. Therefore, in order of decreasing sensitivity, the methods used can be
ranked as miR ratio> spectrophotometry> visual inspection> Coulter1 AcT diff™ Analyzer.
Next, we determined the hemolysis levels of 86 samples (56 women with ovarian cancer and
30 age-matched, healthy females) using visual inspection, spectrophotometric absorbance and
the miR ratio (S2 File). Using the miR ratio as the ‘gold standard’, 16% (14/86), 48% (41/86) and
36% (31/86) of the samples were found to have low (miR ratio<5), moderate (miR ratio between
5 and 7) or severe (miR ratio>7) hemolysis, respectively, according to the criteria defined by
Blondal et al. (2013), highlighting hemolysis as potentially a problematical factor, even when
serum samples are collected under optimal conditions (Fig 2A). The miR ratio of the unhemo-
lyzed sample used to construct the dilution series was 4.59 ± 0.10. In contrast, the miR ratio for
the 0.25% hemolyzed sample, the limit of visual inspection, was 7.67 ± 0.14. Furthermore, 100%
of the samples with pink discoloration (8/8) had a miR ratio>7, suggesting that any samples
with visible pink discoloration were already severely affected by hemolysis (Fig 2A).
Identification of severely hemolyzed samples using visual inspection
and the absorbance of hemoglobin
Since the majority of the severely hemolyzed samples based on the miR ratio (74%; 23/31) were
visually undetectable, we investigated whether the absorbance of hemoglobin could be utilized
Detection of Low Levels of Hemolysis in Serum
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to detect additional severely hemolyzed samples, i.e miR ratio>7. The samples with pink dis-
coloration had both higher absorbance (0.46 ± 0.11) and miR ratios (8.29 ± 0.51; Fig 2B).
No significant differences were observed between the absorbance of low and moderate
hemolyzed samples as classified by the miR ratio (P = 0.13; Fig 3A); however, low and
Fig 1. Sensitivities of four methods to detect hemolysis. (A) A hemolysis series was prepared by diluting 100% hemolyzed sample with unhemolyzed
serum (0%), and the sensitivity of each method determined by its ability to detect hemolysis (indicated by arrows). (B—E) Detection of hemolysis using four
methods. For visual inspection, samples were scored from 0 (unhemolyzed sample) to 5 (100% hemolysis). Averages of technical replicates are shown
where appropriate. ‘Unhem’ denotes unhemolyzed serum. Absorbance measures (D) and miR ratios (E) are noted on the graphs.
doi:10.1371/journal.pone.0153200.g001
Detection of Low Levels of Hemolysis in Serum
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moderately hemolyzed samples were significantly different from the severely hemolyzed sam-
ples (P<0.001 &<0.0001, respectively). In other words, the miR ratio could further quantify
hemolysis in the samples that were indistinguishable by absorbance. Severely hemolyzed sam-
ples (miR ratio>7) had 1.85-fold higher absorbance than low and moderately hemolyzed sam-
ples combined together (miR ratio<7; P<0.0001; Fig 3B), indicating that the absorbance of
hemoglobin could have predictive value in discriminating severely hemolyzed (miR ratio>7)
samples. The receiver operator characteristic (ROC) curve separated severely hemolyzed sam-
ples from the rest with an area under curve (AUC) of 0.8038 (P<0.0001; Fig 3C). The cut-off
absorbance of 0.3 identified 48.4% (15/31) of hemolyzed samples, of which 8 were visually
undetectable. The accuracy of prediction using this cut-off (True PositiveþTrue Negative
PositiveþNegtive ) was 0.779.
We tested whether a similar analysis could identify an absorbance cut-off below which a
sample is likely to have low levels of hemolysis (miR ratio<5; Fig 3D). Despite similar median
values between the two groups (miR ratio<5 and>5), the cut-off absorbance of 0.072 could
identify samples with a low risk of hemolysis with AUC of 0.7173 (Fig 3E). In general, absor-
bance-based tests to predict hemolysis suffered from low sensitivity, but offered high specificity
and moderate positive and negative predictive values (Table 1).
Impact of hemolysis on hemolysis-sensitive microRNAs
Since the microRNAs affected by hemolysis originate predominantly from the rupture of red
blood cells (RBC), the extent to which a specific microRNA is altered may depend on its abun-
dance in RBC. Using RBC-derived miR-16-5p and miR-15b-3p surrogates for hemolysis-sensi-
tive high and low abundant microRNAs based on Cq values in the cohort as a whole (Fig 4), we
calculated differences in their levels across the 3 categories defined by the miR ratio, especially
for miR-15b-3p as most microRNAs in serum are likely to present at moderate or low levels.
The levels of miR-16-5p and miR-15b-3p increased as the miR ratio increased (Fig 4A and 4B).
miR-16-5p and miR-15b-3p were found to be altered by 5.9-fold (P<0.0001) and 4.5-fold (P
<0.0001), respectively, in the samples at severe risk of hemolysis (miR ratio>7) compared to
Fig 2. Comparison of methodologies for determining hemolysis in serum samples. Serum samples
(N = 86) categorized by low (miR ratio <5; N = 14), moderate (miR ratio 5–7; N = 41) and severe (miR ratio >7;
N = 31) hemolysis. Results of visual inspection are recorded for each category as the proportion of samples
that are clear, cloudy or visibly pink. (B) Absorbance at 414 nm and the miR ratio of the cohort (N = 86). The
dotted line represents the threshold above which samples are considered to be severely hemolysed
according to the miR ratio (>7). Samples are color-coded according to their visual appearance (clear, cloudy
or visibly pink).
doi:10.1371/journal.pone.0153200.g002
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those at low risk (miR ratio<5). Both microRNAs were also found to be elevated by approxi-
mately two-fold between miR ratio categories<5 compared to 5–7, as well as 5–7 compared to
>7. Thus, both high and low abundant microRNAs susceptible to hemolysis are significantly
Fig 3. Identification of samples with low or severe hemolysis by spectrophotometric absorbance. (A) Cohort (N = 86) is grouped by low (miR ratio <5;
N = 14), moderate (miR ratio 5–7; N = 41) and severe (miR ratio >7; N = 31) predicted risk of hemolysis, and absorbance at 414 nm was compared between
groups. No significant differences in absorbance of samples were observed between the low and moderate groups; however, both were significantly different
to the severe hemolysis group. (B-C) Absorbance of samples with miR ratio >7 was 1.85-fold higher than those with miR ratio <7. ROC analysis suggested
that absorbance could predict severely hemolyzed samples (miR ratio >7). The cut-off for absorbance of 0.3 identified by ROC is shown as a dotted red line.
(D-E)ROC analysis revealed a cut-off for absorbance of 0.072 (depicted as a dotted red line) below which samples would be predicted to have low levels of
hemolysis (miR ratio <5). ** P < 0.001, *** P < 0.0001 and ## Mann-Whitney U test P < 0.001. ‘TPR’ and ‘FPR’ refer to true and false positive rates,
respectively.
doi:10.1371/journal.pone.0153200.g003
Table 1. Assessment of performance of the spectrophotometric absorbance of hemoglobin at 414 nm for predicting the miR ratio.
Low risk (miR ratio <5) Severe risk (miR ratio >7)
All samples (N = 86) Clear samples* (N = 77) All samples (N = 86) Clear samples* (N = 77)
Cut-off absorbance 0.072 0.072 0.300 0.300
AUC 0.717 0.733 0.804 0.756
Accuracy 0.849 0.831 0.779 0.779
Sensitivity 0.250 0.250 0.484 0.333
Speciﬁcity 0.986 0.984 0.946 0.981
PPV 0.800 0.800 0.833 0.889
NPV 0.852 0.833 0.765 0.765
Absorbance measurements of samples were split into two groups for each comparison: (I) prediction of low risk of hemolysis (miR ratio <5): <5 versus >5,
and (II) prediction of high risk of hemolysis (miR ratio >7): >7 versus <7. ROC analysis was performed for each comparison, and the cut-off absorbance
that maximized the accuracy of prediction was selected. Sensitivity, speciﬁcity, PPV and NPV were calculated based on the chosen cut-off.
PPV: positive predictive values
NPV negative predictive values
*refers to samples that did not have a pink discoloration or were cloudy.
doi:10.1371/journal.pone.0153200.t001
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altered amongst 3 categories defined by the miR ratio. miR-23a-3p was present at a similar
level in each of the 3 categories as expected (Fig 4C).
Discussion
Serum microRNAs are attractive non-invasive biomarkers because of their disease-specific
expression and stability in a wide range of conditions. However, a series of pre-analytical and
analytical variables must be considered in the development of robust and reliable microRNA-
based tests [1, 2, 5–7, 9, 15, 16, 21]. The effect of release of the microRNA content of blood cells
upon hemolysis dramatically alters the level of specific serum microRNAs. Recent studies have
shown that 58% (46/79) of proposed microRNA biomarkers [25] for solid cancers were highly
expressed in one or more blood cell types, and up to 65% of detectable microRNAs in plasma
were affected by hemolysis [23]. Hemolysis in clinical samples is common. Reports have sug-
gested that approximately 43% of clinical samples are hemolyzed as determined by free hemo-
globin>0.5 g/L, whereas visual detection indicated by the presence of a pink discoloration is
seen in less than 6% of samples [28, 29]. Therefore, quantifying hemolysis is an essential step
for any procedure measuring circulatory microRNAs for diagnostic purposes or biomarker dis-
covery. A number of methods to measure hemolysis in serum have been described; however, a
direct comparison assessing their sensitivities has not been reported.
In our study of serum, using a 4-fold dilution series, visual inspection could only detect
down to 0.25% hemolysis (v/v). This is comparable to the detection limit of 0.125% (v/v) iden-
tified by Kirschner et al. (2011) using a 2-fold dilution series of plasma [24]. We and others
have shown that visual inspection, i.e. identification of visible pink, as a measure of hemolysis
is insufficient as levels of hemolysis-sensitive microRNA such as miR-451a are already com-
promised prior to visual detection [22, 24].
The ratio of miR-451a to miR-23a-3p was found to be the most sensitive method that could
detect down to 0.001% hemolysis in serum. We quantified hemolysis levels of 86 samples using
Fig 4. Hemolysis-sensitive high and low abundant microRNAs are significantly altered between categories defined by the miR ratio. (A) Levels of
hemolysis-sensitive highly abundant serummicroRNAmiR−16−5p was found to be significantly altered across low, moderate and severely hemolyzed
serum samples defined by miR ratios (B) Levels of a hemolysis-sensitive low abundant microRNAmiR−15b−3p were also different across all miR ratio
categories. (C)miR−23a−3p was present at a similar level amongst three categories, supporting its use as a reference microRNA in determining the miR
ratio. * P <0.05, ** P < 0.001 and *** P < 0.0001.
doi:10.1371/journal.pone.0153200.g004
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the miR ratio, and discovered that hemolysis-sensitive microRNAs miR-15b-3p and miR-16-
5p were significantly affected in the categories of hemolysis (low, moderate and severe) defined
by Blondal et al. (2013) [22]. In particular, the levels of low abundant, hemolysis-sensitive
miR-15b-3p were approximately 4.5-fold higher in the samples with low (miR ratio<5) versus
severe (miR ratio>7) risk of hemolysis. The differences were greater for the more abundant
miR-16-5p between the same groups (5.9-fold).
While the miR ratio was the most sensitive method to detect low levels of hemolysis, it may
not be suitable for all large-scale screening for hemolysis due to additional cost and a relatively
large requirement for starting material (200 μl serum). The absorbance of hemoglobin at 414
nm, on the other hand, is a suitable alternative as it overcomes these restrictions and was found
to be more sensitive than visual inspection in our dataset. We tested whether absorbance could
identify samples that are at a severe risk of hemolysis (miR ratio>7) but remained undetect-
able by visual inspection. ROC analysis revealed that absorbance at 414 nm>0.3 (water as
blank) identified severely hemolyzed samples with accuracy, PPV and NPV of approximately
80% (Fig 5). Over half (8/15) of the samples were visually undetectable. Similarly, Kirschner
et al. (2013) suggested use of absorbance at 414 nm>0.2 (unhemolyzed plasma as blank) to
identify hemolysis in plasma as it reduced variability in miR-451 levels [23]. The different
choices of blanks and serum versus plasma may have led to the differences observed. Interest-
ingly, some samples in our study had lower absorbance than the unhemolyzed serum used in
the dilution series; therefore, water seemed to be an appropriate choice of blank. Similarly,
Fig 5. Assessment of hemolysis in serum samples. All serum samples exhibiting pink discoloration were found to be strongly affected by hemolysis for
microRNA profiling according to the miR ratio. After exclusion of the visibly hemolyzed samples, samples with absorbance at 414 nm of >0.3 are also likely to
be have miR ratio >7, predicting severe hemolysis. In contrast, samples with an absorbance at 414 nm of <0.072 are predicted to have a miR ratio <5.
Samples meeting these criteria may be excluded frommiR ratio for the purpose of determining hemolysis; however, the miR ratio should be determined for
samples with absorbance between 0.072 and 0.3. PPV and NPV refer to positive and negative predictive values after removal of visibly hemolyzed or cloudy
samples, respectively.
doi:10.1371/journal.pone.0153200.g005
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based on our data, samples with absorbance less than 0.072 are likely to be at low risk of hemo-
lysis (miR ratio<5).
Given that a substantial number of circulatory microRNAs are known to be affected by
hemolysis, the miR ratio is recommended as the final quality control step unless clearly indi-
cated in the literature that the microRNA of interest is not affected by hemolysis, for example
miR-122 [15, 30, 31]. If a promising microRNA is found to be sensitive to hemolysis, clinical
interpretation of the test should evaluate the extent to which it is modified by the underlying
condition or disease as well as hemolysis. Since hemolysis is common in clinical samples, this
comparison will also help identify levels of hemolysis that are acceptable in the samples without
significantly affecting the performance of a given test. Failure to meet quality standards would
jeopardize accuracy of measurement in the context of a disease specific relationship of any
microRNA known to be affected by hemolysis. Measuring absorbance of hemoglobin at 414
nm can identify samples that are likely to be at either a low or severe risk of hemolysis, reducing
the total number of samples that would require testing by miR ratio to determine hemolysis.
Despite high specificity, we have shown that the absorbance-based method is inaccurate for
predicting hemolysis between absorbance readings at 414 nm of 0.3 and 0.072, and suggest that
the miR ratio should be used to test for hemolysis in samples that fall within this range. Fur-
ther, bilirubin is known to interfere with the absorbance of hemoglobin, rendering this method
inaccurate in conditions such as jaundice where serum bilirubin levels are elevated [32].
Conclusion
The pivotal role of hemolysis as a quality control measure in any serum microRNA profiling
cannot be underestimated. The ratio of miR-451a to miR-23a-3p proposed by Blondal et al.
(2013) was found to be the most sensitive method to detect low levels of hemolysis, and should
be routinely employed. High and low abundant microRNAs sensitive to hemolysis are signifi-
cantly altered in the three categories of hemolysis (low, moderate and severe) defined by Blon-
dal et al. (2013). Visual inspection to detect hemolysis is insufficient as microRNA in serum
samples that do not display a visible pink discoloration can still show effects of hemolysis, as
shown by a miR ratio>7. Measuring hemoglobin’s absorbance at 414 nm can identify samples
that are likely to be at a low or high risk of hemolysis, therefore reducing the total number of
samples that should be further analysed for hemolysis using the miR ratio test.
Supporting Information
S1 File. Sensitivities of four methods to detect hemolysis. This table shows levels of hemoly-
sis measured by Coulter1 AcT diff™ Analyzer, visual inspection, absorbance at 414 nm and
the miR ratio in the hemolysis dilution series. The values represent averages of technical repli-
cates.
(XLSX)
S2 File. Hemolysis levels in the cohort. This table shows hemolysis levels in 86 serum samples
measured by visual inspection, absorbance at 414 nm and the miR ratio. In addition, levels of
hsa-miR-16-5p and hsa-miR-15b-3p are also displayed. The values represent averages of tech-
nical replicates.
(XLSX)
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Epithelial ovarian cancer has the highest mortality of the gynecological malignancies. High
grade serous epithelial ovarian cancer (SEOC) is themost common subtype, with themajor-
ity of women presenting with advanced disease where 5-year survival is around 25%.
Platinum-based chemotherapy in combination with paclitaxel remains the most effective
treatment despite platinum therapies being introduced almost 40 years ago. Advances in
molecular medicine are underpinning new strategies for the treatment of cancer. Major
advances have been made by international initiatives to sequence cancer genomes. For
SEOC, with the exception ofTP53 that is mutated in virtually 100% of these tumors, there
is no other gene mutated at high frequency. There is extensive copy number variation,
as well as changes in methylation patterns that will influence gene expression. To date,
the role of histones and their post-translational modifications in ovarian cancer is a rela-
tively understudied field. Post-translational histone modifications play major roles in gene
expression as they direct the configuration of chromatin and so access by transcription
factors. Histone modifications include methylation, acetylation, and monoubiquitination,
with involvement of enzymes including histone methyltransferases, histone acetyltrans-
ferases/deacetylases, and ubiquitin ligases/deubiquitinases, respectively. Complexes such
as the Polycomb repressive complex also play roles in the control of histone modifica-
tions and more recently roles for long non-coding RNA and microRNAs are emerging.
Epigenomic-based therapies targeting histone modifications are being developed and offer
new approaches for the treatment of ovarian cancer. Here, we discuss histone modifica-
tions and their aberrant regulation in malignancy and specifically in ovarian cancer. We
review current and upcoming histone-based therapies that have the potential to inform
and improve treatment strategies for women with ovarian cancer.
Keywords: histone, ovarian cancer, splicing, lncRNA, polycomb repressive complex, histone deacetylase inhibitors,
deubiquitinases, histone methyltransferases
INTRODUCTION
Epithelial ovarian cancer has the highest mortality of all of the
gynecologicalmalignancies,with high grade serous epithelial ovar-
ian cancer (SEOC) the most common subtype. Due to general
or non-descript symptoms of early stage disease, the majority of
women initially present with advanced malignancy (Stage III or
IV) where 5-year survival can be as low as 25% (1, 2). Standard
of care is surgical debulking followed by combinations of platin-
based drugs such as carboplatin with paclitaxel [reviewed in Ref.
(3)]. Cisplatin was first approved by the Food and Drug Admin-
istration (FDA) for the treatment of ovarian cancer in 1978 (4),
while paclitaxel was approved in 1992 (5). Some evidence exists
to support the success of neoadjuvant chemotherapy in women
who present with advanced, unresectable primary ovarian cancer,
followed by interval debulking; however, data also exist suggesting
there is little or no benefit to this approach (6, 7). Most women
respond to standard of care chemotherapeutic drugs initially; but
the majority relapse within 2 years, ultimately developing broad
chemoresistance (8, 9).
Additional factors complicating the success of current treat-
ment strategies for SEOC is lack of a clear understanding of the
true site and cells of origin of this malignancy, with evidence
mounting that SEOC may in fact arise in the secretory fimbr-
ial cells of the fallopian tube (10, 11). Molecular heterogeneity
of ovarian cancer also poses challenges, with distinct molecu-
lar subtypes based on gene expression identified within identical
histopathological groupings such as SEOC (12). Knowledge of
post-translational histone modifications associated with cancer,
including ovarian cancer, is emerging. This review discusses his-
tones and their post-translational modifications (PTMs) as key
regulators of gene expression and DNA repair with relevance for
the treatment of ovarian cancer.
GENETICS AND GENOMICS OF SEOC, INFORMING NEW
THERAPIES
While advances in genetics have not fully addressed the chal-
lenges of treating ovarian cancer, elucidation of the mutational
SEOC landscape is informing the development of therapies tar-
geting DNA damage signaling pathways. Extensive international
efforts channeled into sequencing a large cohort of sporadic
SEOC through The Cancer Genome Atlas (TCGA) project has
been revealing. With the exception of TP53 that is mutated in
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almost 100% of these cancers, there is a relatively low frequency
of mutations (approximately 2–6%) in genes including BRCA1,
BRCA2, CSMD3, NF1, CDK12, FAT3, GABRA6, and RB1, that
might otherwise have been more directive for therapeutic tar-
geting (13). Determining the role of multiple gene mutations in
relation to the activation of cancer-associated signaling pathways
for individual tumors will however be of value for guiding targeted
therapies. The development of strategies to targetmutant p53 pro-
teins will clearly havemajor relevance to SEOC (14). Furthermore,
large cohort studies of primary SEOC and SEOC cell line mod-
els have revealed extensive copy number variations that would
function as a major driver of aberrant gene expression (13, 15).
Creating great excitement in this field is the introduction of
a new class of drugs known as [poly (ADP-ribose) polymerase,
PARP] inhibitors, including drugs such as Olaparib® (AZD2281,
AstraZeneca), Rucaparib® (AG 014699, Clovis), and Veliparib®
(ABT-888, Abbot) (16, 17). PARP1 is important in the cellular
response to DNA damage, binding to single and double-strand
breaks where it mediates recruitment of factors activated in the
DNA damage response such as the serine/threonine protein kinase
Ataxia telangiectasia mutated (ATM) (18). In cells lacking func-
tional homologous recombination pathways, e.g., with mutation,
silencing, or other functional dysregulation of proteins involved in
DNA repair such as BRCA1 and BRCA2,PARP1 inhibition leads to
persistent double-strand breaks and cell death. This is particularly
relevant to SEOCwhere aberrations in DNA damage pathways are
well recognized as major driver of these tumors. The frequency of
germline BRCA1 and BRCA2 mutation in familial ovarian cancer
is around 17% (19, 20). While encouraging, not all women with
SEOC respond to PARP1 inhibition, and some that dowill develop
resistance. Key molecular drivers of PARP1 sensitivity and resis-
tance are beginning to be elucidated (21–23) and trials of PARP1
inhibitors have shown promise (24). It is interesting to speculate
that manipulation of factors involved in chromatin accessibility
may have the potential to increase the success of PARP1 inhibitors
that are undoubtedly an excitingnew therapeutic option for SEOC.
EPIGENOMICS AND SEOC, UNLOCKING NEW
OPPORTUNITIES FOR THERAPY
Aberrant DNA methylation and microRNA (miRNA) expression
have also been identified in SEOC(25,26).DNAmethylation refers
to the addition of a methyl group to the cytosine-5 position of a
CpG dinucleotide that is controlled by DNA methyltransferases.
There are well described cases of gene regulation in ovarian cancer
relying on hyper- or hypomethylation, including down-regulation
of both BRCA1 and the PTEN tumor suppressors by promoter
hypermethylation (27, 28). Of note, the cell surfacemarker CD133
that is part of a panel used to define ovarian cancer-initiating
cells has been shown to be regulated by both histone modifi-
cation and promoter methylation (29). Other cancer-associated
genes with increased expression in ovarian cancer due to pro-
moter hypomethylation include TUBB3 and HOXA10 (30, 31).
Epigenetic silencing of genes has been linked to the develop-
ment of platin-based resistance in ovarian cancer, including DNA
hypermethylation at CpG sites of MLH1, ARMCX2, COL1A1,
MDK, and MEST gene promoters (26, 32). Treatment of cis-
platin resistant human ovarian cancer cell line xenografts with the
demethylating agent 5-aza-2′-deoxycytidine resensitized tumors
to platin-based therapy, likely through re-expression of MLH1
associated with a decrease in MLH1 promoter hypermethylation
(33).While unlikely to be efficacious as monotherapy, the value of
demethylating agents for the treatment of ovarian cancer may be
in combinatorial treatments with more conventionally used DNA
damaging agents such as the platin-drugs or other epigenomic-
based therapies. Interactions between histone modifications and
DNA methylation that together influence gene expression have
been reported (34). A number of reviews addressing the topic
of DNA methylation in ovarian cancer, including discussion of
clinical trials of demethylating agents, are available (25, 35, 36).
Elucidation of the role of post-translational histone modifica-
tions and parallel development of therapeutic strategies targeting
them is gaining momentum in many tumor streams; however,
this area of epigenomics is to date relatively understudied in ovar-
ian cancer, although examples of this form of gene regulation
are emerging. Targeting histone modifications has the potential
to be of particular relevance to the treatment of SEOC given
that these strategies embrace a whole genome approach, and so
have the potential to overcome issues created by focusing on infre-
quently mutated genes. Furthermore,many histone modifications
have been implicated in the DNA damage response given their
fine control of chromatin configuration that determines access
by transcription factors and DNA repair proteins (37). SEOC is
undoubtedly a tumor driven by aberrant DNA damage signaling,
therefore the potential exists to improve the way this pathway is
targeted with current therapies by a greater understanding of the
chromatin landscape. It has recently been stated that we stand at
the“tipping point” for epigenetic based therapies for the treatment
of cancer (38). The strategies being developed have large potential
for the treatment of ovarian cancer.
MODIFYING CORE HISTONES
POST-TRANSLATIONAL HISTONE MODIFICATIONS
Histones are small basic proteins of around 14 kDa that contain
a high percentage of positively charged amino acids (39). They
are the most abundant proteins bound to DNA in eukaryotic cells
and predominantly function to regulate gene expression andDNA
packaging aroundnucleosomes, the functional units of chromatin.
Nucleosomes are comprised of a histone octamer with two copies
each of the core histone proteins H2A, H2B, H3, and H4 wrapped
around by approximately 147 bp of DNA (39). Within this struc-
ture,H3:H4 exists as a tetramer and there are twoH2A:H2Bdimers
(40). The histone linker H1 binds nucleosomes together thereby
participating in a higher order compaction of chromatin (41).
NH2-terminal histone tails protrude from the core octamer struc-
ture, with residues located in these tails subject to a large number
of dynamic and reversible PTMs that include, but are not limited
to,methylation, acetylation, phosphorylation, ubiquitination, and
SUMOylation (42).
Post-translational modifications of core histone proteins reg-
ulate gene transcription, replication, and DNA repair processes
by influencing chromatin configuration and providing impor-
tant platforms or docking sites for the recruitment of proteins
and enzyme complexes such as methyltransferases and acetylases
required for chromatin modeling. New terminology has recently
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entered this field describing chromatin “writers” that lay down
histone modifications, chromatin “erasers” that remove them, and
chromatin “readers” that are involved in interpretation of signals
that may influence subsequent changes (40). Histone H3 lysine
4 di- and tri-methylation (H3K4me2 and H3K4me3), as well as
histone H3 lysine 79 methylation (H3K79me), histone H3 lysine
36 (H3K36me), histone acetylation and monoubiquitination of
histone H2B at lysine 120 (H2Bub1) have been linked to “open”
chromatin and active transcription. Other modifications, includ-
ing methylation of histone H3 lysine 9 (H3K9me), histone H3
lysine 27 (H3K27me), and histone H4 lysine 20 (H4K20me) are
associated with “closed” chromatin and transcriptional repression
(42, 43). Suppression of H3K27me3 in cell lines overexpressing the
dominant negative mutant H3-K27R led to re-expression of the
RASSF1 tumor suppressor and resensitization of ovarian cancer
cells to cisplatin, likely due to a more relaxed and open chromatin
configuration (44). Methylation is controlled in a reversible fash-
ion by methyltransferases and demethyltransferases, often asso-
ciating in complexes, whilst monoubiquitination is dynamically
controlled by ubiquitin ligases such as the RING finger proteins
RNF20 and RNF40 (45, 46) and deubiquitinases (DUBs), again
often in complex structures.
Histone acetylation is generally associated with an open chro-
matin structure that facilitates transcription, controlled in a
dynamic fashion by histone acetyltransferases (HATs) and histone
deacetyltransferases (HDACs) (47). Acetylation acts to neutral-
ize the positive charge of lysine residues located on histone tails,
resulting in disruption of nucleosomal structure and promoting
unfolding of local DNA making it more accessible by transcrip-
tion machinery. HDACs remove acetyl residues and consequently
are associated with gene repression. In many cancers including
ovarian, aberrant HDAC pathways are believed to promote cancer
growth and metastasis (48–50). Histone tail residues can provide
platforms for multiple enzyme writers, such as lysine 120 of his-
toneH2B that in addition to beingmonoubiquitinated, can also be
acetylated (H2BK120ac). It is thought in this case that H2BK120ac
precedes H2Bub1 in a temporal fashion, suggesting that it may be
an early mark of poised or active chromatin functioning as a dual
switch to keep nucleosomes “hot” for rounds of induction and
transcriptional elongation (51).
Histone deacetyltransferases that are aberrantly expressed in
cancer include sirtuins of which there are seven family members.
Sirtuins are mammalian homologs of the yeast silent informa-
tion regulator (Sir2), that as well as functioning as HDACs can
act as deacetylases for non-histone proteins such as p53 (52).
SIRT1 is a nicotinamide adenine dinucleotide (NAD+) – depen-
dent lysine deacetylase and a class III HDAC. SIRT1 expression
was reported to be higher in malignant EOC compared to benign,
and expression was seen more commonly in SEOC relative to
mucinous tumors (53). This same study reported higher levels
of SIRT1 in a subset of malignant SEOC that correlated with
increased overall survival. Of note, BRCA1-associated breast can-
cers have been reported to have lower levels of SIRT1 relative
to BRCA1 wild-type (54). To date, levels of SIRT1 in BRCA1-
associated EOCs have not been assessed. SIRT1 is also associated
with acquired drug resistance, influencing the tumor microenvi-
ronment, functioning in DNA repair and promoting cancer stem
cell survival (55). For all these reasons,SIRT1 is being considered as
a possible target to overcome drug resistance seen in many malig-
nancies and may have relevance to future treatment strategies for
SEOC.
There is emerging evidence to support the theory that sub-
populations of cells exist in SEOC that are of a stem cell-like
nature, demonstrate resistance to chemotherapy and are respon-
sible for the development of chemoresistance in women with
ovarian cancer (56–58). This is supported by a recent study
demonstrating that the bivalent chromatin mark seen in embry-
onic stem cells and required for silencing of developmental genes,
H3K27me3/H3K4me3, is found in SEOC at the transcription
start sites of silenced genes (59). H3K27 methylation is written
by the methyltransferase Enhancer of Zeste Homolog 2 (EZH2)
that forms the catalytic unit of Polycomb repressive complex 2
(PRC2). EZH2 is overexpressed in SEOC, as well as in cancer-
associated stromal cells (60). H3K27me has also been associated
with chemoresistance in ovarian cancer (59). Histone PTMs play
a major role in maintenance of an undifferentiated stem cell
phenotype (61, 62).
Studies of histone PTMs in primary tumors support discoveries
in cancer cell line models of complex histone modifications and
furthermore, have been shown to correlate with tumor stage and
prognosis. Loss of globalH3K27me3 has been shown in ovarian, as
well as breast andpancreatic cancers, correlatingwith shorter over-
all survival (63). Loss of global levels of H2Bub1 has been reported
in advanced breast tumors, as well as colon, lung, parathyroid, and
ovarian cancers (64–67).
CROSS-TALK BETWEEN HISTONE MODIFICATIONS
Histone cross-talk is defined as the influence that one or more
post-translationally modified histones have on the writing, eras-
ing, and reading of other histone PTMs. The language of histones
is both complex and wide spread, influencing processes involved
in development, stem cell differentiation, transcription, replica-
tion, and DNA repair with a major role in the regulation of gene
expression (68, 69). Examples of histone cross-talk include the
recruitment of the methyltransferase complex COMPASS (com-
plex of proteins associated with Set1) by H2Bub1 that is involved
in the methylation of lysine 4 on histone H3 (70–73) (Figure 1).
This cross-talk also has implications for DNA damage signaling as
methylated H3K4 recruits the DNA damage-associated chromatin
remodeling factor SNF2H leading to recruitment of DNA repair
proteins RAD51 and BRCA1 (74, 75). The DOT1L methyltrans-
ferase has been shown to methylate H3K79 after its expression
was first stimulated by increased H2Bub1 (76). Complex patterns
of cross-talk and their influence on gene expression and cellular
processes are only just beginning to be elucidated. This will be an
area of considerable focus in the future given the importance of
understanding how therapies targeting one histone modification
may in fact be influencing another.
DIFFERENTIAL HISTONE SPLICING
The study of histone splice variants in ovarian cancer is still in
its infancy, with few studies published to date, although evidence
suggests roles in tumor progression (77). Slight structural changes
to the core histone octamer as the result of incorporation of
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FIGURE 1 | Postulated patterns of histone cross-talk in malignancy.
(A) Lysine 120 of histone H2B is acetylated by histone acetyltransferases
(HATs), acting as a precursor for histone H2B monoubiquitination at the same
amino acid residue. (B) Lysine 120 of histone H2B becomes deacetylated via
histone deacetylases (HDACs), allowing for the E3 ubiquitin ligase complex of
RNF20/RN40, in association with the PAF1 transcriptional regulatory complex
(PAFC) to facilitate monoubiquitination of lysine 120 (H2Bub1). (C) SET1 is
recruited to the site of H2Bub1 where it interacts with COMPASS (complex of
proteins associated with Set1) to facilitate the active mark of methylated
histone 3 at lysine 4 (H3K4me). (D) H2Bub1 can recruit and activate the
DOT1L methyltransferase, responsible for the active chromatin mark of
methylated histone H3 at lysine 79 (H3K79me).
differentially spliced histones can alter the overall structure of the
nucleosome, changing the way in which DNAwraps around it and
influencing nucleosomedynamics (78). These non-canonical vari-
ants can influence the function of chromatin domains and lead to
differences in nucleosome stability causing aberrant transcription
and DNA repair (79). Roles for histone splicing are just beginning
to be elucidated in ovarian cancer. A link between alternative his-
tone splicing of a group of H2A-type histone variants, referred to
as macroH2As (macroH2A1.1, macroH2A1.2, and macroH2A2),
andproliferationhas been reported in anumber of cancers, includ-
ing ovarian (80). The RNA binding protein QKI (Quaking) was
shown to regulate alternative pre-mRNA splicing of macroH2A1.
Interestingly, macroH2A1.1-mediated suppression of prolifera-
tion occurs, at least in part, through the reduction of PARP1
protein levels. Given the interest in PARP1 inhibition for therapy,
this area requires further attention.
Another histone variant identified to be down-regulated in
ovarian cancer is histone variant H2A.Z, loss of which resulted
in tumor progression (81). H2A.Z is a conserved variant of his-
tone H2A, and has recently been shown to regulate a variety of
targets including the glucocorticoid receptor (82), estrogen recep-
tor (83), and p53 (84). The ovarian cancer cell lines A2780 and
OVCAR3 were shown to have lost H2A.Z from regulatory regions
of the urokinase receptor (u-PAR) leading to activation of this
receptor and suggesting a mechanism for upregulation of u-PAR
that is seen in a number of different malignancies (81, 85, 86).
Furthermore, expression of linker histone H1 splice variants has
been shown to discriminate ovarian adenocarcinomas from ade-
nomas, suggesting their value as potential epigenetic biomarkers
of ovarian cancer (87).
ROLE OF NON-CODING RNAs IN THE REGULATION OF
HISTONES
The surprising finding that at least 80% of the human genome is
transcribed has boosted an interest in understanding the role of
non-coding RNAs (lncRNAs) in biological processes and diseases.
The number of protein coding genes has remained relatively sta-
ble at approximately 21,000 during the last decade; however, the
number of lncRNAs has grown to 9000 small lncRNAs (<200 nt)
and 10,000–32,000 long lncRNAs (>200 nt) (88).
The role of miRNAs, a subset of small lncRNAs, in regulation of
post-transcriptional gene silencing has beenwell established; how-
ever, our understanding of their effects on biological networks is
still far from complete (88). Global deregulation of miRNAs has
been implicated in ovarian cancer, and miRNAs have been found
to target DICER, a key enzyme in miRNA processing, in breast
cancer (13, 89–92). Of note, DICER levels do not appear to be
altered in ovarian cancer (91). DNA methyltransferases such as
DNMT1 and DNMT3B, histone deacetylases such as HDAC2 and
HDAC4, andHATs such as KAT2B and KAT6A themselves are pre-
dicted to be targeted by dysregulated miRNAs in ovarian cancer
(miR-100, 140, 145, 21, 26a, and 93) according to miRTarBase, a
database of experimentally validated miRNA targets, influencing
the epigenome (93).
HOTAIR, EZH2, AND THE POLYCOMB REPRESSIVE COMPLEX
Non-codingRNAs are versatile,with roles ranging fromchromatin
structuremodification,X chromosome inactivation, scaffold func-
tion, miRNA decoys, nuclear import and export, RNA splicing,
and the regulation of gene expression (94–96). Recently, approx-
imately 20% of long intergenic lincRNAs, a subset of lncRNAs,
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FIGURE 2 | HOTAIR -directed epigenetic reprograming of the cancer
genome. (A)The long intergenic non-coding (linc) RNA HOTAIR recognizes
specific DNA sequences and targets chromatin-modifying complexes PRC2
and LSD1 to silence gene loci. The 5′ end of HOTAIR tethers the PRC2
complex to the target by binding to the non-coding RNA binding domain
(ncRBD) of the HMTase EZH2, catalyzing tri-methylation of H3K27. The 3′
end of HOTAIR facilitates demethylation of H3K4me2 by the lysine-specific
demethylase LSD1. Both H3K27me3 and lack of methylation at H3K4 are
repressive chromatin marks associated with gene silencing. (B) Expression
of HOTAIR results in silencing of >40-kb region spanning HOXD8–11 of the
HOXD locus. Aberrant HOTAIR expression in multiple cancers has been
shown to promote invasiveness.
have been found to be associated with PRC2 that functions
as a chromatin-modifying complex (97). HOTAIR (HOX tran-
script antisense intergenic RNA), an approximately 2.1 kb lin-
cRNA transcribed from the HOXC locus, is known to alter
chromatin configuration and promote cancer. In healthy cells,
HOTAIR functions to epigenetically silence approximately 40 kb
spanning HOXD8–HOXD11 of the HOXD region on chromo-
some 2 (98, 99). By working as a scaffold, HOTAIR tethers and
directs the PRC2 containing the H3K27 methylase EZH2, and
the lysine-specific demethylase 1 (LSD1) to silence targets by
catalyzing H3K27me3 and demethylating H3K4me2, depicted in
Figure 2 (100).
Over-expression of HOTAIR promotes metastasis of breast,
pancreatic, endometrial, colorectal, and other cancers (99, 101–
104). Conversely, silencing of HOTAIR impaired migration and
invasion of EOC cells in vitro, as well as inhibited tumor spread
in a mouse model of intraperitoneal metastasis, likely via met-
alloproteinases (MMP3 and matrix metalloproteinase-9, MMP9)
and epithelial-to-mesenchymal pathways (105). HOTAIR levels
were reported to be elevated in ovarian cancer relative to normal
ovary, and its expression was inversely correlated with the degree
of differentiation (101, 105). Elevated levels ofHOTAIR correlated
with worse overall and disease free survival in women with EOC
and were also correlated with the presence of lymph node metas-
tasis (105). Furthermore,HOTAIR is expressed at a fivefold higher
level in cisplatin resistant A2780cisR cells compared to parental
A2780 cells, and its down-regulation restored cisplatin sensitivity
(106). Levels of HOTAIR have been reported to be fourfold higher
in colon and breast cancer stem cell-like cells (CD133+/CD44+)
compared to non-stem cell-like cells (CD133−/CD44−), and
its down-regulation reduced the number and size of colonies
assessed by anchorage-independent growth (107). HOTAIR was
also shown to induce epithelial-to-mesenchymal transition (EMT)
following TGF-β1 treatment in colon and breast cancer cell
lines (107).
Polycomb-group (PcG) proteins are involved in maintaining
the repression of genes in specific cells and subsequent cells
originating from them. These proteins are essential in lineage
commitment where they and their antagonists, Trithorax pro-
teins, selectively express and repress a subset of HOX genes
required to specify a particular cell type. Tumor suppressors
including p16Ink4a, p19Arf , and p15Ink4b are epigenetically silenced
due to abrogation of PcG proteins in cancer (108). Most PcG
proteins form multimeric complexes of either Polycomb repres-
sive complex 1 (PRC1) or 2 (PRC2). Mammalian PRC2 com-
plex comprises four core PcG proteins: EED, SUZ12, EZH1/2,
and RbAp46/48, with many other proteins interacting with this
core complex. EZH1 and EZH2 are histone methyltransferases
(HMTases) and form part of the PRC2 complex that initiates
gene silencing. As HMTases, gene silencing is enabled as both
EZH1 and EZH2 contain SET domains required to catalyze
di- or tri-methylation of H3K27 (H3K27me2 and H3K27me3)
and repress chromatin. The PRC1 complex binds to chromatin
bearing the H3K27me3 mark. PRC1 is composed of ubiqui-
tin ligases RING1A and RING1B together with BMI1, MEL18
(PCGF2), and NSPC1 (PCGF1), with RING proteins functioning
to monoubiquitinate histone H2A at lysine 119 (H2AK119ub1)
(108). Both PRC1 and PRC2 are required to maintain gene sup-
pression, and remain associated with condensed chromatin, even
in the absence of the initial trigger. Although PRC1 usually fol-
lows the activity of PRC2, there are some reports where PRC2
silenced genes do not contain the PRC1-mediated H2AK119ub1
mark (108).
The components of PRC2 are upregulated in many malig-
nancies such as melanoma, lymphoma, and breast cancers. High
expression of EZH2 is seen in ovarian cancer, correlating with
advanced stage and is a predictor of poor survival (109). Further-
more, higher levels of EZH2 have been seen in a subpopulation
of ovarian cancer cells with stem cell-like properties at relapse fol-
lowing platinum-based chemotherapy. Down-regulation of EZH2
in these stem cell-like populations in ovarian cancer cell mod-
els reduced anchorage-independent growth and tumor growth
in vivo (110). Furthermore, down-regulation of EZH2 was shown
to resensitize cisplatin resistant ovarian cancer cells to cisplatin
and decrease H3K27me3 levels (111). In line with this discovery,
down-regulation of EZH2 leads to re-expression of p21waf1/cip1,
subsequently promoting apoptosis (112).
www.frontiersin.org June 2014 | Volume 4 | Article 144 | 5
Appendix D. Publications
239
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marsh et al. Histone modifications and ovarian cancer
FIGURE 3 | Current and upcoming therapies for the targeting of
epigenetic modifiers in ovarian cancer. Tumor suppressor genes are
commonly silenced in ovarian cancer through epigenetic writers and erasers
(blue ovals). These proteins regulate a variety of modifications including DNA
methylation (DNMTs), histone methylation (EZH2), the removal of both
histone acetylation (HDACs), and histone monoubiquitination (DUBs). Various
inhibiting agents (red ovals) have been designed to stop the action of these
enzymes. DNA methyltransferases (DNMTs) silence tumor suppressor genes
(red line) by hypermethylation of CpG islands in gene promoters (yellow line).
Consequently, DNMT inhibitors (DNMTi) are currently being trialed in ovarian
cancer cell models with value in the reactivation of a tumor suppressive
phenotype. Deubiquitinating enzymes (DUBs) function to cleave ubiquitin
from their target proteins. Recent research has demonstrated H2Bub1 is lost
in ovarian cancer, implicating H2Bub1-specific DUBs. H2Bub1-associated
DUB inhibitors (DUBi) may be viable treatments for ovarian cancer. The
histone methyltransferase EZH2 is a member of the Polycomb repressive
complex 2 (PRC2). EZH2 functions to tri-methylate lysine 27 of histone H3
(H3K27), a repressive chromatin mark. Consequently, EZH2-inhibitors (EZH2i)
are currently being trialed to remove this repressive mark. Histone
deacetylase (HDACs) remove acetyl groups from specific histone residues.
HDAC inhibitors (HDACi) prevent this enzymatic function, facilitating gene
transcription.
The PRC2 complex proteins rely on association with molecules
that have DNA-binding abilities such as the lncRNAs HOTAIR
and Xist or the transcription factor JARID2 to direct it to its
target (108). A number of repressed or deleted miRNAs associated
with ovarian cancer, including miR-199a, miR-214, and miR-26a
(89, 90), are also predicted (miRTarBase)1 and/or reported to
directly target EZH2 suggesting a possible mechanism of its over-
expression (113, 114). Interestingly, the tumor suppressor BRCA1
negatively modulates PRC2 by interacting with EZH2 due to over-
lap in the BRCA1-binding region and HOTAIR binding domain
of EZH2 (115). HOTAIR reprograms luminal breast cancer cells
into an aggressive, basal-like state in the absence of functionally
wild-type BRCA1 (115). Although the dominant mechanism of
PRC2 function is via the H3K27me3 repressive mark on target
loci, multiple epigenetic mechanisms could also be involved in
PRC2-mediated gene silencing since EZH2 and EED are reported
to interact with DNMTs and HDACs (25). Unlike EZH1, which is
present in both dividing and differentiated cells, EZH2 expression
is specific to actively dividing cells (108), making it an attractive
therapeutic target for cancer.
1http://mirtarbase.mbc.nctu.edu.tw/
RISE OF EPIGENETIC THERAPIES TARGETING HISTONE
MODIFICATIONS
Knowledge of epigenetic modifications and the enzymes that reg-
ulate them underpin new options for the treatment of ovarian
cancer. Drugs specifically targeting DNA methylation will not
be discussed but we recommend a recent review addressing this
topic (116). In this section, we will examine the rapidly expanding
field of drugs targeting histone modifications and the enzymatic
machinery driving these changes with the view of application for
the treatment of ovarian cancer. Figure 3 depicts histone modify-
ing enzymes currently being targeted or in pre-clinical models for
ovarian cancer.
HISTONE DEACETYLASE INHIBITORS
Histone deacetyltransferase inhibitors have been demonstrated
to decrease cancer cell growth, induce apoptosis and promote
cell differentiation (117). Currently, there exists a wide variety
of compounds that can function as HDAC inhibitors including;
organic hydroxamic acids, short-chain fatty acids, benzamides,
cyclic tetrapeptides, and sulfonamides (118). Many different type
of agents derived from these fundamental families are currently
going through clinical trials.Of the currentHDAC inhibitors, three
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have been tested in ovarian cancer; suberoylanilide hydroxamic
acid (SAHA), valproic acid (VPA), and Romidepsin, either as
standalone treatments or in conjunction with DNA damaging
agents such as cisplatin. Although this section will focus on FDA
approved HDAC inhibitors, other HDAC inhibitors have also
recently shown for the potential treatment of ovarian cancer. The
HDAC inhibitorM344,which is specific forHDAC6 and to a lesser
extent HDAC1, has been shown to promote growth inhibition, cell
cycle arrest, and apoptosis, as well as inhibit BRCA1 expression in
ovarian cancer cell lines (119, 120). The HDAC inhibitor Tricho-
statinA (TSA),which specifically inhibits class I and IImammalian
HDAC families, has been shown to increase p73 expression and
promote Bax-dependent apoptosis in cisplatin resistant ovarian
cancer cells (121).
SAHA (Vorinostat®)
Suberoylanilide hydroxamic acid has showed promising results in
a number of in vitro models of ovarian cancer. Early research
demonstrated that SAHA was capable of promoting cell cycle
arrest, apoptosis, and caspase 3 activation, as well as decrease cell
viability in ovarian cancer cell lines and isolated primary cancer
cells (122–124).More recent studies havedemonstrated that SAHA
works effectively in conjunction with paclitaxel in ovarian cancer
cell lines (125), while a SAHA–decitabine combination inhibited
ovarian cancer cell growth in both in vitro and in xenograftmodels,
in addition to increasing the expression of imprinted tumor sup-
pressor genes, increasing apoptosis, cell cycle arrest, and autophagy
(126). Further work has shown SAHA to be effective in combina-
tion with cisplatin in platinum resistant ovarian cancer cells (127,
128); however, the mechanism of this effectiveness is still poorly
defined. Research has linked SAHA treatment to growth arrest,
apoptosis and differentiation in a wide range of cancers. The anti-
proliferative effect of SAHA has been suggested to be a result of
the accumulation of acetylated proteins, including; BCL6, p53,
Hsp90, and the core histones (129). Currently,Vorinostat has been
through phase I and II clinical trials for ovarian cancer. Phase II
trials in women with recurrent platinum-refractory ovarian can-
cers showed little benefit when this drug was used as a single agent,
although the drug was well tolerated (130). Vorinostat was FDA
approved in 2006 for the treatment of Cutaneous T-cell lymphoma
(CTCL).
Valproic acid (Valproate®)
Another HDAC inhibitor showing promise is the short-chain fatty
acid drugVPA.Valproate has the advantage of already being a well
establish FDA approved drug, used clinically as an anticonvulsant.
VPA acts to directly inhibit HDAC activity; however, the specific
details of how it exerts its effects are still unclear. Early research
demonstrated that VPA promoted cell cycle arrest and apoptosis
in ovarian cancer cell lines (122). VPA was also demonstrated to
sensitize ovarian cancer cell lines to cisplatin treatment and to
resensitize cisplatin resistant cells to treatment (131). More recent
research showed that VPA was effective at treating a mouse sub-
cutaneous xenograft model of ovarian cancer, as well as ovarian
cancer cell lines (132). This same study demonstrated that VPA
treatment resulted in an increase in E-cadherin expression, while
decreasingMMP9 and vascular endothelial growth factor (VEGF).
Similar to SAHA,VPA has been shown to act as an effective treat-
ment against ovarian cancer cells by itself and in combinationwith
other drugs. Combination treatments of ovarian cancer cell line
models with VPA and the Aurora Kinase inhibitor VE465 showed
increased apoptosis compared to VE465 alone (133). Monti and
colleagues offer an extensive review of VPA mechanisms (134).
Romidepsin (FK228, Istodax®)
Romidepsin is a class I HDAC inhibitor, which received FDA
approval in 2009 for the treatment of CTCL. In a biological system
Romidepsin functions as a pro-drug whereby its reduction results
in the release of a thiol, which blocks the activity of Zn-dependent
histone deacetylase through its interactions with the zinc atom
present in the deacetylase’s binding domain (135). A study has
demonstrated that Romidepsin inhibited cell viability and induced
apoptosis in ovarian cancer cell lines (136). More recent work by
the same group demonstrated that Romidepsin worked effectively
in combination with cisplatin increasing cell apoptosis in in vitro
and in vivomodels (137). Romidepsin is currently in phase 2 trials
for ovarian cancer2 (NCT00085527).
DEUBIQUITINASES – TARGETING MONOUBIQUITINATED HISTONE H2B
(H2BUB1)
Ubiquitin is traditionally thought of in the context of polyubiq-
uitination that leads to protein degradation via the ubiquitin–
proteasome system; however, monoubiquitination of histones
H2A and H2B are clear instances of alternative roles for ubiq-
uitin in transcription and DNA repair (45, 46, 138). DUBs are
proteases that cleave ubiquitin from target proteins, including core
histone proteins, and are recognized as important regulators of the
ubiquitin–proteasome system. Given that DUBs occur upstream
of the proteasome, they have the potential to show greater speci-
ficity and less toxicity compared to FDA approved proteasome
inhibitors such as Velcade® (bortezomib) or Kyprolis® (carfil-
zomib). For these reasons, extensive efforts are currently being
focused on DUBs as drug targets (139, 140). Currently, no specific
DUB inhibitor has entered clinical trials; however, DUB inhibitors
have shown promise in pre-clinical models, including P0591, an
inhibitor of USP7, that has amongst its substrates H2Bub1 and
the p53 regulator HDM2 (141). In studies of multiple myeloma,
P5091 was demonstrated to induce apoptosis in both bortezomib
refractorymultiplemyeloma cells and animal tumormodels (141).
Further, there is considerable interest in the H2Bub1-targeting
DUB USP22 given its membership of an 11-gene panel termed
the “Death-from-Cancer” signature that predicts rapid disease
recurrence, distal metastasis, and poor response to therapy (142).
HISTONE METHYLTRANSFERASES – TARGETING EZH2
Like DNMTs, HMTases such as EZH2 can be targeted for ther-
apy. 3-DeazaneplanocinA (DZNep) was the first indirect inhibitor
of EZH2, leading to decreased global levels of H3K27me3 and
restoration of expression of genes involved in growth inhibition
or apoptosis (143). It was subsequently discovered that DZNep
also inhibited other HMTases (60, 143, 144). Specific inhibitors of
2http://clinicaltrials.gov/ct2/crawl/42
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EZH2 have since been developed including GSK126, EPZ005687,
and EI1 (60, 145–147). Recently, a peptide-based inhibitor, SAH-
EZH2,was developed to target the PRC2 by disrupting EZH2/EED
interactions (148).
Results of preliminary studies of EZH2-inhibitors in com-
bination with other drugs have been encouraging. DZNep was
shown to enhance the anti-proliferative effects of Gemcitabine
in pancreatic cancer cells (149). The combination of both DNA
demethylating agents (5-aza-2′-deoxycytidine) and DZNep tar-
geting histone methylation has shown promise in cell line models
of leukemia (150). A report on the use of DZNep treatment of the
ovarian cancer cell line A2780 showed reduction in proliferation,
an increase in apoptosis, inhibition of migration, and upregula-
tion of E-cadherin expression (151). It remains to be seen whether
these therapeutic strategies may be of value for the treatment of
ovarian cancer.
CONCLUDING REMARKS
Targeting of histone modifications and the enzymes regulating
them in the ovarian cancer epigenome represents, to date essen-
tially an unmet opportunity. With further focus on this field, it is
probable that within the next decade new drugs targeting HDACs,
HTMases, and DUBs will emerge as the next generation of cancer
therapeutics. Whether these drugs will be most efficacious as sin-
gle agents, or in combinatorial approaches with more traditional
DNA damage-based chemotherapeutics, or with other perhaps
yet to be developed molecular based targeted drugs remains to be
determined. It is clear that complex networks of histone cross-talk
will need to be understood and markers of histone dysregulation
will need to be identified to ensure that patients receive maxi-
mal benefit from these therapies (152). In summary, the field of
epigenomic-based histone therapies promises to offer a new gen-
eration of cancer therapeutics giving fresh hope for the treatment
of women with ovarian cancer.
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